<SEC-DOCUMENT>0000059478-23-000162.txt : 20230427
<SEC-HEADER>0000059478-23-000162.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427115656
ACCESSION NUMBER:		0000059478-23-000162
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		23853561

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lly-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e,d:bcc38c3f782c4545ad9dc8c7f1087104--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lly="http://www.lilly.com/20230331" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV8zLTEtMS0xLTI0NjI2Mw_4ba14db7-b395-4984-aa34-df528612879a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV80LTEtMS0xLTI0NjI2Mw_bea165c9-98e3-492e-b740-8ef51f7edd01">2023</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV81LTEtMS0xLTI0NjI2Mw_e045a789-23ea-475a-b88f-6f007d698076">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV82LTEtMS0xLTI0NjI2Mw_c8b5ceaf-6608-488d-9d99-636833b5af61">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV83LTEtMS0xLTI0NjI2Mw_70944b16-5c43-4904-b524-219b6c999671">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV84LTEtMS0xLTI3MDkyMw_9782e2f9-109c-4e87-81bd-e9e6957f166f">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV85LTEtMS0xLTI3MDkyOQ_82b01142-a55c-4ab4-bbce-9a71580520e2">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c39e441ad84014878b856a1411f674_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e37ea68750472dae583b744621207e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1700NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ff8c3480034649af99d9e4b0f62406_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927e3b53935c4022981ef2bcccb6abdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2d9ab3c1794f1d8b361cd95d702eb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf9b65901614ec99ac3f7f3cf96ba0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db0e5f4479b4590a17a13660ba7120f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaef6a6bd5dd4d8bb6af6b8e7f16c197_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7656e7caa28247f39bd611bc66416bd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95753ad64fa24dfc9db4020a919ed2e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id978959344a247b69b4db196a5f33b07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c601fdfc135468b9efa7eeeaaf2bbdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a04715762e44a39f3f2505d74a6ea1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2186586b7322416183b886001b72303f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3148a12fb5994593a755fff70b7d4470_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16887cea932f44c3a6088e33ecfb7490_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8048a6c27248afac7fffd0fe38b008_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2097ff769544728b3e0e7f64451512e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3edace87bee46b0bf89263a4a4be3b1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c67213efc434eb9ac796a4c1a04c8da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8dbf8ede644257a18c8621fa65c557_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic813de36efc74513bd64da94a269adfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188c9e0e0deb45c7ac4c04ec58fafeae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68e310320e9466d8f5ba3eb98d90284_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637339e89f374f98959ff8ae6e6501d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439164f165d34e9bb97df6c5e992ff8b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if684f40112064b11b340468506a32fa3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc91a78b7e994d8a828ad6accd7e7eb9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie33c470d29b348aaaf9cacc62407b9b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f1bc66163b41baa48cbf1328b78bbc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae9598be4a64cd69d5667e9e70ca761_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153592c1af1f4910bf06d43f543dcc71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e11d3a40394c318b16109c7c0fecf6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e757fc239f4499e91acfaeb16335063_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7699e9bf7f941dcb048f29c3aada3b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88d6c314da94d23b9e30802e9728044_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib386950c303c4cfa991af56051f481c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118b413e750a419a8eea249e9dec5ea8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f70762797b4c7eb12579a57e4a0f1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41563e4306144d7db1ae5fab5a13d025_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia45726ea3ba342708ad76343e7d8ea9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776dd251590543c2aa2cb51a4dab931f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de368b269ea4b33baf0dc1ce490d43c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ba05d67547242b28419ed4e7793321c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if0cc6e06de26466c90d397554c65af18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b0d2e9299804c05b2243243ee5f298f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3800138a064caf84059e7b7ac1f59f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e8033ea6754341b21a71b5dd3e785c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dd59e0fdc74287873fca650e145c15_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4e39b3439c480c8742d89f8399bc82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13290ff47804307a44e2f065e33dd7d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac33e8897674b85a6950df08eee5bf8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a28a52e5fa34f38a6ecc947140b6edb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a6d8bc4d434540ad95d77f973fa070_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d89a91c0fbb4dd195707004ab1a00b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4783bd0e08d47d29ab78b3d697d290f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c7662e4b8c740ebba1d408fa1765201_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97119da1943c4d1e95f0e996e9f315be_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c27dd4f47b47239694dc03b4ecc6ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e4c56100484d70a675bd288c597049_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2f9585c7204b33beb2bc33724774a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16fef32b8fb476596fe6c4d0bb25380_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i811218a96d2b41c0a71ad7a4b77e56b2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b94ba9dd63247d5b32ffa10006a021e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id898a8a22f0e4880a5338b8467984755_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3450a514000e4564aed94e9856bd66d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bd2ba8150f4e69a8256ef87cc94d2d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb86385cc8eb4bed91738b3eec15d109_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5f5c213bf74ee680df8883531a880e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ac73e33e864d3d85f05e179d6e0ab5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93975c00ca0e44ba99e88b2a02696fbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41870e267fbe402dad822ec24c06b44f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39805ee81eec439aa8c2e397f5508410_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4655d36440574fbeab0c91fc7b019703_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44114472bba24a3b91861ccdbb5b23ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1aed3d8f0c4cb293c37cdc3196c8d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eee894daf9648e981d2c1b49f7448e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ff4b5d9df8493fbd95a0e88fe1cc78_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4dc93a102494bcdb03aacc7bbba37f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3506079381447bd842f668fa1edf8bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67d2dd261224805ac90f2f1b66659e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2548d402f8348a19d3cdabfabed7bbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ee45c4c43e47b6a8bf88847481e710_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78c1dab52df4fad8c34b85682e70bf9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93368f3f449f4b9fbf16c9329f7056bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc66ce8e6de454cac39d92a460a5da5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5306573ee5f40fe87015d1bead33c79_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67961791f67f455a9e83bdd66879e1e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7827ab11ad634535a354ffe9397dee6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9800b2536c0a4887b5ab9dd03310e3d5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4913832cdf6c42bfa9d7047743a02c46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7fe4b4cb9d4e1eb78bf2b8fc45025b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7380748fafce4bbeb79b3fb7212654a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff8425fbfc64303ae4dd3c6a3664599_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f4e2ee8a2d34917bdcc965e7626ef0e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56eaf4a89a44762b2ad02723519711d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a88ab4c21743beb4653082449b8794_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ec6bedcbf8431996d351090aeb835f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec65e20bbe8429d8374bab94fff526d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ee755aa5ec43ce8d7d5b0801744953_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a7138a41b64af0b3d3bffc680013e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4850b75145f14e119182161edd48e156_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eea234886e74de6bc9398e17900aabf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c07348838844f9927b4f1042344fc8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54de819fdc34f43a6a60f819b305005_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia728bce450914e0ab2648a04596d1d35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d1f99b0aa548e694ca63f72c14567a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9140b6e5e49c43dbb2dbd87cb8181bbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7070b3ba7a54482a84f745990995ccdd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia688e1f2870e4ce7ad9e8932949035dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb82241d17ed4a128f5799c977329bf4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79547491309b4e5393994557f1671667_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5886df3058224ce1aa56b3af9d1a1dc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65a58b1573343a39b71e05ab32cc416_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecbc3c01d7643c3888c9bb26a95292d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d13f666ff449d7a621398eaa0ef2d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74abf3ad08e8479fbc7b50f9e8bccaf1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49343f97cd6f47108d6fd5848cd54864_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808d86cf633c44669b50bbdecdb33551_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795c0bdc41294080907d9ea59944ead4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df5f251db6448df818fab73530a644a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417d453530f54ca0b2209fa1faf5306d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29c502013aa40aeb696d62e85288626_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff009e5b94684162a6c0b8401522ef69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id944e42934f04a7f867c267ec9717aff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5231a969184a4364a058bc909f82fe8b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf70417fae9467fa9f5e6435d854dfd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d99551c34a4e858ad1c4e0502e76dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18890600eb448588714f8ad882431ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69246a482ad44038a5cc2d5c54873ae2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58a7cb2a4a0485d96deb76ac57931ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f65318bd79648b998f3e5df408c0412_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3213310f015747d080af9a1ff48b5ad8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16329625fa6f44a6a1c064ac7d4ec9dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153b28fedc304d3e8ffde2bdf7f073c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0385f2c26b2f4d3e8fb95aaa85d8bc2a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e0e3a0711046c39391d2d3cf445882_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6d1650065e4c768674409d266dca06_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d09044e85e405bae8df74949e8712b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e50725af9a34d7a98f04d67cb123a30_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e7240880ac4123a3894cbb650d0172_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4c963f8e9e4b4db60302cf2284c762_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269467655eda495eb32d7ecade1d1990_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b2366367f84820bf8ace8d801f1c7d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96f23fe8818410dbe8e8a34a66455ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957ffa2d2be34dee93676a024e802aa2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef141b8c87343e8a397e0bf1e526680_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c7539f3edc4efaa041fe0e65fdc6ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367924f0fc6a4ee6b301ed3d61eb59d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice3f5be448854af1bc7435c75e8fd14a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf75f8c30aff470988cc19ce904d3fe4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf7bba33b974a30af558c8ffb0eff76_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab868bc977a9479b97ce8c1d76008a42_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b5d56ba3c84300a4655bfc90d63682_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da9824d115d4642b33d62110647bc25_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f0a7c14210458f99c56d32fab18cae_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0577f0dc20c64f89a47c8c6dea223e7e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9816923eb3343fcb3c969e22954983c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974f97a08b2246b99fad08fcff9d907b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b0c35171b54d0e8199472f276c3efd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0c12862e7a4f5295df6787910e6d95_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf02a47c1f054f6cab10a1350b11ca78_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3846c71ac29e4037bc0323344ed7bf33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1943dbb4c94472d9c47d4588395f87d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c58df1da1424666b72028b96c96e821_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948eeabb45154555a0aa21e3c99f533f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696edc9f8e1843b28ed762a1347db26b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703ac11468d54f86bf1f951723906604_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb41e587fef4c8aaeee5a0e8d565098_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7157b6266b57432189b37acac4c62b1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f7663963954d37992ed44ffb330868_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6109f92c24420fb119449586e2d751_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f6d319daa54e91842b67dd9ad0ca0d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a86976547184c9aa6f46daea7912cde_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0798771ccf6491d8bf4e3a529a99992_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bebcb77e7cc46c4a0f6232d59204728_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afe04177a85445183aee9c1f1a104cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b8c13f78ef499fa5e3a82aa88d9a10_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd5a2af9de84cfc812225bc521e17bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf0b36bab2d459389f2adb7bf797fc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3508798f670645c0af6c4e615ca44088_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a904aef68a4f45b2b86bf8b5576e30_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5103a4e13b1f49fcb43c76f4ef1e1696_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e758f49518403ab2b0c55235561aa3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51e24ac8e8b450599cdde81c0c8a8db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0b13b0180da45dabb7f682f854e3394_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd283be94b6d4f30af788ea943b170d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ac892edbf94f62919a942916235192_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic522b3c6168f49769bd3610b3cfb9fd2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394796b389834a5d8a4a6a52018ea5e4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf536f227695468d8955c509d0cac28a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fbeb1df59694ca1a5121853310fe013_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd8ff202c66402cb6acdcfb73f456e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b193d99bd84b609a946006de3ff5b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce552cbf23a4e5e87ebb11e406b4c7c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f75bb32e91f4c8c914a357a961a505e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591aacf4b21b4fb6af4a84ef723f602d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e43da972920406cb8cec2e4ac4f504a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546300f8490545128a0251b2fdd2206b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3357638f0d364662b153eab67fa8550f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91090e6b25c497aa5caa5cd3b067650_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8415110eb3486093fdd56a22adfd54_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a092f91d8a468d8c4c31d4148a904b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if724a8d2f737491298c6d043d5a7b8fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="i445c404661b9435abdfa6e32f19fa84d_I20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae82f601bab2473da6f28b70df983fa5_D20221201-20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7692466539d946a186b9e8a3794403e0_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:OlanzapinePortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7897a00ac5944569e250a8e3e4f0b96_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:OlanzapinePortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100bf53cad0845918532d994ef899f46_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:BaqsimiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1373c2b92194421a101613e8613e0bd_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:BaqsimiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d0abcdee3334210846272da16cb8bf0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd665f0b61e04e9290ab394dc775adfc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0be196fbee4b99986d201abe4c40cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff485149e744b8388e86b2d61f131bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78acf8b5d08a423ab887d0babcc4c793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20238217248b408d991f048bd5cb02de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c97dbdad3e47c19014952cddab28fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92837642c10f4f2d8a9378d7a850d897_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609b231bb46d449cb0c55bf0feca2672_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5463e57189f4d458870b77c846c8470_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbee495f74d4bc7ac390f3934fd8dec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103526d82f5c4005b57a6ca769c093a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489cad1a4170481f8dc4678a75f24771_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa643ca7a9684ef7bc9e57583e9f2c9f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f28555ca5d9421a9bb743d1916adb6c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64cc16dbdab440cba483787915c9d53d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab4c398ad894122bc46ff06e78555c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1477b2c322fa4d258992d89c08206da3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07ca7f96ff047149b52aa21f1419c5d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f030511d7046938601479dedb444f4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7566c897554984865a313ce03a9329_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0134da41219f40099434bf6b0e92907f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cac2c8384d54ca495e549787dc20271_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1879600e47a94b1ca76977132157c1f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3918b47b0546407986bcb5eb572cf16a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51606337f7734c3486883b088d9e425b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d8251eccdf47259566f7ce1b910246_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc74babfb5f48019438eb1839ff23ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c819184949c43c88caf8d26d02607fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8026bc96eb9499a97499c0c3a47904d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a28c2c52e041b8bda2d6528cde8205_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afb33798b944ff09e0d384619049f08_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14fba24e65df4393afd80bbbfba657c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0237a8c7ae47d897c07629a4ccd158_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i837f1e72cbb14e459cf199db8d586de3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b28da6dd9e645d398bc98f07007e279_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id276c57f9b1f4968a4c1e9e22e9ca168_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bfc537fc2c649e6a5a5f04fa5e3eac0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060e380eb6bd4c7b8d931a5b7fe8ee32_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c95303f9a0d4b8dbc0cd35c9ab50369_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2aee17f60b34dfaa64036bd799907ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdd4b1a54e04c3a9406a84414b9f579_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5575d654b61f4900b3705243433ef745_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c516fae2e94d6dbda47e05ce423f1b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef8ccfb7b53440397caf6f2176ec2c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1914622ec74bfc91e9e91e6b7153e4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i954f45623ee841cbbb44ef65dc983e82_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdc87b2e3b847c699cc755d5929caa3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93672f2b12e14d149242b511c86a6250_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f02815ce424e099d024a5372594f49_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3620be0cd8f6437c993131b23aae9aa0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c92706e1f14b06b6f276c841acc827_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87fe25007da841e6a6dfa7dea8abca12_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ebed6fdc46043b680d5a256576f2871_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb98f1aad55409684b3ba48c8c07916_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6dbc248c1574a47a024938a5536f95c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b8cd580dcd4aa7a914f8764250a273_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19353eef79fe415d9f09bbb87f88817e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001f8aeb21bc42778b5ba830866254e9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55cf7db1bd84431d8151876c0779039f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2f853a69374cc289e36b04c56dc656_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cea0f1817514262a527599b1b82ff06_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if48d0a0094404e7283b202d1e3bddef6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97234b19add45c8a1264d62a11227cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfbfe46c3934f43b65aa033cc031c63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c78f11ff6a047f081fced706e82fafa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dbd154370ab46c5aa386577c6e77972_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2be3d28f17b4d53b00d099d33166a22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a551b91bdf34460b537440476918ed1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf82c4e9f9fd4a0db74790b311d892d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14330e00eca04b5aa32be284d320080f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851cea55d9ca4dada65a5272023c5cf5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d33a84402254240a7b6fd4134d0c50d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ace9101d47e4406b2a9101fde438cc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8619a22dba4e4f568d1919d6cd7c5376_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9a47c0173949d69d205062ba1a08a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022f12bcdcd0432a8bf7bd1609fcd81f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813ca92d3c304796b09a1c1b8cd503cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77fd8621adac49b9a812a1b54ce30bd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3bbe0151d1d436383b9c9a162467d10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ca25f6912d4deaa22749065f92f810_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800172f3d41a475b95bc904fa96bc892_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf1513ec6fe42dc8fc97dacbcbb2f7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f0aee5c436422aacd166802e150362_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2930663eccea45d3ab83ffbf88977505_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55dd2b5a2b18473582bd68be66d7d771_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0881c8a632db4b36a3e7ecfd7928e941_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564f1f9a74ad45f6b61966a59691288e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489bce7d4ec7404b9664b907c028323f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245ac866b994442fbc4b1f2c0864fe2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6856168703f140ec90f1f07f17cc591d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42aa25d783514516803c587532a3c61e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa8c24cfa2d4bbb8bac085b94dea6e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c245d1c06644e1b6ab489c2e9f6916_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ecc19905f14bd28130682e968375e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e06948912d142179578cad05d244ac3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96286855c6b74d7ca6b4c49c79940a71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2035cc82b2c4f2984eefd8ae524520a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9458648cddd94b1e98f28b8ab753bc74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463ce48ff9854c67b168581527823709_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A50NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5629b4e2ef53489dbf21e68abf79b47a_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A47NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2aa54d93fb744f09a03b3641900a309_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A4875NotesDue2053Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6c5f93596b48d09753ee6dac6abb6c_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A495NotesDue2063Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2c8b929e4c4bc5a32d8aa02836cac1_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDue202620332053And2063Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d458da5e9246b8a8c0b7b714992619_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0331e3cce77463eab1cf2359214ff10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if485cce9601842de8e0453ea2c5bdb90_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c397a2da7e467c86ff6be26f9e20c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac66d67a45e4eb9b8df6e33b966bdeb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeac312680b340f5b5e739bbc1e1882d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia278d7067652484dac30db72abe60a63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ea2a3ccd6c4b00ba12b0f45309f52f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f2344b073f45f7b33a4471dd2abba3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a314d1e73864fd780eeebcc4f2a1867_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf771418ff145e48f59e9ff50e2c708_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if6e0597d66944d53bf676c80d6b96114_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c08ba67b1c94a638f7917eaf0032bad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="id0507f641e794b5a91c61ce38a4c073c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i429677c58b714ca8a8137930ebb1264e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf306204988949a8a9f4c724f64060af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3cd20496f3d4a06a9644d09794a69a7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260b5249d7e84893aefd8c83c3d04825_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i645e8bd9724c4c4cab525b0c0ce2038a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a44228b4f8545afb2c73892b5d2dc61_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77245def3f8b4e7dab758e4a8bde31a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8cd03fb09db4a7d82b3453427246d58_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a702b6516d4b76a6b7e939ece50067_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c2892bae36442e8926b2ce9c0668bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4c3a1eaec84aa68e202c8ea853063b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e9490fbbc14d76ab189e023cf3f228_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e32bbc79574914bba00cdb0742b99b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f19b8ba9ed454fa02e5160a844f996_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a614a742164e49b4da60cae000aac8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee17b04babc40a6ab35eccdf222fe82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72e1ac48fd74f079d8811bbcae3d5d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c553f14757453c942a550f354e3a74_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6789d3ab2e2e4887828f80411eaa0097_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b68c8b710bd465cb70d755bbb9d33df_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea8c83934624a97a1dc11e68563bf6e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332f789539594747bf8464ec5cafdb0b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0de9c67450541c296870312132a3b92_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5442836a58a740f9a2ec6a5044876fa3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4345c04245449db88cb19f4963073ed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6128cb3f8b34eb38e4ba315f7d53bbf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5624b505084aa68791383a31649f60_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3441b768235345d7a17d1010afb3aa34_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5b9b0ce2374a22a8d5ea231570946a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b75c331361d44ec829664b5a49b1365_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ed07ce471c498fafc8e126e65bf30b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b86836fd2b4c638e1b4648bb0f535f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1b2d2ba1774f099d8109747e8c6a95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4aaf0f785e46d39d0b337f7ca1aa83_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33268d4bc0be4bfeb735237bbf2beaa5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f8023d0e15487abe65174ea5fdd911_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27a50fefdd14c2f984c86fe00f4646c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb4d961f831495a8982fcca640793b2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i606b780fae204c2fb03456ec7d4609ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b291e9275fa4cdea832b11022bb1650_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17408fcf4a6444ca4350f667c9e2531_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10c867d799d4679b141e08dc578e51f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f0c78f29754db2b760047cbe32a568_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5964e87d1767486d9c9f3e69ea87005f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8899346d6d43418aa5c2c278c01334_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b3318a1c6d4b2989d8bd17e5d7fa8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c721984329042fa98416c00587829be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b26c90f2d0f429498c69e75f2486afb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia203e1c41a27445f9ac21572233934b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff538190e8dd49b1a7a2291adead31c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3322119f512345d8bdc5b393121fe2a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddbfbaced29242dabda4aa8d0200d534_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61271b58943e4dfe8d82e39de366487a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6961e3f6be845d49d270b23ae0eb760_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee7bb9be4e14b0199dbb8ff375c4fd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42c0160e96e4f31982f3ea5eddf15be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebbad1803617416b8a7575b6635bd9e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec954c0cc0a4864a3be7c95f0bbbba3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f5e9a727714d8e9d04fd093c69c3f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023e643351984eaa8065abddb7c0e922_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d6338210f24d0b8761f25b6917fedf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0289f9ec779478ca9a7d9feaa66a043_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27e470a377e24131be208163db576480_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17bd13ed9bbb44bd9b794d91b7205501_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if16b30290f524f5ba8cd96a652b77f18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cac47e76cf444dcab2ac2c436b08b33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9f543aacc94384a647f3a1c0667ca4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df7036cdae24b0a97dccbbd25afe031_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8664bea8164219ad1c5f82db48f0b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94edd79b891548bd83088ab50b487992_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id027583937064a45b5174328a3e4fd18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed5b21a16d248339ba5818828910280_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0157807f4391408d931450405bc79b5f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1429cdab82b46a7a0ad4c4e85647f6a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="i8d76ed1b0d8a474586570b1b99086173_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4ab320c12a472eb82bbab75fbf501b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="id56d2b03dc9949ebb50d95e71f042821_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2018RulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2018RulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad20ef67d2f430481744471c5b56210_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6d0498b5f448c7a43cd5218c9d9457_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7954361cad5e468189b61f0e148dc919_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea4ac837c5c446c91d4a1eadb1660df_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="if52058720702455ab18d11fcfce47593_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c57ea452d543e989f9536150f9db93_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd425dd4dd0841579d320a37187ecdef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e2ca758e964af8b28d95fd2e6bc9cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653d3a81e6b14167933ef66d19e6c10c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51d9a0f258444078ac8ef9caa739449_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ddf45785ed4e96a99f49ff596d8acb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e2bb76dd4f4adab26a41f1f82d2c2b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510af8b9f1844bed829cb00dfc685190_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e84d8dd08244d678c234bae2809c48c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d4430e40014abc901dd4edd7cb49e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie00101643b4643a483d888a017ecd8ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6c49fd39884008bd1780b0e7dd589d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9209cc4104c44020b5cca0fb5e342032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6a9fdaf2f44f0ab06f86a366185a4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b36144f48ef40aea33af45869704e46_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea75053548e54a9383137eac2aa979bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e1942610fb4fe3b661fe8f47c36101_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6d6a2a126f4ea8916e435402446e81_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie708bb24249c494bac718b7262662532_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1057b3b5f0c84df780eeb0542ab9296b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0424c9ff126d4e098f24803951d6a61e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5badb1e9e9416281833c0e936313e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92b4b2cc38546abbedc7e893d1b940c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17225a13a894c18ab97a3b6bf0fb9b2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5514dfeeac4fd79d56e6bb4067d42e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5724b7029fb74929941da12378c70867_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc8829f02584de496f6271827b1daa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6504efffb904c0bb389e6b7ec4a995b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8b989d89ce4af9a4cc6f268d29ee6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a88826d3584cfc872524cbbc7ff75c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44 id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM4_bfcf660f-9088-45f4-828a-13f03a81c41e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMTA_69633f54-4d5b-45ea-86fa-bc96eefa44be">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQy_ad6c1f5d-262f-419d-9340-c473d2cbbd9c">001-6351</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM5_39eb969b-bcb7-4936-99f8-41507909f549">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ODA0N2NmY2RjNjAyNDVhY2I2ODRiODJiMGMzNDViNjEvdGFibGVyYW5nZTo4MDQ3Y2ZjZGM2MDI0NWFjYjY4NGI4MmIwYzM0NWI2MV8wLTAtMS0xLTI0NjI2Mw_245d858a-bf47-4ba5-bfc1-a8cf29f81b7e">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ODA0N2NmY2RjNjAyNDVhY2I2ODRiODJiMGMzNDViNjEvdGFibGVyYW5nZTo4MDQ3Y2ZjZGM2MDI0NWFjYjY4NGI4MmIwYzM0NWI2MV8wLTItMS0xLTI0NjI2Mw_c2ebf22a-c2d2-40f0-985d-b283c0c3dcc3">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQw_34fea546-fff5-4de9-9ffb-6b3be82c578a">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM0_45f9e6e3-face-4e61-bdaa-dd0efb32e1f3">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ0_4fb19e34-5fd4-4343-a2e8-e5172e082b8f">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM1_e2c1fe7b-a992-402c-86b3-50db2d0a501c">46285</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code (<ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM2_2b3ec243-e04f-4773-94dc-ce514208bb28">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQz_7e0ad5b3-4144-429e-8452-eab1838675d6">276-2000</ix:nonNumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTAtMS0xLTI0NjI2Mw_19610aae-6a1d-44f1-854a-cc93f1b62657">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTEtMS0xLTI0NjI2Mw_0910fe6d-706a-472a-94ad-4d325d83c1d4">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTItMS0xLTI0NjI2Mw_30ee7d80-cc7b-49c9-9541-d73e4f759123">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTAtMS0xLTI0NjI2Mw_9f2e8b68-6862-47d7-a710-15a0d07adc7d">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTEtMS0xLTI0NjI2Mw_3ea03f38-9851-436d-b212-112999a72da0">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTItMS0xLTI0NjI2Mw_0a9bb5ba-85de-4e5a-a9c1-8ff33f583312">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTAtMS0xLTI0NjI2Mw_dd435779-373e-45bb-94bf-ed66ca7eea1a">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTEtMS0xLTI0NjI2Mw_9405c5a5-da61-4c4c-973b-b277a9daa8ca">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTItMS0xLTI0NjI2Mw_bf186a3f-8eed-46a8-9eed-43a94d8b860d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTAtMS0xLTI0NjI2Mw_ca964212-0318-4b32-aa3e-eabdbb944a8a">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTEtMS0xLTI0NjI2Mw_0121b6e7-26d6-4775-a577-89354ea01f8a">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTItMS0xLTI0NjI2Mw_5914cdba-68ee-4567-aacb-004fc55468c7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTAtMS0xLTI0NjI2Mw_c4f20e8f-2150-48f5-8edd-b82116e8b34e">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTEtMS0xLTI0NjI2Mw_1dc59cab-4291-4ce8-afa2-41a0552ffd5e">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTItMS0xLTI0NjI2Mw_a14a080f-2767-4f7b-9f40-0c9c5e7f8802">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTAtMS0xLTI0NjI2Mw_4c35434e-a478-4b7b-ab1b-b36f224fd1f8">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTEtMS0xLTI0NjI2Mw_caf68901-bbfd-4785-ac60-b06072789838">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTItMS0xLTI0NjI2Mw_7b8831b8-55ae-4f00-926f-5889833dde7a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTAtMS0xLTI0NjI2Mw_bb3df26e-2825-4fd1-bd4c-e83f5ccd4cf9">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTEtMS0xLTI0NjI2Mw_ffe90418-7e0e-4b60-acc0-e87fa3da708e">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTItMS0xLTI0NjI2Mw_7377d5c4-e319-4835-b2aa-404621ffd4c6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTAtMS0xLTI0NjI2Mw_f4f4a117-2287-4a07-9a19-c610f623e485">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTEtMS0xLTI0NjI2Mw_80c20f8b-0e43-424a-a817-12c6f6076c69">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTItMS0xLTI0NjI2Mw_8e4daa6d-5fb9-4b6a-bdfd-96ca20bde5c3">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTAtMS0xLTI0NjI2Mw_efb6126e-a5fc-4d6b-b03c-31ab11d31408">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTEtMS0xLTI0NjI2Mw_4fe8dfc3-877f-49ff-83a5-d41f7c13eb12">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTItMS0xLTI0NjI2Mw_042ef758-d03d-4587-ab64-c78afb2d9ed5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0wLTEtMS0yNDYyNjM_7cfbc39a-939b-4a74-8d77-7ad4623a7890">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0xLTEtMS0yNDYyNjM_63ffe111-9f84-4395-89d6-c43291c9c2bc">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0yLTEtMS0yNDYyNjM_f16c4a8e-a4e8-4731-bcf5-1ff232606130">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0wLTEtMS0yNDYyNjM_908d70e1-7e05-4349-8981-7435f30808cc">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0xLTEtMS0yNDYyNjM_ecd153cc-7c39-4628-a11a-221fea3bf23f">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0yLTEtMS0yNDYyNjM_f3a26945-b0cd-404e-90ea-70ff7b7bd69b">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM3_9b0cbba3-587f-4689-bd59-e4201a17dc58">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ1_4e9ef0b0-9926-47e5-8d03-c5430256076d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8wLTAtMS0xLTI0NjI2Mw_9c4c50ea-7e07-489f-ab07-1467ef556af1">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8xLTctMS0xLTI0NjI2Mw_e821753e-76e5-455d-b227-b1b088e2ea72">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8yLTctMS0xLTI0NjI2Mw_be1da75d-2e9e-4449-ab3f-33ba46baa759">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ3_9fb80416-d08a-49ed-91f8-c30c9db724dc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of April&#160;24, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42ff8c3480034649af99d9e4b0f62406_I20230424" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ZGJkYzRmOGE0MmZlNGRiNGExMmE5ZjNiYWQyMWUxOGYvdGFibGVyYW5nZTpkYmRjNGY4YTQyZmU0ZGI0YTEyYTlmM2JhZDIxZTE4Zl8xLTItMS0xLTI0NjI2Mw_8257dbbb-2e28-493b-938f-7abd4aa9cd1d">949,272,933</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended March&#160;31, 2023 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_22">Consolidated Condensed Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_28">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_34">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_37">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_37">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_82">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_82">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_82">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_85">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_85">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_91">Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_91">38</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_103">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_103">41</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_106">Critical Accounting Estimates</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_106">41</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_109">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_109">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_1121">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_1121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_1121">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_112">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_112">43</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_115">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_115">44</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_118">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_118">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_121">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_124">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_124">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_127">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_127">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_127">45</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_130">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibcc38c3f782c4545ad9dc8c7f1087104_130">45</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under "Management's Discussion and Analysis of Results of Operations and Financial Condition" includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "intend," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact and outcome of acquisitions and business development transactions and related costs;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding operations and products; </span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates or changes in interest rates and inflation;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC);</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations; and</span></div><div style="margin-top:2.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, particularly under the caption "Risk Factors." Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Part I, Item 1A, "Risk Factors" of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMi0xLTEtMS0yNDYyNjM_7b71abc2-0516-49a9-acc6-c84837ef3d49">6,960.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMi0zLTEtMS0yNDYyNjM_e1758cf5-d9b1-4eaf-a995-d1400510ab44">7,810.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNC0xLTEtMS0yNDYyNjM_d877dc93-fcb5-4d28-ac9f-9ad43a9c8472">1,626.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNC0zLTEtMS0yNDYyNjM_21aa468f-81f9-48ea-857e-d83222588254">2,072.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNS0xLTEtMS0yNDYyNjM_b9d25593-c40c-41cf-ad0a-c38a9370cfcf">1,985.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNS0zLTEtMS0yNDYyNjM_a8400133-bd0d-4e1c-b5d2-232e95b4eed9">1,610.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNi0xLTEtMS0yNDYyNjM_b7993d1a-4b61-48b3-874d-a197c24dfcb9">1,749.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNi0zLTEtMS0yNDYyNjM_aeab0a9e-72e2-4437-a7f8-7007ff706725">1,557.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNy0xLTEtMS0yNDYyNjM_213ddecc-db78-4f71-b291-981fa5cc30dd">105.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNy0zLTEtMS0yNDYyNjM_bf6b77c5-9405-489d-83a6-06d768b2908e">165.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfOS0xLTEtMS0yNDYyNjM_449d44ca-5bd8-47ad-beec-05ec75001f20">35.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfOS0zLTEtMS0yNDYyNjM_d4409b0a-0e3b-4a05-a825-799f4f158585">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTAtMS0xLTEtMjQ2MjYz_dea2cdda-41c6-4735-8ab7-336f2fee06c4">5,430.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTAtMy0xLTEtMjQ2MjYz_7b425efa-05bf-45cb-adc6-b53478b2da65">5,756.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTEtMS0xLTEtMjQ2MjYz_6f4861fb-202a-466b-b72e-b17e44cb6e4c">1,529.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTEtMy0xLTEtMjQ2MjYz_4586a835-5dd1-47f6-9d98-8c22bcb6bf95">2,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTItMS0xLTEtMjQ2MjYz_e6cfb438-2b68-4564-bdb7-f01b0a3021e9">184.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTItMy0xLTEtMjQ2MjYz_ea34c09b-f550-4479-9afd-c0f576c3b0ac">150.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTMtMS0xLTEtMjQ2MjYz_d593d4e7-1d67-42fa-80b5-244b61fdb8c5">1,344.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTMtMy0xLTEtMjQ2MjYz_17a1d23a-591c-4127-baa0-550d4b7d4a74">1,902.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTgtMS0xLTEtMjQ2MjYz_b0a9a1dd-67f9-432c-912c-4b7885616a3a">1.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTgtMy0xLTEtMjQ2MjYz_145cf2fc-d703-458a-ae5e-0b7b83d2b579">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjAtMS0xLTEtMjQ2MjYz_28f1ea59-79dd-4538-9ce5-fbcaa579de8b">1.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjAtMy0xLTEtMjQ2MjYz_870a0df2-dcef-459a-8d9a-1e1dd287da12">2.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjQtMS0xLTEtMjQ2MjYz_dd7b3d5e-b7ae-4f93-96d6-5b9635914cb5">901.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjQtMy0xLTEtMjQ2MjYz_2cb027b7-7902-446c-a85f-f7139e7a95ab">903.7</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjUtMS0xLTEtMjQ2MjYz_581bcef1-bb65-4c1b-ac35-ef284444c564">903.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjUtMy0xLTEtMjQ2MjYz_f7af531a-c494-4303-a543-b9852779940b">906.4</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMi0xLTEtMS0yNDYyNjM_d593d4e7-1d67-42fa-80b5-244b61fdb8c5">1,344.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMi0zLTEtMS0yNDYyNjM_17a1d23a-591c-4127-baa0-550d4b7d4a74">1,902.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (Note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMy0xLTEtMS0yNDYyNjM_431c0852-4d8d-4fd8-8553-fd3980b86916">67.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMy0zLTEtMS0yNDYyNjM_f104c56b-f1c8-4383-89b5-8ab68a9f337a">117.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfNC0xLTEtMS0yNDYyNjM_71bb4432-e33e-4260-a000-aa140db02a72">1,412.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfNC0zLTEtMS0yNDYyNjM_74071ba7-dd74-491c-9e80-1cfacca616fe">2,020.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_25"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.715%"><tr><td style="width:1.0%"></td><td style="width:65.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 5)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMy0xLTEtMS0yNDYyNjM_341139b8-4030-492b-a969-fe8dd4412c1f">3,545.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMy0zLTEtMS0yNDYyNjM_4ea3b86a-a56c-413a-9ef1-448148b1e18b">2,067.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNC0xLTEtMS0yNDYyNjM_f2057217-8061-46c6-a039-0a5f18310c1a">123.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNC0zLTEtMS0yNDYyNjM_43ba1f34-6b11-48fe-b553-4a8e0c4d041d">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0wLTEtMS0yNDYyNjMvdGV4dHJlZ2lvbjpkOGQyNmYyMzkxZTk0OTVkYWI2ZGIzMjUzZmI2NTgzMl80Nw_c75c96f6-189c-4825-bcc7-177f2141b20b">14.0</ix:nonFraction> (2023)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0wLTEtMS0yNDYyNjMvdGV4dHJlZ2lvbjpkOGQyNmYyMzkxZTk0OTVkYWI2ZGIzMjUzZmI2NTgzMl82MA_9060ae71-c8e9-4022-a800-601c3979a22e">16.0</ix:nonFraction> (2022)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0xLTEtMS0yNDYyNjM_72a21dfa-c0fe-4e8c-8b2c-a8bc2fae16b2">7,526.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0zLTEtMS0yNDYyNjM_5d71f6ff-3cc3-4b83-b890-4ebcdb578ff1">6,896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNi0xLTEtMS0yNDYyNjM_d1c4bc1b-1dbc-47f7-9c4c-b2d818a4697f">1,495.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNi0zLTEtMS0yNDYyNjM_ac47af60-3e69-48b3-a7fd-d5f934a25ab5">1,662.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNy0xLTEtMS0yNDYyNjM_84450690-0c3c-436e-9886-62d3791d52e0">4,544.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNy0zLTEtMS0yNDYyNjM_26c571e5-7db4-4f90-bfac-26573bfaac15">4,309.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOC0xLTEtMS0yNDYyNjM_264446b4-73ff-4e0b-8da1-99bd9e45a537">3,575.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOC0zLTEtMS0yNDYyNjM_5f8f4f08-61ad-4ada-83d7-89fd8fee4238">2,954.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOS0xLTEtMS0yNDYyNjM_8b01cde4-e06b-4946-ae68-c5d6782f2c01">20,811.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOS0zLTEtMS0yNDYyNjM_c59f5dea-69ea-4f67-81e4-19f7cad757e6">18,034.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTAtMS0xLTEtMjQ2MjYz_e068b5ac-d11f-472c-ad01-1181b2c55182">2,750.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTAtMy0xLTEtMjQ2MjYz_22548887-ad8f-476a-a253-4e3d71d73cc0">2,901.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTEtMS0xLTEtMjQ2MjYz_709e1125-7ec4-4875-bf12-5fa7ccdd7d11">4,073.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTEtMy0xLTEtMjQ2MjYz_28b737d0-18fb-4727-a4ba-45f3408d7b04">4,073.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTItMS0xLTEtMjQ2MjYz_0e900319-4dc3-4bbc-9f34-c0d7a11b1bd7">7,087.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTItMy0xLTEtMjQ2MjYz_2af41bc4-f4e2-41f8-baeb-a4ad49a2ccc7">7,206.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTMtMS0xLTEtMjQ2MjYz_066f41c8-08c6-4f8b-904e-a2fa80a764cf">3,406.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTMtMy0xLTEtMjQ2MjYz_d80e2f67-7f61-411f-a93d-ccc010c35322">2,792.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMC0xLTEtMjQ2MjYzL3RleHRyZWdpb246NTM4NmJiYjNhMjU2NGRiOTg4MDIxNTVlOWJmMGM2NjBfNjM_bc3fc5c1-8f07-4642-8a3c-41d3d8667938">10,486.0</ix:nonFraction> (2023) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMC0xLTEtMjQ2MjYzL3RleHRyZWdpb246NTM4NmJiYjNhMjU2NGRiOTg4MDIxNTVlOWJmMGM2NjBfNzU_1ca5a11d-9050-4064-8bd9-dc8a464f9c8d">10,233.4</ix:nonFraction> (2022)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMS0xLTEtMjQ2MjYz_14bc75a8-93be-4923-af0a-f37fd12bcc3f">10,546.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMy0xLTEtMjQ2MjYz_2a98d60c-40bd-459c-ab74-da82ad89b80d">10,144.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTUtMS0xLTEtMjQ2MjYz_76966e60-f532-403c-9861-1708e7f63819">4,488.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTUtMy0xLTEtMjQ2MjYz_4dc796e9-cdb5-48a7-b767-419678dd97b1">4,337.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTYtMS0xLTEtMjQ2MjYz_ca00794e-0cab-49bb-9be0-9cbfb4b2700f">53,163.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTYtMy0xLTEtMjQ2MjYz_1a30b059-6b34-4b1a-b7b8-0158dcf6e74d">49,489.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTktMS0xLTEtMjQ2MjYz_46f7f080-58b6-4cc3-a7e2-124ce3b087ae">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTktMy0xLTEtMjQ2MjYz_70803f64-645e-4450-8009-32891444ade2">1,501.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjAtMS0xLTEtMjQ2MjYz_f5f282c2-2acd-406b-8079-a8859156e4e1">2,015.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjAtMy0xLTEtMjQ2MjYz_6bb79a39-3932-49e5-96e7-3c487ef69657">1,930.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjEtMS0xLTEtMjQ2MjYz_4116fd9d-ea92-46de-9397-1f85b1b87c47">739.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjEtMy0xLTEtMjQ2MjYz_1b941a70-cae2-4da3-8d72-81ad40aa81fa">1,059.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjItMS0xLTEtMjQ2MjYz_cf10fdc8-9a2f-4485-82fb-119d1c5f83f4">9,529.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjItMy0xLTEtMjQ2MjYz_51916739-c9d0-4bf9-8ea0-fa6657c93029">8,784.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:DividendsPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjMtMS0xLTEtMjQ2MjYz_4f473932-9190-432a-baba-2813de8ee23e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjMtMy0xLTEtMjQ2MjYz_0f92ca19-c93a-4de2-9cc5-7ae1466abab2">1,017.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjQtMS0xLTEtMjQ2MjYz_124de0e1-c9b0-4d7c-b879-09a642da88eb">1,528.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjQtMy0xLTEtMjQ2MjYz_28c0d9e5-4d54-4bc1-ad5f-294e4638ccc3">475.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjUtMS0xLTEtMjQ2MjYz_0ab75143-c67c-4f43-acb9-8f74462a2d0d">2,193.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjUtMy0xLTEtMjQ2MjYz_7f1d78ca-ec53-4033-87b0-c798d37cde09">2,370.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjYtMS0xLTEtMjQ2MjYz_9dcc427b-9e68-4641-82a3-8c0e94a7e003">16,010.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjYtMy0xLTEtMjQ2MjYz_042077c3-a9f6-4478-b16a-8dd207913397">17,138.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjgtMS0xLTEtMjQ2MjYz_be6bd450-74d1-40ee-a9b9-c6de949bba67">18,880.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjgtMy0xLTEtMjQ2MjYz_47321fe3-026b-48a4-8a03-620438c15621">14,737.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjktMS0xLTEtMjQ2MjYz_c6ca8285-a194-4083-90f5-acd3d1e02d4d">1,313.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjktMy0xLTEtMjQ2MjYz_9f693368-bd1a-4f20-b478-4320ca35772e">1,305.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzAtMS0xLTEtMjQ2MjYz_b7a73c0f-00d3-41d3-a3c1-4a1481cffe5f">3,842.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzAtMy0xLTEtMjQ2MjYz_6a5216ce-9b8a-4d4a-9601-3668a2eb645b">3,709.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzItMS0xLTEtMjQ2MjYz_33abc0a0-d561-436a-b321-6a1e6048a684">1,822.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzItMy0xLTEtMjQ2MjYz_0753a8d9-6813-4493-8fd3-4fb2ac19e658">1,824.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzMtMS0xLTEtMjQ2MjYz_8eaed607-6aff-41b8-a4c5-d102b1788403">25,858.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzMtMy0xLTEtMjQ2MjYz_cca19963-cae1-4aa3-b7c5-7392efff6c46">21,576.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzQtMS0xLTEtMjQ2MjYz_aa6348db-59e6-4b8b-b635-36593c5cdbfb"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzQtMy0xLTEtMjQ2MjYz_84d8127c-0401-47ee-bd88-7d42161e355a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzYtMS0xLTEtMjQ2MjYz_f8ee7b3d-2cd0-4888-aefe-9a0e1ed7c653">593.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzYtMy0xLTEtMjQ2MjYz_16bdbbcd-69bd-4475-ba97-00f4125b6476">594.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzctMS0xLTEtMjQ2MjYz_6b561e73-f2c6-4098-8294-56619860883c">6,793.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzctMy0xLTEtMjQ2MjYz_088254fc-e1ef-4a43-8a15-56327f4206e3">6,921.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzgtMS0xLTEtMjQ2MjYz_cb980380-591e-4154-9822-9ac0a5d2f6e0">10,639.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzgtMy0xLTEtMjQ2MjYz_cb16c103-e91c-448b-b5a4-f2f08edb3199">10,042.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzktMS0xLTEtMjQ2MjYz_711d0919-34b7-48d8-a580-14812d0ea1d2">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzktMy0xLTEtMjQ2MjYz_7cc4a2a3-cedd-4db8-b3cf-de208890f760">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDAtMS0xLTEtMjQ2MjYz_968c77d4-a5ee-4c64-87ed-89eeb6042f58">3,777.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDAtMy0xLTEtMjQ2MjYz_107c4d27-3c39-4aba-84c7-f6207aa7ee40">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDEtMS0xLTEtMjQ2MjYz_363f02e9-a92a-4ffe-bc4d-6979f368b685">45.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDEtMy0xLTEtMjQ2MjYz_36d2e0ea-e9ba-46e7-bd1e-390b6843492b">50.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDItMS0xLTEtMjQ2MjYz_4bdf6bb9-f969-4349-8a58-875e1f90d657">11,190.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDItMy0xLTEtMjQ2MjYz_f249bcdc-c6b9-4501-add4-6b34dc1637ca">10,649.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDMtMS0xLTEtMjQ2MjYz_9a6c9131-794a-4209-8d1d-0a49f213e7e7">104.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDMtMy0xLTEtMjQ2MjYz_fb797967-4485-4714-b99b-d29ed246315f">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDQtMS0xLTEtMjQ2MjYz_1da68fc5-5347-4fa5-9334-b19ade40e41a">11,294.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDQtMy0xLTEtMjQ2MjYz_39b0c1d8-f8cb-4c39-bd7e-39162960f342">10,775.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDUtMS0xLTEtMjQ2MjYz_aa3054ca-3f5d-4385-8eca-d15c7684ee0f">53,163.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDUtMy0xLTEtMjQ2MjYz_d19e29dc-8f7f-4d66-9501-9f175f83176f">49,489.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xLTEtMS0yNDYyNjM_788a7be3-49ad-4a9b-8177-8ab03b92389f">954,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0zLTEtMS0yNDYyNjM_6fac41c9-0b7e-47fe-b985-afde23838f4f">596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b2d9ab3c1794f1d8b361cd95d702eb9_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy01LTEtMS0yNDYyNjM_22294fc6-2e9a-43c3-af65-99e3d443b4f6">6,833.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf9b65901614ec99ac3f7f3cf96ba0f_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy03LTEtMS0yNDYyNjM_de1befc8-9cc0-4f49-8845-e6c5dc267f86">8,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3db0e5f4479b4590a17a13660ba7120f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy05LTEtMS0yNDYyNjM_bc260d35-5241-4066-b9cd-3a20de8a06a5">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaef6a6bd5dd4d8bb6af6b8e7f16c197_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMS0xLTEtMjQ2MjYz_5ecec8f8-136e-4965-a078-6be6e5de478a">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7656e7caa28247f39bd611bc66416bd7_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7656e7caa28247f39bd611bc66416bd7_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95753ad64fa24dfc9db4020a919ed2e6_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNy0xLTEtMjQ2MjYz_3e7c5275-4244-4eac-859d-d3898e7fbbae">175.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNC03LTEtMS0yNDYyNjM_bec454cb-9dfa-4f46-a23d-cd758b50ceb9">1,902.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNC0xNy0xLTEtMjQ2MjYz_f1e7d27b-ffb9-4132-93d7-e1b6f7ed5617">36.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c601fdfc135468b9efa7eeeaaf2bbdc_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNS0xMS0xLTEtMjQ2MjYz_d62a331c-8844-492e-8b93-a75058ead15b">117.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xLTEtMS0yNDYyNjM_1f816b57-d65d-4cb6-8d72-50b059630207">5,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0zLTEtMS0yNDYyNjM_43626a72-2ffe-47fa-a2e9-4edf53ceb99c">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC03LTEtMS0yNDYyNjM_87026b9f-0b47-4d62-ba32-d3f7ce95214b">1,496.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d">5,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMS0xLTEtMjQ2MjYz_a775202d-4838-4fca-add6-3e5cc1ef7348">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMy0xLTEtMjQ2MjYz_2b33ce06-d3bb-4b5c-afcf-3388be7f2841">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtNS0xLTEtMjQ2MjYz_b14b3af3-35bb-4e66-b5eb-1cea49b13f70">278.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTEtNS0xLTEtMjQ2MjYz_1398406b-8aa1-496a-8086-806bf0f6da80">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTMtNy0xLTEtMjQ2MjYz_e1435be1-4812-4bb7-94be-06f030e0265c">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTMtMTctMS0xLTI0NjI2Mw_eb8c3bd0-ca03-4355-a459-f55cfd03b36e">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50a04715762e44a39f3f2505d74a6ea1_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMS0xLTEtMjQ2MjYz_3e3e6429-faa2-4ae1-a1b0-c473c2c742d9">950,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a04715762e44a39f3f2505d74a6ea1_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMy0xLTEtMjQ2MjYz_a45a66fd-97f2-410d-8540-f55665e36f45">594.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2186586b7322416183b886001b72303f_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtNS0xLTEtMjQ2MjYz_b977e204-b892-4282-9e51-4a4e28db0c5a">6,656.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3148a12fb5994593a755fff70b7d4470_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtNy0xLTEtMjQ2MjYz_2d68e6d0-6e59-4c81-865f-a8957ef33861">9,369.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16887cea932f44c3a6088e33ecfb7490_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtOS0xLTEtMjQ2MjYz_ddc3237d-bd23-493c-9667-74b96dabe760">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8048a6c27248afac7fffd0fe38b008_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTEtMS0xLTI0NjI2Mw_1f60487c-e214-4df1-8325-cd40b52455d8">4,225.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2097ff769544728b3e0e7f64451512e_I20220331" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2097ff769544728b3e0e7f64451512e_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3edace87bee46b0bf89263a4a4be3b1_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTctMS0xLTI0NjI2Mw_77e913b7-69a3-4dcd-8345-da4a010d72ad">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c67213efc434eb9ac796a4c1a04c8da_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMS0xLTEtMjQ2MjYz_29471574-c48a-4c86-a226-2662ab8b5216">950,632</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c67213efc434eb9ac796a4c1a04c8da_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMy0xLTEtMjQ2MjYz_18f45a21-d29f-4804-9977-4fec647e3e86">594.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8dbf8ede644257a18c8621fa65c557_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtNS0xLTEtMjQ2MjYz_d56962df-07dc-4f5e-a0ab-da90e2f519ef">6,921.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic813de36efc74513bd64da94a269adfe_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtNy0xLTEtMjQ2MjYz_aad3d355-5599-48f1-9770-8e741a78af5a">10,042.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i188c9e0e0deb45c7ac4c04ec58fafeae_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtOS0xLTEtMjQ2MjYz_076e4922-95a1-488b-af18-b51567230d55">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib68e310320e9466d8f5ba3eb98d90284_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTEtMS0xLTI0NjI2Mw_52012914-e3ae-4faf-8561-ca004d88d99f">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606">450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622">50.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637339e89f374f98959ff8ae6e6501d3_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTctMS0xLTI0NjI2Mw_81ff4ff1-edfd-4ad6-a64d-7441252e88ff">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTctNy0xLTEtMjQ2MjYz_ac9e5e50-5edf-4244-bc9b-0b35bdba40ba">1,344.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTctMTctMS0xLTI0NjI2Mw_1613c1aa-8a7b-4e54-852f-a0089caa2b5d">10.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439164f165d34e9bb97df6c5e992ff8b_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTgtMTEtMS0xLTI0NjI2Mw_68e57724-9011-4854-88c4-8f5b242b5808">67.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMS0xLTEtMjQ2MjYz_f04c4be6-f203-4fc6-8a7d-f3f5f5f68158">2,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMy0xLTEtMjQ2MjYz_c3a255b4-458b-404c-a9a6-aca995cc285e">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtNy0xLTEtMjQ2MjYz_4ad1acb4-b5a7-4ff8-bcaa-535bf74338a2">748.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2">2,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf">750.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271">2,299</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44">750.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMS0xLTEtMjQ2MjYz_1bc5b45c-40be-4c7d-80fd-1edc256e54d4">1,336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMy0xLTEtMjQ2MjYz_6b51c4e2-2321-4e17-860c-7ab6093ec0c0">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItNS0xLTEtMjQ2MjYz_d7319568-0c3b-4638-a582-e7135d42b747">259.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978">8.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjMtNS0xLTEtMjQ2MjYz_f4171d19-0669-4819-a386-c1bff24424a4">131.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtNy0xLTEtMjQ2MjYz_11fa4709-2198-431a-bf09-340837237a89">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtMTUtMS0xLTI0NjI2Mw_b5fcb825-25eb-4c3c-a678-6818d0849108">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtMTctMS0xLTI0NjI2Mw_0d5bf8b9-5945-4292-9b9b-0fffeadee1ad">31.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMS0xLTEtMjQ2MjYz_82c11aaa-d1af-4555-84cc-e9cdc7e64e9f">949,669</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMy0xLTEtMjQ2MjYz_8371939d-a520-40a2-a240-5baaa1bec655">593.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc91a78b7e994d8a828ad6accd7e7eb9_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtNS0xLTEtMjQ2MjYz_d4d2eb97-886f-4156-9de3-682b69ec1fa0">6,793.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33c470d29b348aaaf9cacc62407b9b1_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtNy0xLTEtMjQ2MjYz_77f5a716-e638-49c3-9a88-b8e9ad25dc53">10,639.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66f1bc66163b41baa48cbf1328b78bbc_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtOS0xLTEtMjQ2MjYz_62a20c12-20b4-4d66-98fe-0cfad6cf52b3">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ae9598be4a64cd69d5667e9e70ca761_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTEtMS0xLTI0NjI2Mw_12ff479e-a9f1-4133-869c-bb9915703ea0">3,777.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153592c1af1f4910bf06d43f543dcc71_I20230331" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f">402</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153592c1af1f4910bf06d43f543dcc71_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5">45.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e11d3a40394c318b16109c7c0fecf6_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTctMS0xLTI0NjI2Mw_73e00f8a-8fb7-4206-9a85-0abe1195be5c">104.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMTI2_62140bf1-54af-4617-829d-72564082bc91">2.50</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="i6e757fc239f4499e91acfaeb16335063_I20210531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMTQ5_8b558f14-6334-41d3-a565-122e863b8e37">5.00</ix:nonFraction> billion share repurchase program authorized in May 2021.</ix:footnote> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMy0xLTEtMS0yNDYyNjM_1cb1196f-b2a7-476a-ad77-9fff48b28189">1,344.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMy0zLTEtMS0yNDYyNjM_fd0af7f2-d0eb-4326-9599-26af0bab2156">1,902.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNi0xLTEtMS0yNDYyNjM_78bb8f7e-706f-4889-88b6-0be6743ff430">362.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNi0zLTEtMS0yNDYyNjM_a64d330d-fb2d-435c-872e-53b20137d6f9">435.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNy0xLTEtMS0yNDYyNjM_73069978-78c8-41af-b7b8-80622f2b8aea">559.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNy0zLTEtMS0yNDYyNjM_c225658b-78c8-463c-9dfb-84e0c435f472">506.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfOS0xLTEtMS0yNDYyNjM_f861715e-7cb3-4ed1-82a1-0e91f0d663b4">131.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfOS0zLTEtMS0yNDYyNjM_faa7a6ca-3c4a-4f94-b26c-65098180fdbd">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTEtMS0xLTEtMjQ2MjYz_61d8122b-780f-4db9-89e2-b8cc9b41b29a">14.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTEtMy0xLTEtMjQ2MjYz_a7347b8a-f80c-4dca-803e-00ca486ecb96">426.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTItMS0xLTEtMjQ2MjYz_b2c8f983-8368-425e-877d-6acfec10f1bd">105.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTItMy0xLTEtMjQ2MjYz_d446b70b-f1de-4b62-ba2e-572e092d8089">165.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTMtMS0xLTEtMjQ2MjYz_093a8526-d222-41d8-b34c-3c49344a6406">164.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTMtMy0xLTEtMjQ2MjYz_c4b1900c-dfeb-4bc6-ac96-fe17795922d0">34.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTQtMS0xLTEtMjQ2MjYz_8047e388-04d0-4f7c-9719-68a84bf9a8ba">168.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTQtMy0xLTEtMjQ2MjYz_b29713b0-ce66-4d91-92b3-d072b73c29f2">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTUtMS0xLTEtMjQ2MjYz_c27c3855-f29e-4753-b684-7a05707d70a1">1,730.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTUtMy0xLTEtMjQ2MjYz_57a195ff-02cc-4de3-b719-a956495077e2">2,523.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTctMS0xLTEtMjQ2MjYz_75d520d2-e6bc-414a-9ad0-b5dc6ec73b11">668.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTctMy0xLTEtMjQ2MjYz_5f07ba16-f660-4215-b4ab-3be7a1d85bf4">365.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTgtMS0xLTEtMjQ2MjYz_502b2ef7-9f88-4335-a4e2-1a02e4983a38">61.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTgtMy0xLTEtMjQ2MjYz_387fd437-ffbe-4b68-91c6-fc9cb5c943b0">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTktMS0xLTEtMjQ2MjYz_d4f7a058-ce42-4865-8d67-28d7ab97efed">23.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTktMy0xLTEtMjQ2MjYz_9530eda6-8c39-4a71-8fc9-ea56ac72ed36">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of and distributions from noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjAtMS0xLTEtMjQ2MjYz_ce512557-582a-484f-88d6-7b7f18732aa1">281.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjAtMy0xLTEtMjQ2MjYz_aeeb598f-2338-42d6-a3aa-f7088b1b9aa5">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjEtMS0xLTEtMjQ2MjYz_b4e62995-c80e-46da-bb02-951254778733">146.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjEtMy0xLTEtMjQ2MjYz_2a4333d3-b872-4709-b828-5d90c0ff82c7">116.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:PurchasesOfInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjQtMS0xLTEtMjQ2MjYz_94aebea1-ab55-4d8b-84b6-c9f870cc8aeb">235.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:PurchasesOfInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjQtMy0xLTEtMjQ2MjYz_0dc6ef2e-1766-4e93-8b08-8b41338fb3db">515.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjUtMS0xLTEtMjQ2MjYz_f5afc049-0334-4e59-8ee6-787370371a2c">40.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjUtMy0xLTEtMjQ2MjYz_0ae4af4f-94d3-4131-a384-67309fbaae4f">133.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjYtMS0xLTEtMjQ2MjYz_112d89e0-a568-4848-9bb1-aba8bc158c89">688.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjYtMy0xLTEtMjQ2MjYz_f047cdf3-bfed-4fdc-bdd9-ccfd5fdbbbf3">1,037.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjgtMS0xLTEtMjQ2MjYz_f073194e-3894-427f-aa5e-37bb83bba768">1,017.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjgtMy0xLTEtMjQ2MjYz_0ac262a1-884f-4ca4-804a-099465e850b5">885.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjktMS0xLTEtMjQ2MjYz_cea8427c-93a5-49ac-9957-dbf774a7765d">1,498.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjktMy0xLTEtMjQ2MjYz_cd1a3b88-7b68-4fa0-aef4-d016ace23aeb">499.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzAtMS0xLTEtMjQ2MjYz_7456ef5a-fe04-484a-a683-502c9b78d2a7">3,958.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzAtMy0xLTEtMjQ2MjYz_8d6c2e70-4b83-4014-8b45-2e7739c5ab5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzEtMS0xLTEtMjQ2MjYz_a2297274-6135-4405-a42b-ca82a06f483b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzEtMy0xLTEtMjQ2MjYz_1601a976-5109-4095-9c15-b7be2cb57218">710.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzItMS0xLTEtMjQ2MjYz_5c56a282-53bf-484a-a95d-349a875d7443">750.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzItMy0xLTEtMjQ2MjYz_38166322-fa38-4744-b245-eaf2e1d77247">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzQtMS0xLTEtMjQ2MjYz_06de43ab-4f09-4cdc-a543-2e8f3ef491d4">281.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzQtMy0xLTEtMjQ2MjYz_518bbd47-ca4b-4004-a170-bb491a65ed42">282.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by (Used for) Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzUtMS0xLTEtMjQ2MjYz_23b50dce-4887-4e93-b996-11049a2612e6">412.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzUtMy0xLTEtMjQ2MjYz_a42cbdc0-3350-449f-b230-2087dc485930">2,878.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzYtMS0xLTEtMjQ2MjYz_1f7ada39-7963-4743-a990-37a20911977a">24.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzYtMy0xLTEtMjQ2MjYz_ede130d2-8e6e-4c92-a311-1a2985751ac8">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzgtMS0xLTEtMjQ2MjYz_5f9bb384-c384-4247-99db-a78c57df9829">1,478.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzgtMy0xLTEtMjQ2MjYz_70d3b02d-85d9-410a-8cca-c538a5b0e9ab">1,359.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzktMS0xLTEtMjQ2MjYz_c766b674-199e-4172-8e0a-0387bdc85165">2,067.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7699e9bf7f941dcb048f29c3aada3b7_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzktMy0xLTEtMjQ2MjYz_06607aca-f1b6-4c3b-ac89-9739368ef35e">3,818.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at March 31</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNDAtMS0xLTEtMjQ2MjYz_3daf9465-9abc-4774-8be2-902bb6144c31">3,545.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88d6c314da94d23b9e30802e9728044_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNDAtMy0xLTEtMjQ2MjYz_2d9b117b-9d86-49cf-8151-4adbcfd3f2a8">2,459.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDE2OQ_4d8ccd0e-4cc2-4f68-9451-f016ec87add5" continuedAt="i5a5ade1977da412c89cfce0719ef018d" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i5a5ade1977da412c89cfce0719ef018d" continuedAt="ia75f40e47a294defb1cbecab42570633"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. We issued our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDE2NA_2f45f1f4-9e51-48d4-83b9-9ec5bf299af1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D includes the initial costs and development milestones incurred related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNQ_de891727-b040-410a-808b-4693400f6c97" continuedAt="if2cd70fb9ec74d4d9b1fd84de970907d" escape="true">Reclassifications</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia75f40e47a294defb1cbecab42570633"><ix:continuation id="if2cd70fb9ec74d4d9b1fd84de970907d">Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. Development milestone payments related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, were previously included in cash flows from operating activities in the consolidated condensed statements of cash flows and are now included in purchases of IPR&amp;D in cash flows from investing activities.</ix:continuation> The reclassification resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $<ix:nonFraction unitRef="usd" contextRef="ib386950c303c4cfa991af56051f481c7_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNA_381e0f0c-43b2-429e-ae4f-48261dfe27c0"><ix:nonFraction unitRef="usd" contextRef="ib386950c303c4cfa991af56051f481c7_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNA_422bc3d2-080e-4a50-9ecc-ea94a50af223">23.8</ix:nonFraction></ix:nonFraction>&#160;million for the three months ended March 31, 2022.</ix:continuation> </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzcwMA_7ea1bef3-783c-44a4-9d3b-e75ec8b59297" continuedAt="i31aa085433fb4159aa3ea68490ee34f0" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i31aa085433fb4159aa3ea68490ee34f0" continuedAt="iba7898f1b4974b3ba80568d2424835ec"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzY5NQ_c8f17dcd-049a-4b4d-aa46-d11f1f6ff801" continuedAt="i4482c6236d464e3db91ddaf22a662006" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118b413e750a419a8eea249e9dec5ea8_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMi0xLTEtMS0yNDYyNjM_25bcd39b-25ac-43ef-8ce6-efa0ae234c6c">6,238.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f70762797b4c7eb12579a57e4a0f1f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMi0zLTEtMS0yNDYyNjM_b4bbc33d-8686-42d7-a427-4e3957733c6c">7,132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41563e4306144d7db1ae5fab5a13d025_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMy0xLTEtMS0yNDYyNjM_364c9fc0-37b6-427d-a523-cdafbcf27bfc">721.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45726ea3ba342708ad76343e7d8ea9a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMy0zLTEtMS0yNDYyNjM_acaddd68-be75-4433-a6c4-d882f29fd810">677.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfNC0xLTEtMS0yNDYyNjM_4e9c6d69-5c4c-42de-aaab-8a2b6e7cbb10">6,960.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfNC0zLTEtMS0yNDYyNjM_3f6a212d-bae7-4c34-a834-bbe80896f748">7,810.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="i776dd251590543c2aa2cb51a4dab931f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMjM3_38a499d2-eb89-4a59-8795-789769e7e70e">25.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1de368b269ea4b33baf0dc1ce490d43c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfNTQ5NzU1ODE3Njk2_300409f4-1fe4-4d10-a97f-5459f9d8a217">53.2</ix:nonFraction> million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than <ix:nonFraction unitRef="number" contextRef="i8ba05d67547242b28419ed4e7793321c_D20230101-20230331" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMTQ3Mw_2b2acf87-a275-492c-bfef-bde55fb58e2d"><ix:nonFraction unitRef="number" contextRef="if0cc6e06de26466c90d397554c65af18_D20220101-20220331" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMTQ3Mw_73cb78ae-4328-42eb-8b9d-5123c6e00b30">1</ix:nonFraction></ix:nonFraction> percent of U.S. revenue during each of the three months ended March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzY5Ng_0da280c4-6741-441c-99eb-9ae218a6ab08" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjdhYTQ3N2RhZjQyNTRlOWJhNjYwMWUwODZhYTU5YjIyL3RhYmxlcmFuZ2U6N2FhNDc3ZGFmNDI1NGU5YmE2NjAxZTA4NmFhNTliMjJfMS0xLTEtMS0yNDYyNjM_c1b22cc7-acb2-4901-a1a4-c390614e9f21">220.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjdhYTQ3N2RhZjQyNTRlOWJhNjYwMWUwODZhYTU5YjIyL3RhYmxlcmFuZ2U6N2FhNDc3ZGFmNDI1NGU5YmE2NjAxZTA4NmFhNTliMjJfMS0zLTEtMS0yNDYyNjM_dafa893e-946a-4f1f-ac7a-5cea7ffef3f5">219.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba7898f1b4974b3ba80568d2424835ec" continuedAt="ibdc8b37193b642feb06f32306d60232c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="i4482c6236d464e3db91ddaf22a662006" continuedAt="ie4b046759e2a4d1492156a97b0f4c078"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March&#160;31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0d2e9299804c05b2243243ee5f298f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0xLTEtMS0yNDYyNjM_91bd3301-19e3-47fa-b0af-5930dd810c78">1,547.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3800138a064caf84059e7b7ac1f59f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0yLTEtMS0yNDYyNjM_0d6e8cab-e316-450d-9583-fcae6a22f5fb">429.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e8033ea6754341b21a71b5dd3e785c_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0zLTEtMS0yNDYyNjM_47861f79-cb3f-4203-b4ea-cc5f773abaf6">1,977.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dd59e0fdc74287873fca650e145c15_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS01LTEtMS0yNDYyNjM_ad1c42ac-fcc3-4377-83c0-9a6461f643fd">1,313.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4e39b3439c480c8742d89f8399bc82_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS02LTEtMS0yNDYyNjM_a64ec98a-5e48-46ce-b554-04e9502ae609">427.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13290ff47804307a44e2f065e33dd7d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS03LTEtMS0yNDYyNjM_e293b33e-875d-4329-a1f7-0eee1a234f51">1,741.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac33e8897674b85a6950df08eee5bf8_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0xLTEtMS0yNDYyNjM_7a4f1b5f-23a4-49b1-846a-8ec7f02b939e">329.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a28a52e5fa34f38a6ecc947140b6edb_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0yLTEtMS0yNDYyNjM_7f4e4454-5c4e-4064-bf27-84d5d15a24e1">248.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0zLTEtMS0yNDYyNjM_9e453744-0f16-4d42-b455-2a333f27de56">577.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a6d8bc4d434540ad95d77f973fa070_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi01LTEtMS0yNDYyNjM_9ca06592-571a-407a-9013-013a2723132a">229.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d89a91c0fbb4dd195707004ab1a00b9_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi02LTEtMS0yNDYyNjM_96db241f-d392-4b42-9c87-79391384b9b8">189.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi03LTEtMS0yNDYyNjM_d56e4fa9-e4a9-46e5-89e4-4f3cf62afa31">419.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4783bd0e08d47d29ab78b3d697d290f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0xLTEtMS0yNjI2MzA_7dcbc679-3cd6-4d5f-baf9-a39c03a9043d">536.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c7662e4b8c740ebba1d408fa1765201_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0yLTEtMS0yNjI2MzA_2e2387b7-322d-47ed-a89c-2d876542e2e1">32.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97119da1943c4d1e95f0e996e9f315be_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0zLTEtMS0yNjI2MzA_fbfd47e2-c779-45d4-a86e-a30cf2ee8110">568.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c27dd4f47b47239694dc03b4ecc6ad_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy01LTEtMS0yNjI2MzA_4839194a-8849-4db9-a634-10ec16e24087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e4c56100484d70a675bd288c597049_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy02LTEtMS0yNjI2MzA_48807874-5904-43e5-8edb-54ca7d4cb540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2f9585c7204b33beb2bc33724774a0_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy03LTEtMS0yNjI2MzA_a1b5c104-e84c-4ae0-b188-26b7270ae6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16fef32b8fb476596fe6c4d0bb25380_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0xLTEtMS0yNDYyNjM_9af69c5f-6ae4-4861-a3f2-c02c12af93eb">271.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811218a96d2b41c0a71ad7a4b77e56b2_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0yLTEtMS0yNDYyNjM_2633197c-00f8-4c6b-b8c5-141db2f2c484">189.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b94ba9dd63247d5b32ffa10006a021e_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0zLTEtMS0yNDYyNjM_37d569ba-6277-4e32-a78c-c7be40cad9a4">460.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id898a8a22f0e4880a5338b8467984755_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy01LTEtMS0yNDYyNjM_1f92bd7c-48f7-45c1-be66-56349fef00c3">368.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3450a514000e4564aed94e9856bd66d6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy02LTEtMS0yNDYyNjM_a4d14368-8a84-4d7c-8d3a-093826e46cd2">249.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bd2ba8150f4e69a8256ef87cc94d2d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy03LTEtMS0yNDYyNjM_cad1b61f-cf0d-4563-b05a-e7cda99a015c">618.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb86385cc8eb4bed91738b3eec15d109_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0xLTEtMS0yNDYyNjM_bda70036-53fe-444a-959e-bf43c8c75afd">198.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5f5c213bf74ee680df8883531a880e_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0yLTEtMS0yNDYyNjM_03df56a2-3fbc-4c47-96df-6272a1edde26">53.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ac73e33e864d3d85f05e179d6e0ab5_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0zLTEtMS0yNDYyNjM_f1922377-d703-4160-8713-ea75042b7110">252.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93975c00ca0e44ba99e88b2a02696fbb_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC01LTEtMS0yNDYyNjM_7d83d022-02c9-4fc5-8faa-8fb6fad10e60">190.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41870e267fbe402dad822ec24c06b44f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC02LTEtMS0yNDYyNjM_138664e6-e6d7-4ee2-b2e5-ef61bcab0fbf">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39805ee81eec439aa8c2e397f5508410_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC03LTEtMS0yNDYyNjM_190cf235-7e69-41a6-9f4d-aad939944e12">273.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4655d36440574fbeab0c91fc7b019703_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0xLTEtMS0yNDYyNjM_38f92685-72b5-4d2e-8ca4-17b7cfaf438e">135.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44114472bba24a3b91861ccdbb5b23ed_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0yLTEtMS0yNDYyNjM_8e0bf244-69b8-4ccc-babc-be5b451bbbd2">73.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0zLTEtMS0yNDYyNjM_9f3ac19a-040a-4f01-a141-9eab10f9514d">209.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1aed3d8f0c4cb293c37cdc3196c8d8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS01LTEtMS0yNDYyNjM_51492cfe-3a50-425c-bf6f-32ac44a8be2e">119.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eee894daf9648e981d2c1b49f7448e5_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS02LTEtMS0yNDYyNjM_fc60ed39-ce2a-4791-99ec-85be7f0bdea6">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS03LTEtMS0yNDYyNjM_62d820c8-b9e1-4212-9602-4b275f323165">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ff4b5d9df8493fbd95a0e88fe1cc78_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMS0xLTEtMjQ2MjYz_efbf96a7-31a9-443e-8d6a-24451de60840">56.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dc93a102494bcdb03aacc7bbba37f8_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMi0xLTEtMjQ2MjYz_c9832a14-b3d7-4fd3-ab7b-43c5a69dbf58">89.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3506079381447bd842f668fa1edf8bc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMy0xLTEtMjQ2MjYz_8bbb8e98-db84-424b-84f1-b20ba24bd64a">145.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67d2dd261224805ac90f2f1b66659e9_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNS0xLTEtMjQ2MjYz_6e33b2af-205f-4a2f-b1b2-8766ea718787">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2548d402f8348a19d3cdabfabed7bbd_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNi0xLTEtMjQ2MjYz_2b766747-0a8e-4ad6-821c-5d73d69f2b0b">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ee45c4c43e47b6a8bf88847481e710_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNy0xLTEtMjQ2MjYz_c10d61cd-8e58-41d2-bd61-4ac7482bfd12">144.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78c1dab52df4fad8c34b85682e70bf9_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMS0xLTEtMjQ2MjYz_f344aafc-3fb1-4628-b863-07ad5b422f93">3,075.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93368f3f449f4b9fbf16c9329f7056bc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMi0xLTEtMjQ2MjYz_e7d512cc-722f-45bd-b648-f53c1c78b174">1,115.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc66ce8e6de454cac39d92a460a5da5_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMy0xLTEtMjQ2MjYz_21b57dbe-29f5-4234-9eda-8d954429e108">4,190.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5306573ee5f40fe87015d1bead33c79_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNS0xLTEtMjQ2MjYz_235cf968-2d6a-4611-84de-8cee5abd0b88">2,276.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67961791f67f455a9e83bdd66879e1e3_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNi0xLTEtMjQ2MjYz_633ec603-f07c-4c8e-a720-205fb1c78f0c">1,111.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7827ab11ad634535a354ffe9397dee6a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNy0xLTEtMjQ2MjYz_7ec90077-5c47-4cf8-b189-85b10e791253">3,388.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9800b2536c0a4887b5ab9dd03310e3d5_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMS0xLTEtMjQ2MjYz_382857e1-8114-44cf-b17e-1d90c08b9c8a">461.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4913832cdf6c42bfa9d7047743a02c46_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMi0xLTEtMjQ2MjYz_ba4f63a1-1a27-473c-a52a-ef2814690ce2">289.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7fe4b4cb9d4e1eb78bf2b8fc45025b_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMy0xLTEtMjQ2MjYz_f64be617-b3d3-4162-81c2-b507ca9ecc05">750.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7380748fafce4bbeb79b3fb7212654a4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNS0xLTEtMjQ2MjYz_4fef8c67-2e87-4942-a68f-c529843c968f">301.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8425fbfc64303ae4dd3c6a3664599_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNi0xLTEtMjQ2MjYz_34192a5f-809d-446c-a8f2-443939a0865b">167.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4e2ee8a2d34917bdcc965e7626ef0e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNy0xLTEtMjQ2MjYz_b80155a0-fab3-4fc8-8a48-a7c5b7ec0996">469.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56eaf4a89a44762b2ad02723519711d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMS0xLTEtMjQ2MjYz_5ba0b9fd-3532-4d45-b8a8-918e6a9930a0">100.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a88ab4c21743beb4653082449b8794_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMi0xLTEtMjQ2MjYz_ed991db9-a915-4fce-aa98-08230c171b7b">136.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ec6bedcbf8431996d351090aeb835f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMy0xLTEtMjQ2MjYz_6f7ece45-2497-4d7b-afc6-d88a1094cd1e">236.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec65e20bbe8429d8374bab94fff526d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNS0xLTEtMjQ2MjYz_5a838db2-e3d3-4097-b7d6-a1222a724d17">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ee755aa5ec43ce8d7d5b0801744953_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNi0xLTEtMjQ2MjYz_ad9cffde-721f-44d7-aae0-be65316ca4ef">151.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a7138a41b64af0b3d3bffc680013e2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNy0xLTEtMjQ2MjYz_42b815bf-d196-4a91-bb37-afdf6f20c657">230.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4850b75145f14e119182161edd48e156_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMS0xLTEtMjQ2MjYz_7efb9b0e-3850-4eeb-bff2-2ad4f94cc932">118.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eea234886e74de6bc9398e17900aabf_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMi0xLTEtMjQ2MjYz_8f9ff7c5-1fa3-40df-a577-dfd9693145cc">11.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c07348838844f9927b4f1042344fc8_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMy0xLTEtMjQ2MjYz_28317433-e828-4d29-818b-e208ef410cac">129.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54de819fdc34f43a6a60f819b305005_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNS0xLTEtMjQ2MjYz_c53e426f-299c-4538-9ebd-8c8ff0a29766">109.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia728bce450914e0ab2648a04596d1d35_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNi0xLTEtMjQ2MjYz_4ba53b70-ac87-447e-8359-83dca26f4277">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d1f99b0aa548e694ca63f72c14567a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNy0xLTEtMjQ2MjYz_638431ea-be67-4973-85b0-c03935d60e7d">122.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9140b6e5e49c43dbb2dbd87cb8181bbd_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMS0xLTEtMjQ2MjYz_24ef3ba8-8060-487a-adf4-a3a173b327a4">20.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7070b3ba7a54482a84f745990995ccdd_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMi0xLTEtMjQ2MjYz_21ad0c41-da9a-4df1-8d55-1390db9250e6">38.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia688e1f2870e4ce7ad9e8932949035dc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMy0xLTEtMjQ2MjYz_f0223546-1476-4ba6-af7b-89d14811d2fa">58.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82241d17ed4a128f5799c977329bf4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNS0xLTEtMjQ2MjYz_5d372309-d5f8-442f-b8f4-3e6ee25873a0">254.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79547491309b4e5393994557f1671667_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNi0xLTEtMjQ2MjYz_bdf64f9e-8329-4066-bbb1-d1eb4e70470d">89.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5886df3058224ce1aa56b3af9d1a1dc3_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNy0xLTEtMjQ2MjYz_c2b5084d-556a-483d-9268-8dc774419e3a">343.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65a58b1573343a39b71e05ab32cc416_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMS0xLTEtMjQ2MjYz_7be5e06a-337c-4ea5-8dba-f0f6288b01c7">52.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecbc3c01d7643c3888c9bb26a95292d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMi0xLTEtMjQ2MjYz_9423e3b1-4cdc-4f47-94c6-d4ef67a1edc7">127.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d13f666ff449d7a621398eaa0ef2d1_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMy0xLTEtMjQ2MjYz_9d3466c0-a6ee-4e49-817d-597f164b37d3">180.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74abf3ad08e8479fbc7b50f9e8bccaf1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNS0xLTEtMjQ2MjYz_1257459e-806f-40cb-9705-a5bd82c7520c">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49343f97cd6f47108d6fd5848cd54864_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNi0xLTEtMjQ2MjYz_53906c9a-1a2f-4b49-80a8-6cdba5ff56ed">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808d86cf633c44669b50bbdecdb33551_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNy0xLTEtMjQ2MjYz_b7d2b8e1-dca4-4363-bfb5-4a82a6f85eb9">186.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795c0bdc41294080907d9ea59944ead4_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMS0xLTEtMjQ2MjYz_8495d9a6-529c-4a58-b00c-3beb030b279a">753.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df5f251db6448df818fab73530a644a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMi0xLTEtMjQ2MjYz_fc8eebe3-2aab-4c56-9f1b-f120f7d9f418">602.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417d453530f54ca0b2209fa1faf5306d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMy0xLTEtMjQ2MjYz_7fc262ee-6acd-4334-b105-be3be78a9342">1,356.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29c502013aa40aeb696d62e85288626_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNS0xLTEtMjQ2MjYz_5b460de1-d453-4dc7-8efa-ceffd915e058">783.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff009e5b94684162a6c0b8401522ef69_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNi0xLTEtMjQ2MjYz_d159cf1c-d751-49a4-8a8c-d08b9d82065e">569.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id944e42934f04a7f867c267ec9717aff_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNy0xLTEtMjQ2MjYz_86f1f8ad-b0f0-46dd-ba6a-9aedd5567669">1,353.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5231a969184a4364a058bc909f82fe8b_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMS0xLTEtMjQ2MjYz_608e1a61-9200-4506-aa07-5fa90f1c9de6">312.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf70417fae9467fa9f5e6435d854dfd_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMi0xLTEtMjQ2MjYz_b1eef842-5aa5-42b2-8499-bc720eee452a">214.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d99551c34a4e858ad1c4e0502e76dc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMy0xLTEtMjQ2MjYz_7c13d3d3-d9aa-471b-8475-dfd1c09abebf">527.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18890600eb448588714f8ad882431ea_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNS0xLTEtMjQ2MjYz_8406ff0e-7c2a-4d27-b0e9-9c89bca77550">307.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69246a482ad44038a5cc2d5c54873ae2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNi0xLTEtMjQ2MjYz_75ed85bd-44e4-49b9-bb3f-9308f79556bc">180.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58a7cb2a4a0485d96deb76ac57931ab_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNy0xLTEtMjQ2MjYz_4e21eb01-2a78-4223-8fe0-aedb01f5db66">488.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f65318bd79648b998f3e5df408c0412_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMS0xLTEtMjQ2MjYz_f5460905-16a2-4811-9b3d-e459f0387de3">42.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3213310f015747d080af9a1ff48b5ad8_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMi0xLTEtMjQ2MjYz_eaac88ea-875e-4c5b-9e17-9d68edf44e13">186.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMy0xLTEtMjQ2MjYz_88bd67c2-172b-409d-a6fd-e4d07376a1e4">228.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16329625fa6f44a6a1c064ac7d4ec9dc_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNS0xLTEtMjQ2MjYz_cd26a57d-024c-45e0-911f-55c3a49e3a42">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153b28fedc304d3e8ffde2bdf7f073c5_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNi0xLTEtMjQ2MjYz_1dc437dd-c214-464c-ac13-138bdf579a4d">184.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNy0xLTEtMjQ2MjYz_bb7172ff-48cd-4d93-87a9-48088e92bc32">255.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0385f2c26b2f4d3e8fb95aaa85d8bc2a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMS0xLTEtMjQ2MjYz_2ac4a9da-40f3-4f02-a901-3108f394b63f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e0e3a0711046c39391d2d3cf445882_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMi0xLTEtMjQ2MjYz_da1fe737-acc4-445f-a9be-cadb2c0c5c15">22.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6d1650065e4c768674409d266dca06_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMy0xLTEtMjQ2MjYz_47e8caa2-ecd4-41b9-b587-108fce0418e7">22.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31d09044e85e405bae8df74949e8712b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNS0xLTEtMjQ2MjYz_14438f4c-40fb-42a0-b464-b1b81eee6c43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e50725af9a34d7a98f04d67cb123a30_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNi0xLTEtMjQ2MjYz_9b9188c4-c746-427b-8665-60859ebbda69">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e7240880ac4123a3894cbb650d0172_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNy0xLTEtMjQ2MjYz_0728483a-77c2-4e59-8974-ebd05ede5631">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4c963f8e9e4b4db60302cf2284c762_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMS0xLTEtMjQ2MjYz_2db73657-dce6-4b24-81a9-c538172ee262">354.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269467655eda495eb32d7ecade1d1990_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMi0xLTEtMjQ2MjYz_2b2202aa-e24b-40c1-8638-ad71ffb00ced">423.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b2366367f84820bf8ace8d801f1c7d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMy0xLTEtMjQ2MjYz_78c2ae4d-d768-45b8-ba66-6b81a58a034d">777.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96f23fe8818410dbe8e8a34a66455ee_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNS0xLTEtMjQ2MjYz_abef739f-1f3e-407b-9026-507f8e36b915">378.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957ffa2d2be34dee93676a024e802aa2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNi0xLTEtMjQ2MjYz_feb61b3a-039b-418b-be5b-c58fe54fd878">369.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef141b8c87343e8a397e0bf1e526680_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNy0xLTEtMjQ2MjYz_8bed7b88-2e74-4e81-8799-f1e843695348">748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c7539f3edc4efaa041fe0e65fdc6ab_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMS0xLTEtMjQ2MjYz_3731e66c-b7a1-4900-aebd-3661905c6b7f">108.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367924f0fc6a4ee6b301ed3d61eb59d9_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMi0xLTEtMjQ2MjYz_bdb79d14-902d-4f27-943b-b68b040e290f">45.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3f5be448854af1bc7435c75e8fd14a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMy0xLTEtMjQ2MjYz_827cc052-9570-48b0-8ef5-843daf9e28b7">154.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf75f8c30aff470988cc19ce904d3fe4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNS0xLTEtMjQ2MjYz_b0e03b28-9fd7-4965-b3ad-cb126a7f2ee3">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf7bba33b974a30af558c8ffb0eff76_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNi0xLTEtMjQ2MjYz_a1564aec-e044-4f86-bd55-ffe88835f20c">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab868bc977a9479b97ce8c1d76008a42_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNy0xLTEtMjQ2MjYz_f459abdb-7676-4091-b4c6-ac58052415a6">149.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b5d56ba3c84300a4655bfc90d63682_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMS0xLTEtMjQ2MjYz_4c997dc8-d727-4427-954d-337c7585a749">35.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da9824d115d4642b33d62110647bc25_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMi0xLTEtMjQ2MjYz_e76b7996-6ad6-4196-b5b3-aec90c9b6257">170.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f0a7c14210458f99c56d32fab18cae_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMy0xLTEtMjQ2MjYz_9abccb3f-54bb-4ad8-bfd4-4675e84b6445">206.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0577f0dc20c64f89a47c8c6dea223e7e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNS0xLTEtMjQ2MjYz_70c46110-63a5-4252-bbf1-fa8c5a10fa3e">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9816923eb3343fcb3c969e22954983c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNi0xLTEtMjQ2MjYz_a6a50c64-eced-4bca-b863-24249fd14d34">203.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974f97a08b2246b99fad08fcff9d907b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNy0xLTEtMjQ2MjYz_e11645b3-351e-4ae5-889e-51425cdd20fb">248.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b0c35171b54d0e8199472f276c3efd_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMS0xLTEtMjQ2MjYz_45078688-8d95-4bf1-ac02-40a1c50bf478">144.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0c12862e7a4f5295df6787910e6d95_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMi0xLTEtMjQ2MjYz_e6d7744b-02f4-4705-a246-8e76e95c5344">216.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf02a47c1f054f6cab10a1350b11ca78_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMy0xLTEtMjQ2MjYz_8fa2722d-cafc-4d0f-b496-ebd19e6d1d7b">360.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3846c71ac29e4037bc0323344ed7bf33_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNS0xLTEtMjQ2MjYz_aab88bf3-7d2f-4937-883c-32e3f55adf9d">153.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1943dbb4c94472d9c47d4588395f87d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNi0xLTEtMjQ2MjYz_174ec021-e1eb-4343-9264-4d32d09397e5">244.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c58df1da1424666b72028b96c96e821_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNy0xLTEtMjQ2MjYz_408a52c4-ceb4-4ce1-9028-f0489755a968">397.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948eeabb45154555a0aa21e3c99f533f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMS0xLTEtMjQ2MjYz_746f0d85-057f-4ff9-ae91-8c3ebe6f84b2">70.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696edc9f8e1843b28ed762a1347db26b_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMi0xLTEtMjQ2MjYz_f9314ee1-7542-4030-839e-bc4bfbe03236">51.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703ac11468d54f86bf1f951723906604_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMy0xLTEtMjQ2MjYz_00e0f158-71f9-45b3-9e66-09cf69fc60f4">122.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb41e587fef4c8aaeee5a0e8d565098_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNS0xLTEtMjQ2MjYz_827892fb-94f5-4b14-b152-0e388527307b">70.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7157b6266b57432189b37acac4c62b1d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNi0xLTEtMjQ2MjYz_4bbc7460-0eda-43d2-802b-b22f71a3d875">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f7663963954d37992ed44ffb330868_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNy0xLTEtMjQ2MjYz_2a3c1cf9-bc1f-414c-b0b7-be05642793de">137.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6109f92c24420fb119449586e2d751_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMS0xLTEtMjQ2MjYz_0964be4e-6138-4029-9548-1bf58b47aff3">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f6d319daa54e91842b67dd9ad0ca0d_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMi0xLTEtMjQ2MjYz_85c658bf-1e30-4acc-83ed-b2fe37d1bbe3">92.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a86976547184c9aa6f46daea7912cde_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMy0xLTEtMjQ2MjYz_d8c6892d-6d44-4e8b-b171-8048dc682515">100.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0798771ccf6491d8bf4e3a529a99992_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNS0xLTEtMjQ2MjYz_4a13dcee-1e6e-4d72-8ca5-5ffcbe0a5286">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bebcb77e7cc46c4a0f6232d59204728_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNi0xLTEtMjQ2MjYz_89789ade-bcac-4073-bf13-b2da6ed5f6f6">210.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afe04177a85445183aee9c1f1a104cf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNy0xLTEtMjQ2MjYz_bdc340bd-fb25-4f39-a132-9dac30791e67">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b8c13f78ef499fa5e3a82aa88d9a10_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMS0xLTEtMjYwMDQ5_5eff7fb4-9b57-4108-91c5-40aed2e6fc2f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd5a2af9de84cfc812225bc521e17bd_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMi0xLTEtMjYwMDQ5_2607743a-f17e-4b70-a489-90d2d75512db">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMy0xLTEtMjYwMDQ5_80a5dfb5-0969-489a-bbbd-911f64c3d22b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf0b36bab2d459389f2adb7bf797fc3_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNS0xLTEtMjYwMDQ5_c06335c3-2540-4784-9f58-cb144794bdf8">1,455.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3508798f670645c0af6c4e615ca44088_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNi0xLTEtMjYwMDQ5_760afdf2-316e-4ea8-81fe-ad800edb53c0">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNy0xLTEtMjYwMDQ5_82b8383e-2440-4a9d-b12a-d10afb102b11">1,469.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a904aef68a4f45b2b86bf8b5576e30_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMS0xLTEtMjQ2MjYz_02b03305-1037-4ad7-b245-02dd000fd17f">30.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5103a4e13b1f49fcb43c76f4ef1e1696_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMi0xLTEtMjQ2MjYz_ade5b4b5-6174-4d29-8320-de19911eede3">22.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e758f49518403ab2b0c55235561aa3_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMy0xLTEtMjQ2MjYz_eeec99d1-19be-49cd-bcf7-3886899c5675">52.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if51e24ac8e8b450599cdde81c0c8a8db_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNS0xLTEtMjQ2MjYz_394543f7-1648-474d-9bd4-5a4b630841d3">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b13b0180da45dabb7f682f854e3394_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNi0xLTEtMjQ2MjYz_217a33e0-f1ea-4041-817f-cfbd3e758b8f">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd283be94b6d4f30af788ea943b170d1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNy0xLTEtMjQ2MjYz_b4c5953a-2ef2-495d-b998-89797c21ed4a">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ac892edbf94f62919a942916235192_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMS0xLTEtMjQ2MjYz_3225636e-7a9b-4783-9207-e6607559b913">108.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic522b3c6168f49769bd3610b3cfb9fd2_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMi0xLTEtMjQ2MjYz_76a4e0a2-eb32-4cf5-aeef-a87cd0e7b4b8">166.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394796b389834a5d8a4a6a52018ea5e4_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMy0xLTEtMjQ2MjYz_7e12d57a-9345-4d53-ad7d-098275aaf4af">275.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf536f227695468d8955c509d0cac28a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNS0xLTEtMjQ2MjYz_bd41a722-7d38-4868-a656-483acb558b0f">1,582.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbeb1df59694ca1a5121853310fe013_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNi0xLTEtMjQ2MjYz_d044435f-49af-4026-86ba-f4bac0e63e6e">340.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd8ff202c66402cb6acdcfb73f456e0_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNy0xLTEtMjQ2MjYz_3c4d2003-22d1-4165-ab50-ce115638e684">1,923.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMS0xLTEtMjQ2MjYz_ef5e269d-9a55-40b0-80a7-2be2614970bd">4,436.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b193d99bd84b609a946006de3ff5b5_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMi0xLTEtMjQ2MjYz_8e9984e0-9689-4c28-afc5-0f35ae05a7ec">2,523.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMy0xLTEtMjQ2MjYz_05afefe8-b62c-4249-bcf0-cc72a3a3cdbb">6,960.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNS0xLTEtMjQ2MjYz_129288ed-9f93-4b49-b90f-0d9f2d71d58e">5,174.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce552cbf23a4e5e87ebb11e406b4c7c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNi0xLTEtMjQ2MjYz_4c6a9d5d-92e6-4d94-b8ad-03d2a081d220">2,635.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNy0xLTEtMjQ2MjYz_59ea5ba3-491d-42c9-be30-1d5f114d3b32">7,810.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibdc8b37193b642feb06f32306d60232c"><ix:continuation id="ie4b046759e2a4d1492156a97b0f4c078"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfMy0xLTEtMS0yNDYyNjM_0b564e47-c010-4508-b09a-020e27d83bfe">4,436.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfMy0zLTEtMS0yNDYyNjM_0580a056-1f86-4f1c-b7f1-1b8b544ccc10">5,174.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f75bb32e91f4c8c914a357a961a505e_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNC0xLTEtMS0yNDYyNjM_51ae4351-1c81-4463-bb7c-1e6b85b3b95f">1,090.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591aacf4b21b4fb6af4a84ef723f602d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNC0zLTEtMS0yNDYyNjM_00eed427-fd5a-40da-8e93-813b7f67a1e7">1,067.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e43da972920406cb8cec2e4ac4f504a_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNS0xLTEtMS0yNDYyNjM_43f294c3-c35d-4707-955c-cbc2402cb8b5">387.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546300f8490545128a0251b2fdd2206b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNS0zLTEtMS0yNDYyNjM_925cccb0-aca9-4f42-bebb-c1c327f350e4">410.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3357638f0d364662b153eab67fa8550f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNi0xLTEtMS0yNDYyNjM_34d6cdf2-fce9-4b69-8345-9f5b9c46d8d7">372.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91090e6b25c497aa5caa5cd3b067650_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNi0zLTEtMS0yNDYyNjM_4d46fc37-3629-4a39-ba3e-18bd33955b47">406.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8415110eb3486093fdd56a22adfd54_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNy0xLTEtMS0yNDYyNjM_0ab621ba-ceb8-4c4e-872e-97d327e1f69e">673.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a092f91d8a468d8c4c31d4148a904b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNy0zLTEtMS0yNDYyNjM_495a071a-ba57-4a41-93c9-5a4374715b87">751.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfOC0xLTEtMS0yNDYyNjM_9fb19e9a-fc78-4884-8abd-2d14fa316327">6,960.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfOC0zLTEtMS0yNDYyNjM_72ea520a-73ca-456c-be0b-3316af327e38">7,810.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ2MA_d7dbed87-bb25-4271-9cfd-4754ed9a86f4" continuedAt="i8c65d77be7fd416b87e3024a70a8b24a" escape="true"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ2MA_f4ba9f19-899a-4d84-94c6-3b5e9ccaa7d2" continuedAt="i2fe4710219cd4097a1990e083f6359f8" escape="true">Acquisitions and Divestitures</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i8c65d77be7fd416b87e3024a70a8b24a" continuedAt="ie28905ef116146cb86a61cfb73a6f2dc"><ix:continuation id="i2fe4710219cd4097a1990e083f6359f8" continuedAt="id9ea4bd1487c4acc94013008cef696d6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we completed the acquisition of Akouos, Inc. (Akouos). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ1Mw_7d93ec18-f7ad-4508-8b47-2c88e41522d3" continuedAt="ieed5cff16e7e476baa37540ce82c4bfb" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. <ix:continuation id="ieed5cff16e7e476baa37540ce82c4bfb">Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;D when the event triggering an obligation to pay the milestone occurs.</ix:continuation> We recognized acquired IPR&amp;D charges of $<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTc1NQ_213ddecc-db78-4f71-b291-981fa5cc30dd">105.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MDE1MA_bf6b77c5-9405-489d-83a6-06d768b2908e">165.6</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE4NQ_3db0b52f-541f-4f71-aaf6-db5762971662">12.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTYzNDQyMg_d106f938-d187-4eea-a770-9fbba8083b2e">327.2</ix:nonFraction>&#160;million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE5Nw_57dc7a8f-e4a5-4a9f-933f-c71e780f732e">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE5MA_fc2de477-3109-4153-971d-0f6527a6f52f">3.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTYzNDYyOA_3373c9f7-95f2-42da-8b7d-3c592920cd74">122</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie28905ef116146cb86a61cfb73a6f2dc"><ix:continuation id="id9ea4bd1487c4acc94013008cef696d6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUyNTUzMw_1e15164b-d309-4c2d-a4ca-623c2cba5c63" continuedAt="idfeb42b31ca94f278d4b2804790c4f15" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMS0xLTEtMS0yNDg0MTg_f395ffba-c466-40a0-8bbc-8d442212cdc9">153.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMi0xLTEtMS0yNDg0MTg_1d647dad-51e3-494f-91c8-a804c626e38c">184.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMy0xLTEtMS0yNDg0MTg_c244c065-3da4-4291-a8ef-234a31b65d59">181.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfNS0xLTEtMS0yNDg0MTg_24af5b4f-f46a-4564-940a-bdf419a1660a">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfNi0xLTEtMS0yNDg0MTg_5f51910a-4ba0-49b6-bb6d-94903aee81a9">547.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae82f601bab2473da6f28b70df983fa5_D20221201-20221201" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfOC0xLTEtMS0yNDg0MTg_6c355424-d455-44f5-84b2-c4d0e1d86d20">153.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfOS0xLTEtMS0yNDg0MTg_d37bacc5-d968-421c-b32a-3f65df41b575">66.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMTAtMS0xLTEtMjUwODQ1_0e5373a4-af43-4530-bc2c-4b68d270f053">327.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="idfeb42b31ca94f278d4b2804790c4f15" continuedAt="i99c7dc39763e4de0bb1fa19b3f025e37">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i99c7dc39763e4de0bb1fa19b3f025e37">See Note 5 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the three months ended March&#160;31, 2023 were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we acquired a Priority Review Voucher from BioMarin Pharmaceutical Inc. for $<ix:nonFraction unitRef="usd" contextRef="i7692466539d946a186b9e8a3794403e0_D20220201-20220228" decimals="-5" name="lly:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNTQ5NzU1ODI5OTEz_936c4f8e-faaf-4274-bb39-87eaf072cb91">110.0</ix:nonFraction>&#160;million. We recognized no other significant acquired IPR&amp;D charges during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events - Divestitures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of the olanzapine portfolio, including Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to Cheplapharm Arzneimittel GmbH. Under the terms of the agreement, we will receive $<ix:nonFraction unitRef="usd" contextRef="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430" decimals="-7" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzUxNw_c067d827-3c8b-45e1-9550-9a47c43ac528">1.05</ix:nonFraction>&#160;billion in cash upon successful closing of the transaction and an additional $<ix:nonFraction unitRef="usd" contextRef="ic7897a00ac5944569e250a8e3e4f0b96_I20230430" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzUzMg_0e2d5465-fc8c-45e7-9b23-b3a6fb0ce5d8">305</ix:nonFraction>&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430" decimals="-6" name="lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU0Ng_8601f4df-bdb8-481e-ac63-1a562b97e722">50</ix:nonFraction>&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Amphastar Pharmaceuticals, Inc. Under the terms of the agreement, we will receive $<ix:nonFraction unitRef="usd" contextRef="i100bf53cad0845918532d994ef899f46_D20230401-20230430" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU1OQ_a4b19c74-49b0-4f65-8496-9e3239b1ffbf">500</ix:nonFraction>&#160;million in cash upon successful closing of the transaction and an additional $<ix:nonFraction unitRef="usd" contextRef="ie1373c2b92194421a101613e8613e0bd_I20230430" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU3Mw_c61ec6ea-3019-4b74-bf73-247912a1f2d2">125</ix:nonFraction>&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i100bf53cad0845918532d994ef899f46_D20230401-20230430" decimals="-6" name="lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU4Nw_43f9ff71-a6c6-4d81-91f8-33238b873bbb">450</ix:nonFraction>&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These transactions are subject to customary closing conditions and regulatory approval.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTA0MjY_f30a8934-a80b-47d8-b00b-7b91d42722b1" continuedAt="ia78f9041d5594c84b8c1175acd7fca93" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="ia78f9041d5594c84b8c1175acd7fca93" continuedAt="iee3e66b94e36438eaa3e9ddcbebf0e16"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulins, Basaglar and Rezvoglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. Rezvoglar is included in the Basaglar product family.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTA0Mjc_60de8424-e408-4794-9d3c-062309864f2b" continuedAt="ib979a0d59e084ab29c75a1c7167ade1d" escape="true">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to the Basaglar product family as of March&#160;31, 2023 and December&#160;31, 2022: </ix:nonNumeric></span></div><ix:continuation id="ib979a0d59e084ab29c75a1c7167ade1d" continuedAt="id7054589ef554738bae30c033268bbf1"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMi0xLTEtMS0yNDYyNjM_dc63b064-af2f-4343-a61a-d65157c5ebbc">111.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0abcdee3334210846272da16cb8bf0_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMi0yLTEtMS0yNDYyNjM_2a2a4281-8ea9-41f0-a4f1-387c835903c5">116.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd665f0b61e04e9290ab394dc775adfc_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMy0xLTEtMS0yNDYyNjM_ddb3c83c-f0c1-475c-bdcb-f96090f2b16e">57.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0be196fbee4b99986d201abe4c40cd_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMy0yLTEtMS0yNDYyNjM_ffb224d1-ce4c-4849-bede-d341625d3bc5">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff485149e744b8388e86b2d61f131bf_I20230331" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfNC0xLTEtMS0yNDYyNjM_813bb5cc-89ad-430d-9353-edb39f3557cf">126.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78acf8b5d08a423ab887d0babcc4c793_I20221231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfNC0yLTEtMS0yNDYyNjM_c7565f60-31f8-4f56-910d-8f6401b79b63">130.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim generally share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for the Basaglar product family in the U.S. We record our sales of the Basaglar product family to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee3e66b94e36438eaa3e9ddcbebf0e16" continuedAt="i0b28854dfedc4db09ca06f827a09eb11"><ix:continuation id="id7054589ef554738bae30c033268bbf1" continuedAt="i67ab25eda7124731801184a91e195e29"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to the Basaglar product family:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMi0xLTEtMS0yNDYyNjM_9e453744-0f16-4d42-b455-2a333f27de56">577.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMi0zLTEtMS0yNDYyNjM_d56e4fa9-e4a9-46e5-89e4-4f3cf62afa31">419.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMy0xLTEtMS0yNDYyNjM_9f3ac19a-040a-4f01-a141-9eab10f9514d">209.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMy0zLTEtMS0yNDYyNjM_62d820c8-b9e1-4212-9602-4b275f323165">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20238217248b408d991f048bd5cb02de_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfNC0xLTEtMS0yNDYyNjM_91300226-67b6-4d69-b8cb-e75a9114c13f">85.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c97dbdad3e47c19014952cddab28fa_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfNC0zLTEtMS0yNDYyNjM_cb5bf639-54e7-4e93-a006-a05b7c328088">92.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="i92837642c10f4f2d8a9378d7a850d897_D20230101-20230331" decimals="2" name="lly:CollaborativeArrangementRightsAndObligationsPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNDY2MQ_b5337318-2bbd-4dcc-92b2-c455b802ec09">20</ix:nonFraction> percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i609b231bb46d449cb0c55bf0feca2672_I20221231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTE2Nw_9ab4e743-1164-4fb8-aa42-defbd5df967c"><ix:nonFraction unitRef="usd" contextRef="ic5463e57189f4d458870b77c846c8470_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTE2Nw_c785c441-f44d-4c3d-a519-624a3b06cd44">330.0</ix:nonFraction></ix:nonFraction> million were capitalized as intangible assets as of March&#160;31, 2023 and December&#160;31, 2022 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i5cbee495f74d4bc7ac390f3934fd8dec_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTUxNw_9b1ae04f-dd22-4b8f-a3c1-f9c28eb03eae">100.0</ix:nonFraction>&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="i67ab25eda7124731801184a91e195e29" continuedAt="i5f6994dcb6d44fd4a10087bb85d876b2">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="i5f6994dcb6d44fd4a10087bb85d876b2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjM3ZWFkM2Q0OWI3NDQxZmE4NzA1ZTU0OTNiYmZmMTU2L3RhYmxlcmFuZ2U6MzdlYWQzZDQ5Yjc0NDFmYTg3MDVlNTQ5M2JiZmYxNTZfMi0xLTEtMS0yNDYyNjM_88bd67c2-172b-409d-a6fd-e4d07376a1e4">228.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjM3ZWFkM2Q0OWI3NDQxZmE4NzA1ZTU0OTNiYmZmMTU2L3RhYmxlcmFuZ2U6MzdlYWQzZDQ5Yjc0NDFmYTg3MDVlNTQ5M2JiZmYxNTZfMi0zLTEtMS0yNDYyNjM_bb7172ff-48cd-4d93-87a9-48088e92bc32">255.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera were recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331" decimals="-7" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTQ5NzU1ODI1OTA2_ff54c655-df4f-4b9f-be08-9d3b240838e8">1.47</ix:nonFraction> billion, primarily related to bebtelovimab, for the three months ended March&#160;31, 2022. We did <ix:nonFraction unitRef="usd" contextRef="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNDM5ODA0NjUyMzM2OQ_3d55d78b-61da-4f2c-ac03-a3b2414dae4c">not</ix:nonFraction> have sales of our COVID-19 antibodies during the three months ended March&#160;31, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2023, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i103526d82f5c4005b57a6ca769c093a5_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfOTI5Ng_325cc008-68e7-435f-8156-ebbdd9af6907">160.0</ix:nonFraction>&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i489cad1a4170481f8dc4678a75f24771_I20230331" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfOTQwMA_21ad027f-5894-4fb9-89aa-e04af5045fb9">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b28854dfedc4db09ca06f827a09eb11">We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2023, we are eligible to receive payments of $<ix:nonFraction unitRef="usd" contextRef="ifa643ca7a9684ef7bc9e57583e9f2c9f_I20230331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTAwMTM_c7834dfe-5109-428d-88c7-6bf4ebface67">65.0</ix:nonFraction>&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i7f28555ca5d9421a9bb743d1916adb6c_I20230331" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTAxMTE_e17b2c84-824d-4a31-b372-a1e96f7cc6ff">1.25</ix:nonFraction>&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the three months ended March&#160;31, 2023 and 2022, collaboration and other revenue recognized was not material.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3ODc_f06653ab-231e-4327-81d8-594c35cd6f47" continuedAt="ib46a3c2ec46d494ea6257bb6255cd8ae" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ib46a3c2ec46d494ea6257bb6255cd8ae" continuedAt="ie888954afef34e7b8b20109289af8e3c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Equity and Debt Securities</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE2OQ_2983c6ae-7384-480c-8443-28e5612cc6c1" continuedAt="i8c7b2f2d48cb4824ba1479836da86509" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c7b2f2d48cb4824ba1479836da86509" continuedAt="ib464ae68edd84a599b31bdf547fa5d5e">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.</ix:continuation> Adjustments recorded for the three months ended March&#160;31, 2023 and 2022 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net losses recognized in our consolidated condensed statements of operations for equity securities were $<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1Mjc4_68e10cae-f071-4d81-be0a-57c97e0a1818">13.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTA5OTUxMTY2NjA3MQ_204c1a91-3ef9-493d-b815-9a1e9a73f4dd">425.4</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. The net gains (losses) recognized for the three months ended March&#160;31, 2023 and 2022 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1NzI4_a36fd1be-9fbf-418a-9ad0-51e6e61f1325">950</ix:nonFraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1ODQ4_d4ada807-6bb3-45bd-a43a-ce21f764ff97">10</ix:nonNumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib464ae68edd84a599b31bdf547fa5d5e">We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</ix:continuation> Impairment and credit losses related to available-for-sale securities were not material for the three months ended March&#160;31, 2023 and 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie888954afef34e7b8b20109289af8e3c" continuedAt="i2a42df7d312048eabc49f0439ccd624f"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3MA_9eaac882-35b7-4cee-9a1c-5d61751c86e1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi0xLTEtMS0yNDg5NzI_35238c3a-cc8a-4255-b2a5-592308bd6cc5">648.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi0zLTEtMS0yNDg5NzI_2caf6d8f-3392-40c6-ad62-5d06591c7eb9">76.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi01LTEtMS0yNDg5NzI_75f7155a-7ed1-4d8b-a146-cd5423985d6b">219.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi03LTEtMS0yNDg5NzI_7accc03c-ef49-49f1-9bdb-27bb715ff53a">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi05LTEtMS0yNDg5NzI_d82d3175-9b8e-429c-84cc-c8d48dfd796f">237.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3MQ_3034751f-7d8b-46bd-989b-faa0d1b1c81d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMS0xLTEtMS0yNDg5NzI_4fe24878-551a-43b9-9790-7dccfa4f335d">1.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMS0zLTEtMS0yNDg5NzI_d73dfa97-9815-411a-916c-03b449bb904f">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMi0xLTEtMS0yNDg5NzI_2bf512e9-2782-4eb9-ba08-965f43b57f15">39.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMi0zLTEtMS0yNDg5NzI_babae84a-4c56-40a5-88dc-2fb6ec5df0f0">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMy0xLTEtMS0yNDg5NzI_3e852ea8-1c82-4859-8b93-cda15c86f8b5">120.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMy0zLTEtMS0yNDg5NzI_afa08fc5-6749-4fed-a65c-cfe22c51d08b">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfNC0xLTEtMS0yNDg5NzI_eeea00f7-4593-4fdc-82d8-e53fb5e259bf">512.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfNC0zLTEtMS0yNDg5NzI_42dc2392-2de4-4cba-87b7-eb26090e81be">568.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="2" name="lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM4OTQ4_310db327-7d3b-46ee-a08c-e390755e4201">99</ix:nonFraction> percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2023, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Mg_5e851e93-7172-4502-8623-acab54bffbf1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMi0xLTEtMS0yNDg5NzI_4dc10da9-586e-4509-ac04-1dbf36f54856">27.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMi0zLTEtMS0yNDg5NzI_c92cd937-8e20-4860-857d-8e470140e26a">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMy0xLTEtMS0yNDg5NzI_fa9dced4-859f-4c8f-b67b-c89ebeec956e">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMy0zLTEtMS0yNDg5NzI_13b1b197-cd5c-4b4e-9ff5-7ab2e6cecb2d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfNC0xLTEtMS0yNDg5NzI_2f13c0a5-00bc-4fe2-bab8-6f03c2dc6639">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfNC0zLTEtMS0yNDg5NzI_259ce67e-2204-4f6a-bd2a-d2007e9ce5c4">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2a42df7d312048eabc49f0439ccd624f" continuedAt="i19a5ab399ad7447a91aef6db6cb3a320"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Investments</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Mw_0455110f-d5e5-43e4-be97-c9aeaa3b0d89" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0xLTEtMS0yNDg5OTI_6a7a271f-a1db-48d2-b567-a455411d453c">2,343.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cc16dbdab440cba483787915c9d53d_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0zLTEtMS0yNDg5OTI_91e81f69-14cb-4ef4-af21-9ed185effad2">2,343.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy01LTEtMS0yNDg5OTI_eba791b9-ed4f-4aa4-a488-082388ee53b6">2,330.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy03LTEtMS0yNDg5OTI_183fe6e7-93ab-4ebb-96da-c7adbe0a848f">12.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy05LTEtMS0yNDg5OTI_43fb6de9-b9f0-4063-b6d8-c7a6b1cb28f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f030511d7046938601479dedb444f4_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0xMS0xLTEtMjQ4OTky_354a8ae1-25f2-4111-bfbb-ebaa9e8e2efa">2,343.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7566c897554984865a313ce03a9329_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0xLTEtMS0yNDg5OTI_230e90c5-16ef-4527-b66a-4756d5028118">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0134da41219f40099434bf6b0e92907f_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0zLTEtMS0yNDg5OTI_1c7f14b1-2f24-4b5f-ad99-12668c068f90">23.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cac2c8384d54ca495e549787dc20271_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi01LTEtMS0yNDg5OTI_4080ce1f-2ef8-49cf-a6e4-440634040a7f">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1879600e47a94b1ca76977132157c1f5_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi03LTEtMS0yNDg5OTI_a47b612b-fa4f-450a-8430-6db36d4dbf0c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi05LTEtMS0yNDg5OTI_5bbe459a-6319-42fe-840b-79060aa4dc7c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3918b47b0546407986bcb5eb572cf16a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0xMS0xLTEtMjQ4OTky_ef741514-7ca1-4bf8-b4ef-0246bba527f9">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51606337f7734c3486883b088d9e425b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0xLTEtMS0yNDg5OTI_7077f164-9df1-48ab-ae60-29903cb9e29e">50.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d8251eccdf47259566f7ce1b910246_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0zLTEtMS0yNDg5OTI_f9e697e0-5607-45f8-9289-918ebfdb643e">50.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc74babfb5f48019438eb1839ff23ad_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy01LTEtMS0yNDg5OTI_4db966fe-f7bd-4acf-b942-fc2c6c000214">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c819184949c43c88caf8d26d02607fc_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy03LTEtMS0yNDg5OTI_c3cbc17e-3682-4b36-8d98-d84c88e52ec1">50.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8026bc96eb9499a97499c0c3a47904d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy05LTEtMS0yNDg5OTI_5f2064bd-5923-462b-b0fb-ca0a0f0c831b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a28c2c52e041b8bda2d6528cde8205_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0xMS0xLTEtMjQ4OTky_0cd65073-f999-498b-a096-462ee8eb1556">50.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afb33798b944ff09e0d384619049f08_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0xLTEtMS0yNDg5OTI_5d8522e2-7beb-4451-a664-ea4994d4939e">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14fba24e65df4393afd80bbbfba657c7_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0zLTEtMS0yNDg5OTI_86a7575d-a92f-4a1c-b1e1-98a190abc66c">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0237a8c7ae47d897c07629a4ccd158_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS01LTEtMS0yNDg5OTI_20505bfb-8623-4be5-b042-477ffbf50912">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837f1e72cbb14e459cf199db8d586de3_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS03LTEtMS0yNDg5OTI_e67d80c4-6504-4116-9805-586a248a37c8">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS05LTEtMS0yNDg5OTI_8ff53ec5-98ee-4b1d-995d-5908fdd87ea2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0xMS0xLTEtMjQ4OTky_42e22831-8cef-45ea-a885-816886c30a0a">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b28da6dd9e645d398bc98f07007e279_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMS0xLTEtMjQ4OTky_796e38b3-8dbc-47ca-aa80-8893936a232e">47.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id276c57f9b1f4968a4c1e9e22e9ca168_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMy0xLTEtMjQ4OTky_7f9b095a-2e9b-4f7a-9c08-9f503fa82ed4">47.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfc537fc2c649e6a5a5f04fa5e3eac0_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtNS0xLTEtMjQ4OTky_e7d37e33-cc4f-413e-8583-855295b99be5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060e380eb6bd4c7b8d931a5b7fe8ee32_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtNy0xLTEtMjQ4OTky_ce91d36b-319f-46e8-8e5d-793eebd63158">28.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c95303f9a0d4b8dbc0cd35c9ab50369_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtOS0xLTEtMjQ4OTky_d95f2a61-3379-4ece-9ed1-d2f69fc68f80">19.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee17f60b34dfaa64036bd799907ea_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMTEtMS0xLTI0ODk5Mg_070762a7-980f-42c0-a647-df3b9c8c5fc2">47.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTItMS0xLTEtMjQ4OTky_88951dc8-5101-48a1-9f3b-6ad0c19f3a29">123.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7566c897554984865a313ce03a9329_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMS0xLTEtMjQ4OTky_33f34bfb-e466-4d14-8330-c37f4d4e842e">145.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0134da41219f40099434bf6b0e92907f_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMy0xLTEtMjQ4OTky_d767ef7b-511e-40bf-a17d-f844ecbaf8f6">157.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cac2c8384d54ca495e549787dc20271_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtNS0xLTEtMjQ4OTky_da0857fb-f1f0-4957-9174-2051e95814a1">145.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1879600e47a94b1ca76977132157c1f5_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtNy0xLTEtMjQ4OTky_99035c10-e39e-4a09-82e7-47f23d3bee35">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtOS0xLTEtMjQ4OTky_a5c82405-c6e6-4d81-9b3d-082a00a8b39e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3918b47b0546407986bcb5eb572cf16a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMTEtMS0xLTI0ODk5Mg_05a75c24-7baf-412d-a8e1-9d781c8df9f1">145.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51606337f7734c3486883b088d9e425b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMS0xLTEtMjQ4OTky_398f2c21-afd2-41e1-8eaf-a4398c77287c">214.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d8251eccdf47259566f7ce1b910246_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMy0xLTEtMjQ4OTky_05247952-63e8-42ed-93be-5a10a9ab5128">232.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc74babfb5f48019438eb1839ff23ad_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctNS0xLTEtMjQ4OTky_2e28d213-fba3-46d9-9053-78662cacd800">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c819184949c43c88caf8d26d02607fc_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctNy0xLTEtMjQ4OTky_e2db395d-eb18-4ff5-af14-11f4586d674d">214.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8026bc96eb9499a97499c0c3a47904d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctOS0xLTEtMjQ4OTky_4fcecd7e-bb2b-4a33-9194-e43575e1b855">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a28c2c52e041b8bda2d6528cde8205_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMTEtMS0xLTI0ODk5Mg_164d9b5f-fc19-493b-bd6b-925373257bae">214.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdd4b1a54e04c3a9406a84414b9f579_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMS0xLTEtMjQ4OTky_c0933550-4aff-4147-a847-96a8d41c735f">155.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5575d654b61f4900b3705243433ef745_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMy0xLTEtMjQ4OTky_fb2165e7-0dc9-434e-a5da-77f8f0275f3b">165.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c516fae2e94d6dbda47e05ce423f1b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtNS0xLTEtMjQ4OTky_1f514da8-b3e2-48f7-93cc-1c0d9cd27419">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef8ccfb7b53440397caf6f2176ec2c9_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtNy0xLTEtMjQ4OTky_06cf22d1-20a8-4f77-adba-a8002ed318ab">155.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1914622ec74bfc91e9e91e6b7153e4_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtOS0xLTEtMjQ4OTky_a934e2a5-7cbe-42c0-981d-3f67ea790992">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954f45623ee841cbbb44ef65dc983e82_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMTEtMS0xLTI0ODk5Mg_06bc770d-b842-47c9-b253-24664981f833">155.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afb33798b944ff09e0d384619049f08_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMS0xLTEtMjQ4OTky_04c8acb5-50fc-4700-8316-6af3f0985dd2">56.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14fba24e65df4393afd80bbbfba657c7_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMy0xLTEtMjQ4OTky_01227cb6-4076-4903-b847-f1df310b0ed0">58.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0237a8c7ae47d897c07629a4ccd158_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktNS0xLTEtMjQ4OTky_834a9687-f0f4-42fc-8738-f1a419bec20d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837f1e72cbb14e459cf199db8d586de3_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktNy0xLTEtMjQ4OTky_e520304f-d4ad-4029-9215-2697079c5f7e">56.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktOS0xLTEtMjQ4OTky_183c6a70-90e6-4804-811f-8d5902862d36">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMTEtMS0xLTI0ODk5Mg_0cd3c036-b2b5-4389-b2a9-ce3cf244fb76">56.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdc87b2e3b847c699cc755d5929caa3_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMS0xLTEtMjQ4OTky_6afea0e4-af14-4a57-a67d-89a20b6c9100">204.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93672f2b12e14d149242b511c86a6250_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMy0xLTEtMjQ4OTky_89a96509-8bf8-40ed-92b7-778a19c6b1a0">22.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f02815ce424e099d024a5372594f49_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtNS0xLTEtMjQ4OTky_a8789259-2cbd-40c3-9ead-3d5e03b17e62">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3620be0cd8f6437c993131b23aae9aa0_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtNy0xLTEtMjQ4OTky_1e6fe78b-1e69-4aff-aa61-92bfb71fcf54">113.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c92706e1f14b06b6f276c841acc827_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtOS0xLTEtMjQ4OTky_3de3ae38-1a7b-4ff4-a381-69932eb9e53f">90.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fe25007da841e6a6dfa7dea8abca12_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMTEtMS0xLTI0ODk5Mg_9caf7b94-15fc-4829-bd68-076c81ea0693">204.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebed6fdc46043b680d5a256576f2871_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMS0xLTEtMjQ4OTky_a3a556c7-7957-4d7c-91d2-b5d36be10a33">624.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb98f1aad55409684b3ba48c8c07916_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMy0xLTEtMjQ4OTky_84bf1d33-c1cb-47d3-a56e-d483103e2864">475.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6dbc248c1574a47a024938a5536f95c_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtNS0xLTEtMjQ4OTky_354cbd04-bf50-4a56-afc6-8b51c44b33e2">624.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b8cd580dcd4aa7a914f8764250a273_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtNy0xLTEtMjQ4OTky_78704e1f-f393-46ba-ac76-1124cc6691a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19353eef79fe415d9f09bbb87f88817e_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtOS0xLTEtMjQ4OTky_1fd1a29a-2e98-4d26-ab1d-2fbf3b65632c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001f8aeb21bc42778b5ba830866254e9_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMTEtMS0xLTI0ODk5Mg_415c3eab-d9d9-47a4-81d5-2e60f89fb82e">624.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjItMS0xLTEtMjQ4OTky_32761728-d153-4225-bcd9-28dd9a6be25a">516.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjMtMS0xLTEtMjQ4OTky_cdd37972-85c8-4b10-b6f5-4d940e8c0b68">833.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjQtMS0xLTEtMjQ4OTky_818886c1-4b7f-4ee3-b89b-99299c61312b">2,750.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMS0xLTEtMjQ4OTky_8c50135d-3b3f-4117-86dc-c02fa3045e2e">657.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cf7db1bd84431d8151876c0779039f_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMy0xLTEtMjQ4OTky_2e4ea817-f40c-4d66-a5af-85c56bdcae19">657.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctNS0xLTEtMjQ4OTky_0cc9cb7d-541c-4b00-9bcd-808d6b9e8a91">650.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctNy0xLTEtMjQ4OTky_a7dea9f6-aece-42e8-a95a-2e9d43cce624">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctOS0xLTEtMjQ4OTky_1dd32a57-7e23-4871-8e01-5889c8c20f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMTEtMS0xLTI0ODk5Mg_d6388fe0-9887-4787-83fc-3a8b09d84c80">657.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMS0xLTEtMjQ4OTky_0cc98dcd-155f-4998-837a-fb2474ded131">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48d0a0094404e7283b202d1e3bddef6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMy0xLTEtMjQ4OTky_34454e77-ffc5-43ae-a5c6-e5a00eb7d601">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97234b19add45c8a1264d62a11227cd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtNS0xLTEtMjQ4OTky_e897232d-f858-4b3d-9a5e-6555d4b544b7">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbfe46c3934f43b65aa033cc031c63_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtNy0xLTEtMjQ4OTky_3454f8ab-2e47-4457-9199-ae7268846820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c78f11ff6a047f081fced706e82fafa_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtOS0xLTEtMjQ4OTky_1d02783a-f55f-450e-9cc0-91142f36a3c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dbd154370ab46c5aa386577c6e77972_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMTEtMS0xLTI0ODk5Mg_35c00278-37ea-44c9-ae43-a36f2c804ea4">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMS0xLTEtMjQ4OTky_b4a585b4-d278-4ca2-ae4a-1442cb3bffa6">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMy0xLTEtMjQ4OTky_8ea80b7d-56e5-4851-bb69-a9debcb417a6">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtNS0xLTEtMjQ4OTky_b03770b8-060a-4ba9-b301-2cd589600e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2be3d28f17b4d53b00d099d33166a22_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtNy0xLTEtMjQ4OTky_5c9f8aca-2435-4f8a-911f-fe574317769e">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a551b91bdf34460b537440476918ed1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtOS0xLTEtMjQ4OTky_4559fa6c-7dec-4dc5-8a4b-e1a5223033df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf82c4e9f9fd4a0db74790b311d892d9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMTEtMS0xLTI0ODk5Mg_1c298bee-c710-4e18-a9e7-19187d5c200d">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14330e00eca04b5aa32be284d320080f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMS0xLTEtMjQ4OTky_d0a11a51-1b31-4b2f-9fa0-95d9a7f64cf3">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851cea55d9ca4dada65a5272023c5cf5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMy0xLTEtMjQ4OTky_89b1bbad-fdac-43dd-b99a-27bbe8e8dadc">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33a84402254240a7b6fd4134d0c50d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtNS0xLTEtMjQ4OTky_2d181ed8-5b2d-4b70-acc2-1e4fa297f48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ace9101d47e4406b2a9101fde438cc6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtNy0xLTEtMjQ4OTky_13dbbc7d-b5e8-4e25-b757-569a445b0587">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8619a22dba4e4f568d1919d6cd7c5376_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtOS0xLTEtMjQ4OTky_d1026a88-4938-4668-8533-4da8952fda44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9a47c0173949d69d205062ba1a08a1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMTEtMS0xLTI0ODk5Mg_e044b540-fd31-491e-bc50-6f8bbff1b681">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022f12bcdcd0432a8bf7bd1609fcd81f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMS0xLTEtMjQ4OTky_2cc579bf-716f-4570-a862-f84a8308e334">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813ca92d3c304796b09a1c1b8cd503cd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMy0xLTEtMjQ4OTky_ee164d1b-e391-43a3-933f-688a0c4d4910">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77fd8621adac49b9a812a1b54ce30bd6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtNS0xLTEtMjQ4OTky_7d74cb23-c464-4614-8247-dfe4fa7e9ee2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3bbe0151d1d436383b9c9a162467d10_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtNy0xLTEtMjQ4OTky_2fa21e1c-d561-4375-8a9c-7195353e4e24">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ca25f6912d4deaa22749065f92f810_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtOS0xLTEtMjQ4OTky_05c7e9db-d78d-4d55-8690-25f1c4ae3afd">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800172f3d41a475b95bc904fa96bc892_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMTEtMS0xLTI0ODk5Mg_bde93499-7a00-471f-8ad0-9c591a3850f0">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzYtMS0xLTEtMjQ4OTky_5971f044-383d-475f-873b-293e3fe9500c">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMS0xLTEtMjQ4OTky_0e7e0f33-bbd8-43e6-8f7d-ca50623f3fd9">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48d0a0094404e7283b202d1e3bddef6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMy0xLTEtMjQ4OTky_a7bda349-3d7b-4769-8bbd-1fb5b63629c2">163.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97234b19add45c8a1264d62a11227cd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktNS0xLTEtMjQ4OTky_716a8031-16b4-4cdf-8b40-8f3202d84541">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfbfe46c3934f43b65aa033cc031c63_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktNy0xLTEtMjQ4OTky_569be551-ddc1-4522-b4c1-a865b5b38088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c78f11ff6a047f081fced706e82fafa_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktOS0xLTEtMjQ4OTky_427a3772-7999-4f85-8cd6-3f634a293778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dbd154370ab46c5aa386577c6e77972_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMTEtMS0xLTI0ODk5Mg_e69a2ebe-ec26-4f23-b153-b796ebd9d154">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMS0xLTEtMjQ4OTky_f3c492dc-5caf-4515-9fb3-00690edb8046">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMy0xLTEtMjQ4OTky_11d58875-4dd2-40dc-a076-6d38405d21c4">235.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtNS0xLTEtMjQ4OTky_afdf95b7-4617-443b-9ece-41c8af87beab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2be3d28f17b4d53b00d099d33166a22_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtNy0xLTEtMjQ4OTky_8da06ba3-7513-4054-8e71-cadb137c8bae">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a551b91bdf34460b537440476918ed1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtOS0xLTEtMjQ4OTky_47b57eb8-d27f-4b51-9f69-6c050327ae54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf82c4e9f9fd4a0db74790b311d892d9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMTEtMS0xLTI0ODk5Mg_2f4c8888-95ac-44c1-9183-109607e4c2f9">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf1513ec6fe42dc8fc97dacbcbb2f7b_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMS0xLTEtMjQ4OTky_179c2a4d-795e-4dfa-b0d5-1baa7477262b">149.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f0aee5c436422aacd166802e150362_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMy0xLTEtMjQ4OTky_796c97a3-1036-4fa6-92f5-ff17a3b676eb">161.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2930663eccea45d3ab83ffbf88977505_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtNS0xLTEtMjQ4OTky_14ccc746-ed10-45d1-9095-6cd67163a46a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd2b5a2b18473582bd68be66d7d771_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtNy0xLTEtMjQ4OTky_38c3e58d-a01d-4877-bb50-2f2259442e3c">149.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0881c8a632db4b36a3e7ecfd7928e941_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtOS0xLTEtMjQ4OTky_f63529eb-9b70-4eb9-b377-cc629f18af8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564f1f9a74ad45f6b61966a59691288e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMTEtMS0xLTI0ODk5Mg_4c8a99f0-763b-4a6b-bb26-e1e01b261b93">149.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14330e00eca04b5aa32be284d320080f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMS0xLTEtMjQ4OTky_d95a9bfa-325b-4652-9afd-bc83569fd180">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851cea55d9ca4dada65a5272023c5cf5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMy0xLTEtMjQ4OTky_85981be8-88d2-495d-a629-aff3fd04aca7">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33a84402254240a7b6fd4134d0c50d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItNS0xLTEtMjQ4OTky_37ce99f3-1f69-439b-9b01-d565ef0f2259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ace9101d47e4406b2a9101fde438cc6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItNy0xLTEtMjQ4OTky_f3884780-93a5-4cfd-9b29-9fa49959721c">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8619a22dba4e4f568d1919d6cd7c5376_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItOS0xLTEtMjQ4OTky_c2f0b2bc-c052-4787-bc3c-6d2f76c8ec76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9a47c0173949d69d205062ba1a08a1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMTEtMS0xLTI0ODk5Mg_d465224a-9004-43f3-88ae-96e311b92918">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489bce7d4ec7404b9664b907c028323f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMS0xLTEtMjQ4OTky_7f0820be-a09c-451c-8070-fae4e6530d18">398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245ac866b994442fbc4b1f2c0864fe2f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMy0xLTEtMjQ4OTky_8780fb51-70c1-4e4f-b3a7-db4268ff8167">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6856168703f140ec90f1f07f17cc591d_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtNS0xLTEtMjQ4OTky_22c3ed55-1575-4671-969c-a4440445a268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42aa25d783514516803c587532a3c61e_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtNy0xLTEtMjQ4OTky_4ddc181f-c8e3-43fe-99b6-dcfc3af86fb7">311.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa8c24cfa2d4bbb8bac085b94dea6e3_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtOS0xLTEtMjQ4OTky_f3154b17-fc4e-4322-84be-6e86ff6112af">87.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c245d1c06644e1b6ab489c2e9f6916_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMTEtMS0xLTI0ODk5Mg_f6345c95-c68c-4d10-bef5-46b9661c278e">398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ecc19905f14bd28130682e968375e7_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMS0xLTEtMjQ4OTky_630f192a-831a-4a8a-86e2-7ded3263c1d2">683.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e06948912d142179578cad05d244ac3_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMy0xLTEtMjQ4OTky_1cbd3fb1-1221-45b1-b3f9-54aee05be743">484.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96286855c6b74d7ca6b4c49c79940a71_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtNS0xLTEtMjQ4OTky_165d53c5-83f7-4bae-97ee-8c78120b229c">683.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2035cc82b2c4f2984eefd8ae524520a_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtNy0xLTEtMjQ4OTky_0bf6ebfe-0863-45e3-9430-e49a6d87ccc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9458648cddd94b1e98f28b8ab753bc74_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtOS0xLTEtMjQ4OTky_9280fb00-a9e3-4dcd-815f-f6bc12f8a971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463ce48ff9854c67b168581527823709_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMTEtMS0xLTI0ODk5Mg_74adf8bb-b645-418e-82d1-9bd1fd3d27ab">683.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDUtMS0xLTEtMjQ4OTky_c9ca9d54-c176-42d7-8352-87e0848747c6">478.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDYtMS0xLTEtMjQ4OTky_be4aaf13-260d-4480-a884-a486f318be41">781.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDctMS0xLTEtMjQ4OTky_9c910f37-853e-4259-9502-979132dff09d">2,901.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i19a5ab399ad7447a91aef6db6cb3a320" continuedAt="ice8ad4d9776b433a9e0a853c024cba13"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we issued $<ix:nonFraction unitRef="usd" contextRef="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDQyMQ_c063b326-f9fa-4809-8df8-a72f14dc59bb">750.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDUyNg_6b6164a2-4c99-460c-84e5-ef8d79076463">5.000</ix:nonFraction> percent fixed-rate notes due in 2026, which are callable at par after one year, $<ix:nonFraction unitRef="usd" contextRef="i5629b4e2ef53489dbf21e68abf79b47a_I20230228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkwMA_c5f8f883-325c-42b8-aeb1-8cabd1f3d662">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i5629b4e2ef53489dbf21e68abf79b47a_I20230228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkxNA_bcb04d59-a6a2-4ca3-bc17-09c9f01bc2e2">4.700</ix:nonFraction> percent fixed-rate notes due in 2033, $<ix:nonFraction unitRef="usd" contextRef="ia2aa54d93fb744f09a03b3641900a309_I20230228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkxNg_40b1717f-76c1-46da-981e-a88b1518f31b">1.25</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="ia2aa54d93fb744f09a03b3641900a309_I20230228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkzMA_beb631c2-76ed-4060-a714-2c6c3bb7de6d">4.875</ix:nonFraction> percent fixed-rate notes due in 2053, and $<ix:nonFraction unitRef="usd" contextRef="ied6c5f93596b48d09753ee6dac6abb6c_I20230228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkzMg_f6635c74-8268-4493-98f4-b64aabbd75c9">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="ied6c5f93596b48d09753ee6dac6abb6c_I20230228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODk0Ng_4fd12cde-461b-4d5f-baed-3a2cb6cdbbc0">4.950</ix:nonFraction> percent fixed-rate notes due in 2063, all with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="ice2c8b929e4c4bc5a32d8aa02836cac1_D20230201-20230228" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDUyOQ_5e64ff77-898b-4af4-ae6c-0d1eeb9e2d2b">3.96</ix:nonFraction>&#160;billion for general business purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Debt</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3NA_41d4afba-1c7d-4c9c-9498-3096b6f73df2" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for our short-term and long-term debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d458da5e9246b8a8c0b7b714992619_I20230331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy0xLTEtMS0yNDkwMTU_039e6efb-c969-45e9-81a6-b838b84b42c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0331e3cce77463eab1cf2359214ff10_I20230331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy0zLTEtMS0yNDkwMTU_edda695e-5d55-4a25-a857-fed920478238">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if485cce9601842de8e0453ea2c5bdb90_I20230331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy01LTEtMS0yNDkwMTU_1635ef6b-c332-4e08-a3be-fe3d68791d77">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c397a2da7e467c86ff6be26f9e20c9_I20230331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy03LTEtMS0yNDkwMTU_5daa58ff-6ac0-4156-b966-0909ae9caceb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac66d67a45e4eb9b8df6e33b966bdeb_I20230331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy05LTEtMS0yNDkwMTU_f936ddbb-aac7-43a3-aaa3-624c95e2949b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeac312680b340f5b5e739bbc1e1882d_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC0xLTEtMS0yNDkwMTU_84e23506-74be-41b3-a53d-468a562a2529">1,498.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia278d7067652484dac30db72abe60a63_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC0zLTEtMS0yNDkwMTU_692d43d9-51b1-4a93-b88f-abb4da4d3f53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30ea2a3ccd6c4b00ba12b0f45309f52f_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC01LTEtMS0yNDkwMTU_33cd2fa0-8a29-4a2f-b660-af53ba9ab95b">1,492.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f2344b073f45f7b33a4471dd2abba3_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC03LTEtMS0yNDkwMTU_ce1070c1-e0f8-4a3f-8bdf-974311fc1816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a314d1e73864fd780eeebcc4f2a1867_I20221231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC05LTEtMS0yNDkwMTU_a9ebc1ab-d281-41fd-bc95-ab71e1b17cf2">1,492.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi0xLTEtMS0yNDkwMTU_a91ea593-739b-4c3c-8aee-f36657462783">18,883.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi0zLTEtMS0yNDkwMTU_2c9d484d-42f7-4761-8c02-e584daac586f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi01LTEtMS0yNDkwMTU_292fe32e-994c-49df-8f05-a314c307307e">16,654.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi03LTEtMS0yNDkwMTU_f163c540-a421-4700-aafb-6645be9c8122">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0f030511d7046938601479dedb444f4_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi05LTEtMS0yNDkwMTU_1971e2b0-8743-4205-9be5-6f4af4a0851a">16,654.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy0xLTEtMS0yNDkwMTU_5ab4de92-b6cc-4b0d-b724-9eb067f55fb8">14,740.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy0zLTEtMS0yNDkwMTU_2a9443e4-3100-4808-8ea4-d300a3f67145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy01LTEtMS0yNDkwMTU_6c829aa0-6949-4d26-9201-15af3233fc0a">12,329.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy03LTEtMS0yNDkwMTU_c7040140-6520-437d-a875-3f926a6df2d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy05LTEtMS0yNDkwMTU_e0f8a4f9-4740-4ba8-be28-fad9c909cb28">12,329.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Related Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. The majority of our cash is held by a few major financial institutions that have been identified as Global Systemically Important Banks (G-SIBs) by the Financial Stability Board. G-SIBs are subject to rigorous regulatory testing and oversight and must meet certain capital requirements. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer based on credit rating of our counterparty. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect significant counterparties to fail to meet their obligations given their investment grade credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQzNzIw_6e691f1a-0e6e-4a74-9994-6c140c549da6">423.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQzNzI4_fd0aac6b-4711-422a-b23e-df7f5d36ece2">422.1</ix:nonFraction> million&#160;of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2023 and 2022&#160;were&#160;not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ice8ad4d9776b433a9e0a853c024cba13" continuedAt="id3eaf94fb7144dbda374802bbc51c0b9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY4MTI_a97e7815-2a54-4f0b-b2a5-9ea237d3ab7e" continuedAt="i37312df363a742bb9bc9e624c27903cb" escape="true">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 9) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 9). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37312df363a742bb9bc9e624c27903cb" continuedAt="i0ce385120927470594a1c185fbaffd1d">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. </ix:continuation>Forward contracts generally have maturities not exceeding <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNjA0NzMxMzk5MjA3MQ_a5b65101-92a7-4305-85ef-0bc363e70300">12</ix:nonNumeric> months. <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3NQ_d7ee457c-4b2d-4f42-81be-a4c4b3d8b432" continuedAt="i1e62831fc9274bc8aa72c4a0f5d9ed73" escape="true">At March&#160;31, 2023, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDY2OA_1a67a6f2-f0ef-46e3-82cb-d3de77182265">180</ix:nonNumeric> days:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i1e62831fc9274bc8aa72c4a0f5d9ed73"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf771418ff145e48f59e9ff50e2c708_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfMy0xLTEtMS0yNDkxNTk_6b22d046-5494-48f8-a001-66523771f213">2,410.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="ibcf771418ff145e48f59e9ff50e2c708_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfMy00LTEtMS0yNDkxNjc_95a4be32-104b-4e5f-83a0-c65d16d36ab4">2,231.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="if6e0597d66944d53bf676c80d6b96114_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNC0xLTEtMS0yNDkxNjM_b32684c4-a549-4924-8ecf-7f7b878501ac">3,667.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e0597d66944d53bf676c80d6b96114_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNC00LTEtMS0yNDkxNjc_9dedbc9f-ccd2-4492-9752-7122b3d85b0d">3,948.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c08ba67b1c94a638f7917eaf0032bad_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNS0xLTEtMS0yNDkxNjM_bb7a863a-a2b1-45d5-b502-b2fe9c28de4a">229.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="i5c08ba67b1c94a638f7917eaf0032bad_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNS00LTEtMS0yNDkxNjc_4c17cb3f-7630-4d80-ad61-d78e7651e24e">1,574.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="id0507f641e794b5a91c61ce38a4c073c_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfOC0xLTEtMS0yNDkxNjM_4a91ae63-7662-4f79-b6c1-5410d18a53fd">216.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0507f641e794b5a91c61ce38a4c073c_I20230331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfOC00LTEtMS0yNDkxNjc_c598b0d0-4869-4300-8968-c51ed8af5757">265.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="i429677c58b714ca8a8137930ebb1264e_I20230331" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDkwMA_49b34ee7-aaa5-44a5-9b97-f8f1bcb88b2a">6.97</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="icf306204988949a8a9f4c724f64060af_I20221231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDkwNw_660e2c89-6556-46aa-95c1-33d1c7216d0a">6.83</ix:nonFraction>&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDk1MA_bf833284-9ca2-4131-b086-3209d3914373">5.58</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDk1Nw_dd3db809-b4a9-4f36-8feb-5fa317c32882">5.45</ix:nonFraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of March&#160;31, 2023 and December&#160;31, 2022, respectively. At March&#160;31, 2023, we had outstanding cross-currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ia3cd20496f3d4a06a9644d09794a69a7_I20230331" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTE4Mg_603399f3-af93-446b-842f-44bee6c1289b">1.02</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="i260b5249d7e84893aefd8c83c3d04825_I20230331" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTIxOQ_c52907d6-fdbc-422e-b743-096906052710">1.00</ix:nonFraction>&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At March&#160;31, 2023, we had outstanding foreign currency forward contracts to sell <ix:nonFraction unitRef="eur" contextRef="i645e8bd9724c4c4cab525b0c0ce2038a_I20230331" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTYzMw_9d414124-c0c5-4ee0-9b39-d2b04b8bebde">1.38</ix:nonFraction> billion euro and to sell <ix:nonFraction unitRef="cny" contextRef="i2a44228b4f8545afb2c73892b5d2dc61_I20230331" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1MjEwMg_9a7a6698-3d46-4f48-9fa3-fdb8ce750750">1.82</ix:nonFraction>&#160;billion Chinese yuan with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ce385120927470594a1c185fbaffd1d" continuedAt="i452fa4ad0dbf4609a68a3a8d4398fabe">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i452fa4ad0dbf4609a68a3a8d4398fabe" continuedAt="i48b720d11ba1406fb024fc8aa1f54bdd">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows.</ix:continuation> At March&#160;31, 2023, all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="2" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNzIxOQ_1ff36b91-b7af-4444-97db-dbb8cd98912f">12</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id3eaf94fb7144dbda374802bbc51c0b9" continuedAt="i476b1dc5a616490ab3744da1763a36d7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i48b720d11ba1406fb024fc8aa1f54bdd">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 9) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</ix:continuation> As of March&#160;31, 2023, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="i77245def3f8b4e7dab758e4a8bde31a4_I20230331" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNzkyOA_f7c22b5b-c4d8-4e92-9db7-02578205cd46">1.00</ix:nonFraction> billion, which have settlement dates ranging through 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Ng_4a6e21ef-b9ed-4557-af5d-2414672819d2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8cd03fb09db4a7d82b3453427246d58_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfMy0xLTEtMS0yNDkwNjg_1e13c79f-ea14-4ba1-a97e-58dac4e18972">35.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43a702b6516d4b76a6b7e939ece50067_D20220101-20220331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfMy0zLTEtMS0yNDkwNjg_6b94db2f-8579-4fd9-b557-5166d25b4532">94.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNC0xLTEtMS0yNDkwNjg_5ce3d405-d0d5-4554-a48f-9dc3263f60f7">35.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNC0zLTEtMS0yNDkwNjg_375b451f-f20e-45b8-aa46-ea26bdd40881">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNi0xLTEtMS0yNDkwNjg_837181f1-6bf6-4426-8a3a-011f562b695f">3.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNi0zLTEtMS0yNDkwNjg_cb871313-1efe-428a-b056-6cff128f8cdc">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1c2892bae36442e8926b2ce9c0668bc_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNy0xLTEtMS0yNDkwNjg_0a179fe5-c16c-424e-8885-f0faba44ed3b">12.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4c3a1eaec84aa68e202c8ea853063b_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNy0zLTEtMS0yNDkwNjg_4a7953ca-915e-436d-903a-4e0f2e8c39ff">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e9490fbbc14d76ab189e023cf3f228_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOC0xLTEtMS0yNDkwNjg_248f9949-a6e6-4c5e-b843-0f3e07af1444">52.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e32bbc79574914bba00cdb0742b99b_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOC0zLTEtMS0yNDkwNjg_6d30f046-26c7-4aef-adce-cb10c939af24">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOS0xLTEtMS0yNTA4NzQ_51a0de66-b62d-405f-b67d-5679e4330c88">61.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOS0zLTEtMS0yNTA4NzQ_8ec008c8-43a0-4cbf-92c8-38bf2d44c699">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Nw_63950ee7-177b-4c4f-b520-b1bb7e2762f2" escape="true"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Nw_feb7f011-7972-424a-8c7d-c89b73898459" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58f19b8ba9ed454fa02e5160a844f996_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfMy0xLTEtMS0yNDkwNjg_d5b40e10-ef48-4046-ae48-db08ea2cb43e">131.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a614a742164e49b4da60cae000aac8_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfMy0zLTEtMS0yNDkwNjg_8b718573-7f8c-4dda-82cf-577553017d06">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNC0xLTEtMS0yNDkwNjg_fdcd6ecd-8c88-4181-ace4-09b658bc8bc3">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNC0zLTEtMS0yNDkwNjg_f9ecbe74-0efa-40f4-af69-5e2cf985f3a0">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ee17b04babc40a6ab35eccdf222fe82_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNS0xLTEtMS0yNDkwNjg_12c7f8cc-91aa-42f9-9363-fc6a9f256d44">46.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72e1ac48fd74f079d8811bbcae3d5d7_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNS0zLTEtMS0yNDkwNjg_3d31281f-c600-4f04-8819-31be7e7bc29e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c553f14757453c942a550f354e3a74_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNy0xLTEtMS0yNDkwNjg_e9a10372-d2ff-489c-b703-a66d8cdca8be">23.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6789d3ab2e2e4887828f80411eaa0097_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNy0zLTEtMS0yNDkwNjg_a8293adb-bfa4-4777-9036-6acb85846b91">122.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfOC0xLTEtMS0yNDkwNjg_03c18d2b-6ce1-4d28-a209-9068e2c57dd2">7.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfOC0zLTEtMS0yNDkwNjg_417938e7-601e-4260-af23-ce9d66b575f3">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQ4ODM2_5953462b-ebbd-4056-bc35-7d54344489a6">13.1</ix:nonFraction>&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three months ended March&#160;31, 2023 and 2022, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i476b1dc5a616490ab3744da1763a36d7" continuedAt="i0191713213734e998e6912629918c048"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Risk-Management Instruments</span></div><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3NzY_7f40eb10-60cd-4d0e-89aa-5bb8c588b53d" continuedAt="id87cdbd296564c2991f05db4ee7b42d9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for risk management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" xsi:nil="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3ODI_85bd923c-76a8-4ea6-8e57-fb09a17ed5d4" escape="true"></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi0xLTEtMS0yNDYyNjM_9673821c-6b86-430b-bd77-9a03b51c5104">2.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi0zLTEtMS0yNDYyNjM_26c26960-8f75-4d2e-a4b5-a4381f0eaf37">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi01LTEtMS0yNDYyNjM_00647f36-3958-432f-9482-8382dbab6d23">2.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi03LTEtMS0yNDYyNjM_632a67c2-cd9c-4cfe-aa9f-af279e4dd46e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi05LTEtMS0yNDYyNjM_217deff5-f30e-4549-b17b-c06e9cc93fee">2.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy0xLTEtMS0yNDYyNjM_86bceabf-660c-4837-b36a-5086827511de">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy0zLTEtMS0yNDYyNjM_9de38d7f-458c-44ba-9f8f-2a4dbd23d768">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy01LTEtMS0yNDYyNjM_c62a1e96-14f2-475e-a220-141fbfa36df6">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy03LTEtMS0yNDYyNjM_16160975-b2ad-4944-9481-ff00b591d177">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy05LTEtMS0yNDYyNjM_2dda236a-58d5-45dc-877e-d6e95c6b9db4">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC0xLTEtMS0yNDYyNjM_128fc141-8656-4555-82ae-f9277cb0a635">91.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC0zLTEtMS0yNDYyNjM_1a437efa-113a-46c3-9561-27e25114779a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC01LTEtMS0yNDYyNjM_b8e9622b-acc2-4299-beb2-dc4095a92c18">91.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC03LTEtMS0yNDYyNjM_5d6c5206-c9cc-4865-aa59-2041d2638429">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC05LTEtMS0yNDYyNjM_896c1e54-d938-4c2f-95c5-848fe5eaaa82">91.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0de9c67450541c296870312132a3b92_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItMS0xLTEtMjQ2MjYz_dec38967-f996-448a-a24e-90870766bf63">228.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5442836a58a740f9a2ec6a5044876fa3_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItMy0xLTEtMjQ2MjYz_370849ab-86db-45ea-8578-6b4ccb700cb2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4345c04245449db88cb19f4963073ed_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItNS0xLTEtMjQ2MjYz_4ef2af5b-c80d-45e7-8381-eb452ceb464a">228.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6128cb3f8b34eb38e4ba315f7d53bbf_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItNy0xLTEtMjQ2MjYz_53aa8512-622e-493f-ab7e-169733b86a89">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5624b505084aa68791383a31649f60_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItOS0xLTEtMjQ2MjYz_12efeabd-c308-4bfa-b70a-f5124958d058">228.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3441b768235345d7a17d1010afb3aa34_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtMS0xLTEtMjQ2MjYz_7aa46533-6933-426d-8b2b-ef238b92b3bf">55.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5b9b0ce2374a22a8d5ea231570946a_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtMy0xLTEtMjQ2MjYz_9b0b85fb-c278-466e-8fa1-ab1a08162dde">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b75c331361d44ec829664b5a49b1365_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtNS0xLTEtMjQ2MjYz_7d8f2806-6bd4-4a08-b7bf-246e65ca8aa6">55.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ed07ce471c498fafc8e126e65bf30b_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtNy0xLTEtMjQ2MjYz_6c79e4cc-cf48-4002-8874-cc03487fde4b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b86836fd2b4c638e1b4648bb0f535f_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtOS0xLTEtMjQ2MjYz_5289684f-9144-49fb-a893-71b743c50a8a">55.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1b2d2ba1774f099d8109747e8c6a95_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtMS0xLTEtMjQ2MjYz_570d7905-eafd-4b11-ac3c-95f1630979b6">58.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4aaf0f785e46d39d0b337f7ca1aa83_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtMy0xLTEtMjQ2MjYz_c26778a5-f61f-4cc0-8f18-84ad34303ff3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33268d4bc0be4bfeb735237bbf2beaa5_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtNS0xLTEtMjQ2MjYz_bbeb3dc6-567c-45c9-8a07-3afea1d7b1b0">58.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f8023d0e15487abe65174ea5fdd911_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtNy0xLTEtMjQ2MjYz_6540669b-d47e-4872-a36e-18209f131377">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27a50fefdd14c2f984c86fe00f4646c_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtOS0xLTEtMjQ2MjYz_1c0d085b-7390-4c3e-bb8f-06d24e85055d">58.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb4d961f831495a8982fcca640793b2_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtMS0xLTEtMjQ2MjYz_4dbe8af3-a2eb-4541-8626-e32fa51bddbb">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606b780fae204c2fb03456ec7d4609ba_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtMy0xLTEtMjQ2MjYz_7a5df109-a643-416f-9d08-8a6545893ae7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtNS0xLTEtMjQ2MjYz_6a80d80e-61d4-4c63-9270-8e260825e8d9">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b291e9275fa4cdea832b11022bb1650_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtNy0xLTEtMjQ2MjYz_9c55bcfd-b854-411a-882e-5f9c1781bd9a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17408fcf4a6444ca4350f667c9e2531_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtOS0xLTEtMjQ2MjYz_68a80549-ffe7-47da-a9ea-af693feb64a9">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcb4d961f831495a8982fcca640793b2_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtMS0xLTEtMjQ2MjYz_e4f26b58-e547-4749-9c5b-a526eb52f5a7">13.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606b780fae204c2fb03456ec7d4609ba_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtMy0xLTEtMjQ2MjYz_cfb09373-b8dd-49dc-a915-6a5774985783">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtNS0xLTEtMjQ2MjYz_5cab6f8c-eedd-4d5a-bb3a-d8e386d755f8">13.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b291e9275fa4cdea832b11022bb1650_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtNy0xLTEtMjQ2MjYz_0c4cf8f1-a500-4f38-9839-ef813fcc44b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17408fcf4a6444ca4350f667c9e2531_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtOS0xLTEtMjQ2MjYz_767f1404-f66c-4764-ba69-a1e72d6cc70b">13.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10c867d799d4679b141e08dc578e51f_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtMS0xLTEtMjQ2MjYz_901152c8-ca70-4114-adda-b8041d071998">63.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f0c78f29754db2b760047cbe32a568_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtMy0xLTEtMjQ2MjYz_bfcafe73-315c-4560-9004-cff0dec3c18d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5964e87d1767486d9c9f3e69ea87005f_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtNS0xLTEtMjQ2MjYz_ffb18762-e826-4872-a7a1-e91491203dab">63.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8899346d6d43418aa5c2c278c01334_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtNy0xLTEtMjQ2MjYz_65b71b9e-c1ea-4461-9c27-90b7d08e409b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtOS0xLTEtMjQ2MjYz_8c4dd5e2-dad1-4fee-9b86-4c278f3ecd6b">63.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie10c867d799d4679b141e08dc578e51f_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctMS0xLTEtMjQ2MjYz_ddd87874-5306-4bb5-9c7d-fbf57fc5bcba">32.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f0c78f29754db2b760047cbe32a568_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctMy0xLTEtMjQ2MjYz_a4d50a10-4398-4bd3-b9c8-25dd0dede6da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5964e87d1767486d9c9f3e69ea87005f_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctNS0xLTEtMjQ2MjYz_ad0aba7d-2e73-464f-9a1b-ea80488c4102">32.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8899346d6d43418aa5c2c278c01334_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctNy0xLTEtMjQ2MjYz_0bb15ea4-aa40-42ab-9650-2370c332e774">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctOS0xLTEtMjQ2MjYz_2a1e9563-8c6f-4ec7-bde9-b11b23919117">32.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtMS0xLTEtMjQ2MjYz_e0757b39-4e4d-4cf4-84c1-9c3d53630ca7">40.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtMy0xLTEtMjQ2MjYz_7e64cb73-a064-4112-bcb0-5cbb71299709">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtNS0xLTEtMjQ2MjYz_66823487-a58f-42af-bc27-7731ba1416ce">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtNy0xLTEtMjQ2MjYz_5120f66a-a395-472c-b05c-d2338a640128">40.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0f030511d7046938601479dedb444f4_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtOS0xLTEtMjQ2MjYz_3dad7303-2a93-4961-b8ac-a06d9cd5385f">40.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItMS0xLTEtMjQ2MjYz_f4aed0dd-c0d9-46b1-99b0-c8a785a26c96">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItMy0xLTEtMjQ2MjYz_da91ef20-cd00-4c57-aadf-061757d57152">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItNS0xLTEtMjQ2MjYz_c3622c0b-23ea-4be5-bf39-2201d8c337c3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItNy0xLTEtMjQ2MjYz_1119d6f7-dd19-4e6a-a2a4-b9ae19787297">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0f030511d7046938601479dedb444f4_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItOS0xLTEtMjQ2MjYz_3215b0af-8809-46e0-bf37-b06597797fb0">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0191713213734e998e6912629918c048"><div style="margin-top:9pt"><ix:continuation id="id87cdbd296564c2991f05db4ee7b42d9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13b3318a1c6d4b2989d8bd17e5d7fa8d_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtMS0xLTEtMjQ2MjYz_92e74eb6-4024-404f-ac68-e53f1f286aef">134.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c721984329042fa98416c00587829be_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtMy0xLTEtMjQ2MjYz_72797242-21c1-4972-bddf-f28e23376363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b26c90f2d0f429498c69e75f2486afb_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtNS0xLTEtMjQ2MjYz_2c8b9bf1-7ab3-4d33-8ff2-acb6616ee373">134.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia203e1c41a27445f9ac21572233934b5_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtNy0xLTEtMjQ2MjYz_5d313091-4e84-4a7c-81df-b1acc6eacfcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff538190e8dd49b1a7a2291adead31c0_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtOS0xLTEtMjQ2MjYz_684741d5-565f-4ef6-b54a-7196b146564a">134.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3322119f512345d8bdc5b393121fe2a2_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMS0xLTEtMjQ5ODIy_4efcb5c7-4c71-49aa-8d76-519aabe6dced">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMy0xLTEtMjQ5ODI5_c08b841c-8d2a-4d13-b39a-d7d5815e9974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbfbaced29242dabda4aa8d0200d534_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNS0xLTEtMjQ5ODM2_5518489f-d7a6-45ee-b5b0-6c3f3559d4ac">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61271b58943e4dfe8d82e39de366487a_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNy0xLTEtMjQ5ODQz_3bc60411-06b4-4d85-bf04-e390e7b39357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6961e3f6be845d49d270b23ae0eb760_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItOS0xLTEtMjQ5ODUw_2035b4b2-b747-42c0-b4b6-d1a845c9bd1a">162.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3322119f512345d8bdc5b393121fe2a2_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMS0xLTEtMjQ2MjYz_ab3af688-58fb-4907-8a2e-8f319f1c17e6">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMy0xLTEtMjQ2MjYz_7520e533-9832-40b1-a0ac-8ddcd073d148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbfbaced29242dabda4aa8d0200d534_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNS0xLTEtMjQ2MjYz_8aa6c950-32f5-4e75-b8df-841395d762a2">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61271b58943e4dfe8d82e39de366487a_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNy0xLTEtMjQ2MjYz_687a70f2-b9af-4e88-8c32-c03003a4bea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6961e3f6be845d49d270b23ae0eb760_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItOS0xLTEtMjQ2MjYz_170357b1-994f-495d-90dd-e1b08d02642c">246.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee7bb9be4e14b0199dbb8ff375c4fd5_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtMS0xLTEtMjQ2MjYz_a693ada3-5367-4b1f-8352-3bdf37d77a80">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c0160e96e4f31982f3ea5eddf15be_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtMy0xLTEtMjQ2MjYz_867a2360-10ae-4e38-abb6-63f70ea86240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbad1803617416b8a7575b6635bd9e5_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtNS0xLTEtMjQ2MjYz_a7115869-dee7-4939-ac72-f61ad28b0b3f">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec954c0cc0a4864a3be7c95f0bbbba3_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtNy0xLTEtMjQ2MjYz_f303438c-6360-4bb4-a487-695af1d21b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f5e9a727714d8e9d04fd093c69c3f9_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtOS0xLTEtMjQ2MjYz_24421d03-07d1-4e1d-b7d0-5a54053d5f83">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023e643351984eaa8065abddb7c0e922_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtMS0xLTEtMjQ2MjYz_3841fb26-7d67-414f-8bc3-3a75bb632e54">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d6338210f24d0b8761f25b6917fedf_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtMy0xLTEtMjQ2MjYz_10a99407-38a3-4eeb-a5bc-5039de0b47c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0289f9ec779478ca9a7d9feaa66a043_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtNS0xLTEtMjQ2MjYz_775dabf9-8c12-470f-9d7d-58df0d71691a">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e470a377e24131be208163db576480_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtNy0xLTEtMjQ2MjYz_dddd7789-45db-495d-9eda-15d97d660ae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17bd13ed9bbb44bd9b794d91b7205501_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtOS0xLTEtMjQ2MjYz_8ce18a44-cf6d-4bf4-b877-236fb72b077e">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if16b30290f524f5ba8cd96a652b77f18_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMS0xLTEtMjcwNzE3_3ee3f829-6afd-4df2-a603-f2ba60872150">38.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cac47e76cf444dcab2ac2c436b08b33_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMy0xLTEtMjcwNzI3_dbbf3e8d-f4dc-40a6-9634-8495db3c9810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb9f543aacc94384a647f3a1c0667ca4_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNS0xLTEtMjcwNzM1_b5651f91-225e-4292-b8ed-6ed5f50992b3">38.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df7036cdae24b0a97dccbbd25afe031_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNy0xLTEtMjcwNzQ0_fb9d3677-b9ca-4d70-8457-b13bac5d6e5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8664bea8164219ad1c5f82db48f0b3_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtOS0xLTEtMjcwNzUy_af525a58-2699-4b6d-a3f8-b926467ab0ab">38.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94edd79b891548bd83088ab50b487992_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtMS0xLTEtMjQ2MjYz_31d26ed1-0e03-42a4-a489-6c710744bdea">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id027583937064a45b5174328a3e4fd18_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtMy0xLTEtMjQ2MjYz_befa0eda-d803-48e7-8bae-348d30bb9cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtNS0xLTEtMjQ2MjYz_804cda63-870a-462b-a402-fffdf2d4255f">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed5b21a16d248339ba5818828910280_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtNy0xLTEtMjQ2MjYz_b90cd925-ef47-45a7-b75e-826746b07778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtOS0xLTEtMjQ2MjYz_980244e2-0640-4a85-b13f-79584d312849">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94edd79b891548bd83088ab50b487992_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMS0xLTEtMjQ2MjYz_3e0e2dda-4fca-4bed-b41a-c6c7c5c653df">21.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id027583937064a45b5174328a3e4fd18_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMy0xLTEtMjQ2MjYz_3c0d856b-a4ae-4a26-9844-bd488e899dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNS0xLTEtMjQ2MjYz_158e86e1-7c54-4938-b60f-baf6c3584b60">21.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed5b21a16d248339ba5818828910280_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNy0xLTEtMjQ2MjYz_729f157c-6b6e-420e-ab50-ddbff94b0b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtOS0xLTEtMjQ2MjYz_42908900-4800-4415-880c-c78b6064120c">21.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtMS0xLTEtMjQ2MjYz_6e0e0889-4b69-4f33-90c5-6aa9068162ad">39.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtMy0xLTEtMjQ2MjYz_137ce972-79a4-4d6b-9c51-70b8caffe488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtNS0xLTEtMjQ2MjYz_0a2b7966-3f4d-4acc-8014-fc1cc03593e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtNy0xLTEtMjQ2MjYz_6e067a5e-fb26-4dba-afad-ccd73b9ca90c">39.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtOS0xLTEtMjQ2MjYz_5368229f-701f-46ae-a526-09743a0047fd">39.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctMS0xLTEtMjQ2MjYz_c63bbcb9-6beb-4ab7-b83e-4f88edaf2630">70.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctMy0xLTEtMjQ2MjYz_348243fa-0a3e-4b3f-b5ba-af4c127abac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctNS0xLTEtMjQ2MjYz_c077228a-3c08-41ce-83c0-03b3c987544b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctNy0xLTEtMjQ2MjYz_79e89781-578f-4885-9424-e8c6b9aeae11">70.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctOS0xLTEtMjQ2MjYz_279cb2f3-d85a-4c43-b297-46045c6c9548">70.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of acquisitions of businesses. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfMTMyMA_8f3b0702-b234-4bb4-bebc-875af7fba4c6" continuedAt="ia5162e25149543dca813a5df10a14a9f" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ia5162e25149543dca813a5df10a14a9f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfNTY_ba3d01c2-4fbc-4132-84cc-c7a6463e2e29">12.1</ix:nonFraction> percent for the three months ended March&#160;31, 2023, reflecting the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit. The effective tax rate was <ix:nonFraction unitRef="number" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfNzA5_b4e440fe-e003-4f5a-acb7-10b171854710">7.3</ix:nonFraction> percent for the three months ended March&#160;31, 2022, reflecting the favorable tax impact of net investment losses on equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RleHRyZWdpb246NGQ4ZmM3ZWY1NjFmNDI0ODg4NDY3ZjM4ODRlNmQ5NjFfMTI5_c7b6d44e-b862-414b-893a-da25edf0f6ac" continuedAt="i88def1f371b248f3bd297ae1900fa789" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i88def1f371b248f3bd297ae1900fa789"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RleHRyZWdpb246NGQ4ZmM3ZWY1NjFmNDI0ODg4NDY3ZjM4ODRlNmQ5NjFfMTMw_73cc4a83-5ea3-4d65-a768-7a3152cf5df1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health (benefit) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNC0xLTEtMS0yNDYyNjM_40ea8486-65df-479f-a177-5876613823d6">70.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNC0zLTEtMS0yNDYyNjM_123dcdd6-bc34-46fd-9249-4994f197724f">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNS0xLTEtMS0yNDYyNjM_f5db5caf-db9d-4c17-bb69-d86b412ba9c7">161.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNS0zLTEtMS0yNDYyNjM_d4abe731-eeb0-4bfc-8482-0bc3185ccebe">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNi0xLTEtMS0yNDYyNjM_aa6cb807-b013-4559-8bb5-6b63edccfa94">263.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNi0zLTEtMS0yNDYyNjM_26670d48-76d8-41e0-adf4-5e7e5ded88c3">239.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNy0xLTEtMS0yNDYyNjM_b36e1dba-9a95-4008-b290-198e78f4845d">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNy0zLTEtMS0yNDYyNjM_dd2c1c6b-9d7a-4f47-b21b-7221a16590e9">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfOC0xLTEtMS0yNDYyNjM_45b0ab06-dff9-4076-a24b-1dc425c61469">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfOC0zLTEtMS0yNDYyNjM_b442789c-60e4-4ffb-a4e5-22b6cf6fedb4">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfMTAtMS0xLTEtMjQ2MjYz_99f23b2e-35d2-41c8-976c-0700fd99d6b2">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfMTAtMy0xLTEtMjQ2MjYz_e66c5dae-63b9-42ad-914b-e50a55247a86">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNC0xLTEtMS0yNDYyNjM_4ce8edaa-b858-40fd-b3f3-486dfc74404b">7.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNC0zLTEtMS0yNDYyNjM_87f6c44c-7291-496b-87ae-30b9ea4cb9b1">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNS0xLTEtMS0yNDYyNjM_d8db39e5-6627-4e3c-9921-c2b73c0f8e4d">15.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNS0zLTEtMS0yNDYyNjM_b8e340ce-6a98-4233-b583-fc4383e29c78">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNi0xLTEtMS0yNDYyNjM_54248396-6923-4db1-807e-2c3d61d078dd">45.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNi0zLTEtMS0yNDYyNjM_f8c58660-e1be-451e-bcd0-cef2e5e9498b">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNy0xLTEtMS0yNDYyNjM_7f2ee86a-b0c1-4cd0-87f9-480ff17608c7">13.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNy0zLTEtMS0yNDYyNjM_4c4b5fad-d6b3-4d18-ba97-eb164afa7d6c">13.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfOC0xLTEtMS0yNDYyNjM_0e30fcbb-83c1-426b-93ec-d1be05504738">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfOC0zLTEtMS0yNDYyNjM_2fc461c0-4f30-483d-a858-310cbb2cd6d1">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfMTAtMS0xLTEtMjQ2MjYz_60f9c9ae-0dd2-4b46-9706-4d818cff7fb6">36.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfMTAtMy0xLTEtMjQ2MjYz_e2d99514-aefb-4f25-b489-d3360b5971d2">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfMjU5OTk_14711df5-2173-4190-8780-0be39cd7acca" continuedAt="if65b8ecc83524f0490d84f37ea1c95b8" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="if65b8ecc83524f0490d84f37ea1c95b8" continuedAt="i90b5dc30666e48efafa5361191e63d27"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNDM5ODA0NjU4NTY4MQ_73d9b8ed-c956-4fbb-9c30-a4ab0703898d" continuedAt="ic56691102fb44be19e9392b1739d2a89" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic56691102fb44be19e9392b1739d2a89">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i90b5dc30666e48efafa5361191e63d27" continuedAt="i1fcfa8bea11c4a48b6f0f74564e4400a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="id1429cdab82b46a7a0ad4c4e85647f6a_I20230331" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODY5MDgz_923ee39f-9d1e-4a38-b4af-081554c63dbc">three</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonFraction unitRef="patent" contextRef="i8d76ed1b0d8a474586570b1b99086173_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODY5NzY3_b867b1ab-2429-463f-ac24-b940bdc07fb1">two</ix:nonFraction> of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these <ix:nonFraction unitRef="patent" contextRef="i8d76ed1b0d8a474586570b1b99086173_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4Mzkx_b867b1ab-2429-463f-ac24-b940bdc07fb1">two</ix:nonFraction> patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests. The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. In April 2023, the Supreme Court of Canada denied Apotex's appeal petition, and this matter is closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="i4b4ab320c12a472eb82bbab75fbf501b_I20230331" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODczOTkz_b0f0c300-6bfa-4ae7-b8e4-ceb408e2580a">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1fcfa8bea11c4a48b6f0f74564e4400a" continuedAt="ic8f4679ba65d47bcb51b7da2c5ef5f49"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP (AstraZeneca), were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi, Novo Nordisk, and AstraZeneca, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic8f4679ba65d47bcb51b7da2c5ef5f49" continuedAt="i8968929525964c8685267fd4ff3863e2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of <ix:nonFraction unitRef="brl" contextRef="id56d2b03dc9949ebb50d95e71f042821_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODc5MDM4_f19db2e6-fa99-495a-9f45-4072d6d37fdc">300</ix:nonFraction> million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately <ix:nonFraction unitRef="brl" contextRef="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331" decimals="-7" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4Mzk2_af40b3ac-8c80-45df-b8ef-2dc8b19a14bc">1.15</ix:nonFraction> billion Brazilian reais (approximately $<ix:nonFraction unitRef="usd" contextRef="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODc5Mjk0_d16c9722-82b5-44ce-b08c-347cbd564beb">226</ix:nonFraction>&#160;million as of March&#160;31, 2023). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST. A mediation hearing is scheduled for May 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of <ix:nonFraction unitRef="brl" contextRef="i3ad20ef67d2f430481744471c5b56210_D20190701-20190731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODgwMzI1_db7de391-aca0-4756-b1c9-4b5d5b53548d">500</ix:nonFraction> million Brazilian reais, which ruling in June 2021 was limited in scope and the security was reduced to <ix:nonFraction unitRef="brl" contextRef="i8c6d0498b5f448c7a43cd5218c9d9457_D20210601-20210630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODgwNDI1_401052c7-0886-4cd6-99b7-e18a0305c92a">100</ix:nonFraction> million Brazilian reais (approximately $<ix:nonFraction unitRef="usd" contextRef="i7954361cad5e468189b61f0e148dc919_D20230101-20230331" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODkxMjQz_d41658fa-1111-43db-bb34-302a821033ee">20</ix:nonFraction>&#160;million as of March&#160;31, 2023). ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Average Manufacturer Price Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i3ea4ac837c5c446c91d4a1eadb1660df_I20191031" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4NDE1_4f68740d-77c7-4200-b95e-8d1e37644687">two</ix:nonFraction> lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8968929525964c8685267fd4ff3863e2" continuedAt="ib281a6b1e4394ec7bf9e0014df872952"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the District of New Jersey, 2018); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023), and Lake County, Illinois (U.S. District Court for the Northern District of Illinois, 2023). These lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021, the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib281a6b1e4394ec7bf9e0014df872952">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. The stay was lifted in April 2023. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing</ix:continuation>.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIyOQ_a7b8e3a2-e4d5-4239-a2b6-caefb739fca6" continuedAt="i92c154c0da1548a8b63f14f3df4c85c4" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i92c154c0da1548a8b63f14f3df4c85c4" continuedAt="i82c80d2b27c34ccf925267b1b80ca040"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIzNA_331bdd02-7b8f-4001-82fc-9879c6fa471a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if52058720702455ab18d11fcfce47593_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0xLTEtMS0yNDYyNjM_fbd33dca-c172-4aef-a32e-c326f4128c51">1,874.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c57ea452d543e989f9536150f9db93_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0zLTEtMS0yNDYyNjM_305fe970-923d-419c-a64f-fe50e1162c41">37.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd425dd4dd0841579d320a37187ecdef_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi01LTEtMS0yNDYyNjM_f8815283-4f7e-403a-97f8-91327b190ec9">2,062.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e2ca758e964af8b28d95fd2e6bc9cc_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi03LTEtMS0yNDYyNjM_e8068f08-04c5-4dfa-a48c-1eb605f63cd1">129.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i653d3a81e6b14167933ef66d19e6c10c_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0xMS0xLTEtMjQ2MjYz_8af349cb-670b-4ac8-88a7-4ab1e73f5d45">3,844.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0xLTEtMS0yNDYyNjM_aec1ebbf-ce04-4ab5-ae59-97f2a592be49">72.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0zLTEtMS0yNDYyNjM_c1820e0e-adf4-438c-97c8-a75ecedee2cf">8.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC01LTEtMS0yNDYyNjM_e019aae9-dbf2-4d77-92cb-a321bc7fa835">16.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC03LTEtMS0yNDYyNjM_e53c020f-3e67-4372-b32c-aa7bec994115">12.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0xMS0xLTEtMjQ2MjYz_27095175-6492-485e-83af-607be5c8bb61">76.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0xLTEtMS0yNDYyNjM_5db5f05c-fa4e-426f-9143-fa47f8384036">25.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0zLTEtMS0yNDYyNjM_de8d3bc1-188a-4c3b-b830-44eea47ea72c">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS01LTEtMS0yNDYyNjM_dbe3711f-a9d9-42cf-bda6-38372dbbdf46">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS03LTEtMS0yNDYyNjM_3c55ab5c-b99b-4ea9-98c1-165f9120d26e">2.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0xMS0xLTEtMjQ2MjYz_37b44e5f-c489-422d-8f4f-3e84a1991577">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0xLTEtMS0yNDYyNjM_b4d9252c-594a-4b40-bc16-9c62422efce6">47.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0zLTEtMS0yNDYyNjM_cafa7c7f-afe1-44a6-b831-dfb44b585733">8.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi01LTEtMS0yNDYyNjM_f460fa4f-7913-4974-8530-b3cb2a46d278">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi03LTEtMS0yNDYyNjM_bfbc55df-c1b1-4219-90cf-def78c57d2dd">14.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0xMS0xLTEtMjQ2MjYz_79cdabf4-8ad4-48a2-aed0-e4a7440cd230">67.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id51d9a0f258444078ac8ef9caa739449_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0xLTEtMS0yNDYyNjM_342762e1-f0e1-4dd5-9eff-c0b09465d54a">1,826.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14ddf45785ed4e96a99f49ff596d8acb_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0zLTEtMS0yNDYyNjM_e5b1709a-f231-469e-aa16-854604da31f4">28.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7e2bb76dd4f4adab26a41f1f82d2c2b_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC01LTEtMS0yNDYyNjM_11f02dbc-d3bd-43b7-b1f1-82eb4265fff1">2,066.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510af8b9f1844bed829cb00dfc685190_I20230331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC03LTEtMS0yNDYyNjM_9d7631cf-03af-4326-9b85-896cfa894517">143.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e84d8dd08244d678c234bae2809c48c_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0xMS0xLTEtMjQ2MjYz_94c6cd00-8cd2-4c6c-9b94-d5550f705cb2">3,777.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0d4430e40014abc901dd4edd7cb49e7_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0xLTEtMS0yNDYyNjM_1e06843d-e9da-4fb8-8d42-c6983426401b">1,550.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00101643b4643a483d888a017ecd8ec_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0zLTEtMS0yNDYyNjM_bcd653eb-43bc-4b2d-92dd-d0f23a465bd7">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6c49fd39884008bd1780b0e7dd589d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi01LTEtMS0yNDYyNjM_cb921d19-3da5-4bac-b170-2c7ba14e647f">2,583.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9209cc4104c44020b5cca0fb5e342032_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi03LTEtMS0yNDYyNjM_d9172682-81cc-442a-93c1-4d7f16967787">213.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b6a9fdaf2f44f0ab06f86a366185a4e_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0xMS0xLTEtMjQ2MjYz_9f0446df-2b6b-4d42-bd21-4498b9e6720e">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0xLTEtMS0yNDYyNjM_c8116f28-e4b9-4164-b8ad-8396482b544e">25.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0zLTEtMS0yNDYyNjM_8e16cb38-5a86-41ee-a6f6-401079b9b577">21.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC01LTEtMS0yNDYyNjM_f7b4151b-a0ac-48ca-9695-29b67ee7ea4b">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC03LTEtMS0yNDYyNjM_46b5b740-cd0e-4e54-a44b-b707894a23c4">109.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0xMS0xLTEtMjQ2MjYz_98be98d5-595d-474e-94e4-22e9cf581cda">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0xLTEtMS0yNDYyNjM_8295dbe3-a364-4793-9aa9-cb63e9943384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0zLTEtMS0yNDYyNjM_0ecaddc5-efd9-4a35-8c0a-c691edae0a75">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS01LTEtMS0yNDYyNjM_92b5e539-c095-4f8b-a7bf-053dd29cc97e">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS03LTEtMS0yNDYyNjM_5abd4d61-4464-4f28-8cac-b828f35020d7">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0xMS0xLTEtMjQ2MjYz_4008b540-757c-46e9-9975-ad00e5b9d575">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0xLTEtMS0yNDYyNjM_de534b5a-b09d-4891-a8dd-464481893de6">25.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0zLTEtMS0yNDYyNjM_ae2a481b-35f0-44e1-bc1c-c39e0921ab6c">21.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi01LTEtMS0yNDYyNjM_137fd90c-dfc3-486a-9073-9ded0ff07af3">52.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi03LTEtMS0yNDYyNjM_03bcf180-730e-4d7a-a61f-7bd11535eb10">112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0xMS0xLTEtMjQ2MjYz_e945a31e-8d2f-4a6f-a948-149d2cb9153d">117.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27e1942610fb4fe3b661fe8f47c36101_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0xLTEtMS0yNDYyNjM_6b4777f0-141e-475c-9287-70e04ad3ceb0">1,575.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6d6a2a126f4ea8916e435402446e81_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0zLTEtMS0yNDYyNjM_ee6a013d-6e70-4c16-9fc9-cbc925be375c">18.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie708bb24249c494bac718b7262662532_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC01LTEtMS0yNDYyNjM_e3c909d3-67ae-44db-b57d-422d065df1eb">2,531.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1057b3b5f0c84df780eeb0542ab9296b_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC03LTEtMS0yNDYyNjM_6722183c-94f0-4f8f-8f50-47e079fb64f9">100.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0424c9ff126d4e098f24803951d6a61e_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0xMS0xLTEtMjQ2MjYz_10b50b90-9ef3-4190-acb4-e31c991ba68f">4,225.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMi0xLTEtMS0yNDYyNjM_7edf5690-6848-439c-b133-5b30892b9c67">46.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMi0zLTEtMS0yNDYyNjM_f151828a-fef1-4220-9fe1-bb984b0609b7">13.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMy0xLTEtMS0yNDYyNjM_25111455-2a92-4bd2-83c0-107cc5aceeb7">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMy0zLTEtMS0yNDYyNjM_9be6e241-11a6-4898-8a0d-7a6bd7fa666d">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNC0xLTEtMS0yNDYyNjM_56e96ab1-e42e-40f8-b5a9-4539c99603e2">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNC0zLTEtMS0yNDYyNjM_904c8826-c5cd-4476-8026-873cdc355304">28.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNS0xLTEtMS0yNDYyNjM_36122c70-8e8b-478d-bc76-6d5531a5724d">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNS0zLTEtMS0yNDYyNjM_5f324c9e-99a5-4b10-a7fb-4700b4275809">29.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNi0xLTEtMS0yNDYyNjM_02a2cea7-7278-4c25-b012-f809182ed8b5">36.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNi0zLTEtMS0yNDYyNjM_829048df-68c7-432f-8adf-ede009a6719a">65.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 5), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i82c80d2b27c34ccf925267b1b80ca040"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIzMg_a303452f-e3ec-4cfd-ae30-3dc82932bc35" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.827%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="30" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5badb1e9e9416281833c0e936313e3_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNC0yLTEtMS0yNDYyNjM_f0681a5b-ae0e-4901-a048-fa5ab3d76f34">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie92b4b2cc38546abbedc7e893d1b940c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNC00LTEtMS0yNDYyNjM_006c5280-2972-4964-a555-5b99ced0f9b3">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17225a13a894c18ab97a3b6bf0fb9b2_D20230101-20230331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNS0yLTEtMS0yNDYyNjM_908c6035-13fa-4fda-8552-d7fcb8d83f72">29.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5514dfeeac4fd79d56e6bb4067d42e_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNS00LTEtMS0yNDYyNjM_9a9e209c-b340-409a-baf1-5bb40318a762">87.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNi0yLTEtMS0yNDYyNjM_5ab7df07-572e-45c0-b712-ee60934c12b2">16.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNi00LTEtMS0yNDYyNjM_29de0064-f1e9-4fde-ab26-aaa6292d539a">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNy0yLTEtMS0yNDYyNjM_400f4a41-87cf-49c8-a621-d358b004d4da">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNy00LTEtMS0yNDYyNjM_6c565b56-cdfe-4397-aed9-dfc60596e077">15.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfOC0yLTEtMS0yNDYyNjM_4b654cef-8cfd-4041-9e24-9ef82688cbc7">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfOC00LTEtMS0yNDYyNjM_bd984eb1-a429-476f-a120-7d140460672d">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bc8829f02584de496f6271827b1daa4_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTAtMi0xLTEtMjQ2MjYz_64fd1cf4-b64a-4edf-8953-4542993050a7">22.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6504efffb904c0bb389e6b7ec4a995b_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTAtNC0xLTEtMjQ2MjYz_87835f14-f282-4359-965b-e5fdeec5f6ec">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8b989d89ce4af9a4cc6f268d29ee6f_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTItMi0xLTEtMjQ2MjYz_cc6f5835-d356-4aed-b1a1-545dbd91d917">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a88826d3584cfc872524cbbc7ff75c_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTItNC0xLTEtMjQ2MjYz_46ebb571-0149-4757-aaf4-50244afc0b37">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RleHRyZWdpb246NDA2MTk3NDRlYzIxNGY5ZmIzOTUxZjg1YjI5MDg2ZThfMTAw_bfdde9d8-1018-491b-90b6-6a6e7daefd0e" continuedAt="i0d4e76cb3ca649469d5fe34769271060" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="i0d4e76cb3ca649469d5fe34769271060"><ix:nonNumeric contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RleHRyZWdpb246NDA2MTk3NDRlYzIxNGY5ZmIzOTUxZjg1YjI5MDg2ZThfMTAy_1f9cba1c-b419-4223-b1e6-ec5effe64f76" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMi0xLTEtMS0yNDYyNjM_27387715-c210-4a1e-b64f-3a3e7574fe2b">102.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMi0zLTEtMS0yNDYyNjM_d02a2129-58ad-4bb8-8bd6-9bac61b0634e">84.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMy0xLTEtMS0yNDYyNjM_443d4661-990e-4533-b825-b3e9adc45697">34.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMy0zLTEtMS0yNDYyNjM_17e082b6-9a67-465c-83b5-f8ddf96e6acb">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment losses on equity securities (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNC0xLTEtMS0yNDYyNjM_e8742930-8b24-4c07-a315-33278d3c189a">13.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNC0zLTEtMS0yNDYyNjM_db37c3f7-baf1-4379-bc2d-8a73ddccc74c">425.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNS0xLTEtMS0yNDYyNjM_b5c60530-e29d-4b5f-a0fc-8804a3ae55b7">115.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNS0zLTEtMS0yNDYyNjM_6d722b9f-34ab-43a5-9272-57bce1b0e8d8">93.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNy0xLTEtMS0yNDYyNjM_c18d5fcc-c517-40e9-b0e5-f1193258361f">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNy0zLTEtMS0yNDYyNjM_9d6d5c0b-9520-44ab-a523-e4c68dc1df27">59.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfOC0xLTEtMS0yNDYyNjM_0bd18910-ff17-4eeb-b2e5-34958ede46bc">35.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfOC0zLTEtMS0yNDYyNjM_0a87fa2a-6f75-4c56-8d77-4a88068474ca">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Management's Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_85"></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to our company's results of operations and financial position. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXECUTIVE OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain financial information:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue decreased for the three months ended March 31, 2023 driven by lower realized prices, lower volume, and the unfavorable impact of foreign exchange rates. The decline in revenue during the three months ended March&#160;31, 2023 was primarily driven by the significant and complete reduction of sales of COVID-19 antibodies, partially offset by sales of Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income and earnings per share for the three months ended March 31, 2023 decreased primarily due to lower revenue, partially offset by lower net investment losses on equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Results of Operations" for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certain new molecular entities (NMEs) and new indication line extension (NILEX) products are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have received regulatory approval in the United States (U.S.), Europe, or Japan. The table reflects the status of these NMEs and NILEX products, including relevant developments since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes and Obesity</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted U.S. Food and Drug Administration (FDA) Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in Japan in 2022 and in the U.S. and Europe in the first quarter of 2023.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:65pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide (Mounjaro)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in Europe in the first quarter of 2023. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Initiated a rolling submission in the U.S. in 2022. Announced in April 2023 that a Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obstructive sleep apnea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trial is ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insulin Efsitora Alfa<br/>(Basal Insulin-Fc)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LP(a) siRNA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Muvalaplin<br/>(LP(a) Inhibitor)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orforglipron</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials were completed.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Relaxin-LA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2023.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retatrutide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials were completed. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solbinsiran<br/>(ANGPTL3 siRNA)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:65pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Omvoh</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in Japan in the first quarter of 2023. Submitted in the U.S. and Europe in 2022. Received a complete response letter from the FDA in April 2023. Received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe in the first quarter of 2023.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. and Europe in 2022 and in Japan in the first quarter of 2023. Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BTLA MAB Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eltrekibart<br/>(CXCR1/2 Ligands Monoclonal Antibody)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Peresolimab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatoid arthritis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rezpegaldesleukin </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial failed to meet primary endpoint in the first quarter of 2023.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:65pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete Response Letter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. in 2022 under the accelerated approval pathway. Received a complete response letter from the FDA in the first quarter of 2023 for the accelerated approval submission. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remternetug</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gaucher disease Type 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in April 2023.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O-GlcNAcase Inh</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P2X7 Inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial failed to meet primary and secondary endpoints in the first quarter of 2023.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials discontinued in the first quarter of 2023.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Jaypirca</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA granted accelerated approval</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in the U.S. in the first quarter of 2023. Submitted in Europe in 2022. Received a positive opinion from the CHMP in Europe in April 2023. Phase III trial is ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjuvant breast cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2- metastatic breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. in Europe.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the expiration of patent exclusivity for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have faced generic competition that has rapidly and severely eroded revenue from prior levels. This decline in revenue will continue to impact period-over-period financial results comparisons, particularly during the first half of 2023. See Note 8 to the consolidated condensed financial statements for a description of legal proceedings currently pending regarding certain of our patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patents for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) have expired in the U.S. and major international markets, and we have also introduced lower-priced versions of Humalog as part of our insulin access and affordability solutions. On March 1, 2023, we announced price reductions for Humalog and an expansion of our Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. A competitor has a similar version of insulin lispro in the U.S. and in certain European markets. Due to the expansion of our insulin access and affordability solutions in the U.S. and the impact of competition and pricing pressure in the U.S. and certain international markets, we expect that lower revenue for Humalog due to realized price decline will continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reforms, including those that may stem from periods of economic downturn or uncertainty, or as a result of high inflation, emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war), or government budgeting priorities, may continue to result in added pressure on pricing and reimbursement for our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA). Among other measures, the IRA will require the U.S. Department of Health and Human Services to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply nine (medicines approved under a New Drug Application) or thirteen (medicines approved under a Biologics License Application) years following initial FDA approval and will be capped at a statutory ceiling price that is likely to represent a significant discount from average prices to wholesalers and direct purchasers. While the law specifies a ceiling price, it does not set a minimum or floor price. Given our product portfolio, we expect some of our significant products will be selected, which would have the effect of accelerating revenue erosion prior to patent expiry. The effect of reducing prices and reimbursement for certain of our products would significantly impact our business and consolidated results of operations. The establishment of payment limits or other restrictions by drug affordability review boards and other state level actors would similarly impact us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other IRA provisions provide for rebate obligations on drug manufacturers that increase prices of Medicare Part B and Part D medicines at a rate greater than the rate of inflation and Part D benefit redesign that includes replacing the Part D coverage gap discount program with a new manufacturer discounting program. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties, which could be significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA takes effect progressively starting in 2023, with the first government-set prices effective in 2026. The IRA may meaningfully influence our business strategies and those of our competitors. In particular, the nine-year timeline to set prices for medicines approved under a new drug application reduces the attractiveness of investment in small molecule innovation. The full impact of the IRA on our business and the pharmaceutical industry, including the implications to us of a competitor's product being selected for price setting, remains uncertain. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional policies, regulations, legislation, or enforcement, including those proposed and/or pursued by the U.S. Congress, the current U.S. presidential administration, and regulatory authorities worldwide, could adversely impact our business and consolidated results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidation and integration of private payors and pharmacy benefit managers in the U.S. has also significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price or rebate concessions and pharmacy reimbursement rates. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, such as the Centers for Medicare &amp; Medicaid Services' national coverage determination for monoclonal antibodies for the treatment of Alzheimer's Disease, may adversely impact our business and consolidated results of operations. We expect that these actions may intensify and could particularly affect certain products, such as insulin, which could adversely affect our business. In addition, we are engaged in litigation and investigations related to our 340B program, access to insulin, and other matters that, if resolved adversely to us, could negatively impact our business and consolidated results of operations. It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulatory issues concerning compliance with current Good Manufacturing Practices, quality assurance, evolving standards, and increased scrutiny around excipients and potential impurities such as nitrosamines, and similar regulations and standards (and comparable foreign regulations and standards) for our products can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. Moreover, increased focus on business combinations across industries and jurisdictions can lead to impediments to the completion of business combinations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Business&#8212;Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access" in Part I, Item 1 and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. See also Note 8 to the consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced challenges, and expect to continue to face challenges, meeting strong demand for our incretin products. In the U.S., given very strong uptake of Mounjaro following its launch in the U.S. for type 2 diabetes in the second quarter of 2022, and as demand for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has remained strong, we have experienced intermittent delays in fulfilling certain U.S. orders for these products. Outside the U.S., we have implemented certain actions to minimize the impact on existing Trulicity patients, but we expect to continue to experience intermittent disruptions in our supply of Trulicity in international markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate tight supplies of our incretin products will persist until additional manufacturing capacity is operationalized. We expect additional internal and contracted manufacturing capacity will become fully operational around the world in the next several years, with significant expansion in 2023, as part of our ongoing efforts to meet the significant demand for our incretin medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows. The U.S. and countries around the world are actively proposing and enacting tax law changes. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate. Tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions. Changes to existing U.S. and foreign tax laws and increased scrutiny by tax authorities in the U.S. and other jurisdictions could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rates and Other Impacts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our consolidated results of operations in any given period. During the three months ended March&#160;31, 2023, revenue was unfavorably impacted by 2 percent due to foreign exchange rates compared to the three months ended March 31, 2022. There is uncertainty in the future movements in foreign exchange rates, and fluctuations in these rates could adversely impact our consolidated results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, cost inflation, the strain on global transportation, logistics, and labor markets (including as exacerbated by the COVID-19 pandemic and the emergence or escalation of, and responses to, war or unrest, including the Russia-Ukraine war), global economic downturns or uncertainty, and an increase in overall demand in our industry for certain products and materials have had, and may continue to have, a number of impacts on our business, including increased costs and disruptions in the supply of our medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements. We view our business development activity as a way to enhance our pipeline and strengthen our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the effects of the COVID-19 pandemic have evolved, we remain focused on protecting the health, safety, and well-being of our employees; supporting the medical system and our communities; and affordability of and access to our medicines. At the outset of the COVID-19 pandemic, we also focused on researching, developing, and supplying COVID-19 therapies. During 2022, we recognized $2.02 billion in revenue from COVID-19 antibodies and do not anticipate any revenue from COVID-19 antibodies in 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations across markets to varying and fluctuating degrees, including as a result of cost inflation and strain on the global transportation, manufacturing, and labor markets, fewer in-person interactions among patients and healthcare providers and our employees with healthcare professionals in certain markets, pricing pressures, rebates, clawbacks, and other changes in reimbursement policies resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems, and risks related to our COVID-19 therapies. The degree to which the COVID-19 pandemic could continue to affect us will depend on developments that are highly uncertain and beyond our knowledge or control. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022 for additional information on risk factors that could impact our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_91"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three months ended March&#160;31, 2023, the decrease in volume was primarily driven by COVID-19 antibodies and, to a lesser extent, Alimta following the entry of multiple generics in the first half of 2022, partially offset by increased volume for Mounjaro, Trulicity, and Verzenio. In the U.S. for the three months ended March&#160;31, 2023, the decrease in realized prices was primarily driven by Humalog, due to unfavorable segment mix, and Trulicity, due to higher contracted rebates as well as unfavorable segment mix.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three months ended March&#160;31, 2023, the increase in volume was primarily driven by Verzenio, Jardiance, Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Trulicity, partially offset by the decrease in volume due to the sales of our rights to Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Taiwan and Saudi Arabia during the three months ended March&#160;31, 2022. Outside the U.S. for the three months ended March&#160;31, 2023, the decrease in realized prices was primarily driven by the impact of government pricing in China from volume-base procurement for Humalog.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended March&#160;31, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,547.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">429.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,977.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mounjaro</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">527.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">606.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity increased 18 percent in the U.S. during the three months ended March&#160;31, 2023, driven by increased demand and, to a lesser extent, wholesaler buying patterns, partially offset by lower realized prices driven by higher contracted rebates as well as unfavorable segment mix. We experienced intermittent delays in fulfilling certain U.S. Trulicity orders during the fourth quarter of 2022. These delays persisted through the first quarter of 2023, but at a reduced level. Revenue outside the U.S. increased 1 percent during the three months ended March&#160;31, 2023, driven by increased volume, largely offset by the unfavorable impact of foreign exchange rates and lower realized prices. Actions to manage strong demand across our incretin portfolio, including measures to minimize existing patient impact in international markets, also affected volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio increased 53 percent in the U.S. during the three months ended March&#160;31, 2023, primarily driven by increased demand, partially offset by customer buying patterns. Revenue outside the U.S. increased 73 percent during the three months ended March&#160;31, 2023, driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance increased 43 percent in the U.S. during the three months ended March&#160;31, 2023, primarily driven by increased demand. Revenue outside the U.S. increased 31 percent during the three months ended March&#160;31, 2023, primarily driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Mounjaro in the U.S. during the three months ended March&#160;31, 2023 was $536.4 million. Mounjaro launched in the U.S. for the treatment of type 2 diabetes in June of 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz increased 2 percent in the U.S. during the three months ended March&#160;31, 2023, driven by increased demand, largely offset by lower realized prices. Revenue outside the U.S. increased 19 percent during the three months ended March&#160;31, 2023, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_97"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gross margin, costs, and expenses:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,333.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,737.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,985.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,749.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue for the three months ended March&#160;31, 2023 increased 3.1 percentage points compared with the three months ended March&#160;31, 2022, primarily driven by sales of COVID-19 antibodies during the three months ended March&#160;31, 2022, partially offset by lower realized prices. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Res</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earch and development expenses increased 23 percent for the three months ended March&#160;31, 2023, primarily driven by higher development expenses for late-stage assets.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 percent for the three months ended March&#160;31, 2023, primarily driven by costs associated with launches of new products and indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $105.0 million of acquired IPR&amp;D for the three months ended March&#160;31, 2023. We recognized $165.6 million of acquired IPR&amp;D for the three months ended March&#160;31, 2022, primarily related to a purchase of a Priority Review Voucher. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense included net investment losses on equity securities of $13.7 million and $425.4 million for three months ended March&#160;31, 2023 and 2022, respectively. See Note 10 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 12.1 percent for the three months ended March&#160;31, 2023, reflecting the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit. The effective tax rate was 7.3 percent for the three months ended March&#160;31, 2022, reflecting the favorable tax impact of net investment losses on equity securities.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">FINANCIAL CONDITION AND LIQUIDITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have announced additional investment commitments in new facilities in Indiana, North Carolina, and Limerick, Ireland to manufacture existing and future products. We expect that these investments will result in higher capital expenditures in excess of $8 billion over the next several years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents increased to $3.55 billion as of March&#160;31, 2023, compared with $2.07 billion as of December&#160;31, 2022. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the three months ended March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $2.87 billion and $3.05 billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively. See Note 5 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, total debt was $18.88 billion, an increase of $2.65 billion compared with $16.24&#160;billion as of December&#160;31, 2022. In February 2023, we issued $750.0&#160;million of 5.000 percent fixed-rate notes due in 2026, which are callable at par after one year, $1.00&#160;billion of 4.700 percent fixed-rate notes due in 2033, $1.25&#160;billion of 4.875 percent fixed-rate notes due in 2053, and $1.00&#160;billion of 4.950 percent fixed-rate notes due in 2063, all with interest to be paid semi-annually. We used the net cash proceeds from the offering of $3.96&#160;billion for general business purposes, including the repayment of outstanding commercial paper. See Note 5 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had a total of $7.33 billion of unused committed bank credit facilities, $7.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we repurchased $750.0&#160;million of shares under our $5.00&#160;billion share repurchase program authorized in May 2021. As of March&#160;31, 2023, we had $2.50 billion remaining under this program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we paid dividends of $1.02&#160;billion, or $1.13 per share, to our shareholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview&#8212;Other Matters&#8212;Patent Matters" for information regarding recent losses of patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of healthcare legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview&#8212;Other Matters&#8212;Foreign Currency Exchange Rates and Other Impacts"), and fair values of equity securities.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, refer to "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and the notes to our consolidated financial statements in Part II, Item 8 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. See also Note 1 to the consolidated condensed financial statements. There have been no material changes to our critical accounting estimates since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">AVAILABLE INFORMATION ON OUR WEBSITE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely post important information for investors in the &#8220;Investors&#8221; section of our website, www.lilly.com. We may use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the &#8220;Investors&#8221; section of our website, in addition to following our press releases, filings with the SEC, public conference calls, presentations, and webcasts. We may also use social media channels to communicate with investors and the public about our business, products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels, is not incorporated by reference into, and is not a part of, this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_1121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our market risk, see &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; in Part II, Item 7A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_112"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&#160;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David Ricks, president and chief executive officer, and Anat Ashkenazi, executive vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022) as of March&#160;31, 2023, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter of 2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_118"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 8 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_121"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. There have been no material changes from the risk factors previously disclosed in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_124"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price Paid&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number of Shares<br/>Purchased&#160;as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we repurchased $750.0 million of shares under our $5.00 billion share repurchase program authorized in May 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/articlesofincorporationlly.htm">Amended Articles of Incorporation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/articlesofincorporationlly.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/articlesofincorporationlly.htm">incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/bylaws.htm">Bylaws, as amended, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947822000138/bylaws.htm">incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312023x10qxexhibit311.htm">Rule&#160;13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312023x10qxexhibit312.htm">Rule&#160;13a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer*</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312023x10qxexhibit32.htm">Section 1350 Certification*</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Filed herewith.</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt instruments under which the total amount of securities authorized does not exceed 10 percent of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the Securities and Exchange Commission upon request.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ibcc38c3f782c4545ad9dc8c7f1087104_130"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance, and Chief Accounting Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lly-03312023x10qxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib5b13b545fc6414c8871e24391a401b8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Ricks, Chair, President, and Chief Executive Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>lly-03312023x10qxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id2eedb0c27d340cb8d39da4f9400edc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Executive Vice President and Chief Financial Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>lly-03312023x10qxexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iab0dcabf497a46739dccf6a343afbe0b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32 Section 1350 Certification</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#34;Company&#34;), does hereby certify that, to the best of their knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (the &#34;Form 10-Q&#34;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 27, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lly-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperationsUnaudited" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited">
        <link:definition>0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquity" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity">
        <link:definition>0000006 - Statement - Consolidated Condensed Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.lilly.com/role/BasisofPresentation">
        <link:definition>0000009 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>0000010 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitures">
        <link:definition>0000011 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>0000012 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>0000013 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>0000015 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>0000016 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000017 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>0000018 - Disclosure - Other&#8211;Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.lilly.com/role/BasisofPresentationPolicies">
        <link:definition>0000019 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>0000020 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresTables" roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresTables">
        <link:definition>0000021 - Disclosure - Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>0000022 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>0000023 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>0000024 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000025 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>0000026 - Disclosure - Other&#8211;Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.lilly.com/role/BasisofPresentationDetails">
        <link:definition>0000027 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>0000028 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdjustmentstoRevenueDetails" roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails">
        <link:definition>0000029 - Disclosure - Revenue (Adjustments to Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>0000030 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>0000031 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>0000032 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>0000033 - Disclosure - Acquisitions and Divestitures (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000034 - Disclosure - Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails">
        <link:definition>0000035 - Disclosure - Acquisitions and Divestitures (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
        <link:definition>0000036 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNetProductRevenueDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails">
        <link:definition>0000037 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNarrativeDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails">
        <link:definition>0000040 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails">
        <link:definition>0000041 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofFairValueMeasurementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
        <link:definition>0000044 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofEffectofRiskManagementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
        <link:definition>0000047 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesDetails">
        <link:definition>0000048 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000049 - Disclosure - Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>0000050 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAOCIDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails">
        <link:definition>0000051 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTaxEffectDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails">
        <link:definition>0000052 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossReclassificationDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails">
        <link:definition>0000053 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>0000054 - Disclosure - Other&#8211;Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MounjaroMember" abstract="true" name="MounjaroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" abstract="true" name="MilestonePaymentsCapitalizedAsIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SellEuroMember" abstract="true" name="SellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationJuly2018RulingMember" abstract="true" name="EmployeeLitigationJuly2018RulingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" abstract="true" name="AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSDollarSellChineseYuanMember" abstract="true" name="BuyUSDollarSellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A495NotesDue2063Member" abstract="true" name="A495NotesDue2063Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OlanzapinePortfolioMember" abstract="true" name="OlanzapinePortfolioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUsdSellEuroMember" abstract="true" name="BuyUsdSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SellChineseYuanMember" abstract="true" name="SellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BaqsimiMember" abstract="true" name="BaqsimiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SeniorNotesDue202620332053And2063Member" abstract="true" name="SeniorNotesDue202620332053And2063Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BioMarinPharmaceuticalIncMember" abstract="true" name="BioMarinPharmaceuticalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A625NotesDue2031Member" abstract="true" name="A625NotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapU.S.DollarsToEuroMember" abstract="true" name="SwapU.S.DollarsToEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PurchasesOfInProcessResearchAndDevelopment" abstract="false" name="PurchasesOfInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationJuly2019RulingMember" abstract="true" name="EmployeeLitigationJuly2019RulingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyGBPSellUSDMember" abstract="true" name="BuyGBPSellUSDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1700NotesDue2049Member" abstract="true" name="A1700NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A4875NotesDue2053Member" abstract="true" name="A4875NotesDue2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AkouosAcquisitionMember" abstract="true" name="AkouosAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrulicityMember" abstract="true" name="TrulicityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A50NotesDue2026Member" abstract="true" name="A50NotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A47NotesDue2033Member" abstract="true" name="A47NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lly-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77e240ce-c47b-4407-a97a-18a137c870c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8c7fd999-6e4d-41b1-8630-5cbdcb06b033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77e240ce-c47b-4407-a97a-18a137c870c1" xlink:to="loc_us-gaap_Revenues_8c7fd999-6e4d-41b1-8630-5cbdcb06b033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_4b0a2c71-7d8e-4d94-acd0-a97d86b53a26" xlink:href="lly-20230331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77e240ce-c47b-4407-a97a-18a137c870c1" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_4b0a2c71-7d8e-4d94-acd0-a97d86b53a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9fad2b53-3007-42a2-accf-db0f2ca55f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0d29e33f-5f7c-483f-bef0-6b1f5e1e7fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9fad2b53-3007-42a2-accf-db0f2ca55f6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0d29e33f-5f7c-483f-bef0-6b1f5e1e7fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ba6997f-054f-414e-a415-609b6f06bde0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9fad2b53-3007-42a2-accf-db0f2ca55f6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2ba6997f-054f-414e-a415-609b6f06bde0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:href="lly-20230331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_be1c26fc-15f6-4bf6-9a99-590ee1a4a843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_be1c26fc-15f6-4bf6-9a99-590ee1a4a843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a5e817e1-dabb-41fe-90c7-c5ebd4f64ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a5e817e1-dabb-41fe-90c7-c5ebd4f64ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d44d475e-c792-4a3a-9bc8-0c72150f15cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d44d475e-c792-4a3a-9bc8-0c72150f15cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b47fbde0-d1d0-4b90-8f47-58ed7ad4f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b47fbde0-d1d0-4b90-8f47-58ed7ad4f72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_7d554f68-070c-408f-a258-4b6d3a085553" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_2152c3b1-0c5d-4e6c-8513-30def5a2444d" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_7d554f68-070c-408f-a258-4b6d3a085553" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9de6870-c88b-49c9-995b-118f6c244ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d8d55be3-b3ae-44d4-a8f9-659ec79ccefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9de6870-c88b-49c9-995b-118f6c244ab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d8d55be3-b3ae-44d4-a8f9-659ec79ccefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60bd1a5c-97ca-4b0e-9ac1-66c486bd94ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9de6870-c88b-49c9-995b-118f6c244ab7" xlink:to="loc_us-gaap_NetIncomeLoss_60bd1a5c-97ca-4b0e-9ac1-66c486bd94ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_05f4b722-5893-4f2d-8158-762b9b57520a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69c29192-30ec-44a0-97b0-53b20c40b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_05f4b722-5893-4f2d-8158-762b9b57520a" xlink:to="loc_us-gaap_LiabilitiesCurrent_69c29192-30ec-44a0-97b0-53b20c40b422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3cb91958-b531-4323-b3b7-7e4ea19861fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_05f4b722-5893-4f2d-8158-762b9b57520a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3cb91958-b531-4323-b3b7-7e4ea19861fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0eeb21dc-939e-4402-a4d8-b7a2ee27dc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_05f4b722-5893-4f2d-8158-762b9b57520a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0eeb21dc-939e-4402-a4d8-b7a2ee27dc15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9d13e254-2834-4b16-965e-1f5a28a48fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_05f4b722-5893-4f2d-8158-762b9b57520a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9d13e254-2834-4b16-965e-1f5a28a48fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1d42a0cf-aa34-476c-8ebc-327ce37786a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_AccountsPayableCurrent_1d42a0cf-aa34-476c-8ebc-327ce37786a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d00b9345-9b44-4db5-b08a-afb41aeb7aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d00b9345-9b44-4db5-b08a-afb41aeb7aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_7b07e856-5474-48b7-b143-4bc72f75362e" xlink:href="lly-20230331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_lly_SalesRebatesAndDiscounts_7b07e856-5474-48b7-b143-4bc72f75362e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_827f94bc-2144-411d-b2dd-85a76634d23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_DividendsPayableCurrent_827f94bc-2144-411d-b2dd-85a76634d23c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_dfd18b76-4369-44d0-828c-da7ed3902463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_TaxesPayableCurrent_dfd18b76-4369-44d0-828c-da7ed3902463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_471f3c74-e92f-4d47-b6e8-020adac7e896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_471f3c74-e92f-4d47-b6e8-020adac7e896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_3767650d-074c-4f41-a3c3-fdbc5a97ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cde9008f-cb2f-478f-91f2-0860e9413785" xlink:to="loc_us-gaap_DebtCurrent_3767650d-074c-4f41-a3c3-fdbc5a97ca19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8a734d-307c-4ecc-ba89-a46b36a97f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8a734d-307c-4ecc-ba89-a46b36a97f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_de2b3a7a-aceb-4363-b448-453f39573afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_ShortTermInvestments_de2b3a7a-aceb-4363-b448-453f39573afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_00dbb9a5-cad3-401a-87fc-38870e71ca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_00dbb9a5-cad3-401a-87fc-38870e71ca3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_b41bad94-1d0b-4eff-b085-e64b529b717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_b41bad94-1d0b-4eff-b085-e64b529b717d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_99c3b3e9-8f74-4b28-aa25-b52c9567d320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_InventoryNet_99c3b3e9-8f74-4b28-aa25-b52c9567d320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff396ef1-75db-4cbc-a265-6356a07407b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e6f3002-c62b-4106-93c4-a56e0e8744ab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff396ef1-75db-4cbc-a265-6356a07407b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c452e70f-0174-4649-a258-8546c0d0c452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_874b68ff-05bb-4d38-ad1e-67724bb68728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c452e70f-0174-4649-a258-8546c0d0c452" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_874b68ff-05bb-4d38-ad1e-67724bb68728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_985ecdd9-000e-4c66-b661-3bbbc3205810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c452e70f-0174-4649-a258-8546c0d0c452" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_985ecdd9-000e-4c66-b661-3bbbc3205810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_36a8ce8c-c996-455e-9ad8-7a243f33d888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c452e70f-0174-4649-a258-8546c0d0c452" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_36a8ce8c-c996-455e-9ad8-7a243f33d888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3844f2e7-5894-4943-8291-ea7910ce06b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c452e70f-0174-4649-a258-8546c0d0c452" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3844f2e7-5894-4943-8291-ea7910ce06b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8ed68a75-dcac-4b12-990d-6cbff4db5a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_AssetsCurrent_8ed68a75-dcac-4b12-990d-6cbff4db5a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b9504d13-483c-4def-932d-9dd76c35ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_LongTermInvestments_b9504d13-483c-4def-932d-9dd76c35ce8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_66111665-39cc-4d08-bc40-2a085da45ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_Goodwill_66111665-39cc-4d08-bc40-2a085da45ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_00471d8b-becc-4df0-8559-f66212b261cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_00471d8b-becc-4df0-8559-f66212b261cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a339a220-e4a9-42ad-9b7e-a33f879019e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a339a220-e4a9-42ad-9b7e-a33f879019e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83caa058-b5e5-481e-b483-1b1f97ac616d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83caa058-b5e5-481e-b483-1b1f97ac616d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5757fe24-d5df-4461-9425-81f1092e3787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4a764e7f-57c6-48a4-b3df-6762a5e01339" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5757fe24-d5df-4461-9425-81f1092e3787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea8b543f-e3c6-4aab-bb85-4ff8356105ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee78b545-f38a-419e-ad61-c7dafc7e0e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea8b543f-e3c6-4aab-bb85-4ff8356105ee" xlink:to="loc_us-gaap_StockholdersEquity_ee78b545-f38a-419e-ad61-c7dafc7e0e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d6e26625-5388-45bd-8841-fafb6102f447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea8b543f-e3c6-4aab-bb85-4ff8356105ee" xlink:to="loc_us-gaap_MinorityInterest_d6e26625-5388-45bd-8841-fafb6102f447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_047df347-b642-4264-98e4-9470ea23ae4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_047df347-b642-4264-98e4-9470ea23ae4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_9d3b53a3-291f-4341-bcc6-b58f6125194f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_9d3b53a3-291f-4341-bcc6-b58f6125194f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_e23e7638-e53b-42d0-891f-4298210853ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_TreasuryStockCommonValue_e23e7638-e53b-42d0-891f-4298210853ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5aada9a1-ad30-4087-831b-95ebac2891f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5aada9a1-ad30-4087-831b-95ebac2891f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bdd9e62f-c91b-4bf4-a3fd-45cbfb4e436e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_CommonStockValue_bdd9e62f-c91b-4bf4-a3fd-45cbfb4e436e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f130ad0f-5d40-4ca7-995e-94586e0d8c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd06cacf-f156-4588-a570-edfa437b98a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f130ad0f-5d40-4ca7-995e-94586e0d8c5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61189cf1-79e2-420b-9d6c-c695bc2643c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0836c0-10c9-4aec-8729-cd34b60b8059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61189cf1-79e2-420b-9d6c-c695bc2643c1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0836c0-10c9-4aec-8729-cd34b60b8059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6308c4da-310a-4d93-aef9-4d196fd9fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61189cf1-79e2-420b-9d6c-c695bc2643c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6308c4da-310a-4d93-aef9-4d196fd9fb7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b9ef06a-3c12-4c2c-8bf6-44935278853f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61189cf1-79e2-420b-9d6c-c695bc2643c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b9ef06a-3c12-4c2c-8bf6-44935278853f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee4f4746-e542-48cb-b6bc-a496b288878d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_61189cf1-79e2-420b-9d6c-c695bc2643c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee4f4746-e542-48cb-b6bc-a496b288878d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f8acbbfa-a902-48e9-9132-7988a64848b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f8acbbfa-a902-48e9-9132-7988a64848b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_0af0428d-71df-4866-8fdc-769542ff459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_0af0428d-71df-4866-8fdc-769542ff459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0d35e52c-cf81-4872-bf78-fdcdc180d3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0d35e52c-cf81-4872-bf78-fdcdc180d3da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3aad04b0-5eb0-4723-af1c-37a80342c1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3aad04b0-5eb0-4723-af1c-37a80342c1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_deef8590-ba0b-4f33-a839-08ea16e70b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_PaymentsOfDividends_deef8590-ba0b-4f33-a839-08ea16e70b56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5f0a78f2-97e9-45c1-a622-f1f7ab8ca402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86e22aca-6b74-44b7-9d5b-7c4d6ed3a6af" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5f0a78f2-97e9-45c1-a622-f1f7ab8ca402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff56e5ed-1ba7-4346-81d9-652f1752f700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_NetIncomeLoss_ff56e5ed-1ba7-4346-81d9-652f1752f700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8747b2db-8bca-4b32-8932-9c7bd3d1637f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8747b2db-8bca-4b32-8932-9c7bd3d1637f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d825e7a4-ef3f-490c-a650-df4defc279da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d825e7a4-ef3f-490c-a650-df4defc279da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f64a0555-82ea-45b9-ae75-8980a000f317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_ShareBasedCompensation_f64a0555-82ea-45b9-ae75-8980a000f317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_55b33783-5423-480e-8bfe-fee2c1b4c29d" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_55b33783-5423-480e-8bfe-fee2c1b4c29d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b0e3392a-38ac-416f-975e-7f390b407c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b0e3392a-38ac-416f-975e-7f390b407c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_400f3c4c-0c08-487d-8ed4-572aac07b973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_400f3c4c-0c08-487d-8ed4-572aac07b973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3523c833-9c61-4680-8aa8-3fd8cfe0f158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32a92158-8651-47a1-a366-cf3ff618402e" xlink:to="loc_us-gaap_GainLossOnInvestments_3523c833-9c61-4680-8aa8-3fd8cfe0f158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_8b7a4f49-bda7-4368-a65a-28cf6e0e45c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_8b7a4f49-bda7-4368-a65a-28cf6e0e45c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63d4a30d-1759-4906-9baa-d56abaf4924a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63d4a30d-1759-4906-9baa-d56abaf4924a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_0014fd83-2e78-4909-b45f-5251dc3ad106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_0014fd83-2e78-4909-b45f-5251dc3ad106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_47971717-d97f-4212-bac8-c09c58f46805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_47971717-d97f-4212-bac8-c09c58f46805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8c6c230f-901a-4176-b1f3-e4fb9bde0b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8c6c230f-901a-4176-b1f3-e4fb9bde0b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasesOfInProcessResearchAndDevelopment_cdd97226-09f1-4e8a-ad45-f7786ebd1969" xlink:href="lly-20230331.xsd#lly_PurchasesOfInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_lly_PurchasesOfInProcessResearchAndDevelopment_cdd97226-09f1-4e8a-ad45-f7786ebd1969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_a0522f2b-2539-45bb-9784-be5d6528e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3fe4237-8d14-4613-846a-d02c96e7e1a1" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_a0522f2b-2539-45bb-9784-be5d6528e268" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e2cb38fd-95a5-4c25-bb4e-3a30b218198f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c47b811e-ca32-4852-8ff9-c676b777cbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e2cb38fd-95a5-4c25-bb4e-3a30b218198f" xlink:to="loc_us-gaap_Goodwill_c47b811e-ca32-4852-8ff9-c676b777cbca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_25050ebf-4995-48ca-9a62-880e84c6a969" xlink:href="lly-20230331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e2cb38fd-95a5-4c25-bb4e-3a30b218198f" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_25050ebf-4995-48ca-9a62-880e84c6a969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e26dc39a-447b-418e-b604-5f47fab323af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e2cb38fd-95a5-4c25-bb4e-3a30b218198f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e26dc39a-447b-418e-b604-5f47fab323af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d4cc15cd-f7df-4a3c-b25e-6d04e5f639c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e2cb38fd-95a5-4c25-bb4e-3a30b218198f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d4cc15cd-f7df-4a3c-b25e-6d04e5f639c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12306075-44fe-4bed-9615-86abc383869f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b0a7b04d-8da3-48a2-a2c2-a2152aa288ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12306075-44fe-4bed-9615-86abc383869f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b0a7b04d-8da3-48a2-a2c2-a2152aa288ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_90445059-1191-469c-8540-4cd26eb912c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12306075-44fe-4bed-9615-86abc383869f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_90445059-1191-469c-8540-4cd26eb912c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8f4a5cc8-fb8a-4778-9df4-7caa80eb2106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12306075-44fe-4bed-9615-86abc383869f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8f4a5cc8-fb8a-4778-9df4-7caa80eb2106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ad2b26fc-1366-4511-ad49-05f0b170fd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12306075-44fe-4bed-9615-86abc383869f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ad2b26fc-1366-4511-ad49-05f0b170fd2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_e0a8397d-18b4-4a9b-83e9-444a88cf8551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c6dfb284-f95f-4393-80ca-474690b580da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_e0a8397d-18b4-4a9b-83e9-444a88cf8551" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c6dfb284-f95f-4393-80ca-474690b580da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cc3e8298-08d4-4e7f-97c1-d9f346776f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_e0a8397d-18b4-4a9b-83e9-444a88cf8551" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cc3e8298-08d4-4e7f-97c1-d9f346776f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f176fc80-46cf-43b6-ad4e-31eed2e9d605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_e0a8397d-18b4-4a9b-83e9-444a88cf8551" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f176fc80-46cf-43b6-ad4e-31eed2e9d605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fc9efe45-9e21-44d9-9db1-65e911682189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_e0a8397d-18b4-4a9b-83e9-444a88cf8551" xlink:to="loc_us-gaap_EquityMethodInvestments_fc9efe45-9e21-44d9-9db1-65e911682189" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_b54b4396-a3d1-42f3-891b-0bd4c995d28d" xlink:href="lly-20230331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6979958b-68ea-435b-b4af-54803edeea57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_b54b4396-a3d1-42f3-891b-0bd4c995d28d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6979958b-68ea-435b-b4af-54803edeea57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_5e341740-6498-41ed-a2f4-d131e1bbf80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_b54b4396-a3d1-42f3-891b-0bd4c995d28d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_5e341740-6498-41ed-a2f4-d131e1bbf80a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_af17f3f6-3d53-4d70-a894-2e00d790c769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_b54b4396-a3d1-42f3-891b-0bd4c995d28d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_af17f3f6-3d53-4d70-a894-2e00d790c769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_a3f3df5b-aa43-4fce-899c-d31ed1201595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_b54b4396-a3d1-42f3-891b-0bd4c995d28d" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_a3f3df5b-aa43-4fce-899c-d31ed1201595" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_93752830-4440-461b-b91c-47ccbc898164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_93752830-4440-461b-b91c-47ccbc898164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a67a94fa-209a-4b67-8b3b-b11283c4b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a67a94fa-209a-4b67-8b3b-b11283c4b7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_751de772-20c1-4197-be06-4c829da68229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_751de772-20c1-4197-be06-4c829da68229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_481c80fb-b680-472f-9db2-17d169eaf834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_481c80fb-b680-472f-9db2-17d169eaf834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ec3c574-2a9b-49a2-a42f-5eab8b468d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3937a9c3-58d7-4d90-bcd4-25e52e9642f4" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ec3c574-2a9b-49a2-a42f-5eab8b468d88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_af54cef4-0490-46c7-b21e-4385c3a662e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fae3e3cb-60e8-4e43-965b-bb44ba6e3f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_af54cef4-0490-46c7-b21e-4385c3a662e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fae3e3cb-60e8-4e43-965b-bb44ba6e3f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e9ea38c4-3566-4325-936d-bd7161514593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_af54cef4-0490-46c7-b21e-4385c3a662e2" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e9ea38c4-3566-4325-936d-bd7161514593" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9f8b0aca-129b-47b0-bac5-9c93d46cb680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9f8b0aca-129b-47b0-bac5-9c93d46cb680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_79286f66-78f0-4ff1-86ac-8b16260b94bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:to="loc_us-gaap_InterestExpense_79286f66-78f0-4ff1-86ac-8b16260b94bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_067b7ad2-28f7-4425-8091-ce4124066bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_067b7ad2-28f7-4425-8091-ce4124066bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_367d176e-de05-415b-b2cc-36cf6f8cba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:to="loc_us-gaap_InvestmentIncomeInterest_367d176e-de05-415b-b2cc-36cf6f8cba0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_631a1b7b-c9b4-45ed-982e-7cbf81216c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_04a14fd0-a98e-4a70-9919-ecf49f358b77" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_631a1b7b-c9b4-45ed-982e-7cbf81216c41" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lly-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="ibd1ec87326fe4ef9b93a4c1bf749c1eb_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_91821ee9-9230-4bef-b220-8798ae03f3a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentType_91821ee9-9230-4bef-b220-8798ae03f3a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_639ba401-7225-4674-8670-cea1ef95c369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentPeriodEndDate_639ba401-7225-4674-8670-cea1ef95c369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5eeb3272-d966-454b-ab1b-6f8507f0a69d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityFileNumber_5eeb3272-d966-454b-ab1b-6f8507f0a69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5b0e9fe1-a81f-44e9-8447-9b4a84fb2d55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityRegistrantName_5b0e9fe1-a81f-44e9-8447-9b4a84fb2d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5e9bcff4-dba2-4714-9750-4c8f418b6d54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5e9bcff4-dba2-4714-9750-4c8f418b6d54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74741467-a8cc-4208-8881-f51c7988e401" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityTaxIdentificationNumber_74741467-a8cc-4208-8881-f51c7988e401" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_643524ce-2086-4c03-af20-a0adf66ffd7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressAddressLine1_643524ce-2086-4c03-af20-a0adf66ffd7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a180d6af-6b42-4338-ae1e-2590fc61a475" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressCityOrTown_a180d6af-6b42-4338-ae1e-2590fc61a475" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f47027ff-b998-4f71-9276-59d47f20ac8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressStateOrProvince_f47027ff-b998-4f71-9276-59d47f20ac8c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_826d7d82-2f3d-4303-8c4e-702e54413c27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressPostalZipCode_826d7d82-2f3d-4303-8c4e-702e54413c27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d0321cae-e0bf-4bb9-812a-ff06750cf1c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_CityAreaCode_d0321cae-e0bf-4bb9-812a-ff06750cf1c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_14693fd8-c440-4cc7-b7e4-865517500e3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_LocalPhoneNumber_14693fd8-c440-4cc7-b7e4-865517500e3d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f60dd69d-fcb1-4cc3-8bc8-a63a25596480" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_Security12bTitle_f60dd69d-fcb1-4cc3-8bc8-a63a25596480" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b7fe23d5-b3cc-47bd-bcd6-f9611a306131" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_TradingSymbol_b7fe23d5-b3cc-47bd-bcd6-f9611a306131" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b58ece50-cd1c-49a4-a3a8-2440b9256ff7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_SecurityExchangeName_b58ece50-cd1c-49a4-a3a8-2440b9256ff7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8de56ef1-16d6-44e0-82a1-7511d8dd4eb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCurrentReportingStatus_8de56ef1-16d6-44e0-82a1-7511d8dd4eb8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_95dbf4e5-ce8f-472a-9fea-1da48236aeab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityInteractiveDataCurrent_95dbf4e5-ce8f-472a-9fea-1da48236aeab" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1793b8e3-9980-4145-a301-ab8d7c16bdaa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityFilerCategory_1793b8e3-9980-4145-a301-ab8d7c16bdaa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3dbf06b9-5146-4a7a-8d1a-5a4637bc3f68" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntitySmallBusiness_3dbf06b9-5146-4a7a-8d1a-5a4637bc3f68" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_15953539-d6e5-44d6-a6fc-65c176e46d4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityEmergingGrowthCompany_15953539-d6e5-44d6-a6fc-65c176e46d4b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_17184715-fa36-4d14-b7b8-59a531582e55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityShellCompany_17184715-fa36-4d14-b7b8-59a531582e55" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc48a665-4ae8-43f6-aae4-dec174dbc1bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc48a665-4ae8-43f6-aae4-dec174dbc1bd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fede16e9-a00d-4bc1-8e05-994e93c8e0e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_AmendmentFlag_fede16e9-a00d-4bc1-8e05-994e93c8e0e1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cc1cc597-72d9-4c73-a63f-3c5315b23a16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentFiscalYearFocus_cc1cc597-72d9-4c73-a63f-3c5315b23a16" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_761eed55-93a8-4493-bd2e-1195354af0da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentFiscalPeriodFocus_761eed55-93a8-4493-bd2e-1195354af0da" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_207cb73d-ad24-4a57-8cac-5be50b0f8253" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCentralIndexKey_207cb73d-ad24-4a57-8cac-5be50b0f8253" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_77dbc396-c16a-437a-b633-f2713ae97d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_CurrentFiscalYearEndDate_77dbc396-c16a-437a-b633-f2713ae97d6f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_25ce75f7-d709-4755-88ac-8d64e1ee060f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentQuarterlyReport_25ce75f7-d709-4755-88ac-8d64e1ee060f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_56506ac5-2a93-4ae5-bd7e-b1c834e60098" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentTransitionReport_56506ac5-2a93-4ae5-bd7e-b1c834e60098" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_add42f06-7649-4341-b655-9720253e4f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_us-gaap_CommonClassAMember_add42f06-7649-4341-b655-9720253e4f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_2d8bb85b-7f91-4e52-8c97-b33fe47e70bc" xlink:href="lly-20230331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A718NotesDueJune12025Member_2d8bb85b-7f91-4e52-8c97-b33fe47e70bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_4b285a3f-21e2-4135-be05-771278dbf37f" xlink:href="lly-20230331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1.625NotesDueJune22026Member_4b285a3f-21e2-4135-be05-771278dbf37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_04730a88-380c-4ad6-9d88-542e2c801061" xlink:href="lly-20230331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A2.125NotesDueJune32030Member_04730a88-380c-4ad6-9d88-542e2c801061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member_8f225ab9-aafd-43b5-b383-7dc9f1cd8f3c" xlink:href="lly-20230331.xsd#lly_A625NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A625NotesDue2031Member_8f225ab9-aafd-43b5-b383-7dc9f1cd8f3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_b170b23a-6084-489b-8df1-f14d400a8595" xlink:href="lly-20230331.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A500NotesDue2033Member_b170b23a-6084-489b-8df1-f14d400a8595" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_b47bd373-6a37-4c52-9f56-e0211b6500e6" xlink:href="lly-20230331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_b47bd373-6a37-4c52-9f56-e0211b6500e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4461745c-9166-4f67-be67-60ffa7c6f9fc" xlink:href="lly-20230331.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1625NotesDue2043Member_4461745c-9166-4f67-be67-60ffa7c6f9fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member_ba893ab0-18f2-4f49-9cd4-0189b03f0148" xlink:href="lly-20230331.xsd#lly_A1700NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1700NotesDue2049Member_ba893ab0-18f2-4f49-9cd4-0189b03f0148" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_4d0265fb-66ac-4245-b469-7c5e9a6450e8" xlink:href="lly-20230331.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1125NotesDue2051Member_4d0265fb-66ac-4245-b469-7c5e9a6450e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_81337b30-6004-42ea-8c11-4552b861c0d7" xlink:href="lly-20230331.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1375NotesDue2061Member_81337b30-6004-42ea-8c11-4552b861c0d7" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended" id="i3558cd59a35a4d6ab2818e17612f81e8_ConsolidatedCondensedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a72b104d-69fc-49a4-b213-3b75d2c599c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_CommonStockSharesIssued_a72b104d-69fc-49a4-b213-3b75d2c599c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d0b04782-ed77-403c-a0ea-0d3e8fad33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d0b04782-ed77-403c-a0ea-0d3e8fad33c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58db25fd-ba35-42d8-9a52-a8173e4f4af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58db25fd-ba35-42d8-9a52-a8173e4f4af3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b4cd882-7bba-49c8-af37-114bdabbf9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_ProfitLoss_9b4cd882-7bba-49c8-af37-114bdabbf9e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dd4703a-a17d-475b-874c-bdd05f416abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dd4703a-a17d-475b-874c-bdd05f416abb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_41a6fc65-2ffd-4695-bbe9-b03802ba8cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_41a6fc65-2ffd-4695-bbe9-b03802ba8cf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e04e5b2a-a3ef-475b-9529-4bcc8a865046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e04e5b2a-a3ef-475b-9529-4bcc8a865046" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_50fd8edb-b8d7-4123-9def-b3f83da3d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_50fd8edb-b8d7-4123-9def-b3f83da3d17b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_14021eff-b4cc-4fa7-8749-2f35ed92be40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_14021eff-b4cc-4fa7-8749-2f35ed92be40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_941231ba-8077-47a0-9efb-48bc984e2dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_941231ba-8077-47a0-9efb-48bc984e2dfc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d44e060d-5b47-453d-ac0a-b353c26ac101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d44e060d-5b47-453d-ac0a-b353c26ac101" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5fed1afd-2408-4abf-a4cb-277429f2692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5fed1afd-2408-4abf-a4cb-277429f2692a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_5ccc72b9-74ed-4c9f-b734-bdb31e696391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockholdersEquityOther_5ccc72b9-74ed-4c9f-b734-bdb31e696391" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5bdc0e48-52fb-4b0c-8758-6e831c8f398b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_370099e7-bdf9-4b9a-a97c-9b8a3f6d491e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_670b3ba1-7657-432c-8992-59d3117f39d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:to="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:to="loc_us-gaap_EquityComponentDomain_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:to="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_17f4e248-1e54-4fa6-991b-66b6e9c611dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_CommonStockMember_17f4e248-1e54-4fa6-991b-66b6e9c611dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_85f9c0e6-6bb2-42e3-bb41-a86a190cb301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_85f9c0e6-6bb2-42e3-bb41-a86a190cb301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8ab50c98-0c1e-4508-bec1-a819a6647ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_RetainedEarningsMember_8ab50c98-0c1e-4508-bec1-a819a6647ded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_5ac619bb-ffb5-4b27-bafe-293e1a47ca68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_5ac619bb-ffb5-4b27-bafe-293e1a47ca68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00092297-31df-40b6-8838-650c8678d762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00092297-31df-40b6-8838-650c8678d762" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_785efd30-ca89-4c67-93c4-04b54d63b048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_TreasuryStockCommonMember_785efd30-ca89-4c67-93c4-04b54d63b048" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e33154d4-e1ef-4bb9-a520-8016ef9129da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e33154d4-e1ef-4bb9-a520-8016ef9129da" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#BasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BasisofPresentationDetails" xlink:type="extended" id="i2683559761d14c57879c8188b8155934_BasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f698c056-3157-4f10-8297-551b04246f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f698c056-3157-4f10-8297-551b04246f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30d424a5-d2e3-40f2-b463-ed28f3e02308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30d424a5-d2e3-40f2-b463-ed28f3e02308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:to="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:to="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6a670b73-2e3f-4281-8063-fa2caac11d49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:to="loc_srt_RestatementDomain_6a670b73-2e3f-4281-8063-fa2caac11d49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:to="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4d94bc2f-ef82-457b-a6ba-6debaf717f67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4d94bc2f-ef82-457b-a6ba-6debaf717f67" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i4bac9cbec057489a9e587376a87ac58a_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_62038906-fddd-4599-9a60-ec61f4e940ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:to="loc_us-gaap_Revenues_62038906-fddd-4599-9a60-ec61f4e940ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:to="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:to="loc_srt_ProductsAndServicesDomain_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:to="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9dc8ed9e-e47e-493d-8a09-dbd9c1361e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_us-gaap_ProductMember_9dc8ed9e-e47e-493d-8a09-dbd9c1361e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_ddfdffd1-4807-4bd1-9f50-2b2134264461" xlink:href="lly-20230331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_lly_CollaborationandOtherRevenueMember_ddfdffd1-4807-4bd1-9f50-2b2134264461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_566498c0-5772-4d34-8460-926995f839d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_us-gaap_RoyaltyMember_566498c0-5772-4d34-8460-926995f839d0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended" id="i33f96d0561ca414f980b17ed7c2a9756_RevenueAdjustmentstoRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_9f6bcbaf-bdd6-41bb-8beb-d392fc67c3ad" xlink:href="lly-20230331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_9f6bcbaf-bdd6-41bb-8beb-d392fc67c3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:to="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b36a89f1-aa8d-4404-b630-e341d5d86dc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:to="loc_srt_SegmentGeographicalDomain_b36a89f1-aa8d-4404-b630-e341d5d86dc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:to="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_96273f89-7bc7-4c61-b066-9da5b9423305" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:to="loc_country_US_96273f89-7bc7-4c61-b066-9da5b9423305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f8ec683b-832c-4a6e-ab13-875110f5c42c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f8ec683b-832c-4a6e-ab13-875110f5c42c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_581e7902-2015-4315-a8ae-e989ca13e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_581e7902-2015-4315-a8ae-e989ca13e3bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="i6bcf019a065348e1b194eaeccc826044_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_78c015ef-484c-422b-8394-98e06025f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:to="loc_us-gaap_Revenues_78c015ef-484c-422b-8394-98e06025f19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:to="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c571623-5e2f-490b-a994-d093dd103548_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:to="loc_srt_ProductsAndServicesDomain_4c571623-5e2f-490b-a994-d093dd103548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:to="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:href="lly-20230331.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember_b948f168-99e4-41bb-90a5-ee54b41c7f7b" xlink:href="lly-20230331.xsd#lly_TrulicityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_TrulicityMember_b948f168-99e4-41bb-90a5-ee54b41c7f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_55947be5-2d77-4e5e-9b84-e27930550f2e" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_JardianceMember_55947be5-2d77-4e5e-9b84-e27930550f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_b1cc48df-47bb-4d0d-9ea6-f45d2a7306f2" xlink:href="lly-20230331.xsd#lly_MounjaroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_MounjaroMember_b1cc48df-47bb-4d0d-9ea6-f45d2a7306f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_8278e539-6a3e-4e18-88c7-0a065b97e5c5" xlink:href="lly-20230331.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_HumalogMember_8278e539-6a3e-4e18-88c7-0a065b97e5c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_3f704c4a-651f-4936-bad6-61cb22a5166f" xlink:href="lly-20230331.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_HumulinMember_3f704c4a-651f-4936-bad6-61cb22a5166f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_b9b9efc1-de0b-469f-b04e-73331e514bc4" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_BasaglarMember_b9b9efc1-de0b-469f-b04e-73331e514bc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_d936fe8c-56fa-4818-8f26-bbf9f1ee4a95" xlink:href="lly-20230331.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_OtherDiabetesMember_d936fe8c-56fa-4818-8f26-bbf9f1ee4a95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:href="lly-20230331.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_5cb8c2e0-3d1b-49b7-b7a8-5d3230a703b4" xlink:href="lly-20230331.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_VerzenioMember_5cb8c2e0-3d1b-49b7-b7a8-5d3230a703b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_3cc0a724-8df5-4eed-a1c9-7a7f1c66620d" xlink:href="lly-20230331.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_CyramzaMember_3cc0a724-8df5-4eed-a1c9-7a7f1c66620d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_f6d279e7-3330-44f7-8437-b98201e7d86d" xlink:href="lly-20230331.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_ErbituxMember_f6d279e7-3330-44f7-8437-b98201e7d86d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_db94adc7-c8d2-4514-bda7-05feede4d9cb" xlink:href="lly-20230331.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_AlimtaMember_db94adc7-c8d2-4514-bda7-05feede4d9cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_e0fd62ec-78a0-487a-b0ad-2b1d76332fcd" xlink:href="lly-20230331.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_OtherOncologyMember_e0fd62ec-78a0-487a-b0ad-2b1d76332fcd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:href="lly-20230331.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_7b5ccde5-0ba2-4cfd-8ded-0ab735df19df" xlink:href="lly-20230331.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_TaltzMember_7b5ccde5-0ba2-4cfd-8ded-0ab735df19df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_f1f0fc21-1133-4492-b045-89ff490b28ef" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_OlumiantMember_f1f0fc21-1133-4492-b045-89ff490b28ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_166d8f33-7257-4290-a6a4-9f4aa7f8cb18" xlink:href="lly-20230331.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_OtherImmunologyMember_166d8f33-7257-4290-a6a4-9f4aa7f8cb18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:href="lly-20230331.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_d8bda435-5779-43a3-b17c-f08ba8f23ffd" xlink:href="lly-20230331.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:to="loc_lly_EmgalityMember_d8bda435-5779-43a3-b17c-f08ba8f23ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_36e21cf2-fb19-4cb7-9ed9-ec93d31642e2" xlink:href="lly-20230331.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:to="loc_lly_OtherNeuroscienceMember_36e21cf2-fb19-4cb7-9ed9-ec93d31642e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:href="lly-20230331.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_46019148-15d8-49e7-bbc0-d3bfa0e50ba6" xlink:href="lly-20230331.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_ForteoMember_46019148-15d8-49e7-bbc0-d3bfa0e50ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_a8801387-0f2c-497d-9481-6c71df66b374" xlink:href="lly-20230331.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_CialisMember_a8801387-0f2c-497d-9481-6c71df66b374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_e2f45cc7-487d-4968-b786-b59eda5912cf" xlink:href="lly-20230331.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_COVID19AntibodiesMember_e2f45cc7-487d-4968-b786-b59eda5912cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_3945c748-77d7-4cc0-88aa-c5d47107cf65" xlink:href="lly-20230331.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_OtherProductMember_3945c748-77d7-4cc0-88aa-c5d47107cf65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:to="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_647f733e-b55e-4f06-81f6-ca9b01db3a66_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:to="loc_srt_SegmentGeographicalDomain_647f733e-b55e-4f06-81f6-ca9b01db3a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:to="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3854b3a0-1889-44c0-81df-8a90dd4b1a7e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:to="loc_country_US_3854b3a0-1889-44c0-81df-8a90dd4b1a7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_43225b5c-398c-40b2-8728-f40ca0e34fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:to="loc_us-gaap_NonUsMember_43225b5c-398c-40b2-8728-f40ca0e34fab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="idfc4511ab0404dcda196dca363124264_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3c5b0d29-7da2-4a2d-9c8f-b6d7c2843120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:to="loc_us-gaap_Revenues_3c5b0d29-7da2-4a2d-9c8f-b6d7c2843120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:to="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_04ddfdd8-3ebd-491b-945b-7e476d62b2cb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:to="loc_srt_SegmentGeographicalDomain_04ddfdd8-3ebd-491b-945b-7e476d62b2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:to="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7045836f-e28d-4a11-9acd-00edf9b0a3a3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_US_7045836f-e28d-4a11-9acd-00edf9b0a3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_896ecdbb-e6aa-4b67-bede-1d0425418fdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_srt_EuropeMember_896ecdbb-e6aa-4b67-bede-1d0425418fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_560635f1-fdec-4cc3-91e9-02fef2b495a5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_JP_560635f1-fdec-4cc3-91e9-02fef2b495a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_5e887377-a199-4c5b-9141-e53455041a2a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_CN_5e887377-a199-4c5b-9141-e53455041a2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_64473e24-90f1-47bf-afce-a8937fc92386" xlink:href="lly-20230331.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_lly_OtherForeignCountriesMember_64473e24-90f1-47bf-afce-a8937fc92386" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="ia3db879e43454d688e87c3f5403198e6_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_9b3fcccd-3500-4ff5-8afb-4f8a114ac383" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_9b3fcccd-3500-4ff5-8afb-4f8a114ac383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_00407ce6-ed6c-4bf2-8548-699aff120d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_00407ce6-ed6c-4bf2-8548-699aff120d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea1e8423-8827-4134-ad38-16ef50a1534b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea1e8423-8827-4134-ad38-16ef50a1534b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_bfa16a0d-4dd9-46ac-8f40-2589c357ab9f" xlink:href="lly-20230331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_bfa16a0d-4dd9-46ac-8f40-2589c357ab9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_89d083b9-d454-45ba-aeb1-ea73c796c76c" xlink:href="lly-20230331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_89d083b9-d454-45ba-aeb1-ea73c796c76c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_02cd1204-bc44-4c60-9551-cad69dbc0db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_02cd1204-bc44-4c60-9551-cad69dbc0db8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_a27458aa-b303-4adf-9502-c872abc85a9f" xlink:href="lly-20230331.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_PaymentsForAssetAcquisitions_a27458aa-b303-4adf-9502-c872abc85a9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_04445289-22c4-4b25-aa12-adbca0c232e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_04445289-22c4-4b25-aa12-adbca0c232e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2b6d369c-0343-46ba-949d-325c360b385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2b6d369c-0343-46ba-949d-325c360b385e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_7be6f58c-058d-48e7-84fe-5ed3b165cc79" xlink:href="lly-20230331.xsd#lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_7be6f58c-058d-48e7-84fe-5ed3b165cc79" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9bd5f706-993a-48dd-8457-1e6dc1f3566a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9bd5f706-993a-48dd-8457-1e6dc1f3566a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_adf62191-98ba-4069-ae8f-206070d32c6d" xlink:href="lly-20230331.xsd#lly_AkouosAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:to="loc_lly_AkouosAcquisitionMember_adf62191-98ba-4069-ae8f-206070d32c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_011f4cf5-0d3f-4cb7-88df-2339097d334f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_011f4cf5-0d3f-4cb7-88df-2339097d334f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_e30eafb4-e4d5-4d26-8057-1f08a96a29de" xlink:href="lly-20230331.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_e30eafb4-e4d5-4d26-8057-1f08a96a29de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_86bfaf39-2444-45c1-83d3-2657b09f31e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_86bfaf39-2444-45c1-83d3-2657b09f31e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbaf6e57-cdaa-4590-b4fa-bf967e19981b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbaf6e57-cdaa-4590-b4fa-bf967e19981b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlanzapinePortfolioMember_ee641afa-488e-4076-be0a-b5d4372dddaa" xlink:href="lly-20230331.xsd#lly_OlanzapinePortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:to="loc_lly_OlanzapinePortfolioMember_ee641afa-488e-4076-be0a-b5d4372dddaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BaqsimiMember_2597dac2-6c49-400e-a3e2-634c540256e8" xlink:href="lly-20230331.xsd#lly_BaqsimiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:to="loc_lly_BaqsimiMember_2597dac2-6c49-400e-a3e2-634c540256e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a859a4d-6bfb-4026-bec8-774a907a3579_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a859a4d-6bfb-4026-bec8-774a907a3579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ada6b649-572e-453e-976e-61659915e899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:to="loc_us-gaap_SubsequentEventMember_ada6b649-572e-453e-976e-61659915e899" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i7964fb22b1e04f92ae189f0105212cfd_AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7c4a74cd-7ba4-421e-87a5-2ed2c10cb642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7c4a74cd-7ba4-421e-87a5-2ed2c10cb642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b60b127a-88b2-4385-989c-62643f273547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b60b127a-88b2-4385-989c-62643f273547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e636035d-3746-4d26-8097-bb67e44f71fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_Goodwill_e636035d-3746-4d26-8097-bb67e44f71fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_af7dbab2-8966-490b-b276-5c6bd6d8e2bb" xlink:href="lly-20230331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_af7dbab2-8966-490b-b276-5c6bd6d8e2bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4508a85e-3483-4fbd-8584-588b3f5ec214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4508a85e-3483-4fbd-8584-588b3f5ec214" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d100cb9a-687d-47ad-a1b9-966f9ddc76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d100cb9a-687d-47ad-a1b9-966f9ddc76a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0d39b14b-9d13-4259-a4b2-9087133de5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0d39b14b-9d13-4259-a4b2-9087133de5d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe78422d-2bbf-473a-b853-bff46fd240b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe78422d-2bbf-473a-b853-bff46fd240b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30c5d6be-0500-4a7b-9378-1bd1260381b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_30c5d6be-0500-4a7b-9378-1bd1260381b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_09eb3c7c-200a-4fe3-9e00-be40b33a3f82" xlink:href="lly-20230331.xsd#lly_AkouosAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:to="loc_lly_AkouosAcquisitionMember_09eb3c7c-200a-4fe3-9e00-be40b33a3f82" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails" xlink:type="extended" id="id721ff66024745be9da098964080b97a_AcquisitionsandDivestituresAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_b6909ce0-3a54-4509-bbe9-22666656a9ad" xlink:href="lly-20230331.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:to="loc_lly_PaymentsForAssetAcquisitions_b6909ce0-3a54-4509-bbe9-22666656a9ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:to="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9f47d32d-f4f1-40af-abd8-608aea3c9c7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9f47d32d-f4f1-40af-abd8-608aea3c9c7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_ef0c107b-ae22-424b-855d-df8fed380597" xlink:href="lly-20230331.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_ef0c107b-ae22-424b-855d-df8fed380597" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended" id="i90fc1a6da11a46be8f2f5524c1abac53_CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_3dae77a7-75fc-4d88-9420-93905da4d313" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_3dae77a7-75fc-4d88-9420-93905da4d313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:to="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30798e51-8d3f-4d20-90fd-390e18b6bd8e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_30798e51-8d3f-4d20-90fd-390e18b6bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d7e29f5a-4dab-4f5b-974e-c380c8df078d" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_JardianceMember_d7e29f5a-4dab-4f5b-974e-c380c8df078d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_29736153-292f-4ebd-acf3-f5c2478f986d" xlink:href="lly-20230331.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_TrajentaBIMember_29736153-292f-4ebd-acf3-f5c2478f986d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_e3620b8c-24f2-4473-ba3b-dac54ebcc0c4" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_BasaglarMember_e3620b8c-24f2-4473-ba3b-dac54ebcc0c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61737356-a736-487e-a099-d6d47602727c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_61737356-a736-487e-a099-d6d47602727c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_275bfb71-7dac-4a36-936e-01f62d2c2ba3" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_275bfb71-7dac-4a36-936e-01f62d2c2ba3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended" id="ib0ebdffac7c246d8ada1c76e6affedb3_CollaborationsandOtherArrangementsNetProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6d93d44a-0ada-4af7-b9fd-ce0221421d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:to="loc_us-gaap_Revenues_6d93d44a-0ada-4af7-b9fd-ce0221421d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:to="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df127cea-8382-46d5-9562-7da27972968e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:to="loc_srt_ProductsAndServicesDomain_df127cea-8382-46d5-9562-7da27972968e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:to="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d6b4731c-8c8c-4d63-b170-bd53dedef3e2" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_JardianceMember_d6b4731c-8c8c-4d63-b170-bd53dedef3e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_f0946b82-e333-4dcf-9b47-73e920765fbf" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_BasaglarMember_f0946b82-e333-4dcf-9b47-73e920765fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_4a984766-187f-4c6e-a6ce-bd0dfda550a4" xlink:href="lly-20230331.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_TrajentaBIMember_4a984766-187f-4c6e-a6ce-bd0dfda550a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_0dafd6c7-e2e6-4f8f-a5c8-9b93c458a56e" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_OlumiantMember_0dafd6c7-e2e6-4f8f-a5c8-9b93c458a56e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended" id="if1a68195245d461194315a79b0ee77a4_CollaborationsandOtherArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_6b95a4d1-f5db-4366-9d91-6883604dd8e1" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_6b95a4d1-f5db-4366-9d91-6883604dd8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_f7371941-fd94-47fd-a714-398676a27154" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_f7371941-fd94-47fd-a714-398676a27154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_45fba419-0b97-4727-aa40-509644e59b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_us-gaap_Revenues_45fba419-0b97-4727-aa40-509644e59b25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e76c85ad-cd89-4151-b1e1-8e8f1d80d053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e76c85ad-cd89-4151-b1e1-8e8f1d80d053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_18788842-4be4-4330-ae25-83fdb4058e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_18788842-4be4-4330-ae25-83fdb4058e99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_c1fd2c15-54ee-4d49-9f16-44530c4b4975" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_c1fd2c15-54ee-4d49-9f16-44530c4b4975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_16a2b599-7215-450d-aa8a-c585a44219c6" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_16a2b599-7215-450d-aa8a-c585a44219c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_147e2c55-e2bc-4d6b-92be-c30283294cbb" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_147e2c55-e2bc-4d6b-92be-c30283294cbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:to="loc_srt_ProductsAndServicesDomain_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:to="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_1f493837-d1f7-4a17-99b8-18dc79f9d915" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_OlumiantMember_1f493837-d1f7-4a17-99b8-18dc79f9d915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_51a25e81-e1aa-4efa-8626-faee974145f2" xlink:href="lly-20230331.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_COVID19AntibodiesMember_51a25e81-e1aa-4efa-8626-faee974145f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_820b3d5d-cc67-4b99-bcce-de034121d8d8" xlink:href="lly-20230331.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_LebrikizumabMember_820b3d5d-cc67-4b99-bcce-de034121d8d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd3c152d-255d-4c39-83a9-063a9881f05e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:to="loc_dei_EntityDomain_bd3c152d-255d-4c39-83a9-063a9881f05e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:to="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_4f9f89a5-daa8-40ba-a7e2-a6ce08aebf5c" xlink:href="lly-20230331.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:to="loc_lly_RocheMember_4f9f89a5-daa8-40ba-a7e2-a6ce08aebf5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ibd4aa5f7f3544554afe1133404bb4bf8_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f7ba215a-f7c8-4f6d-b72b-53cb7e250acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f7ba215a-f7c8-4f6d-b72b-53cb7e250acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_9a0f6a7c-b911-42d1-8f47-d59cf4e5b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_9a0f6a7c-b911-42d1-8f47-d59cf4e5b2e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_52cf4642-7d12-4eda-817b-17c0dca129c0" xlink:href="lly-20230331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_52cf4642-7d12-4eda-817b-17c0dca129c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_fa647dec-4b6c-46e7-95da-1788532e287a" xlink:href="lly-20230331.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_fa647dec-4b6c-46e7-95da-1788532e287a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_009e8b75-2462-45b2-bf91-a8b3b5ccd9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_009e8b75-2462-45b2-bf91-a8b3b5ccd9c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_102644f2-fbb9-4936-97e1-9476ecdd3681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_102644f2-fbb9-4936-97e1-9476ecdd3681" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_735ea0d0-4610-4b61-b817-2867f11203d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_735ea0d0-4610-4b61-b817-2867f11203d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_10cc9fc0-4be8-407c-8365-1ee065d59d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_10cc9fc0-4be8-407c-8365-1ee065d59d48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_4c802921-9f73-4438-bf1e-c0c99533c990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_4c802921-9f73-4438-bf1e-c0c99533c990" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_2187b78c-794f-4ced-bacb-511578416dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_2187b78c-794f-4ced-bacb-511578416dae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dbb1975e-f491-4566-a918-8c594747df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_LongTermDebt_dbb1975e-f491-4566-a918-8c594747df85" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_64b2223d-7440-4ff0-be3a-a6ddd3e94d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_64b2223d-7440-4ff0-be3a-a6ddd3e94d42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6a463c58-e3f6-4818-be31-49f1685dda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6a463c58-e3f6-4818-be31-49f1685dda8d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_f111f892-8593-4564-8fb7-e4ab3bdfb277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_f111f892-8593-4564-8fb7-e4ab3bdfb277" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_30b258ba-f237-47cf-9d5a-0bba281465c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_30b258ba-f237-47cf-9d5a-0bba281465c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b0a406bd-662b-4134-9254-282c61a723c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b0a406bd-662b-4134-9254-282c61a723c1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_18fa2258-54e3-444f-add8-a8c5dc07305f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_18fa2258-54e3-444f-add8-a8c5dc07305f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ec7c31d-fdf9-454a-b82e-b7e6222dd835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ec7c31d-fdf9-454a-b82e-b7e6222dd835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A50NotesDue2026Member_9cdb6176-3f40-45d8-909d-a7d179f453d3" xlink:href="lly-20230331.xsd#lly_A50NotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A50NotesDue2026Member_9cdb6176-3f40-45d8-909d-a7d179f453d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A47NotesDue2033Member_4758954c-c8c9-4013-85e6-cfed529fe87e" xlink:href="lly-20230331.xsd#lly_A47NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A47NotesDue2033Member_4758954c-c8c9-4013-85e6-cfed529fe87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A4875NotesDue2053Member_a356057c-1ddd-4678-b253-71f00dd4ba51" xlink:href="lly-20230331.xsd#lly_A4875NotesDue2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A4875NotesDue2053Member_a356057c-1ddd-4678-b253-71f00dd4ba51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A495NotesDue2063Member_c51516f6-fae9-461d-9ffc-a468005f229c" xlink:href="lly-20230331.xsd#lly_A495NotesDue2063Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A495NotesDue2063Member_c51516f6-fae9-461d-9ffc-a468005f229c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDue202620332053And2063Member_4c8f1381-821f-4c66-a773-fa367b149856" xlink:href="lly-20230331.xsd#lly_SeniorNotesDue202620332053And2063Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_SeniorNotesDue202620332053And2063Member_4c8f1381-821f-4c66-a773-fa367b149856" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff097ff6-ae1a-4d36-be78-81d9576d3813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff097ff6-ae1a-4d36-be78-81d9576d3813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_1a564006-1845-4244-85e7-139c1e46f943" xlink:href="lly-20230331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_1a564006-1845-4244-85e7-139c1e46f943" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_022203b7-a141-4464-8bf3-8ad2b8e44183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:to="loc_us-gaap_SeniorNotesMember_022203b7-a141-4464-8bf3-8ad2b8e44183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9c1ce914-4a93-4f20-87ae-4be8d46d63b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9c1ce914-4a93-4f20-87ae-4be8d46d63b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_468decf8-031e-4bb6-94da-3a2b6e991def" xlink:href="lly-20230331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_468decf8-031e-4bb6-94da-3a2b6e991def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_3c01439d-9a20-4ab8-8a83-9b900d8be90e" xlink:href="lly-20230331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_3c01439d-9a20-4ab8-8a83-9b900d8be90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_a6192250-cb8f-4aed-b028-a5653fc271b2" xlink:href="lly-20230331.xsd#lly_SellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SellEuroMember_a6192250-cb8f-4aed-b028-a5653fc271b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember_54ddd590-c88c-4537-a365-6bd70f122a2a" xlink:href="lly-20230331.xsd#lly_SellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SellChineseYuanMember_54ddd590-c88c-4537-a365-6bd70f122a2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e2f0e963-7cc5-4e95-87aa-065b22529532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_us-gaap_InterestRateSwapMember_e2f0e963-7cc5-4e95-87aa-065b22529532" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d1c1a2fa-aa25-4283-b505-d002152d3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:to="loc_us-gaap_CashFlowHedgingMember_d1c1a2fa-aa25-4283-b505-d002152d3d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bd4042d1-39c6-4296-b1b8-5154658eadd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_bd4042d1-39c6-4296-b1b8-5154658eadd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c977b4a2-ac9e-4c23-aa56-17a98374c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c977b4a2-ac9e-4c23-aa56-17a98374c41d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended" id="i75e11a87c9024f5cbc474ca7e4281084_FinancialInstrumentsScheduleofFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1fedbd9b-4232-4672-8f9e-6c9e04a71651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1fedbd9b-4232-4672-8f9e-6c9e04a71651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa32a0c6-c2f3-4666-8e4b-9abf512620d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa32a0c6-c2f3-4666-8e4b-9abf512620d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_af6667be-5bd0-4d6e-80e7-ce4b5f8dbfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_af6667be-5bd0-4d6e-80e7-ce4b5f8dbfbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a66ed1a6-0f6f-4b54-9c2c-50ec92ac31b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a66ed1a6-0f6f-4b54-9c2c-50ec92ac31b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_26ed154f-fd50-4fc0-be6d-e903f6a58d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_26ed154f-fd50-4fc0-be6d-e903f6a58d7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_09e4bb54-8e1d-4cad-96bd-b323c7d55ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquityMethodInvestments_09e4bb54-8e1d-4cad-96bd-b323c7d55ef6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_bf5631e4-ed68-4e74-bc3c-d2462b5e2e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_LongTermInvestments_bf5631e4-ed68-4e74-bc3c-d2462b5e2e91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a9416d54-9a96-46ba-b1a3-f3d642b76321_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a9416d54-9a96-46ba-b1a3-f3d642b76321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_41b0ee8f-574c-4def-9029-de68b7f50571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_41b0ee8f-574c-4def-9029-de68b7f50571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_66043d21-2872-4300-9793-fa85519e49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_66043d21-2872-4300-9793-fa85519e49c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_184f1d54-d00d-4753-885d-87f207da2704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_184f1d54-d00d-4753-885d-87f207da2704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1117a84c-c8c6-424f-9df9-1daf455eeb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1117a84c-c8c6-424f-9df9-1daf455eeb6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca7ff207-bc5a-4a09-8ee1-97adfb828f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca7ff207-bc5a-4a09-8ee1-97adfb828f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3ad572a3-b5d6-478f-9f7e-523c414f0c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3ad572a3-b5d6-478f-9f7e-523c414f0c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_119bdb58-c1f9-4113-b6e6-82e978eb2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_119bdb58-c1f9-4113-b6e6-82e978eb2bdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad709e50-8f60-4e3c-a6e7-21649c2e05a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad709e50-8f60-4e3c-a6e7-21649c2e05a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c260440-aa58-48e3-aecb-faafd2cc22fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c260440-aa58-48e3-aecb-faafd2cc22fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0f3c7962-e549-446a-94f9-358abe527b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0f3c7962-e549-446a-94f9-358abe527b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_08b41f14-f36c-41f6-ade9-3b166a33c6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_08b41f14-f36c-41f6-ade9-3b166a33c6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6da22b8e-0ec1-4d21-af77-af5eca3a252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6da22b8e-0ec1-4d21-af77-af5eca3a252e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_30f900f6-958f-4f52-b9cb-24e0f812e2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_30f900f6-958f-4f52-b9cb-24e0f812e2a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_f3c1ef87-3e61-4493-9251-cec7a6c920e1" xlink:href="lly-20230331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_lly_OtherEquitySecuritiesMember_f3c1ef87-3e61-4493-9251-cec7a6c920e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_7d9d8fd6-20ac-4544-9be7-1e67646c7fde" xlink:href="lly-20230331.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_lly_MarketableSecuritiesMember_7d9d8fd6-20ac-4544-9be7-1e67646c7fde" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended" id="i3cb62dc4e2e048c989943ab656416f75_FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_207183b5-9663-4d14-b658-24e8a63e1f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:to="loc_us-gaap_CommercialPaper_207183b5-9663-4d14-b658-24e8a63e1f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_89f0fd02-ae1b-4236-86db-5b38b0340bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:to="loc_us-gaap_LongTermDebt_89f0fd02-ae1b-4236-86db-5b38b0340bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ee858dac-1d7a-47a1-aa36-98e598b04350_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ee858dac-1d7a-47a1-aa36-98e598b04350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04d8bc30-c859-4846-af98-51924637d274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04d8bc30-c859-4846-af98-51924637d274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_186f825a-597a-44b5-9615-c1aca1165ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_186f825a-597a-44b5-9615-c1aca1165ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6b6a3a4b-6bbb-4331-a3b3-e33290794773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6b6a3a4b-6bbb-4331-a3b3-e33290794773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_60962717-93d0-43b6-8c0c-ed9005b41f87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_60962717-93d0-43b6-8c0c-ed9005b41f87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_425daea3-a37b-4c62-a5d8-bb3beb48f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:to="loc_us-gaap_CommercialPaperMember_425daea3-a37b-4c62-a5d8-bb3beb48f4a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_36b36949-531f-4021-9847-4883c40f8f0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_36b36949-531f-4021-9847-4883c40f8f0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_26874b2c-ed21-4b75-93fd-24657d08fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_26874b2c-ed21-4b75-93fd-24657d08fec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82c2c24a-2a89-429a-84d2-209dab970f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82c2c24a-2a89-429a-84d2-209dab970f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_203b08c1-75f0-402b-b483-7c4f37d2e26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_203b08c1-75f0-402b-b483-7c4f37d2e26f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="extended" id="i26e402c55e3c45229480c49d10dc0d79_FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_4abd50a6-b718-418f-9552-1565e4ced0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_4abd50a6-b718-418f-9552-1565e4ced0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_63894024-732d-4047-998b-f59a4ac593b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_63894024-732d-4047-998b-f59a4ac593b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:to="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_e6f1ba02-9a3a-4802-9b2e-b7f460b06fe6" xlink:href="lly-20230331.xsd#lly_BuyUsdSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyUsdSellEuroMember_e6f1ba02-9a3a-4802-9b2e-b7f460b06fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_ac07bae5-d512-4685-9e34-6130a91677ed" xlink:href="lly-20230331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyEuroSellUsDollarMember_ac07bae5-d512-4685-9e34-6130a91677ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_4e6176a7-a8d2-4114-bb8b-e1f8b4848c54" xlink:href="lly-20230331.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_4e6176a7-a8d2-4114-bb8b-e1f8b4848c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_9998053d-50c0-47ce-b690-83d11405a48a" xlink:href="lly-20230331.xsd#lly_BuyGBPSellUSDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyGBPSellUSDMember_9998053d-50c0-47ce-b690-83d11405a48a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended" id="i5fc08b6024c04505917ff090d1f7c3ed_FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:href="lly-20230331.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8ff3e3ef-b08a-4d40-81ab-51bcac6781db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8ff3e3ef-b08a-4d40-81ab-51bcac6781db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6c82175e-ff64-4f0c-a1a5-77204a0dd27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6c82175e-ff64-4f0c-a1a5-77204a0dd27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:href="lly-20230331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_730e941e-8943-4b69-89e0-6e99c96e6197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_730e941e-8943-4b69-89e0-6e99c96e6197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_e8fbf521-662a-4440-a178-6389a4f1772c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_e8fbf521-662a-4440-a178-6389a4f1772c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_6fc16f07-dca2-43cb-ba06-1ae9a0be681f" xlink:href="lly-20230331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_6fc16f07-dca2-43cb-ba06-1ae9a0be681f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4c177526-eeca-41f7-8511-60af7b9073d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4c177526-eeca-41f7-8511-60af7b9073d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_47fba7ad-932b-46f9-ab62-d49b1dc53066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_47fba7ad-932b-46f9-ab62-d49b1dc53066" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:to="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3207b94b-3d55-4766-9579-0d85fa7e06c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:to="loc_us-gaap_HedgingDesignationDomain_3207b94b-3d55-4766-9579-0d85fa7e06c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:to="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6271c20a-29ee-4e47-9ccb-e1f0d418b9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6271c20a-29ee-4e47-9ccb-e1f0d418b9a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_b094c366-d4f8-4db0-8686-9d3f3bf572cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:to="loc_us-gaap_NondesignatedMember_b094c366-d4f8-4db0-8686-9d3f3bf572cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2acea94f-c57b-400c-bb91-be139f769854_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2acea94f-c57b-400c-bb91-be139f769854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_e0fff3c2-593b-486e-8232-7d24a2d0cd00" xlink:href="lly-20230331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_lly_HedgedFixedRateDebtMember_e0fff3c2-593b-486e-8232-7d24a2d0cd00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_fe18cb61-5051-47dc-bfc6-1ff195d3c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_InterestRateContractMember_fe18cb61-5051-47dc-bfc6-1ff195d3c16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_77c072d2-a36f-4b78-9366-47d2de9b265d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_77c072d2-a36f-4b78-9366-47d2de9b265d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_81e10d8d-7b80-4be2-ad11-ef7bcdcffcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_81e10d8d-7b80-4be2-ad11-ef7bcdcffcf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_47954c5e-96bb-4a4e-90ca-b537d3fdaacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_InterestRateSwapMember_47954c5e-96bb-4a4e-90ca-b537d3fdaacb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended" id="i49d7d68947814f2eb07bbcb04feb38bd_FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_aaaf41f3-0742-455c-b784-891f63404bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_aaaf41f3-0742-455c-b784-891f63404bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_e5450af5-ec32-4969-bd7a-025eb1ee98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_e5450af5-ec32-4969-bd7a-025eb1ee98cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9226e936-88d5-438f-b459-2fc3c6b2a8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9226e936-88d5-438f-b459-2fc3c6b2a8ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4447ccda-2155-4362-9461-73132fa7b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4447ccda-2155-4362-9461-73132fa7b809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7ca6b840-b68c-41df-8ad5-e7c3c23bcd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7ca6b840-b68c-41df-8ad5-e7c3c23bcd70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e278c257-6c2a-4f99-a8a5-c1d834f0fe07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e278c257-6c2a-4f99-a8a5-c1d834f0fe07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_63a1fc93-c289-422e-be90-a623ba01cc9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_63a1fc93-c289-422e-be90-a623ba01cc9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e1acb062-3014-4056-baca-95352c6fe674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_FairValueHedgingMember_e1acb062-3014-4056-baca-95352c6fe674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3ba943a9-f0de-4859-af07-3545c98862a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_CashFlowHedgingMember_3ba943a9-f0de-4859-af07-3545c98862a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e415782c-ef77-4877-83f4-0244957471f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e415782c-ef77-4877-83f4-0244957471f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_416f7d68-2dea-454a-a3e7-401d9d373cf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_416f7d68-2dea-454a-a3e7-401d9d373cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edc39c85-631e-48b9-ba7b-810bf437e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edc39c85-631e-48b9-ba7b-810bf437e38c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_69e31b05-c631-4ba2-b404-8ee4fe0b0af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_69e31b05-c631-4ba2-b404-8ee4fe0b0af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94e7a13-b4b5-4e6c-ac39-6b9b7c1cdb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94e7a13-b4b5-4e6c-ac39-6b9b7c1cdb0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6ccb2570-fe53-4609-9784-1ddc73fdfee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6ccb2570-fe53-4609-9784-1ddc73fdfee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a368f75a-f378-474e-88ac-0def74d69a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_InterestRateContractMember_a368f75a-f378-474e-88ac-0def74d69a05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_84dc3642-2ccd-4780-bf62-d02539524a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_84dc3642-2ccd-4780-bf62-d02539524a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e33850ed-8ef1-4b77-b2d5-d5ff4adfb48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e33850ed-8ef1-4b77-b2d5-d5ff4adfb48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e5c3e445-635c-4378-b153-9d20b00ec57e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:to="loc_us-gaap_HedgingDesignationDomain_e5c3e445-635c-4378-b153-9d20b00ec57e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:to="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5013a31-ac90-4feb-8347-9659dffc7c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5013a31-ac90-4feb-8347-9659dffc7c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_99549191-2d29-4132-99fa-18a598ddeef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:to="loc_us-gaap_NondesignatedMember_99549191-2d29-4132-99fa-18a598ddeef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfaa65ed-9a27-45e7-9785-af008c9a70a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfaa65ed-9a27-45e7-9785-af008c9a70a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_511d6b24-1fc2-4940-9e99-2ad2de7433d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_511d6b24-1fc2-4940-9e99-2ad2de7433d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbf6975c-c930-4fa6-b7f8-7d131721aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbf6975c-c930-4fa6-b7f8-7d131721aa3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6dee3ad-f775-4eb5-8db6-81d96d5bd988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6dee3ad-f775-4eb5-8db6-81d96d5bd988" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i2da1ddb385aa4d3fac6c6118f4abb8d6_RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0b767dbd-129d-4a6f-9eae-e9cc01b2474c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0b767dbd-129d-4a6f-9eae-e9cc01b2474c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f583cf7b-8912-4d8c-85b9-f7634e0cb2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f583cf7b-8912-4d8c-85b9-f7634e0cb2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_92e9dc0b-7738-4d3d-a72b-4b6a973ef548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_92e9dc0b-7738-4d3d-a72b-4b6a973ef548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e769f023-9c33-4835-9a9d-a591808f9bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e769f023-9c33-4835-9a9d-a591808f9bd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1f1428d2-6ff2-4d1b-abc4-e2742f8b6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1f1428d2-6ff2-4d1b-abc4-e2742f8b6c9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_01f5db0c-57f9-4530-ac90-9c2dd46c358f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_01f5db0c-57f9-4530-ac90-9c2dd46c358f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7df4ad41-990a-4bf0-b76a-d311d5f9827c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7df4ad41-990a-4bf0-b76a-d311d5f9827c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_807707ac-40ab-462b-8271-0f1de9e8b5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_807707ac-40ab-462b-8271-0f1de9e8b5ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fd229f20-8115-4e62-ab33-c51e2e9d4490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fd229f20-8115-4e62-ab33-c51e2e9d4490" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="ibffe38e714224cb79b6a95756b530850_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_c213e37d-3f6b-4034-99f6-4e5a5873640e" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_lly_LossContingencyNumberOfPatents_c213e37d-3f6b-4034-99f6-4e5a5873640e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9259ec69-9749-4f4b-a386-544416e71972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9259ec69-9749-4f4b-a386-544416e71972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_05a19b2c-e474-451c-b762-1d573b8ea437" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_05a19b2c-e474-451c-b762-1d573b8ea437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a14e0867-4c28-4945-84a3-249febb4fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a14e0867-4c28-4945-84a3-249febb4fb0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f7489a85-1a62-4afb-b4bf-a3a0838949e0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:to="loc_srt_LitigationCaseTypeDomain_f7489a85-1a62-4afb-b4bf-a3a0838949e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:to="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_81707ac1-4dbe-4fa9-9220-7720ef274c25" xlink:href="lly-20230331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmgalityPatentLitigationMember_81707ac1-4dbe-4fa9-9220-7720ef274c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2018RulingMember_008dd0be-127a-46f8-91c2-e80ab8725308" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2018RulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmployeeLitigationJuly2018RulingMember_008dd0be-127a-46f8-91c2-e80ab8725308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2019RulingMember_15a5da4e-1f37-4c82-8065-0864a630fb06" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2019RulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmployeeLitigationJuly2019RulingMember_15a5da4e-1f37-4c82-8065-0864a630fb06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_150cab1b-6f42-455c-b624-811bb11f03c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:to="loc_srt_ProductsAndServicesDomain_150cab1b-6f42-455c-b624-811bb11f03c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:to="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_aa2f359e-133b-495b-ae45-6ae76d10d7f6" xlink:href="lly-20230331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:to="loc_lly_HumalogHumulinAndForteoMember_aa2f359e-133b-495b-ae45-6ae76d10d7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:to="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_3863edab-5a52-4a1e-b602-0e9f662eea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_3863edab-5a52-4a1e-b602-0e9f662eea66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cc76c872-c920-4828-946b-ef54b3127811_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:to="loc_srt_SegmentGeographicalDomain_cc76c872-c920-4828-946b-ef54b3127811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:to="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_6236c618-580b-4f6a-aee7-5c5008942a37" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:to="loc_country_BR_6236c618-580b-4f6a-aee7-5c5008942a37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended" id="i348d405f3b394aa7ac606b06788e81bb_OtherComprehensiveIncomeLossAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75040237-6993-4a4f-a751-9f5781b390db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75040237-6993-4a4f-a751-9f5781b390db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_81d22e0a-9f1e-49f2-a7dd-b29eca8c6a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_81d22e0a-9f1e-49f2-a7dd-b29eca8c6a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_38e2f124-1b27-4af5-ae52-574d07945b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_38e2f124-1b27-4af5-ae52-574d07945b48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c7b32037-3d89-4caf-a38d-2dbcdb5ee347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c7b32037-3d89-4caf-a38d-2dbcdb5ee347" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a92f248-341d-4dfa-8dbe-8755fe23814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_74cca149-be2e-40c0-8d0f-15203a1d2d25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:to="loc_us-gaap_EquityComponentDomain_74cca149-be2e-40c0-8d0f-15203a1d2d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:to="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d5b40580-6102-41d3-869d-301ccf466af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d5b40580-6102-41d3-869d-301ccf466af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a99d825f-eb73-40b7-b933-6fc862ee5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a99d825f-eb73-40b7-b933-6fc862ee5d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_21c249a1-e7f5-4b2f-a808-6b0f56d3ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_21c249a1-e7f5-4b2f-a808-6b0f56d3ab58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_93c33577-c005-4586-ac25-0f173264cd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_93c33577-c005-4586-ac25-0f173264cd3f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended" id="i2eb2bbf06ecb4208a9191a4ecbd82ea1_OtherComprehensiveIncomeLossTaxEffectDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_e7c0b245-856f-4c75-a4a2-29db3077050d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_e7c0b245-856f-4c75-a4a2-29db3077050d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82509cb7-a0ae-493b-8083-058b8371d03a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:to="loc_us-gaap_EquityComponentDomain_82509cb7-a0ae-493b-8083-058b8371d03a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:to="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2ec066f6-2f4d-46b6-89c9-bda675dc030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2ec066f6-2f4d-46b6-89c9-bda675dc030d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c4e7ffb4-3195-4423-a7c6-f6d6cd702b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c4e7ffb4-3195-4423-a7c6-f6d6cd702b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ad23e79a-5085-469b-8120-94948d5104a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ad23e79a-5085-469b-8120-94948d5104a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_ecb0f3ce-71d2-4597-b381-e14efc5ee049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_ecb0f3ce-71d2-4597-b381-e14efc5ee049" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended" id="i649eaa2d9e31443a939dedcb43816f69_OtherComprehensiveIncomeLossReclassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c040524a-81e1-4d32-a96d-3ace7adf4cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c040524a-81e1-4d32-a96d-3ace7adf4cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7796aee3-6762-4f6b-bba6-8d415b822c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7796aee3-6762-4f6b-bba6-8d415b822c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3079b3b-770f-48c3-9a3f-fcadf06cc484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3079b3b-770f-48c3-9a3f-fcadf06cc484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dbcf35d7-88bf-4be8-9c40-7f806929380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_ProfitLoss_dbcf35d7-88bf-4be8-9c40-7f806929380c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe2f8ab2-7a2f-4061-818d-aac2acb0099e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:to="loc_us-gaap_EquityComponentDomain_fe2f8ab2-7a2f-4061-818d-aac2acb0099e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:to="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_f3b0ca2e-5de6-4b62-a1fa-04353e60e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_f3b0ca2e-5de6-4b62-a1fa-04353e60e13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_83fd4868-1dd1-4593-933a-bad223ea6150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_83fd4868-1dd1-4593-933a-bad223ea6150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_648fb5df-8a11-47b5-8925-c4b60014d417" xlink:href="lly-20230331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_648fb5df-8a11-47b5-8925-c4b60014d417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1e902a4a-9035-4218-9652-e45c10885f49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1e902a4a-9035-4218-9652-e45c10885f49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_e427d6e4-675b-411c-a3b6-fc3aebcfdf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_e427d6e4-675b-411c-a3b6-fc3aebcfdf4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lly-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5cf91dcb-b3ed-43ed-9552-28a6b1bbbb9f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f32673ac-7a6c-4f01-8117-58229477e2d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_c18050ef-6afa-4987-ae85-907090b542e9_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b1c3d680-06f9-4a2f-8a8d-d57872dd32aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_50c2b513-b480-494e-9af6-d72a2af5dca0_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6f04fc76-85c7-41ab-8d0c-8225a08bbe11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4a97d8b9-626e-41c8-b880-6b1f8cbc3c9e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3aca5b5e-6313-4b78-b8e3-372eb81b6c21_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_b26b82da-cb0d-4fc1-ae5e-e92519a19938_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_3a58e81a-6ccb-41ad-a6f8-37d9c8380cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlanzapinePortfolioMember_e7f39087-5bef-4240-8c03-9cabad062c72_terseLabel_en-US" xlink:label="lab_lly_OlanzapinePortfolioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olanzapine Portfolio</link:label>
    <link:label id="lab_lly_OlanzapinePortfolioMember_label_en-US" xlink:label="lab_lly_OlanzapinePortfolioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olanzapine Portfolio [Member]</link:label>
    <link:label id="lab_lly_OlanzapinePortfolioMember_documentation_en-US" xlink:label="lab_lly_OlanzapinePortfolioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olanzapine Portfolio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlanzapinePortfolioMember" xlink:href="lly-20230331.xsd#lly_OlanzapinePortfolioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlanzapinePortfolioMember" xlink:to="lab_lly_OlanzapinePortfolioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_2a378f61-1d10-47cd-a3a2-2114e18f94d7_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20230331.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_adb4acbc-268d-4859-a6e0-592c44e834f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_2ff89075-c714-4161-8bc9-1a26569ba065_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20230331.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_c7f21e7f-43a9-440d-88ee-b4eb9cfce260_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment losses</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_9c4b7429-6bf4-478f-9caf-8095e3919e0a_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20230331.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f881426f-c873-446e-b538-668281838fdc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_59fbd192-7ea1-4684-aad6-d31c84982d36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3e5b0e69-12fc-4e40-90a9-2fefa8990ee4_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_08c4cfc3-49e9-4c2a-9f56-cda1c24dbbe3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_89f58727-8a70-43ef-8ce5-e9eaefc1b2a6_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20230331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_c536a797-c4b6-45d1-98a1-0933acc480ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_5b5490c8-3256-4f26-a657-cd80215c3612_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_252c3cb2-044f-45df-b5c7-18c0cc9640e5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8fc1a322-0785-443e-bc6c-25a97322a8ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity and Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8a75d06a-03ab-4f70-8d36-babce7af4ce4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_c1dff77d-ee54-4535-b131-a708e43b3840_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42ea6d8a-1c94-487e-bf2a-5f430a8c747c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_79664387-a2d2-40d6-a872-c78aba571cfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_a73f6022-e611-4ca6-9ee0-a607c9bbfe33_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20230331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_83ad3dcb-3c73-4050-88db-38a8e8ee583a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_8b997dc4-a40d-4c8c-bcf1-03f823e56108_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20230331.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_fc5771a3-a836-4f61-82ec-fbc046562031_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_10cfefe8-9b6b-4314-a745-18221e3a63a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7a324150-0096-4282-bbb3-b0d91bdb6eec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_2be7a965-7e91-4a30-9f24-39e93bc885e2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_70283fb4-325e-4532-a79e-bf4b64007630_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f4b6443c-f9f6-4be5-8455-62a63cf0cd53_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d41fb41b-c87a-460b-bc19-701b29c9dc42_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A495NotesDue2063Member_7db30a56-89ff-43d4-9bea-849983dc055b_terseLabel_en-US" xlink:label="lab_lly_A495NotesDue2063Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Notes Due 2063</link:label>
    <link:label id="lab_lly_A495NotesDue2063Member_label_en-US" xlink:label="lab_lly_A495NotesDue2063Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Notes Due 2063 [Member]</link:label>
    <link:label id="lab_lly_A495NotesDue2063Member_documentation_en-US" xlink:label="lab_lly_A495NotesDue2063Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Notes Due 2063</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A495NotesDue2063Member" xlink:href="lly-20230331.xsd#lly_A495NotesDue2063Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A495NotesDue2063Member" xlink:to="lab_lly_A495NotesDue2063Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_f3f9e9b4-0296-483e-9d1f-688381762a47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2dcef2ad-53b4-4a5c-8962-4896c10f6bfa_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b17d2a33-b145-43c5-a59e-32d1fd17fffd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0d77bace-1fbf-4c52-817e-b4c5cf79d02f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_59812297-b14a-4fa9-a148-ec225167ab1e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_b0f96385-c633-456d-98f3-c5a2f7e9d47a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_37e2b8ec-c03f-48ad-bfec-9260c8341497_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_91b292a2-d035-4c11-b623-3b566e1fae98_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2218c6b2-c63e-4166-a52b-2a41e39940fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_24571e43-e740-45d7-8042-1a50de73abe5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_b2d2f641-7024-4895-a199-f9943d60d11a_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsdSellEuroMember_9bf19980-d056-4cec-a670-2d759750aa92_terseLabel_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember" xlink:href="lly-20230331.xsd#lly_BuyUsdSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsdSellEuroMember" xlink:to="lab_lly_BuyUsdSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTable_a0ef33d3-b1d0-4cc5-aa8b-05f3ac684137_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTable" xlink:to="lab_us-gaap_ReclassificationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f521d4b1-05c2-443c-a363-c9ab2ebc02aa_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_cfd7ca8e-0d0f-4492-a089-301ba7f3a730_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_74f75f1b-5e97-45f2-99d5-4e50bc1ac21f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_f8dbb809-95bf-4137-9145-6cf08033cc7a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_5ba205f0-8645-4fb1-ad99-554faa7c20ea_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_ea356f5a-65e7-4a9a-8c82-40d685c40cee_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_39554baa-e5bb-43e3-bf21-9f7ce3ab8df3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_12ebbfb0-7bce-4635-833e-b91c1e163363_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_10fe223e-c5b7-4ff7-b21d-893e89ed2e40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_d7eae71d-c7bd-4230-a8f4-be04a1949a1f_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds, anticipated payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20230331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_637dc862-1bec-4e78-8a02-7211b688e772_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5a7579d1-3cc7-4ccc-8fd4-4280dcb3efff_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of retirement benefit items</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c47e39d-f8b1-471f-a8ce-4a7ac26b1e57_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8dc8fda7-08fb-4c8b-a811-1b2ee3651e05_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_53f454f7-1ad6-49e0-a937-e5a0e073e6ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_b24a507d-838b-45cd-804c-b9e795f5b607_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20230331.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_dc3274f8-2ce0-4158-bdf5-707cf1e96061_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_86a6fcb1-0bd9-4751-b9fc-c0f44baadacb_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_736dbd08-e178-4433-a63f-5639a1c50013_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses expected to be reclassified in the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_4f8c5468-0846-42f8-b67a-4e9ff491eede_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMember_8b453c42-a8b7-4d73-a6c1-811e52eec164_terseLabel_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMember_label_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member]</link:label>
    <link:label id="lab_lly_TrulicityMember_documentation_en-US" xlink:label="lab_lly_TrulicityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember" xlink:href="lly-20230331.xsd#lly_TrulicityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMember" xlink:to="lab_lly_TrulicityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f74fa1fc-a0ae-4c49-b336-7b1de90c35f3_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b8682faa-f65e-4da8-95ab-c7af098c48b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_104313e0-a7ce-427c-a975-e3c236a51cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4bdb4a89-c16a-4583-ba76-cb8e7b7b98f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_09a3ac2f-3022-4983-ae3e-6c96fe8c1d72_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a87efb01-6ec1-48ae-9b7a-0094816295d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_269bd88a-7f37-4409-b934-dfc9e24fb4bc_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20230331.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9c9ffb8a-a40f-4ee6-9750-40fcb02c70fb_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 7)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b52d8c65-0175-41b4-b93d-022975cca604_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_297d8f24-0297-4891-8b62-368904b52591_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential achievements</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms or rights and obligations under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3021a98f-c845-42ff-8030-950018f7db0c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reclassifications out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_85c031b6-d1a7-4b13-b442-a8cd71db221d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d8ade5ff-c0a8-4e44-8106-87e23f82c36f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65817eda-5b46-4da0-90ff-7a9ce79e995b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0ee69dc6-48ab-429a-81a7-86ba300aeb85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant milestones and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_53399367-7265-45af-84d6-4f7bccab7302_terseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a6925467-42f2-45dd-930f-ebdbc6789a58_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_05dde42b-170c-4067-8914-c61e9784fcfe_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_e1ba2ec1-8803-41a4-ab88-c98058f8397c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_36de6903-e8d4-40a7-bc4f-99121b5dabd8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of and distributions from noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_0289ae38-f58a-43c9-8ffd-e906610f53b4_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20230331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_ece2a8ff-d08c-4810-bcea-6a87ac37e167_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6f3cf482-10fd-480b-a0b9-7540fcc14f92_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_523f59ef-c6e2-49aa-bde1-7b1ff0c203c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains/losses on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_473d7810-b41d-497f-9552-a07646aebaa8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_66ed6c92-31d0-4fe1-8717-f47597cca7ec_terseLabel_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="lly-20230331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_49f9a3be-32ab-428b-b29c-2c4ef8d5cd5a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_fa764104-5ca5-4af4-84e1-605db099c223_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_646c3db5-d6b6-4f25-ab05-8424c329f575_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ff0513f8-0cec-48b2-8145-4df601930f24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_023693f3-9d1a-453b-947a-fd2b08335f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recorded for contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e71c99ca-6ebe-46ad-bca5-fc061e2784d9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1d10a93d-5d3b-4528-b263-ad238f8484c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_32b581b9-f4e5-416c-9066-b398b05ae473_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_221ce7c4-626a-4638-a8f9-65d7999824a1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_d4c52ef9-0b36-4c4c-b77e-f8d9237258fe_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_e5671efe-b13a-4a22-84aa-7b0493c273df_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_3b113760-3dae-4fed-a1f3-832748b8cc25_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20230331.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6926231f-a572-4d1b-a1a4-f2cf8ee073fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used for) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_477ede03-1f20-4e47-8e01-5892e19197ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 5)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_73b89953-95dd-4663-984b-c2afc1c54d36_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d3c656e0-55cd-4319-be0e-aea2f87406e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_73a35227-f097-4601-a75d-339e390ef12e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_6e2c853b-37ba-4121-bdc5-aef7db459fca_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af42b61a-3e93-4756-8f14-447a8ae5a95b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95af7f61-3c08-4b73-a0a2-b6a7cb72afe4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a43fbd05-07ca-4c40-b45d-a54bdc336cd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_be32edcd-f27a-4dc2-b904-da2eee763abc_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_c59019c9-3817-4e5a-8b8c-4d6f7e755232_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20230331.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4ab88b8c-9a9c-4fd0-af73-8e682e478bb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_d93ac03a-d464-4241-8e72-4ab00f75738a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a0af534e-5ca8-496c-8d56-a69e97291559_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_babe2d6a-222e-4cfc-b938-da7a2c5b8e50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9f5bf522-7a89-4c65-8d7b-5aec523c0c71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_52ed6c12-1c42-409e-98b4-5a5b0f8ace8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8ce6a985-0c1d-4f5d-a7fb-84c585d74431_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value, by balance sheet grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_1276c50d-ed36-43ae-93c6-d40188d09b8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_84e60b60-d4f7-46e3-baff-64ff7486a99e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_0b52885e-3d4c-4d58-a4de-b024778ff031_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_96b0021c-a27c-45f6-9f06-3a87fe3541ed_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_946d4631-48e4-4b57-861d-3b772cacddd0_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_fc2d33b0-2260-4b03-93f5-8ec757c5b7c9_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsLineItems" xlink:to="lab_us-gaap_OffsettingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b61cca10-3c05-466a-80c4-235656ff129e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8875fcff-889c-4453-a112-6fdfe136ecc4_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationJuly2019RulingMember_3967532b-db60-4674-b6d7-228d51c520ce_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2019RulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2019 Ruling</link:label>
    <link:label id="lab_lly_EmployeeLitigationJuly2019RulingMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2019RulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2019 Ruling [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationJuly2019RulingMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2019RulingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2019 Ruling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2019RulingMember" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2019RulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationJuly2019RulingMember" xlink:to="lab_lly_EmployeeLitigationJuly2019RulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4516ddc2-4f1f-44c3-9670-33a841794b97_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0f181de-84f8-4f7f-b0ac-f6ec6c57ceb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_427a7218-38f8-4914-9bb9-e5633902cf76_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasesOfInProcessResearchAndDevelopment_2d3efc27-9611-46d0-93c8-e564b3f2da08_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasesOfInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of In-process Research And Development</link:label>
    <link:label id="lab_lly_PurchasesOfInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:href="lly-20230331.xsd#lly_PurchasesOfInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasesOfInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_0ed40c69-82fb-484f-9216-ab9c09f130ab_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20230331.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a44484e1-5e78-4748-98b2-11b61c60ea1a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4bf4572b-5375-4077-b0b2-9a935f00136a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4bf2b66a-5edf-4aa8-b8f5-b83e614bfb1d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationJuly2018RulingMember_ce5e1100-4a10-40ae-a923-fa27cabad71a_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2018RulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2018 Ruling</link:label>
    <link:label id="lab_lly_EmployeeLitigationJuly2018RulingMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2018RulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2018 Ruling [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationJuly2018RulingMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationJuly2018RulingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation, July 2018 Ruling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2018RulingMember" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2018RulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationJuly2018RulingMember" xlink:to="lab_lly_EmployeeLitigationJuly2018RulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_b2ca3595-7720-4d35-85a6-73bcf23bb8d3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_63f7c4c1-044e-4627-9525-b73d73989f4c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56f79047-4420-4ba9-9cbd-279dc1a3199f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_1140e8ef-5ab2-45c1-9889-5f3874a84903_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_886cdb68-695b-402e-bf34-db1177d39d53_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_c99251aa-9eef-4d17-9c98-6c8d7e6d666c_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_de70c5f0-4564-4086-8228-cc2c444e5b72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_43926761-2af0-4f88-a9d1-deac5aa93892_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e69edac5-a5a0-422e-adc7-8d98dba58e69_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d0cf621d-48a8-4e61-9532-6fa5790d402b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_d632c5d6-0afa-499d-944e-f200b6a44307_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20230331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_de8631c2-c466-4fb4-b9ce-5a5393debb60_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_934559d1-eca8-4887-95e4-a96d1a38653c_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5d082db7-cfd0-4ecc-a76c-138de83a76b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_6c07d47f-4c23-4940-942a-b4c4a7f77a6b_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-process Research And Development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d31586b8-190c-4e68-b899-3f0a3e699a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_517eda18-36af-4ca2-b7d5-a775ec9aa86c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_743118ee-d2b3-4d1e-a85f-5e611a008e86_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_391148bf-f884-46e3-bcf5-2daf0b07666f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_81a2661c-df0f-49ca-b5ef-8b77b9254d30_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d9c022b9-cd53-4417-bc3c-77e6825957e2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_6abfad81-16c9-427b-83de-a83bfd2872f8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f773e3bd-6071-41d0-8959-5dd12f9f3592_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b11012d6-6b70-449d-bdf1-73fccfac8ec0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_b262bd7b-47fb-44e0-9acb-603429497a74_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20230331.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4f7f7b20-d619-4ad2-ae66-b500013b2725_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_4747cc00-f0ab-465a-97aa-877aeb6cbb6a_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_71bc125b-64e1-4a63-b44b-9fa5b241e0ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_e032180c-c952-477b-8d77-9baddb8ec1cc_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_457f1ab4-d8ac-44a3-8deb-9b4c1d697b01_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20230331.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_18f447ad-b4f1-40f2-878d-949ba2704c1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_bfe2a058-4679-48ff-92bd-393ee11a4077_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A50NotesDue2026Member_0d1b220a-24d6-4b05-bebf-4cc23e221a49_terseLabel_en-US" xlink:label="lab_lly_A50NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.0% Notes Due 2026</link:label>
    <link:label id="lab_lly_A50NotesDue2026Member_label_en-US" xlink:label="lab_lly_A50NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.0% Notes Due 2026 [Member]</link:label>
    <link:label id="lab_lly_A50NotesDue2026Member_documentation_en-US" xlink:label="lab_lly_A50NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.0% Notes Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A50NotesDue2026Member" xlink:href="lly-20230331.xsd#lly_A50NotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A50NotesDue2026Member" xlink:to="lab_lly_A50NotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_fd6887ef-b89b-4eb2-a00d-cc10dbe5044f_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to U.S. Dollars</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20230331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a31b0ea3-9a68-47b8-a818-4dfeec226b23_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7103dcad-d33a-402f-a846-65677ff889a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at January&#160;1</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b7d82029-e0e9-4812-a5f6-3c4fbb4f80a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at March 31</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_27a1974e-d9be-42f5-b17f-db12a34af825_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20230331.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7a10cd6a-e624-4fa7-8127-a8d5827bf741_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_bc00a4c6-d868-4ac0-a60a-794d63435817_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20230331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_866c68dd-cd71-41a7-b333-8b1b2893c9a1_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_6966f9f7-d978-4aeb-a454-57a6cbbd0ca2_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes Due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20230331.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_d19915b5-e088-430b-bc31-ef5625b392d6_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_2ca53cf3-da44-49f4-b7a0-eaa14c78fbd1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c610330a-f5f0-4265-b413-f20a693687e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_981b904e-22fb-4794-9793-f812cc5c4650_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_404b333f-b6bb-47e4-a51d-6cc2c0f49358_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4649eb0f-b2d4-4953-a2a2-90fdb863f3d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax (Note 9)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f11137d-5093-4e0a-b4de-194732398fac_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4692eda1-9de1-489a-abfe-5723b70808d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7e04f598-1f2c-4ba5-ac54-44bbff2f0e58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b491e187-5eb9-4fd3-aa1e-b29aafd931c0_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_9eb2f671-0a4e-4314-a0f9-beabebbecef6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_4219c55f-4529-4a9e-969c-8cbe9781862f_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales, Operating Expenses, And Other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales, Operating Expenses, And Other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20230331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_6382dc78-ba28-4eb7-9465-afb3a10722d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_3ff8bf0b-6cfc-4698-8061-eb55de350345_terseLabel_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_label_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:href="lly-20230331.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:to="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_f356b180-1c98-4525-8579-51fc7926a95e_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20230331.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8cb1785d-d44a-45f8-a84d-8d2c134395e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6f072cfa-e607-43f0-a67c-70ece7250f18_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SellChineseYuanMember_b59ece28-69e3-4c09-90e1-0e0e426fcd66_terseLabel_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_SellChineseYuanMember_label_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_SellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_SellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember" xlink:href="lly-20230331.xsd#lly_SellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SellChineseYuanMember" xlink:to="lab_lly_SellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6b9a62d3-ec18-4b65-98c6-f24dbf25c25b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_7acc9756-7543-42fa-8b61-44378f4b43b9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_674c9c24-a5d7-4c0f-9e2b-c7080f59e846_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc34696d-b130-42e7-952e-425c324afa30_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a66218a8-46ee-40c8-871d-da9b84cb666c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a0e0f76-0ca5-47f8-963f-494c54c30078_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_6a711173-0b6b-448a-bcca-e5e82f4fc990_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d397711d-b0e1-4dea-8d4d-f1defcb4c37c_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_d428b90f-8904-4906-bf29-d2b3710c41a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bde193ed-df31-4975-8e55-3a7f7b47b7e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $14.0 (2023) and $16.0 (2022)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_90dcb284-6a5a-4011-bfe0-339591f34682_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0e2d39f8-7276-486c-9645-df76119efdae_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_56164542-6c48-41ad-b916-e113731b6264_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_46556d26-73b8-40cf-ac81-6201c74e0c6f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a56df3e0-5556-449b-81dc-8e64f2104e1c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_650ae4c9-abff-4faa-9aea-5448885a4dd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_5900f328-2337-44a9-b8a2-9e1f063f8d4f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash proceeds</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4b6d7336-767d-4afe-9c8e-7d7a82415261_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_14591591-8c54-421d-9e81-843b33ca30de_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20230331.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6dc2c353-e251-481c-94bf-78f02a3b7d18_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense (Note 10)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_80aad0f6-eb0b-44f9-bc0e-2f9689afcac0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_714aee5f-8117-4e2d-a2cf-15860607fdbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c126e88d-76c0-4d82-beda-f075cdfaf755_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7d95513c-6b01-40cd-bad2-9b4a4d53fe2e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_56187bc9-8d18-484b-8d1f-1c30a3cdbd8a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_93c12f1f-3e26-4981-b8fe-9bec6a46acd6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea244865-6751-42aa-892b-eff2b3338360_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_a49838fb-febf-4e51-81a2-07c71c18de29_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_1b2499ca-b20a-4e5b-9d72-864207e55281_terseLabel_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:href="lly-20230331.xsd#lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:to="lab_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_820f9b32-7186-41d3-a2ee-d0637f3dc209_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20230331.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0cd5538f-1c28-4d40-a684-cbd9dc775e54_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_023a624f-ff81-4d76-928c-e18564080fac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2f0139bc-162f-4a81-9575-f41075d5e371_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_72a1ae8a-e007-42d1-9329-3c66c05aa555_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c97006fb-683c-4694-85a5-cb530ac4c430_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_b36e98e2-edad-48d5-93e6-b67b7c246c8f_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20230331.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0620c4b7-6c40-44dc-8ace-08ab8fd50082_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a2f511f8-e447-4112-9f36-7a3a5b0e77d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains/losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_954aaa9e-5c97-43c3-893f-aae25a96e6df_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations percent (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f9022808-608e-462e-81ed-2eebf7926a0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c54791d2-9b68-4c3e-bc04-e9c95ec79056_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_63a456cc-c619-455d-a43f-28647e6d2b7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1c2cb708-be7d-4edd-a94d-d8fc2262a62c_negatedNetLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_185acb48-a88d-45f9-997e-c67d344bd51b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a9f9b4d-cf3e-4f13-bb6b-aa7b9a59b8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8a39df62-7fe6-4feb-80c0-44df46ee1dc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ba7801f1-a462-44c4-bfac-a72b830c91c6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f90423e5-ab69-4d7d-a755-9f112b7cf63b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0db78d03-7c15-455c-8321-3f4cdaa90107_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A4875NotesDue2053Member_e449c1df-3eba-40ad-9faf-e0dc78fb6a02_terseLabel_en-US" xlink:label="lab_lly_A4875NotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Notes Due 2053</link:label>
    <link:label id="lab_lly_A4875NotesDue2053Member_label_en-US" xlink:label="lab_lly_A4875NotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Notes Due 2053 [Member]</link:label>
    <link:label id="lab_lly_A4875NotesDue2053Member_documentation_en-US" xlink:label="lab_lly_A4875NotesDue2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Notes Due 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A4875NotesDue2053Member" xlink:href="lly-20230331.xsd#lly_A4875NotesDue2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A4875NotesDue2053Member" xlink:to="lab_lly_A4875NotesDue2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_3a2d6df1-7cea-405d-b0c0-70680c8ef8fa_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20230331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_97acd237-a1c1-48b9-8d03-2587ba4bdbb1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_eb9f3393-bea7-4666-a2fd-9a6b850e42ce_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20230331.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cfbff607-0db5-4b1f-9c94-d4a26d1619cf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_b7c0f70b-413a-44f0-a6b9-c969b461755f_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20230331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_03bb9899-f997-47f9-a5c9-e36dca632a2f_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7739278-6fd7-45ca-b5a9-40636e3018d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_054717e4-69f1-49f4-9373-5025189ca117_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_c27adf10-e9fd-4da5-928c-0eb85a32a18c_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20230331.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_121d0580-c971-44e2-a53b-99449547a79b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057e6d6f-82a6-4069-80b8-b62de7125f13_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_c1c3210c-59cf-4f6a-825f-6ce0268d4e93_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20230331.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BaqsimiMember_559a150c-9f0e-41f6-8de0-076fbc621059_terseLabel_en-US" xlink:label="lab_lly_BaqsimiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baqsimi&#174;</link:label>
    <link:label id="lab_lly_BaqsimiMember_label_en-US" xlink:label="lab_lly_BaqsimiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baqsimi&#174; [Member]</link:label>
    <link:label id="lab_lly_BaqsimiMember_documentation_en-US" xlink:label="lab_lly_BaqsimiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baqsimi&#174;</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BaqsimiMember" xlink:href="lly-20230331.xsd#lly_BaqsimiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BaqsimiMember" xlink:to="lab_lly_BaqsimiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_4b7f7ee7-ef66-433a-a7d2-45b3f992aa86_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20230331.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6cd50c67-9ca1-458e-9e33-0eed15e8a1fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_86225a33-1ba2-4950-8729-a37b9afe1fc1_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c9dec978-d980-4932-8477-7510b1dd74d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_0d95b486-c878-4b0e-a543-19a598ae0174_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes, designated as hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9cfea43d-6c7f-481a-8642-09bb9254a6ad_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a1d12fbb-48f4-4cd8-9f7e-b30aa1bc5dbc_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_6b85db02-b381-46bb-8859-a7da59a6066b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ab5de996-bc70-4bf6-82c6-db41f14d8d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8ca7c23f-15a4-4dac-a557-579db931ab44_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cc3d47ef-f90b-4dfd-8688-6e00df358eed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8ac74374-bec4-4876-9869-597c91a83c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_457320e2-f3d6-42b3-a975-5d69ba699460_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_66b01c70-10b5-4752-930c-dd348e09e74f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_b3be0fa4-a9f7-4263-b053-8d36ece60502_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (up to) (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20230331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8fd55793-b652-41d0-98d3-1be0da6f869a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ec2c81d5-fd49-4d81-91d2-729f54708714_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_46a0e291-21b3-465d-8c02-a51a82e0cb52_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_44a72557-7ca9-4014-83e2-dbc7d2ff860d_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_4113a95d-7873-475f-b24a-76dcb395fb50_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the fair value of available-for-sale securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_c2f2e0d9-a452-4b37-b6bd-2f6939cbc048_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_414b2e8f-7349-4460-9893-4a92c61c6747_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_492c2362-f9b5-495b-882c-ea5181499c4a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_79e226b0-2893-4b3b-874f-3450b59a1501_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2036e463-8b09-4b08-b574-aa07ca5eeb52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_110e5bb0-cf92-47d8-8494-6cb80038f10a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bc3db6a2-524c-4178-8e6d-fbf794ee2516_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_efb6a610-c684-4dd6-a4f3-46ba0b18bb29_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffc6fa9b-352f-4454-acde-7722535a24c0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_52ac75da-2de3-41d4-9cbb-f266b8afc785_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_992f1db2-f6de-4681-b2fe-c8dfdc326df1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4524371a-8ae6-4eda-a583-9646eeb1777d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_54953834-39a8-4b23-9162-8e04cc6c2394_terseLabel_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D expense</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_lly_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_lly_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions" xlink:href="lly-20230331.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentsForAssetAcquisitions" xlink:to="lab_lly_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a373f80b-5a33-4e24-bcd2-c468d6c4e47b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_68707377-ae14-40d9-bd3f-7f0e1175dbb1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_173700c7-44a0-4ef7-866c-38819498bcd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value information, liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_d1efc5f5-85ee-4f2d-825b-39d15ef85a7b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_738f96e5-7e1f-442c-9de2-bc1d656c40c3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b5b3a1bd-77bb-43fa-8ab4-3a3969655c80_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_39e9889d-3d2e-4617-b107-9ac0c24c376f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_eb4ab9d2-326b-47f8-bc67-b655aaf562d4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_408e44de-b249-450c-989c-380b4f67392f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_1e23ed70-5f85-44ce-be23-9c1c391ffc28_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized as Intangible Assets</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:to="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_c97e8160-020e-4539-b4f0-a0a29f0603a8_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a53c256a-773f-443a-badd-fcc91cb17863_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_00e6210e-c5da-42a1-a7e1-f206e351879f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_f99abb9c-3407-434b-a841-343c6922b70f_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5e4043fe-d43c-410a-b575-17c66522416d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_776085c1-e8d1-4e73-81df-2026c40d1614_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the amounts recognized for assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5ba74ca9-3d13-44a6-88e7-599894ba07f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ecbfda0f-e9b3-4073-add3-a88cd0668012_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fd7ef005-53b4-438b-8d23-4c79372afcca_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_b3f4942c-4cd9-49de-bd30-6619b9583e5c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_170ec0db-4a46-4ff6-bd43-a60c34949315_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_45798dcb-167d-42ec-b954-dcb93afa2571_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77c62b7c-8199-4d3f-833e-2d98504ff777_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_791f3864-8787-471b-8c3a-838185a86718_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $10,486.0 (2023) and $10,233.4 (2022)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_bfaadc81-39a6-433e-9598-b02c1d0dc5a2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_1a27d7c6-b057-4b90-a697-150555211a55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_35ca27af-e7f6-4d42-b01a-843b57117653_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_8f62b9ca-08fe-4aea-abdc-9643404ccda4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_cea02806-20c8-44d9-9028-99a12bf81aba_terseLabel_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1f718446-933c-4b8b-8b7d-3b96e0b79f04_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6c579415-fd4e-478e-9701-2b2d4d7aeb46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f3dd5637-277c-40eb-85ef-8f53dc6a469f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_6c3273e6-9233-4952-a2d6-d617b47ad654_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9b0f6d8d-d5e2-4bdd-8a1e-aed36d554727_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1700NotesDue2049Member_002c0b54-03e8-4e90-a509-20588aaebfd0_terseLabel_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1700NotesDue2049Member_label_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1700NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A1700NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member" xlink:href="lly-20230331.xsd#lly_A1700NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1700NotesDue2049Member" xlink:to="lab_lly_A1700NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_af7d2296-18ca-4002-b471-fab7cfc37bdb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1b73aa1-82b9-4e57-973e-4a3eee6b5e74_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 9)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_46dec8c7-642d-46d8-8e6f-e25b700f4c95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90f21ada-adc8-476f-afa1-d445d5fc5b3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_01072475-3705-418c-aa0c-717de8ed6706_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 5)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_59e387f2-cf06-4088-a4dd-a0107a101189_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of nonperforming assets</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="lly-20230331.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_53f1d8fb-4f5d-425f-92da-60e0c8fbbce5_negatedNetLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_9c809815-21ca-43a9-bbac-8baef2004913_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment losses on equity securities (Note 5)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ce85b7d6-6f6d-42d4-8c50-4cc168e63c50_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c139f5d5-8ffb-40ff-a189-72d68f516e66_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_8b1eee51-915b-4194-b9ab-9ecd0847717d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_711c4714-1873-4809-ad44-440e6dee873f_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20230331.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4f4b2353-25a9-4030-a437-d0cd7d3965ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_66849428-b930-473b-95f6-16f9d987e6cd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d7aea747-0b55-4b21-9dee-b984ac6dfff0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3c3b967f-790a-460c-bd7e-d0d98750c11a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net pension and retiree health (benefit) cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_26754ada-2d11-428c-bd83-2b999758d5a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value information, assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_94e39ca0-4261-4708-a656-cea849679dd7_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20230331.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_df252890-22ed-49fa-8849-5b25adaffbe0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_c74d50a6-1c25-4bd4-8b5c-77df5d0b5508_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20230331.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_b90cf63f-3c9b-4709-97d2-233a5e4fd4c2_terseLabel_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_label_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc [Member]</link:label>
    <link:label id="lab_lly_BioMarinPharmaceuticalIncMember_documentation_en-US" xlink:label="lab_lly_BioMarinPharmaceuticalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioMarin Pharmaceutical Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember" xlink:href="lly-20230331.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BioMarinPharmaceuticalIncMember" xlink:to="lab_lly_BioMarinPharmaceuticalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_31f33aed-d164-43dd-a6f3-d4de724bf394_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bb5046c2-b3bb-479a-bc41-c3c64d32de83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_67f7ef61-fdb7-40d0-b996-1defa672c21d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_a566d6ca-c46d-4c06-9670-186b2ccb62fb_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20230331.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyGBPSellUSDMember_b6fa726d-266b-4cf2-a13a-eab4292c539e_terseLabel_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_label_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD [Member]</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_documentation_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember" xlink:href="lly-20230331.xsd#lly_BuyGBPSellUSDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyGBPSellUSDMember" xlink:to="lab_lly_BuyGBPSellUSDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_42ebf186-dec5-437f-be48-7a3743a178a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 5)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_93233db8-a011-45f4-847b-bd05cbe1a378_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationLineItems_1a971568-f743-406c-902e-dec7bb53b093_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationLineItems" xlink:to="lab_us-gaap_ReclassificationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_91de0e96-f27e-4a17-8fbd-843a97e7bf56_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_b28f0ccb-8b6d-4091-92e7-e6215c18afbe_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20230331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16a56705-2733-4428-bc82-d4653f9c22f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_556eb52c-2b30-4273-b80e-8542a222b202_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625NotesDue2031Member_f1eefbd3-b8a0-4df8-bef9-038b88f46980_terseLabel_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625NotesDue2031Member_label_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes Due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625NotesDue2031Member_documentation_en-US" xlink:label="lab_lly_A625NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member" xlink:href="lly-20230331.xsd#lly_A625NotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625NotesDue2031Member" xlink:to="lab_lly_A625NotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3d8d471-4a59-4086-b823-36e557b123c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_8c6cd194-22b3-4570-85c6-1a240cf8396f_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20230331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_a670cc94-8c93-47a9-9e06-37a7e671d7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c8dde496-bdd6-4823-8df1-2a95a44f24a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_383198eb-d88b-41b4-9d28-7b9ed2770243_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AkouosAcquisitionMember_d42df78d-d8b8-4220-beff-ab728ccbe2d9_terseLabel_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_label_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:label id="lab_lly_AkouosAcquisitionMember_documentation_en-US" xlink:label="lab_lly_AkouosAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akouos Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember" xlink:href="lly-20230331.xsd#lly_AkouosAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AkouosAcquisitionMember" xlink:to="lab_lly_AkouosAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_eb476cdf-7a15-461f-b7da-ff2e32958ecf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_7bdd0a77-4991-4800-93d1-2f665fa44da9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SellEuroMember_1ae10a25-73d7-41d7-b662-d3c4936ccf8a_terseLabel_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro</link:label>
    <link:label id="lab_lly_SellEuroMember_label_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:label id="lab_lly_SellEuroMember_documentation_en-US" xlink:label="lab_lly_SellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember" xlink:href="lly-20230331.xsd#lly_SellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SellEuroMember" xlink:to="lab_lly_SellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_afdc266b-d039-46b8-9b46-bd9635f70dd9_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20230331.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_0470bfe9-0ed4-46c2-8aa5-64aeef30fa7b_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20230331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_03d6792a-03f0-47ae-b2fe-8f457077e681_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_b1c716ef-bf10-477d-adc4-e024b7c3c398_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the contractual maturities of our investments in debt securities measured at fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_f1c5de01-366e-439b-84f7-ba057c388733_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_a1dc6776-4e64-4dbf-9597-a054848695bf_terseLabel_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:label id="lab_us-gaap_OffsettingAssetsTable_label_en-US" xlink:label="lab_us-gaap_OffsettingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffsettingAssetsTable" xlink:to="lab_us-gaap_OffsettingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_58dbb1fd-6c8e-4181-a234-de588398d49d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3335b534-250d-42d7-a661-db9e520f71f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d62ac35-7368-4d89-aea7-4c2dfb017b91_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_bd01a65a-50a5-4fe3-bc97-d0a49c329986_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_5c8be242-109b-4d2f-a56c-ce0113245c4b_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d31861ac-3f78-47a1-8dcb-63f2f084cc31_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bbd5d6fd-4157-40e3-a714-9546afd6d3ff_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_99872e03-3fa5-44a5-9ad2-8df8dbb1e665_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_c4f2930e-fa1c-49fa-b07c-aee3f679fb4a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_e061a53a-4c88-4504-8605-269ee2a4ff01_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_f85f9ab7-56b9-40a5-8d7e-858379ea606b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_b7bacbe4-c62e-47b8-9580-8b26d65ffdfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_25b0c493-328f-4b2a-a39f-ca8cb7c4e971_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_01d3a01a-52f1-44a2-84e1-b519ed1a78eb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7780d81c-0306-411e-9c06-4284859ee21d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6360dbff-f454-4e1b-8be9-6c372de406c1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_3de0b803-2f13-4caa-9970-751562cafb9d_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f8dccc3c-5690-49b9-bc1c-c8e256b5f16b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cd98385b-a7c8-4ab7-a46b-3b98782bce76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_94da1746-f6d3-4963-9088-0448140cbbb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_b8a23cf5-bef4-4989-b995-dc44494ce1dc_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20230331.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_44f85be0-1533-496c-91e6-c2910ab8aabe_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_435182c1-0447-422e-ad8e-20605331c44e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_a67c0fed-3c32-4db9-bd3f-ea4f2170f330_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20230331.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_a8bddd70-d652-4038-83b4-904179fc5f65_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_3562ce54-84fe-4546-bbd2-36540e401ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7da7e004-13ec-4828-a38b-a1f1ba10ee31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ddd837cb-c469-4010-b2c9-c7a06dd1f9d8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_7b787135-a342-4937-bfef-42886aa3c1e6_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c87ad0ad-290d-435f-a726-2b59b1d7a479_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_e3786394-8a1b-4d14-8aa8-9e29a1443bea_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_727156d5-1938-4f62-bfb6-5dc5fe0e39e3_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_eba5e30c-2855-4138-8a0d-9b8f189f4faf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_57ce6c58-7668-4036-ba71-e924f3647d08_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_cebb117a-0701-489c-9b20-6f34a07292a3_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20230331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_a30025c9-bd8e-43a9-9036-8ce3f6d19e0d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_5142524f-f8a0-4f84-b2be-1a6ec4e88ced_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Rebates And Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20230331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ebc9c51-c3d0-401d-95ef-0385dfda5fe7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_562aa8cd-27a6-4c74-b7b8-abdb6f8eb5d9_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b0cac509-0c7d-4648-9ef1-e4383c91ec90_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_82ab5b0c-422e-4eed-915d-912f559cc376_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6a161976-289b-489c-a8ba-d335b341770f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_177b9322-3187-447a-bdfb-2ede80f5f41a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_f11f0f1c-f4b0-4aaf-85b3-de7d2a14e808_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20230331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_e5b7a96b-0c79-4d72-b284-b743a05d763f_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20230331.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_78c6fa88-7e73-4337-8fce-a3c5ffd30c40_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d00062a8-3f98-435b-a8b6-0d96f42fadd9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_9ccbcfcf-0459-45d7-aef4-d98aff9c0761_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, noncurrent investments</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20230331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e251c198-03c4-4de7-a9eb-171ca2db93c8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_9f59d8da-31de-487e-ac6e-0dfb4576103c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More&#160;Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_96b648ed-6aab-48f1-91e2-7bde5a24281c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_82875ba6-4ea6-4030-894e-57cf73b21831_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20230331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9da3c301-da09-4782-9302-b1360a79409e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_72c82c61-ae29-43cf-8595-cc9d2dab24e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of derivative instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6eb4a57d-4bbc-434a-9dcd-95ccd38c7eed_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_91412d0c-fcb1-4d98-b538-7b0b10198316_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2597b1b1-520e-4d72-8637-28625948ce4c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_fd93f763-45ed-45c8-992e-0aada78a948e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SeniorNotesDue202620332053And2063Member_9a4564ec-e83f-4ccf-92a2-9591c265dccd_terseLabel_en-US" xlink:label="lab_lly_SeniorNotesDue202620332053And2063Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2026, 2033, 2053 And 2063</link:label>
    <link:label id="lab_lly_SeniorNotesDue202620332053And2063Member_label_en-US" xlink:label="lab_lly_SeniorNotesDue202620332053And2063Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2026, 2033, 2053 And 2063 [Member]</link:label>
    <link:label id="lab_lly_SeniorNotesDue202620332053And2063Member_documentation_en-US" xlink:label="lab_lly_SeniorNotesDue202620332053And2063Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2026, 2033, 2053 And 2063</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDue202620332053And2063Member" xlink:href="lly-20230331.xsd#lly_SeniorNotesDue202620332053And2063Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SeniorNotesDue202620332053And2063Member" xlink:to="lab_lly_SeniorNotesDue202620332053And2063Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3729864a-14db-4d5a-baa4-cc326c2d84a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4ca9c708-43c2-44c6-8abf-325816637df8_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_3d5a5bfa-8ead-4c69-b2c9-b2e37b2b6caa_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20230331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_62fa6b21-ae79-4eb1-8265-b3287f95d933_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_a74ce8cb-73eb-403d-967e-b29663b362c7_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20230331.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_628e80dc-62fc-4c37-9730-94ed6db7dec6_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_41197c97-1c74-47a0-90c1-b20b90da36a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_bde7d97e-799c-439b-9b19-6e0a1eb3dcf6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2e48785d-06ae-482f-8d8d-88671b5af588_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4c5d005c-fe9d-4b01-a579-7d43bf7d177f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d1b88c91-ac1f-4604-87bd-f0420df0d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_75ebe490-44b0-460b-b9d2-8ff0fedc777f_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_8a5502d2-40cb-44aa-ac9d-a7cf0f475506_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20230331.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_96a3f7da-1650-4683-b038-d5ad4976285a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_534ddcbf-243f-462e-b23f-53fbf6e437d0_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20230331.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_aee47b10-e5a4-4e32-8019-34b37d3a0085_terseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_c9725609-9f77-45a4-8a68-702cc3b9cb11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36d09e5c-474f-4b68-a350-a744d2f5beb7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_7eebddc3-d9b3-4441-aca9-6e7fc6059a94_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_103b0c9d-d83d-4c2d-9082-f7e027e3879c_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4eb3453a-cff1-48d4-ab50-3aefd8f19ea5_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_314f2315-21a6-45ac-9c65-3ab0ba809e64_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20230331.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_cad9d6f0-1c46-4494-b4f7-dff63d28fef3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0b5add83-65db-4afa-938e-8ab47722c68c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_ebf781ef-743c-43bc-a227-3e14dc188b31_terseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20230331.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_63394444-9000-4fe9-ab90-e7ed36108561_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a63aac9e-b53f-4c8b-8ab7-3ea6d3953c73_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_858f80fa-3fa9-4a4e-a7d1-9ea8c4c60d7c_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20230331.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6b4dec12-c9ff-4937-8b82-94c7793366de_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_05c2ca37-2822-4002-bb2a-53f3e5062b9a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c25e3964-8582-4958-b4df-701f18c311b2_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_aedcc559-4f4e-4399-8ab6-738db176d904_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_c64842a7-ac58-463a-ac7d-aa2474f8459e_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euros Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20230331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e100a4d0-0870-41b7-8a9a-2124273ca8c2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4944ad4-6258-405c-94b5-25af08f0421e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1f33d94b-448a-46b1-91a3-eb7ca4daff79_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ab99d017-f17f-4bba-bcfa-4240e066a49f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c4add291-8102-4d47-8968-1269ef888740_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_224393b4-e766-4be5-888f-ebf5665a9e22_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a570a7c4-183b-4e1e-a88c-5568b298d851_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_a42ff7dd-33cd-4a78-8c57-264cbade2307_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f222a117-00ad-459e-bea0-3dc08abc57e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_9a2b40db-5247-44e4-880e-cfbf35d4a39b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_abfe47ec-a9e0-49a0-b2de-f3be95b6ad8f_terseLabel_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars to Euro</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_label_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_documentation_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember" xlink:href="lly-20230331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapU.S.DollarsToEuroMember" xlink:to="lab_lly_SwapU.S.DollarsToEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A47NotesDue2033Member_2606d10e-e38a-4e1b-bace-6a4675827230_terseLabel_en-US" xlink:label="lab_lly_A47NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.7% Notes Due 2033</link:label>
    <link:label id="lab_lly_A47NotesDue2033Member_label_en-US" xlink:label="lab_lly_A47NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.7% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A47NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A47NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.7% Notes Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A47NotesDue2033Member" xlink:href="lly-20230331.xsd#lly_A47NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A47NotesDue2033Member" xlink:to="lab_lly_A47NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_79f66df5-406c-45b6-8a5e-f4ec441d2b62_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_748d2c92-5f10-4489-8c89-44195f355b35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6950948e-dcf8-4a99-ae0f-30331979a998_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_aa8ca2d6-1179-436e-876c-971fafcd96cd_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of activity related to our available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_2747ec37-a3d4-4123-8d4b-98f17f1b4b57_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d4594233-722a-4ee2-9c10-2706294c5396_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a95b0f8d-7ed7-41a7-b152-8f300f8bb754_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_fc7f81c0-aacd-4265-8e1d-b964a0b246b3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_d47f9669-48a8-41e4-88f3-983c9a358184_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MounjaroMember_c4e4bfad-4ad9-4553-9fdf-7dd8fbb1dc66_terseLabel_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro&#174;</link:label>
    <link:label id="lab_lly_MounjaroMember_label_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro [Member]</link:label>
    <link:label id="lab_lly_MounjaroMember_documentation_en-US" xlink:label="lab_lly_MounjaroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounjaro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember" xlink:href="lly-20230331.xsd#lly_MounjaroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MounjaroMember" xlink:to="lab_lly_MounjaroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_b6ac9ebc-ff7c-4a9c-9f74-736edb5f1ed4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7ab1c5d3-fef8-49b0-8518-ff10255c5a37_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5637db83-811d-4c89-9103-6e42dcbcc825_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_9057acab-ac87-4d94-9094-5641da0af3d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lly-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb696e89-33dc-46c1-8b0a-06e7c94e2493,g:84666321-8aeb-4ed9-ba40-f600d0efd75e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_82f16798-40ba-4b04-9d93-ca333e45b8ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_82f16798-40ba-4b04-9d93-ca333e45b8ae" xlink:to="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c9a6d56d-1925-48bb-8d1c-c8f1c4559fa8" xlink:to="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_add42f06-7649-4341-b655-9720253e4f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_us-gaap_CommonClassAMember_add42f06-7649-4341-b655-9720253e4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_2d8bb85b-7f91-4e52-8c97-b33fe47e70bc" xlink:href="lly-20230331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A718NotesDueJune12025Member_2d8bb85b-7f91-4e52-8c97-b33fe47e70bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_4b285a3f-21e2-4135-be05-771278dbf37f" xlink:href="lly-20230331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1.625NotesDueJune22026Member_4b285a3f-21e2-4135-be05-771278dbf37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_04730a88-380c-4ad6-9d88-542e2c801061" xlink:href="lly-20230331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A2.125NotesDueJune32030Member_04730a88-380c-4ad6-9d88-542e2c801061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625NotesDue2031Member_8f225ab9-aafd-43b5-b383-7dc9f1cd8f3c" xlink:href="lly-20230331.xsd#lly_A625NotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A625NotesDue2031Member_8f225ab9-aafd-43b5-b383-7dc9f1cd8f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_b170b23a-6084-489b-8df1-f14d400a8595" xlink:href="lly-20230331.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A500NotesDue2033Member_b170b23a-6084-489b-8df1-f14d400a8595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_b47bd373-6a37-4c52-9f56-e0211b6500e6" xlink:href="lly-20230331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_b47bd373-6a37-4c52-9f56-e0211b6500e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4461745c-9166-4f67-be67-60ffa7c6f9fc" xlink:href="lly-20230331.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1625NotesDue2043Member_4461745c-9166-4f67-be67-60ffa7c6f9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1700NotesDue2049Member_ba893ab0-18f2-4f49-9cd4-0189b03f0148" xlink:href="lly-20230331.xsd#lly_A1700NotesDue2049Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1700NotesDue2049Member_ba893ab0-18f2-4f49-9cd4-0189b03f0148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_4d0265fb-66ac-4245-b469-7c5e9a6450e8" xlink:href="lly-20230331.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1125NotesDue2051Member_4d0265fb-66ac-4245-b469-7c5e9a6450e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_81337b30-6004-42ea-8c11-4552b861c0d7" xlink:href="lly-20230331.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8caa5d8-d602-4f79-b355-df13bd4de710" xlink:to="loc_lly_A1375NotesDue2061Member_81337b30-6004-42ea-8c11-4552b861c0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8c810a77-bcfc-4b83-98a4-a4a481bbd8fe" xlink:to="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_91821ee9-9230-4bef-b220-8798ae03f3a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentType_91821ee9-9230-4bef-b220-8798ae03f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_639ba401-7225-4674-8670-cea1ef95c369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentPeriodEndDate_639ba401-7225-4674-8670-cea1ef95c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5eeb3272-d966-454b-ab1b-6f8507f0a69d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityFileNumber_5eeb3272-d966-454b-ab1b-6f8507f0a69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5b0e9fe1-a81f-44e9-8447-9b4a84fb2d55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityRegistrantName_5b0e9fe1-a81f-44e9-8447-9b4a84fb2d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5e9bcff4-dba2-4714-9750-4c8f418b6d54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5e9bcff4-dba2-4714-9750-4c8f418b6d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74741467-a8cc-4208-8881-f51c7988e401" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityTaxIdentificationNumber_74741467-a8cc-4208-8881-f51c7988e401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_643524ce-2086-4c03-af20-a0adf66ffd7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressAddressLine1_643524ce-2086-4c03-af20-a0adf66ffd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a180d6af-6b42-4338-ae1e-2590fc61a475" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressCityOrTown_a180d6af-6b42-4338-ae1e-2590fc61a475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f47027ff-b998-4f71-9276-59d47f20ac8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressStateOrProvince_f47027ff-b998-4f71-9276-59d47f20ac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_826d7d82-2f3d-4303-8c4e-702e54413c27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityAddressPostalZipCode_826d7d82-2f3d-4303-8c4e-702e54413c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d0321cae-e0bf-4bb9-812a-ff06750cf1c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_CityAreaCode_d0321cae-e0bf-4bb9-812a-ff06750cf1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_14693fd8-c440-4cc7-b7e4-865517500e3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_LocalPhoneNumber_14693fd8-c440-4cc7-b7e4-865517500e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f60dd69d-fcb1-4cc3-8bc8-a63a25596480" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_Security12bTitle_f60dd69d-fcb1-4cc3-8bc8-a63a25596480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b7fe23d5-b3cc-47bd-bcd6-f9611a306131" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_TradingSymbol_b7fe23d5-b3cc-47bd-bcd6-f9611a306131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b58ece50-cd1c-49a4-a3a8-2440b9256ff7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_SecurityExchangeName_b58ece50-cd1c-49a4-a3a8-2440b9256ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8de56ef1-16d6-44e0-82a1-7511d8dd4eb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCurrentReportingStatus_8de56ef1-16d6-44e0-82a1-7511d8dd4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_95dbf4e5-ce8f-472a-9fea-1da48236aeab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityInteractiveDataCurrent_95dbf4e5-ce8f-472a-9fea-1da48236aeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1793b8e3-9980-4145-a301-ab8d7c16bdaa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityFilerCategory_1793b8e3-9980-4145-a301-ab8d7c16bdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3dbf06b9-5146-4a7a-8d1a-5a4637bc3f68" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntitySmallBusiness_3dbf06b9-5146-4a7a-8d1a-5a4637bc3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_15953539-d6e5-44d6-a6fc-65c176e46d4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityEmergingGrowthCompany_15953539-d6e5-44d6-a6fc-65c176e46d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_17184715-fa36-4d14-b7b8-59a531582e55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityShellCompany_17184715-fa36-4d14-b7b8-59a531582e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc48a665-4ae8-43f6-aae4-dec174dbc1bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc48a665-4ae8-43f6-aae4-dec174dbc1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fede16e9-a00d-4bc1-8e05-994e93c8e0e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_AmendmentFlag_fede16e9-a00d-4bc1-8e05-994e93c8e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cc1cc597-72d9-4c73-a63f-3c5315b23a16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentFiscalYearFocus_cc1cc597-72d9-4c73-a63f-3c5315b23a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_761eed55-93a8-4493-bd2e-1195354af0da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentFiscalPeriodFocus_761eed55-93a8-4493-bd2e-1195354af0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_207cb73d-ad24-4a57-8cac-5be50b0f8253" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_EntityCentralIndexKey_207cb73d-ad24-4a57-8cac-5be50b0f8253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_77dbc396-c16a-437a-b633-f2713ae97d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_CurrentFiscalYearEndDate_77dbc396-c16a-437a-b633-f2713ae97d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_25ce75f7-d709-4755-88ac-8d64e1ee060f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentQuarterlyReport_25ce75f7-d709-4755-88ac-8d64e1ee060f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_56506ac5-2a93-4ae5-bd7e-b1c834e60098" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c5b4703f-d43a-4da7-abfa-22d8b79bf167" xlink:to="loc_dei_DocumentTransitionReport_56506ac5-2a93-4ae5-bd7e-b1c834e60098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5be19b02-47cf-45dd-bd87-69fc5cf512b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_Revenues_5be19b02-47cf-45dd-bd87-69fc5cf512b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_378808d8-e45c-494b-ba0e-b9209e84dee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_378808d8-e45c-494b-ba0e-b9209e84dee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_35381588-e7da-4949-88c6-12af22289283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_35381588-e7da-4949-88c6-12af22289283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_492c2ec0-368a-431d-ad60-67a227c260c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_492c2ec0-368a-431d-ad60-67a227c260c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_c16a0ef2-27db-41d8-a74b-c1a2bd0ef012" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_c16a0ef2-27db-41d8-a74b-c1a2bd0ef012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c7eb3be2-058e-4a92-a2fd-f67260328a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c7eb3be2-058e-4a92-a2fd-f67260328a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_458014b9-720d-4c97-82ab-60aef417522d" xlink:href="lly-20230331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b9f968f7-1064-4c0e-915b-3c5a22247d14" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_458014b9-720d-4c97-82ab-60aef417522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aa3aa0a-7cef-48db-89a1-41ef687a2597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aa3aa0a-7cef-48db-89a1-41ef687a2597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a1dd8448-eab0-42c3-b477-930e8e7a848f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a1dd8448-eab0-42c3-b477-930e8e7a848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6476cab-764f-430a-8857-c3be86ec727e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_NetIncomeLoss_f6476cab-764f-430a-8857-c3be86ec727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_74ab7f22-8fd7-4062-8482-b9e1d66ead64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_74ab7f22-8fd7-4062-8482-b9e1d66ead64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b8b586ba-add1-4ae1-b0b2-bd781bac0c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_74ab7f22-8fd7-4062-8482-b9e1d66ead64" xlink:to="loc_us-gaap_EarningsPerShareBasic_b8b586ba-add1-4ae1-b0b2-bd781bac0c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_01601f87-d419-4041-9d92-c5de3a186cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_74ab7f22-8fd7-4062-8482-b9e1d66ead64" xlink:to="loc_us-gaap_EarningsPerShareDiluted_01601f87-d419-4041-9d92-c5de3a186cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9f6a8ed9-762a-4364-bd76-f25a042c710d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14449c1d-4ed4-4d4e-a605-fe30e79a810d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9f6a8ed9-762a-4364-bd76-f25a042c710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ad22fea0-36b7-49b2-a336-17e497d0ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9f6a8ed9-762a-4364-bd76-f25a042c710d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ad22fea0-36b7-49b2-a336-17e497d0ce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a40b167-6f56-4878-97e5-db88ca3b63a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9f6a8ed9-762a-4364-bd76-f25a042c710d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a40b167-6f56-4878-97e5-db88ca3b63a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d638ceba-4d7b-44d2-882c-f342d2404b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_32742793-50f2-4792-bbf3-8dbc8f581469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d638ceba-4d7b-44d2-882c-f342d2404b9c" xlink:to="loc_us-gaap_NetIncomeLoss_32742793-50f2-4792-bbf3-8dbc8f581469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_849932e4-1d2e-428d-b8e2-4a16d864b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d638ceba-4d7b-44d2-882c-f342d2404b9c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_849932e4-1d2e-428d-b8e2-4a16d864b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_16073b2e-72c1-47f8-9bfd-f67b5eb37dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d638ceba-4d7b-44d2-882c-f342d2404b9c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_16073b2e-72c1-47f8-9bfd-f67b5eb37dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1f4f4e51-0362-4035-ae1b-acf0d93361c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f4f4e51-0362-4035-ae1b-acf0d93361c8" xlink:to="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3883b3cb-4782-4514-b0dd-62c33b549a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3883b3cb-4782-4514-b0dd-62c33b549a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_efb71310-4f05-4cb9-aef3-cd4b0c85cf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_ShortTermInvestments_efb71310-4f05-4cb9-aef3-cd4b0c85cf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e6c8fba8-05fe-44a6-88fd-800c81d42356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e6c8fba8-05fe-44a6-88fd-800c81d42356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f9a76e50-9c98-48f0-91fe-188462a10bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f9a76e50-9c98-48f0-91fe-188462a10bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_542bad53-2f0c-4c5c-9fbc-2bb8809b1fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_InventoryNet_542bad53-2f0c-4c5c-9fbc-2bb8809b1fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cafa137a-fb73-4af8-8555-f7687e9f9f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cafa137a-fb73-4af8-8555-f7687e9f9f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d803c8c1-d880-4093-a8fb-6d4c1d56b358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07cd4927-d8d8-4974-b9a1-4ec8fffbc24e" xlink:to="loc_us-gaap_AssetsCurrent_d803c8c1-d880-4093-a8fb-6d4c1d56b358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_53f19367-ef99-47b0-8bcf-f49ac38a9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_LongTermInvestments_53f19367-ef99-47b0-8bcf-f49ac38a9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fe87feee-742a-4177-ac5c-1bb58ec03a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_Goodwill_fe87feee-742a-4177-ac5c-1bb58ec03a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c631158d-5aea-4623-9f57-0ed197bdd223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c631158d-5aea-4623-9f57-0ed197bdd223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a7b920c8-d16e-4f2c-9304-ab7009e46f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a7b920c8-d16e-4f2c-9304-ab7009e46f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6ac09a2-a2c5-4c04-b58c-da14204c179c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6ac09a2-a2c5-4c04-b58c-da14204c179c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e0d551f-f4c2-44e5-9558-8ef023a38053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e0d551f-f4c2-44e5-9558-8ef023a38053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c964ab82-98a2-4d52-b037-71849c4b53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19bc9070-fd8d-466a-a0c0-96dee3a55ae0" xlink:to="loc_us-gaap_Assets_c964ab82-98a2-4d52-b037-71849c4b53f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f4f4e51-0362-4035-ae1b-acf0d93361c8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e69afea4-0474-4e6e-b34b-76b5f3fcda29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_DebtCurrent_e69afea4-0474-4e6e-b34b-76b5f3fcda29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b5bfb141-ef23-48db-bb10-be0ba451bde0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_AccountsPayableCurrent_b5bfb141-ef23-48db-bb10-be0ba451bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f502f197-79f2-451d-9e3a-890f9bd858a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f502f197-79f2-451d-9e3a-890f9bd858a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_c2f9b7eb-bcf4-4b54-b6b4-2978f323e0ca" xlink:href="lly-20230331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_lly_SalesRebatesAndDiscounts_c2f9b7eb-bcf4-4b54-b6b4-2978f323e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_9e79a270-e459-420d-939b-5592dd517f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_DividendsPayableCurrent_9e79a270-e459-420d-939b-5592dd517f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_61ac358e-8196-4895-b0ad-6bd53098a61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_TaxesPayableCurrent_61ac358e-8196-4895-b0ad-6bd53098a61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fc518b4c-b0cf-4027-ba9b-50a31569eebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fc518b4c-b0cf-4027-ba9b-50a31569eebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_020658d0-69e7-4530-9fd3-e98565793816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f77890b6-19d1-4e21-b675-edcd5210962a" xlink:to="loc_us-gaap_LiabilitiesCurrent_020658d0-69e7-4530-9fd3-e98565793816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d157c65-51b4-46ed-bd9e-545492aae27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d157c65-51b4-46ed-bd9e-545492aae27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e6c40019-27e5-4e74-8d5e-25bbd171aecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e6c40019-27e5-4e74-8d5e-25bbd171aecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7ea96986-5d34-428a-8bf6-384a6a06af31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7ea96986-5d34-428a-8bf6-384a6a06af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0a18c0dc-e8ec-408c-8c36-b7c8163418da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0a18c0dc-e8ec-408c-8c36-b7c8163418da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1b13b48f-6b42-4d11-a829-363c77479352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fda37dbb-01f2-452b-9a30-7ed16cb813d2" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1b13b48f-6b42-4d11-a829-363c77479352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_742f59a0-79dd-4e45-bf3c-932075915c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_CommitmentsAndContingencies_742f59a0-79dd-4e45-bf3c-932075915c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e5328340-e0da-4e01-b421-fafb96a2acdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_CommonStockValue_e5328340-e0da-4e01-b421-fafb96a2acdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47c7b4d9-5b9f-4b65-bf5a-40b0ff99b547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47c7b4d9-5b9f-4b65-bf5a-40b0ff99b547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2104df8-f5fb-42ee-884d-1947abd6fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2104df8-f5fb-42ee-884d-1947abd6fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_54f62d9f-1716-48f1-b344-a7316d080d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_54f62d9f-1716-48f1-b344-a7316d080d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2d8a41b-c124-404b-8870-d3a548bd5bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2d8a41b-c124-404b-8870-d3a548bd5bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_48490a82-eaed-46be-9c9d-b80f1b1f2486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_TreasuryStockCommonValue_48490a82-eaed-46be-9c9d-b80f1b1f2486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7557b57f-4ff3-40f1-9829-667c0d7a8fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5fd8cb1-a110-46f4-99e3-ccc845215bcc" xlink:to="loc_us-gaap_StockholdersEquity_7557b57f-4ff3-40f1-9829-667c0d7a8fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d57ff6bd-1a23-4ba4-8686-eb3ce63733f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_MinorityInterest_d57ff6bd-1a23-4ba4-8686-eb3ce63733f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c6e912b-eba1-4b14-8f14-bb032fe3f23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c6e912b-eba1-4b14-8f14-bb032fe3f23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7c39b1d-1b9c-4e4b-bc1b-d4536e3601dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f538910-5901-462c-af72-4f39a3571374" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7c39b1d-1b9c-4e4b-bc1b-d4536e3601dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_a12142ad-4c88-4d87-8d07-e8624d29fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_49aeca1b-eacc-4128-8760-8bb71a445433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_a12142ad-4c88-4d87-8d07-e8624d29fc84" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_49aeca1b-eacc-4128-8760-8bb71a445433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18452f94-5ee5-402b-8367-fac60e8f3cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_a12142ad-4c88-4d87-8d07-e8624d29fc84" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18452f94-5ee5-402b-8367-fac60e8f3cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_17fe5788-baec-42c4-91eb-80f006882b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_17fe5788-baec-42c4-91eb-80f006882b6a" xlink:to="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b3b2ad47-581c-47d7-b32c-d6f8fe42e5a1" xlink:to="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_17f4e248-1e54-4fa6-991b-66b6e9c611dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_CommonStockMember_17f4e248-1e54-4fa6-991b-66b6e9c611dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_85f9c0e6-6bb2-42e3-bb41-a86a190cb301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_85f9c0e6-6bb2-42e3-bb41-a86a190cb301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8ab50c98-0c1e-4508-bec1-a819a6647ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_RetainedEarningsMember_8ab50c98-0c1e-4508-bec1-a819a6647ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_5ac619bb-ffb5-4b27-bafe-293e1a47ca68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_5ac619bb-ffb5-4b27-bafe-293e1a47ca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00092297-31df-40b6-8838-650c8678d762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00092297-31df-40b6-8838-650c8678d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_785efd30-ca89-4c67-93c4-04b54d63b048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_TreasuryStockCommonMember_785efd30-ca89-4c67-93c4-04b54d63b048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e33154d4-e1ef-4bb9-a520-8016ef9129da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dd56e78-e161-42bb-abbe-ae78a02b2601" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e33154d4-e1ef-4bb9-a520-8016ef9129da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d4afb54-6ebd-4d53-a5b8-0236cfb26791" xlink:to="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a85a7b84-e14a-41ed-b53f-5a14bdc699cf" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a72b104d-69fc-49a4-b213-3b75d2c599c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_CommonStockSharesIssued_a72b104d-69fc-49a4-b213-3b75d2c599c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d0b04782-ed77-403c-a0ea-0d3e8fad33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d0b04782-ed77-403c-a0ea-0d3e8fad33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58db25fd-ba35-42d8-9a52-a8173e4f4af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58db25fd-ba35-42d8-9a52-a8173e4f4af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b4cd882-7bba-49c8-af37-114bdabbf9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_ProfitLoss_9b4cd882-7bba-49c8-af37-114bdabbf9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dd4703a-a17d-475b-874c-bdd05f416abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0dd4703a-a17d-475b-874c-bdd05f416abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_41a6fc65-2ffd-4695-bbe9-b03802ba8cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_41a6fc65-2ffd-4695-bbe9-b03802ba8cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e04e5b2a-a3ef-475b-9529-4bcc8a865046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e04e5b2a-a3ef-475b-9529-4bcc8a865046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_50fd8edb-b8d7-4123-9def-b3f83da3d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_50fd8edb-b8d7-4123-9def-b3f83da3d17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_14021eff-b4cc-4fa7-8749-2f35ed92be40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_14021eff-b4cc-4fa7-8749-2f35ed92be40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_941231ba-8077-47a0-9efb-48bc984e2dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_941231ba-8077-47a0-9efb-48bc984e2dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d44e060d-5b47-453d-ac0a-b353c26ac101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d44e060d-5b47-453d-ac0a-b353c26ac101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5fed1afd-2408-4abf-a4cb-277429f2692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5fed1afd-2408-4abf-a4cb-277429f2692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_5ccc72b9-74ed-4c9f-b734-bdb31e696391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockholdersEquityOther_5ccc72b9-74ed-4c9f-b734-bdb31e696391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5bdc0e48-52fb-4b0c-8758-6e831c8f398b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_CommonStockSharesIssued_5bdc0e48-52fb-4b0c-8758-6e831c8f398b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_370099e7-bdf9-4b9a-a97c-9b8a3f6d491e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_370099e7-bdf9-4b9a-a97c-9b8a3f6d491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_670b3ba1-7657-432c-8992-59d3117f39d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cc4ffbf2-47f6-40df-9e51-8fc1513558f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_670b3ba1-7657-432c-8992-59d3117f39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_98385782-539b-4867-924a-df17e1960ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6a342dcb-5aaa-4677-8ed8-f8a05fd6576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_98385782-539b-4867-924a-df17e1960ebe" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_6a342dcb-5aaa-4677-8ed8-f8a05fd6576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_cc6fd794-ef73-408b-9fc4-ba8a25f2b6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_98385782-539b-4867-924a-df17e1960ebe" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_cc6fd794-ef73-408b-9fc4-ba8a25f2b6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20230331.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed260b5c-5a97-410f-b0f9-1043cab9b949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed260b5c-5a97-410f-b0f9-1043cab9b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17f5e87b-3ee3-43c6-8f8c-7aa672f19010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed260b5c-5a97-410f-b0f9-1043cab9b949" xlink:to="loc_us-gaap_NetIncomeLoss_17f5e87b-3ee3-43c6-8f8c-7aa672f19010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed260b5c-5a97-410f-b0f9-1043cab9b949" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ffefd9f6-e7b9-48dc-aeb0-34dae0228654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ffefd9f6-e7b9-48dc-aeb0-34dae0228654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b34b5abc-2d73-4450-a610-d17763b016fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b34b5abc-2d73-4450-a610-d17763b016fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a8322aaf-31a0-4e40-b580-b8f669f1b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_ShareBasedCompensation_a8322aaf-31a0-4e40-b580-b8f669f1b1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_a86d23ef-585f-47fc-92c0-58b5d48eae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_GainLossOnInvestments_a86d23ef-585f-47fc-92c0-58b5d48eae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_1887e347-e00b-4a50-87c6-a62215f2c0c0" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_1887e347-e00b-4a50-87c6-a62215f2c0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1c6cd2fe-8e0c-425d-901b-7b90f275da44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1c6cd2fe-8e0c-425d-901b-7b90f275da44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_11e09d3d-4585-4aad-9945-dc8ff0866a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83945e24-c6df-4dd4-b3f3-3b08d20151c8" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_11e09d3d-4585-4aad-9945-dc8ff0866a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8c47bc9-61a4-4ec6-95a7-1d46ea0b9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed260b5c-5a97-410f-b0f9-1043cab9b949" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8c47bc9-61a4-4ec6-95a7-1d46ea0b9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_43ddbc8e-d5e9-419c-9e8f-2e17fae5635d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_43ddbc8e-d5e9-419c-9e8f-2e17fae5635d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_68b6150c-0e7c-4841-9a22-0609e4128e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_68b6150c-0e7c-4841-9a22-0609e4128e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_94af05ea-30e9-43a8-96dd-cfeacd4cc22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_94af05ea-30e9-43a8-96dd-cfeacd4cc22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_30bd2590-ed80-4386-8f90-9a2c895c7543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_30bd2590-ed80-4386-8f90-9a2c895c7543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_3059449f-00d8-4bfa-86e8-85f2f45e7646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_3059449f-00d8-4bfa-86e8-85f2f45e7646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasesOfInProcessResearchAndDevelopment_b3005b93-f83d-4d27-82d4-a83628c01283" xlink:href="lly-20230331.xsd#lly_PurchasesOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_lly_PurchasesOfInProcessResearchAndDevelopment_b3005b93-f83d-4d27-82d4-a83628c01283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7c5cb0b0-787a-41c3-8912-30c570f22689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7c5cb0b0-787a-41c3-8912-30c570f22689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe2bf3cd-2317-4083-8234-01fe7ec05cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2682c513-b079-4eab-a2ec-23f0cdaff520" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe2bf3cd-2317-4083-8234-01fe7ec05cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_faa36250-7290-4820-b972-0f5dba3e0ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_PaymentsOfDividends_faa36250-7290-4820-b972-0f5dba3e0ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_9ab8b421-5613-4773-b611-887f83a70678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_9ab8b421-5613-4773-b611-887f83a70678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_89307183-0102-4214-a252-abdb8080c790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_89307183-0102-4214-a252-abdb8080c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a4097776-aeff-47c9-b82c-ccf88e5131e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a4097776-aeff-47c9-b82c-ccf88e5131e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66b47d64-e3f9-407f-af45-864283f3f068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66b47d64-e3f9-407f-af45-864283f3f068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a35788c-7111-4719-b630-22989a0a5127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a35788c-7111-4719-b630-22989a0a5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc1cfd28-ad57-4e82-ab6c-4e8d3bfe7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aaa8e1bb-385e-4215-806e-2b0b6af03bea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc1cfd28-ad57-4e82-ab6c-4e8d3bfe7297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_831477db-41cd-4b25-bda0-6c86805e1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_831477db-41cd-4b25-bda0-6c86805e1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13bfba9-6ef0-48a7-9518-549c38da11de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13bfba9-6ef0-48a7-9518-549c38da11de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_36348bf9-0ede-4897-adb8-4aaa1f039a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_36348bf9-0ede-4897-adb8-4aaa1f039a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_77b22086-aade-44c1-bb9d-33ba6d6b9200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d995f433-3e8b-40e5-a3b6-3d4c79cc02e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_77b22086-aade-44c1-bb9d-33ba6d6b9200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentation" xlink:type="simple" xlink:href="lly-20230331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b92bc6a-cb99-48ff-9deb-b89a42f5073f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_21d13a46-073c-40f4-8479-403a6830a050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b92bc6a-cb99-48ff-9deb-b89a42f5073f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_21d13a46-073c-40f4-8479-403a6830a050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b37dcd89-decf-45ff-b107-abeabbfad60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_17865ec8-c793-4d55-be5b-0497f26cc84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b37dcd89-decf-45ff-b107-abeabbfad60f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_17865ec8-c793-4d55-be5b-0497f26cc84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7275c17f-1c15-4d0d-b871-95d80d9bcf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_60bcaf57-5095-4b8f-9cdd-03273dffbee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7275c17f-1c15-4d0d-b871-95d80d9bcf97" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_60bcaf57-5095-4b8f-9cdd-03273dffbee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_a2cfeaed-4a51-44bb-9799-c1b6b0ba17e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7275c17f-1c15-4d0d-b871-95d80d9bcf97" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_a2cfeaed-4a51-44bb-9799-c1b6b0ba17e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f022ae35-e62d-49ad-bf90-44d31dcaffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14202653-fe0b-4023-bdf1-7895cacfc5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f022ae35-e62d-49ad-bf90-44d31dcaffd2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14202653-fe0b-4023-bdf1-7895cacfc5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b297591a-408c-41c4-b9dd-ea674d1f09f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4d543a09-2905-4141-8cf0-a0127d711108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b297591a-408c-41c4-b9dd-ea674d1f09f1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4d543a09-2905-4141-8cf0-a0127d711108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b9c2838-3496-4c3b-b124-61eb21f2d031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd383e97-4759-476a-a772-dbe936377541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b9c2838-3496-4c3b-b124-61eb21f2d031" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd383e97-4759-476a-a772-dbe936377541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20230331.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_3a4a13ff-58bb-4c64-9868-80e617a90997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a9d80b56-9839-4c81-a0f6-689a5f7bd0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_3a4a13ff-58bb-4c64-9868-80e617a90997" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a9d80b56-9839-4c81-a0f6-689a5f7bd0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20230331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2492dbb-0588-4b1d-9ed7-0c66a0a229a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52c3341b-5576-472e-ac5c-2abb019763ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2492dbb-0588-4b1d-9ed7-0c66a0a229a8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52c3341b-5576-472e-ac5c-2abb019763ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d11e0d00-87c7-4c78-b314-50d15814d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_72d9dcaf-e9bf-4d38-bd37-0ee1fe6375c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d11e0d00-87c7-4c78-b314-50d15814d7c2" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_72d9dcaf-e9bf-4d38-bd37-0ee1fe6375c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e1b84ed8-a83b-4fbd-93e0-87b0addc7646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1b63bb46-eaa3-44f3-ac2c-806267f0367d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e1b84ed8-a83b-4fbd-93e0-87b0addc7646" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1b63bb46-eaa3-44f3-ac2c-806267f0367d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="lly-20230331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d758bec5-fdcf-4c5d-886f-ba71d80d077f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d758bec5-fdcf-4c5d-886f-ba71d80d077f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f3827151-a133-4dc8-88bc-befc210059c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f3827151-a133-4dc8-88bc-befc210059c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_dc6b0837-db9f-4e8e-93ba-65bfd4f67f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_dc6b0837-db9f-4e8e-93ba-65bfd4f67f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_83caae50-1d1f-42f9-a831-b5487f11cff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_83caae50-1d1f-42f9-a831-b5487f11cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_2e663e67-dfca-4caa-9cc8-79f31061ace0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_2e663e67-dfca-4caa-9cc8-79f31061ace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e6306149-646f-451c-bf53-e168ad280956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3e1301a-fa76-4a9d-9df1-00ae4400a0d4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e6306149-646f-451c-bf53-e168ad280956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d31b6fe-10ad-4042-98f7-024b70ab732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a0bfbbca-5373-4e42-ab01-1a3ab8c84652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d31b6fe-10ad-4042-98f7-024b70ab732b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a0bfbbca-5373-4e42-ab01-1a3ab8c84652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d0acf951-d473-43ff-b126-01f85084bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d31b6fe-10ad-4042-98f7-024b70ab732b" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d0acf951-d473-43ff-b126-01f85084bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_969cc6cb-e0d9-41f4-8725-c44d21143235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9290697e-d24d-4d8c-ae91-dd72de844314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_969cc6cb-e0d9-41f4-8725-c44d21143235" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9290697e-d24d-4d8c-ae91-dd72de844314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85f9151c-e179-4195-ab4c-9dbcd76e7c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2c5a4a62-a121-4609-8a32-69ca6247a205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85f9151c-e179-4195-ab4c-9dbcd76e7c5c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2c5a4a62-a121-4609-8a32-69ca6247a205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7a6418f0-d642-4078-b722-d09f5c8ded54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7a6418f0-d642-4078-b722-d09f5c8ded54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_36ef4b20-449f-44e9-89e2-2d4ed6932868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_36ef4b20-449f-44e9-89e2-2d4ed6932868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_dce12926-cbeb-41a1-80e4-b7bc971f0103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_dce12926-cbeb-41a1-80e4-b7bc971f0103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cb8c2458-056b-4f0b-8c1a-cb275a950db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cb8c2458-056b-4f0b-8c1a-cb275a950db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_037640be-6e41-4857-9b7c-7ffb6d9c2966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_037640be-6e41-4857-9b7c-7ffb6d9c2966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_c248adec-73d5-4ca8-ad90-1965e28ff1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_c248adec-73d5-4ca8-ad90-1965e28ff1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0771d49b-f643-4437-b8ed-d7fd9b702e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0771d49b-f643-4437-b8ed-d7fd9b702e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e714de3a-25a5-4b29-bf35-8f8987d04cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e714de3a-25a5-4b29-bf35-8f8987d04cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_62764503-dbca-46eb-81e6-4d2014dea03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_62764503-dbca-46eb-81e6-4d2014dea03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_f34157ab-bc2f-44f4-ad5a-574bc3acdcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b2d3276-acd3-406f-b140-a82ebb611c6b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_f34157ab-bc2f-44f4-ad5a-574bc3acdcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20230331.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_29851b04-d816-4099-998f-57b436f979b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3c09df28-28b7-4eac-87b2-00f415bf7326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_29851b04-d816-4099-998f-57b436f979b9" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3c09df28-28b7-4eac-87b2-00f415bf7326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2e9f33f6-2938-4dda-b0f1-37bdd6c6a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3e76b02d-f795-4493-b8c1-5b2e0adbbfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2e9f33f6-2938-4dda-b0f1-37bdd6c6a0ae" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3e76b02d-f795-4493-b8c1-5b2e0adbbfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_26980daa-5092-4e69-922d-23b51d561da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2e9f33f6-2938-4dda-b0f1-37bdd6c6a0ae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_26980daa-5092-4e69-922d-23b51d561da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c1877810-f16d-4f3d-aa97-1fe1c9090fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_132ddeda-15ff-4f0e-8008-6dd77dc5d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c1877810-f16d-4f3d-aa97-1fe1c9090fee" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_132ddeda-15ff-4f0e-8008-6dd77dc5d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_493cf223-f6e3-42e5-9315-ef72629d385a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_493cf223-f6e3-42e5-9315-ef72629d385a" xlink:to="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:to="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_6a670b73-2e3f-4281-8063-fa2caac11d49" xlink:to="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4d94bc2f-ef82-457b-a6ba-6debaf717f67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3192b6d2-8e08-4bd5-a840-d291b83d26cf" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4d94bc2f-ef82-457b-a6ba-6debaf717f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_da1f7e5f-0d14-4c07-84a3-720eca39aa39" xlink:to="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f698c056-3157-4f10-8297-551b04246f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f698c056-3157-4f10-8297-551b04246f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30d424a5-d2e3-40f2-b463-ed28f3e02308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_41f0be49-cad5-4c18-b7cb-b5e6e81a1034" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_30d424a5-d2e3-40f2-b463-ed28f3e02308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de439dcb-4fa2-45dc-825d-81835268e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de439dcb-4fa2-45dc-825d-81835268e5ea" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:to="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ed2687b9-651c-4cc8-8c4d-ffe43ec759d2" xlink:to="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9dc8ed9e-e47e-493d-8a09-dbd9c1361e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_us-gaap_ProductMember_9dc8ed9e-e47e-493d-8a09-dbd9c1361e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_ddfdffd1-4807-4bd1-9f50-2b2134264461" xlink:href="lly-20230331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_lly_CollaborationandOtherRevenueMember_ddfdffd1-4807-4bd1-9f50-2b2134264461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_566498c0-5772-4d34-8460-926995f839d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7af5c6c3-29a8-4b6c-848d-858b7d09647e" xlink:to="loc_us-gaap_RoyaltyMember_566498c0-5772-4d34-8460-926995f839d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_362173b3-ea57-4f76-a627-6e5317eba0f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_62038906-fddd-4599-9a60-ec61f4e940ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6cb98ea4-66a5-4850-a30c-29d637e74d36" xlink:to="loc_us-gaap_Revenues_62038906-fddd-4599-9a60-ec61f4e940ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_df8439a9-1f40-4090-a7d0-3a9f998b931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_df8439a9-1f40-4090-a7d0-3a9f998b931b" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:to="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b36a89f1-aa8d-4404-b630-e341d5d86dc9" xlink:to="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_96273f89-7bc7-4c61-b066-9da5b9423305" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_65014b20-0abc-4b61-835e-f6900bce99d5" xlink:to="loc_country_US_96273f89-7bc7-4c61-b066-9da5b9423305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f8ec683b-832c-4a6e-ab13-875110f5c42c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_581e7902-2015-4315-a8ae-e989ca13e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_19462d31-2b16-493d-85fd-08824e7b1ac7" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_581e7902-2015-4315-a8ae-e989ca13e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49f0479f-a25a-4d67-86b1-84d977a8baae" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_9f6bcbaf-bdd6-41bb-8beb-d392fc67c3ad" xlink:href="lly-20230331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_4c335c33-5962-4899-8fe7-b4e5dad8fcb7" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_9f6bcbaf-bdd6-41bb-8beb-d392fc67c3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_03f4973c-ac9e-4ff2-bf56-b3e4f37cb003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_275ebc7e-bb11-45a6-b906-3624a37b6a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_03f4973c-ac9e-4ff2-bf56-b3e4f37cb003" xlink:to="loc_us-gaap_ContractWithCustomerLiability_275ebc7e-bb11-45a6-b906-3624a37b6a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4059be7e-07fb-483f-b050-75f0b22d2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4059be7e-07fb-483f-b050-75f0b22d2e33" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:to="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4c571623-5e2f-490b-a994-d093dd103548" xlink:to="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:href="lly-20230331.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMember_b948f168-99e4-41bb-90a5-ee54b41c7f7b" xlink:href="lly-20230331.xsd#lly_TrulicityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_TrulicityMember_b948f168-99e4-41bb-90a5-ee54b41c7f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_55947be5-2d77-4e5e-9b84-e27930550f2e" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_JardianceMember_55947be5-2d77-4e5e-9b84-e27930550f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MounjaroMember_b1cc48df-47bb-4d0d-9ea6-f45d2a7306f2" xlink:href="lly-20230331.xsd#lly_MounjaroMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_MounjaroMember_b1cc48df-47bb-4d0d-9ea6-f45d2a7306f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_8278e539-6a3e-4e18-88c7-0a065b97e5c5" xlink:href="lly-20230331.xsd#lly_HumalogMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_HumalogMember_8278e539-6a3e-4e18-88c7-0a065b97e5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_3f704c4a-651f-4936-bad6-61cb22a5166f" xlink:href="lly-20230331.xsd#lly_HumulinMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_HumulinMember_3f704c4a-651f-4936-bad6-61cb22a5166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_b9b9efc1-de0b-469f-b04e-73331e514bc4" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_BasaglarMember_b9b9efc1-de0b-469f-b04e-73331e514bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_d936fe8c-56fa-4818-8f26-bbf9f1ee4a95" xlink:href="lly-20230331.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_9de41ff8-7459-4d92-bdf0-f5296e20b1a5" xlink:to="loc_lly_OtherDiabetesMember_d936fe8c-56fa-4818-8f26-bbf9f1ee4a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:href="lly-20230331.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_5cb8c2e0-3d1b-49b7-b7a8-5d3230a703b4" xlink:href="lly-20230331.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_VerzenioMember_5cb8c2e0-3d1b-49b7-b7a8-5d3230a703b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_3cc0a724-8df5-4eed-a1c9-7a7f1c66620d" xlink:href="lly-20230331.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_CyramzaMember_3cc0a724-8df5-4eed-a1c9-7a7f1c66620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_f6d279e7-3330-44f7-8437-b98201e7d86d" xlink:href="lly-20230331.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_ErbituxMember_f6d279e7-3330-44f7-8437-b98201e7d86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_db94adc7-c8d2-4514-bda7-05feede4d9cb" xlink:href="lly-20230331.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_AlimtaMember_db94adc7-c8d2-4514-bda7-05feede4d9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_e0fd62ec-78a0-487a-b0ad-2b1d76332fcd" xlink:href="lly-20230331.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_ef08f7ce-52f1-4805-8d95-0df47cdd647c" xlink:to="loc_lly_OtherOncologyMember_e0fd62ec-78a0-487a-b0ad-2b1d76332fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:href="lly-20230331.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_7b5ccde5-0ba2-4cfd-8ded-0ab735df19df" xlink:href="lly-20230331.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_TaltzMember_7b5ccde5-0ba2-4cfd-8ded-0ab735df19df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_f1f0fc21-1133-4492-b045-89ff490b28ef" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_OlumiantMember_f1f0fc21-1133-4492-b045-89ff490b28ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_166d8f33-7257-4290-a6a4-9f4aa7f8cb18" xlink:href="lly-20230331.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_2eae93ec-7fd8-4eeb-a3e5-9972ae807b8a" xlink:to="loc_lly_OtherImmunologyMember_166d8f33-7257-4290-a6a4-9f4aa7f8cb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:href="lly-20230331.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_d8bda435-5779-43a3-b17c-f08ba8f23ffd" xlink:href="lly-20230331.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:to="loc_lly_EmgalityMember_d8bda435-5779-43a3-b17c-f08ba8f23ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_36e21cf2-fb19-4cb7-9ed9-ec93d31642e2" xlink:href="lly-20230331.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_1a685ed4-dc29-4980-a88f-ad06de38edbf" xlink:to="loc_lly_OtherNeuroscienceMember_36e21cf2-fb19-4cb7-9ed9-ec93d31642e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:href="lly-20230331.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42125024-8981-46fa-a119-2a676e0c151c" xlink:to="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_46019148-15d8-49e7-bbc0-d3bfa0e50ba6" xlink:href="lly-20230331.xsd#lly_ForteoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_ForteoMember_46019148-15d8-49e7-bbc0-d3bfa0e50ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_a8801387-0f2c-497d-9481-6c71df66b374" xlink:href="lly-20230331.xsd#lly_CialisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_CialisMember_a8801387-0f2c-497d-9481-6c71df66b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_e2f45cc7-487d-4968-b786-b59eda5912cf" xlink:href="lly-20230331.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_COVID19AntibodiesMember_e2f45cc7-487d-4968-b786-b59eda5912cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_3945c748-77d7-4cc0-88aa-c5d47107cf65" xlink:href="lly-20230331.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_c7409534-b35a-4a83-816d-10b29f9714da" xlink:to="loc_lly_OtherProductMember_3945c748-77d7-4cc0-88aa-c5d47107cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:to="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_647f733e-b55e-4f06-81f6-ca9b01db3a66" xlink:to="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3854b3a0-1889-44c0-81df-8a90dd4b1a7e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:to="loc_country_US_3854b3a0-1889-44c0-81df-8a90dd4b1a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_43225b5c-398c-40b2-8728-f40ca0e34fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_882c7186-b27c-44ce-ad7c-419d7ae9a923" xlink:to="loc_us-gaap_NonUsMember_43225b5c-398c-40b2-8728-f40ca0e34fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28fa0906-fa02-4a0c-847a-a2296bdad323" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_78c015ef-484c-422b-8394-98e06025f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_986ca1ea-27fa-45aa-87cb-f152fe591d46" xlink:to="loc_us-gaap_Revenues_78c015ef-484c-422b-8394-98e06025f19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_69209488-43f4-452c-8204-9d67f7ec91d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_69209488-43f4-452c-8204-9d67f7ec91d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:to="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_04ddfdd8-3ebd-491b-945b-7e476d62b2cb" xlink:to="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7045836f-e28d-4a11-9acd-00edf9b0a3a3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_US_7045836f-e28d-4a11-9acd-00edf9b0a3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_896ecdbb-e6aa-4b67-bede-1d0425418fdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_srt_EuropeMember_896ecdbb-e6aa-4b67-bede-1d0425418fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_560635f1-fdec-4cc3-91e9-02fef2b495a5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_JP_560635f1-fdec-4cc3-91e9-02fef2b495a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_5e887377-a199-4c5b-9141-e53455041a2a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_country_CN_5e887377-a199-4c5b-9141-e53455041a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_64473e24-90f1-47bf-afce-a8937fc92386" xlink:href="lly-20230331.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a117a852-93ff-4488-956d-30de4541b421" xlink:to="loc_lly_OtherForeignCountriesMember_64473e24-90f1-47bf-afce-a8937fc92386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f200d20-c83a-4675-8ee4-12a852ab02b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3c5b0d29-7da2-4a2d-9c8f-b6d7c2843120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4fe149-aee5-41dc-bb53-c8a5d72ad581" xlink:to="loc_us-gaap_Revenues_3c5b0d29-7da2-4a2d-9c8f-b6d7c2843120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9bc554fb-058a-4d2a-8bef-c3b4a9413fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9bc554fb-058a-4d2a-8bef-c3b4a9413fd8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bd5f706-993a-48dd-8457-1e6dc1f3566a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_adf62191-98ba-4069-ae8f-206070d32c6d" xlink:href="lly-20230331.xsd#lly_AkouosAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4a0449-f373-49e6-963c-b1279e355709" xlink:to="loc_lly_AkouosAcquisitionMember_adf62191-98ba-4069-ae8f-206070d32c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_011f4cf5-0d3f-4cb7-88df-2339097d334f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_e30eafb4-e4d5-4d26-8057-1f08a96a29de" xlink:href="lly-20230331.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_17efdf41-3bf4-4f7c-aae5-184513d9846a" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_e30eafb4-e4d5-4d26-8057-1f08a96a29de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_06bea61e-22ab-43b6-b2f9-48ce2a56f0f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_86bfaf39-2444-45c1-83d3-2657b09f31e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7d4f2b43-2231-4b70-9850-b5493cb1be22" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_86bfaf39-2444-45c1-83d3-2657b09f31e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fbaf6e57-cdaa-4590-b4fa-bf967e19981b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlanzapinePortfolioMember_ee641afa-488e-4076-be0a-b5d4372dddaa" xlink:href="lly-20230331.xsd#lly_OlanzapinePortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:to="loc_lly_OlanzapinePortfolioMember_ee641afa-488e-4076-be0a-b5d4372dddaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BaqsimiMember_2597dac2-6c49-400e-a3e2-634c540256e8" xlink:href="lly-20230331.xsd#lly_BaqsimiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_40990c85-735d-4e93-a1c8-a5f1264737b6" xlink:to="loc_lly_BaqsimiMember_2597dac2-6c49-400e-a3e2-634c540256e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a859a4d-6bfb-4026-bec8-774a907a3579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ada6b649-572e-453e-976e-61659915e899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df533dfa-0e4d-4154-97af-4b286584ac1d" xlink:to="loc_us-gaap_SubsequentEventMember_ada6b649-572e-453e-976e-61659915e899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d294fb31-c9ab-45d6-96c9-b8a1e43e5865" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_9b3fcccd-3500-4ff5-8afb-4f8a114ac383" xlink:href="lly-20230331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_9b3fcccd-3500-4ff5-8afb-4f8a114ac383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_00407ce6-ed6c-4bf2-8548-699aff120d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_00407ce6-ed6c-4bf2-8548-699aff120d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea1e8423-8827-4134-ad38-16ef50a1534b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea1e8423-8827-4134-ad38-16ef50a1534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_bfa16a0d-4dd9-46ac-8f40-2589c357ab9f" xlink:href="lly-20230331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_bfa16a0d-4dd9-46ac-8f40-2589c357ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_89d083b9-d454-45ba-aeb1-ea73c796c76c" xlink:href="lly-20230331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_89d083b9-d454-45ba-aeb1-ea73c796c76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_02cd1204-bc44-4c60-9551-cad69dbc0db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_02cd1204-bc44-4c60-9551-cad69dbc0db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_a27458aa-b303-4adf-9502-c872abc85a9f" xlink:href="lly-20230331.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_PaymentsForAssetAcquisitions_a27458aa-b303-4adf-9502-c872abc85a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_04445289-22c4-4b25-aa12-adbca0c232e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_04445289-22c4-4b25-aa12-adbca0c232e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2b6d369c-0343-46ba-949d-325c360b385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2b6d369c-0343-46ba-949d-325c360b385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_7be6f58c-058d-48e7-84fe-5ed3b165cc79" xlink:href="lly-20230331.xsd#lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5856762f-5703-456c-9001-8e9cb5466619" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived_7be6f58c-058d-48e7-84fe-5ed3b165cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ea994abc-555d-4b0f-9cb0-a9b12312bee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ea994abc-555d-4b0f-9cb0-a9b12312bee9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_30c5d6be-0500-4a7b-9378-1bd1260381b1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AkouosAcquisitionMember_09eb3c7c-200a-4fe3-9e00-be40b33a3f82" xlink:href="lly-20230331.xsd#lly_AkouosAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036dd5c6-c0f7-4103-b54c-fce754aa0c35" xlink:to="loc_lly_AkouosAcquisitionMember_09eb3c7c-200a-4fe3-9e00-be40b33a3f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e10fb63-d71b-4c26-b614-452e2cc9e45b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7c4a74cd-7ba4-421e-87a5-2ed2c10cb642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7c4a74cd-7ba4-421e-87a5-2ed2c10cb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b60b127a-88b2-4385-989c-62643f273547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b60b127a-88b2-4385-989c-62643f273547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e636035d-3746-4d26-8097-bb67e44f71fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_Goodwill_e636035d-3746-4d26-8097-bb67e44f71fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_af7dbab2-8966-490b-b276-5c6bd6d8e2bb" xlink:href="lly-20230331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_af7dbab2-8966-490b-b276-5c6bd6d8e2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4508a85e-3483-4fbd-8584-588b3f5ec214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4508a85e-3483-4fbd-8584-588b3f5ec214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d100cb9a-687d-47ad-a1b9-966f9ddc76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d100cb9a-687d-47ad-a1b9-966f9ddc76a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0d39b14b-9d13-4259-a4b2-9087133de5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0d39b14b-9d13-4259-a4b2-9087133de5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe78422d-2bbf-473a-b853-bff46fd240b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7cb29888-18dd-463c-9392-8a3bf2f46ec2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe78422d-2bbf-473a-b853-bff46fd240b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#AcquisitionsandDivestituresAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2475df0b-6b32-4456-b573-6dccedb45f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2475df0b-6b32-4456-b573-6dccedb45f34" xlink:to="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9f47d32d-f4f1-40af-abd8-608aea3c9c7a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BioMarinPharmaceuticalIncMember_ef0c107b-ae22-424b-855d-df8fed380597" xlink:href="lly-20230331.xsd#lly_BioMarinPharmaceuticalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_cc161ff4-54fb-4ce9-8c83-a36e6cd50f32" xlink:to="loc_lly_BioMarinPharmaceuticalIncMember_ef0c107b-ae22-424b-855d-df8fed380597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fdf01089-38ed-4dfb-bdd5-f868e759ad15" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForAssetAcquisitions_b6909ce0-3a54-4509-bbe9-22666656a9ad" xlink:href="lly-20230331.xsd#lly_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_161dc43b-8fef-42d7-ab41-970fd36bdea4" xlink:to="loc_lly_PaymentsForAssetAcquisitions_b6909ce0-3a54-4509-bbe9-22666656a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41fd9767-b83e-478a-9a99-62fae0d20513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41fd9767-b83e-478a-9a99-62fae0d20513" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:to="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_30798e51-8d3f-4d20-90fd-390e18b6bd8e" xlink:to="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d7e29f5a-4dab-4f5b-974e-c380c8df078d" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_JardianceMember_d7e29f5a-4dab-4f5b-974e-c380c8df078d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_29736153-292f-4ebd-acf3-f5c2478f986d" xlink:href="lly-20230331.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_TrajentaBIMember_29736153-292f-4ebd-acf3-f5c2478f986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_e3620b8c-24f2-4473-ba3b-dac54ebcc0c4" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb864ea2-956d-4a68-b3bf-907c6390473f" xlink:to="loc_lly_BasaglarMember_e3620b8c-24f2-4473-ba3b-dac54ebcc0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_61737356-a736-487e-a099-d6d47602727c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_275bfb71-7dac-4a36-936e-01f62d2c2ba3" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bca4a93-15fc-4028-8765-0b2ac4530f34" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_275bfb71-7dac-4a36-936e-01f62d2c2ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20f8b774-8e82-40af-ba56-73149adee209" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_3dae77a7-75fc-4d88-9420-93905da4d313" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfbf8d89-df5d-4ae2-aa6f-cdb3daceec7a" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_3dae77a7-75fc-4d88-9420-93905da4d313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be5e8588-122e-4540-9c2c-7c59bca7761c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be5e8588-122e-4540-9c2c-7c59bca7761c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:to="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_df127cea-8382-46d5-9562-7da27972968e" xlink:to="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d6b4731c-8c8c-4d63-b170-bd53dedef3e2" xlink:href="lly-20230331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_JardianceMember_d6b4731c-8c8c-4d63-b170-bd53dedef3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_f0946b82-e333-4dcf-9b47-73e920765fbf" xlink:href="lly-20230331.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_BasaglarMember_f0946b82-e333-4dcf-9b47-73e920765fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_4a984766-187f-4c6e-a6ce-bd0dfda550a4" xlink:href="lly-20230331.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_TrajentaBIMember_4a984766-187f-4c6e-a6ce-bd0dfda550a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_0dafd6c7-e2e6-4f8f-a5c8-9b93c458a56e" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cac67e8e-3e25-47f3-9f8e-430332e4a143" xlink:to="loc_lly_OlumiantMember_0dafd6c7-e2e6-4f8f-a5c8-9b93c458a56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71c66ba9-11ed-48f8-999d-aeb425b3689b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6d93d44a-0ada-4af7-b9fd-ce0221421d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_289632a1-eaf8-4a2f-9970-4f5698152f77" xlink:to="loc_us-gaap_Revenues_6d93d44a-0ada-4af7-b9fd-ce0221421d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d29996c-a1c0-4bf5-b5fc-9ee23e06f073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d29996c-a1c0-4bf5-b5fc-9ee23e06f073" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e76c85ad-cd89-4151-b1e1-8e8f1d80d053" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_18788842-4be4-4330-ae25-83fdb4058e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_18788842-4be4-4330-ae25-83fdb4058e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_c1fd2c15-54ee-4d49-9f16-44530c4b4975" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_c1fd2c15-54ee-4d49-9f16-44530c4b4975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_16a2b599-7215-450d-aa8a-c585a44219c6" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_16a2b599-7215-450d-aa8a-c585a44219c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_147e2c55-e2bc-4d6b-92be-c30283294cbb" xlink:href="lly-20230331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae44cd0-c4e1-4f9e-b819-2c683a584a64" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_147e2c55-e2bc-4d6b-92be-c30283294cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_46508eb2-74f9-4bd3-8f9c-9bfdb8bc3a45" xlink:to="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_1f493837-d1f7-4a17-99b8-18dc79f9d915" xlink:href="lly-20230331.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_OlumiantMember_1f493837-d1f7-4a17-99b8-18dc79f9d915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_51a25e81-e1aa-4efa-8626-faee974145f2" xlink:href="lly-20230331.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_COVID19AntibodiesMember_51a25e81-e1aa-4efa-8626-faee974145f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_820b3d5d-cc67-4b99-bcce-de034121d8d8" xlink:href="lly-20230331.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22c6cc3a-eb80-4980-967d-b0cb9b58c900" xlink:to="loc_lly_LebrikizumabMember_820b3d5d-cc67-4b99-bcce-de034121d8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bd3c152d-255d-4c39-83a9-063a9881f05e" xlink:to="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_4f9f89a5-daa8-40ba-a7e2-a6ce08aebf5c" xlink:href="lly-20230331.xsd#lly_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_015050b8-bb6b-4f59-90ba-e86cc0dbba26" xlink:to="loc_lly_RocheMember_4f9f89a5-daa8-40ba-a7e2-a6ce08aebf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d564b146-877e-482e-8549-29bc2e771ba9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_6b95a4d1-f5db-4366-9d91-6883604dd8e1" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_6b95a4d1-f5db-4366-9d91-6883604dd8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_f7371941-fd94-47fd-a714-398676a27154" xlink:href="lly-20230331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_f7371941-fd94-47fd-a714-398676a27154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_45fba419-0b97-4727-aa40-509644e59b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83609dc6-5922-4f29-89b0-b61d3a0e7454" xlink:to="loc_us-gaap_Revenues_45fba419-0b97-4727-aa40-509644e59b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b38ada2-a0be-4937-b274-91a76d06972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b38ada2-a0be-4937-b274-91a76d06972b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ec7c31d-fdf9-454a-b82e-b7e6222dd835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A50NotesDue2026Member_9cdb6176-3f40-45d8-909d-a7d179f453d3" xlink:href="lly-20230331.xsd#lly_A50NotesDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A50NotesDue2026Member_9cdb6176-3f40-45d8-909d-a7d179f453d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A47NotesDue2033Member_4758954c-c8c9-4013-85e6-cfed529fe87e" xlink:href="lly-20230331.xsd#lly_A47NotesDue2033Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A47NotesDue2033Member_4758954c-c8c9-4013-85e6-cfed529fe87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A4875NotesDue2053Member_a356057c-1ddd-4678-b253-71f00dd4ba51" xlink:href="lly-20230331.xsd#lly_A4875NotesDue2053Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A4875NotesDue2053Member_a356057c-1ddd-4678-b253-71f00dd4ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A495NotesDue2063Member_c51516f6-fae9-461d-9ffc-a468005f229c" xlink:href="lly-20230331.xsd#lly_A495NotesDue2063Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_A495NotesDue2063Member_c51516f6-fae9-461d-9ffc-a468005f229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDue202620332053And2063Member_4c8f1381-821f-4c66-a773-fa367b149856" xlink:href="lly-20230331.xsd#lly_SeniorNotesDue202620332053And2063Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cd85978-8ef0-4ee4-bda8-c283e183b984" xlink:to="loc_lly_SeniorNotesDue202620332053And2063Member_4c8f1381-821f-4c66-a773-fa367b149856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff097ff6-ae1a-4d36-be78-81d9576d3813" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_1a564006-1845-4244-85e7-139c1e46f943" xlink:href="lly-20230331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_1a564006-1845-4244-85e7-139c1e46f943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_022203b7-a141-4464-8bf3-8ad2b8e44183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8407a3f7-eb0d-43e4-9f6a-dbdb60768faa" xlink:to="loc_us-gaap_SeniorNotesMember_022203b7-a141-4464-8bf3-8ad2b8e44183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c1ce914-4a93-4f20-87ae-4be8d46d63b2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_468decf8-031e-4bb6-94da-3a2b6e991def" xlink:href="lly-20230331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_468decf8-031e-4bb6-94da-3a2b6e991def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_3c01439d-9a20-4ab8-8a83-9b900d8be90e" xlink:href="lly-20230331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_3c01439d-9a20-4ab8-8a83-9b900d8be90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellEuroMember_a6192250-cb8f-4aed-b028-a5653fc271b2" xlink:href="lly-20230331.xsd#lly_SellEuroMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SellEuroMember_a6192250-cb8f-4aed-b028-a5653fc271b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SellChineseYuanMember_54ddd590-c88c-4537-a365-6bd70f122a2a" xlink:href="lly-20230331.xsd#lly_SellChineseYuanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_lly_SellChineseYuanMember_54ddd590-c88c-4537-a365-6bd70f122a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e2f0e963-7cc5-4e95-87aa-065b22529532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cea1caae-c256-40e5-bddc-ca86b38d9cba" xlink:to="loc_us-gaap_InterestRateSwapMember_e2f0e963-7cc5-4e95-87aa-065b22529532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1b6eb1b3-f8f6-4e93-a9f4-5d43e27953a0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d1c1a2fa-aa25-4283-b505-d002152d3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_96ba9851-dedd-42b6-b5e8-1eba90738f51" xlink:to="loc_us-gaap_CashFlowHedgingMember_d1c1a2fa-aa25-4283-b505-d002152d3d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_bd4042d1-39c6-4296-b1b8-5154658eadd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c977b4a2-ac9e-4c23-aa56-17a98374c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2cbb539a-3adc-4372-ba1b-25bec55c57a2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c977b4a2-ac9e-4c23-aa56-17a98374c41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9c7257d0-4157-4d26-937d-05ebb4dc85f7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f7ba215a-f7c8-4f6d-b72b-53cb7e250acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f7ba215a-f7c8-4f6d-b72b-53cb7e250acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_9a0f6a7c-b911-42d1-8f47-d59cf4e5b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_9a0f6a7c-b911-42d1-8f47-d59cf4e5b2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_52cf4642-7d12-4eda-817b-17c0dca129c0" xlink:href="lly-20230331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_52cf4642-7d12-4eda-817b-17c0dca129c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_fa647dec-4b6c-46e7-95da-1788532e287a" xlink:href="lly-20230331.xsd#lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets_fa647dec-4b6c-46e7-95da-1788532e287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_009e8b75-2462-45b2-bf91-a8b3b5ccd9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_009e8b75-2462-45b2-bf91-a8b3b5ccd9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_102644f2-fbb9-4936-97e1-9476ecdd3681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_102644f2-fbb9-4936-97e1-9476ecdd3681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_735ea0d0-4610-4b61-b817-2867f11203d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_735ea0d0-4610-4b61-b817-2867f11203d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_10cc9fc0-4be8-407c-8365-1ee065d59d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_10cc9fc0-4be8-407c-8365-1ee065d59d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_4c802921-9f73-4438-bf1e-c0c99533c990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_4c802921-9f73-4438-bf1e-c0c99533c990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_2187b78c-794f-4ced-bacb-511578416dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_2187b78c-794f-4ced-bacb-511578416dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dbb1975e-f491-4566-a918-8c594747df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_LongTermDebt_dbb1975e-f491-4566-a918-8c594747df85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_64b2223d-7440-4ff0-be3a-a6ddd3e94d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_64b2223d-7440-4ff0-be3a-a6ddd3e94d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_6a463c58-e3f6-4818-be31-49f1685dda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_6a463c58-e3f6-4818-be31-49f1685dda8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_f111f892-8593-4564-8fb7-e4ab3bdfb277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_f111f892-8593-4564-8fb7-e4ab3bdfb277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_30b258ba-f237-47cf-9d5a-0bba281465c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_30b258ba-f237-47cf-9d5a-0bba281465c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b0a406bd-662b-4134-9254-282c61a723c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b0a406bd-662b-4134-9254-282c61a723c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_18fa2258-54e3-444f-add8-a8c5dc07305f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e21be2cd-2b33-44d3-b8fb-fc53e380c9a3" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_18fa2258-54e3-444f-add8-a8c5dc07305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49a9abe2-edd5-4416-a579-5bd4d5517744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_49a9abe2-edd5-4416-a579-5bd4d5517744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ea50f421-8375-4213-be71-9acaa4be4190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ea50f421-8375-4213-be71-9acaa4be4190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_dbf7b58f-6c3f-4a68-bcdb-0464fa730797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_dbf7b58f-6c3f-4a68-bcdb-0464fa730797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_b1e70989-0a8d-4a6f-8710-386a1e2c537e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_b1e70989-0a8d-4a6f-8710-386a1e2c537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_741b10dd-a256-4b1e-8805-e5ed209a690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c81d9441-0423-47a9-935b-8f25388e102f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_741b10dd-a256-4b1e-8805-e5ed209a690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9185ceb-ecc1-4e36-bb83-4d22de2fa93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6a2b0809-906f-4616-8a45-089c7b15cebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9185ceb-ecc1-4e36-bb83-4d22de2fa93b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6a2b0809-906f-4616-8a45-089c7b15cebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96d10828-3ad5-48c7-b098-3f6942248d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9185ceb-ecc1-4e36-bb83-4d22de2fa93b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96d10828-3ad5-48c7-b098-3f6942248d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_88c8452e-0d14-444f-b01e-e27213f20372" xlink:href="lly-20230331.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9185ceb-ecc1-4e36-bb83-4d22de2fa93b" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_88c8452e-0d14-444f-b01e-e27213f20372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fe83f1ff-822b-4b10-8285-bc69d397f7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f9185ceb-ecc1-4e36-bb83-4d22de2fa93b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fe83f1ff-822b-4b10-8285-bc69d397f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77140fa0-5db8-4aaf-99c3-7296811e5092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_18d6813b-b41e-4560-89b7-3112dc2bc0f2" xlink:href="lly-20230331.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77140fa0-5db8-4aaf-99c3-7296811e5092" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_18d6813b-b41e-4560-89b7-3112dc2bc0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_0d62addf-a559-493f-967e-9ccb9c8b1662" xlink:href="lly-20230331.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77140fa0-5db8-4aaf-99c3-7296811e5092" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_0d62addf-a559-493f-967e-9ccb9c8b1662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_dcff0964-cb10-4c18-9c3b-9efa44865c8e" xlink:href="lly-20230331.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77140fa0-5db8-4aaf-99c3-7296811e5092" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_dcff0964-cb10-4c18-9c3b-9efa44865c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e940cb8b-039a-4774-a2a8-bb804db02579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e940cb8b-039a-4774-a2a8-bb804db02579" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a9416d54-9a96-46ba-b1a3-f3d642b76321" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_41b0ee8f-574c-4def-9029-de68b7f50571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_41b0ee8f-574c-4def-9029-de68b7f50571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_66043d21-2872-4300-9793-fa85519e49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_66043d21-2872-4300-9793-fa85519e49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_184f1d54-d00d-4753-885d-87f207da2704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_184f1d54-d00d-4753-885d-87f207da2704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1117a84c-c8c6-424f-9df9-1daf455eeb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_46859fb0-6e16-44ab-9985-bad47f3ba448" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1117a84c-c8c6-424f-9df9-1daf455eeb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88ba2b3e-0f59-4d2e-bf9b-2a857d6750d4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca7ff207-bc5a-4a09-8ee1-97adfb828f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca7ff207-bc5a-4a09-8ee1-97adfb828f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3ad572a3-b5d6-478f-9f7e-523c414f0c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3ad572a3-b5d6-478f-9f7e-523c414f0c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_119bdb58-c1f9-4113-b6e6-82e978eb2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b92119e6-b3c4-4444-86b9-6fb1dd30694e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_119bdb58-c1f9-4113-b6e6-82e978eb2bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad709e50-8f60-4e3c-a6e7-21649c2e05a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c260440-aa58-48e3-aecb-faafd2cc22fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c260440-aa58-48e3-aecb-faafd2cc22fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0f3c7962-e549-446a-94f9-358abe527b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0f3c7962-e549-446a-94f9-358abe527b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_08b41f14-f36c-41f6-ade9-3b166a33c6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_08b41f14-f36c-41f6-ade9-3b166a33c6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6da22b8e-0ec1-4d21-af77-af5eca3a252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6da22b8e-0ec1-4d21-af77-af5eca3a252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_30f900f6-958f-4f52-b9cb-24e0f812e2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_30f900f6-958f-4f52-b9cb-24e0f812e2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_f3c1ef87-3e61-4493-9251-cec7a6c920e1" xlink:href="lly-20230331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_lly_OtherEquitySecuritiesMember_f3c1ef87-3e61-4493-9251-cec7a6c920e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_7d9d8fd6-20ac-4544-9be7-1e67646c7fde" xlink:href="lly-20230331.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_213a31ea-a297-4adf-a059-0548e79c760a" xlink:to="loc_lly_MarketableSecuritiesMember_7d9d8fd6-20ac-4544-9be7-1e67646c7fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59eb1f13-49cf-4921-9870-c867a0626e25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1fedbd9b-4232-4672-8f9e-6c9e04a71651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1fedbd9b-4232-4672-8f9e-6c9e04a71651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa32a0c6-c2f3-4666-8e4b-9abf512620d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fa32a0c6-c2f3-4666-8e4b-9abf512620d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_af6667be-5bd0-4d6e-80e7-ce4b5f8dbfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_af6667be-5bd0-4d6e-80e7-ce4b5f8dbfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a66ed1a6-0f6f-4b54-9c2c-50ec92ac31b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a66ed1a6-0f6f-4b54-9c2c-50ec92ac31b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_26ed154f-fd50-4fc0-be6d-e903f6a58d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_26ed154f-fd50-4fc0-be6d-e903f6a58d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_09e4bb54-8e1d-4cad-96bd-b323c7d55ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_EquityMethodInvestments_09e4bb54-8e1d-4cad-96bd-b323c7d55ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_bf5631e4-ed68-4e74-bc3c-d2462b5e2e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9eda7b3b-ec59-4d18-a98f-8a4d18ce0782" xlink:to="loc_us-gaap_LongTermInvestments_bf5631e4-ed68-4e74-bc3c-d2462b5e2e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37541521-a752-47fe-963b-0c8b141ff71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37541521-a752-47fe-963b-0c8b141ff71e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee858dac-1d7a-47a1-aa36-98e598b04350" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04d8bc30-c859-4846-af98-51924637d274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04d8bc30-c859-4846-af98-51924637d274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_186f825a-597a-44b5-9615-c1aca1165ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_186f825a-597a-44b5-9615-c1aca1165ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6b6a3a4b-6bbb-4331-a3b3-e33290794773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7a6d8ae6-7660-450f-b1a6-5e125f75655f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6b6a3a4b-6bbb-4331-a3b3-e33290794773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_60962717-93d0-43b6-8c0c-ed9005b41f87" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_425daea3-a37b-4c62-a5d8-bb3beb48f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2642e2e7-c4bd-4b27-9c33-fccdba63ef2f" xlink:to="loc_us-gaap_CommercialPaperMember_425daea3-a37b-4c62-a5d8-bb3beb48f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_36b36949-531f-4021-9847-4883c40f8f0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_26874b2c-ed21-4b75-93fd-24657d08fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_26874b2c-ed21-4b75-93fd-24657d08fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82c2c24a-2a89-429a-84d2-209dab970f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82c2c24a-2a89-429a-84d2-209dab970f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_203b08c1-75f0-402b-b483-7c4f37d2e26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a02feb1-38cc-4ce7-ae68-56ba8d0420b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_203b08c1-75f0-402b-b483-7c4f37d2e26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a811dbf7-1a20-4f3c-83c0-2170756bf5f8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_207183b5-9663-4d14-b658-24e8a63e1f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:to="loc_us-gaap_CommercialPaper_207183b5-9663-4d14-b658-24e8a63e1f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_89f0fd02-ae1b-4236-86db-5b38b0340bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a592d95d-6d60-4fa7-9417-d0e79c427548" xlink:to="loc_us-gaap_LongTermDebt_89f0fd02-ae1b-4236-86db-5b38b0340bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b8f79cb-1372-43d7-ab2b-c71a6da784b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b8f79cb-1372-43d7-ab2b-c71a6da784b5" xlink:to="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_356b7b3b-1e35-4d00-b1bb-5a64b9b74d0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_e6f1ba02-9a3a-4802-9b2e-b7f460b06fe6" xlink:href="lly-20230331.xsd#lly_BuyUsdSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyUsdSellEuroMember_e6f1ba02-9a3a-4802-9b2e-b7f460b06fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_ac07bae5-d512-4685-9e34-6130a91677ed" xlink:href="lly-20230331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyEuroSellUsDollarMember_ac07bae5-d512-4685-9e34-6130a91677ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_4e6176a7-a8d2-4114-bb8b-e1f8b4848c54" xlink:href="lly-20230331.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_4e6176a7-a8d2-4114-bb8b-e1f8b4848c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_9998053d-50c0-47ce-b690-83d11405a48a" xlink:href="lly-20230331.xsd#lly_BuyGBPSellUSDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fd48ca77-9349-40c6-a556-555ebf548685" xlink:to="loc_lly_BuyGBPSellUSDMember_9998053d-50c0-47ce-b690-83d11405a48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_c25a16ae-05ed-47c7-8020-2753115ade2c" xlink:to="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_4abd50a6-b718-418f-9552-1565e4ced0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_4abd50a6-b718-418f-9552-1565e4ced0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_63894024-732d-4047-998b-f59a4ac593b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsLineItems_a94a9b67-4271-4376-91eb-90cd6bb814b9" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_63894024-732d-4047-998b-f59a4ac593b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5c81e3a-a6e1-41ff-8c98-e229afb4d7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5c81e3a-a6e1-41ff-8c98-e229afb4d7e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:to="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3207b94b-3d55-4766-9579-0d85fa7e06c1" xlink:to="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6271c20a-29ee-4e47-9ccb-e1f0d418b9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6271c20a-29ee-4e47-9ccb-e1f0d418b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_b094c366-d4f8-4db0-8686-9d3f3bf572cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_000e41d0-a323-4a7d-a112-799303faebb2" xlink:to="loc_us-gaap_NondesignatedMember_b094c366-d4f8-4db0-8686-9d3f3bf572cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2acea94f-c57b-400c-bb91-be139f769854" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_e0fff3c2-593b-486e-8232-7d24a2d0cd00" xlink:href="lly-20230331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_lly_HedgedFixedRateDebtMember_e0fff3c2-593b-486e-8232-7d24a2d0cd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_fe18cb61-5051-47dc-bfc6-1ff195d3c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_InterestRateContractMember_fe18cb61-5051-47dc-bfc6-1ff195d3c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_77c072d2-a36f-4b78-9366-47d2de9b265d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_77c072d2-a36f-4b78-9366-47d2de9b265d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_81e10d8d-7b80-4be2-ad11-ef7bcdcffcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_81e10d8d-7b80-4be2-ad11-ef7bcdcffcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_47954c5e-96bb-4a4e-90ca-b537d3fdaacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7a292eee-a170-4689-945d-fe81a23924a0" xlink:to="loc_us-gaap_InterestRateSwapMember_47954c5e-96bb-4a4e-90ca-b537d3fdaacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9ed1d6a6-20ee-4135-bc96-f80fbf70b261" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:href="lly-20230331.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8ff3e3ef-b08a-4d40-81ab-51bcac6781db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8ff3e3ef-b08a-4d40-81ab-51bcac6781db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6c82175e-ff64-4f0c-a1a5-77204a0dd27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_2fe7bd3d-c65e-4a3a-82a1-5fcbeabee25c" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_6c82175e-ff64-4f0c-a1a5-77204a0dd27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:href="lly-20230331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_730e941e-8943-4b69-89e0-6e99c96e6197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_0c9f46f8-83e3-49ea-901d-eb81d410d481" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_730e941e-8943-4b69-89e0-6e99c96e6197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_e8fbf521-662a-4440-a178-6389a4f1772c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_e8fbf521-662a-4440-a178-6389a4f1772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_6fc16f07-dca2-43cb-ba06-1ae9a0be681f" xlink:href="lly-20230331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_6fc16f07-dca2-43cb-ba06-1ae9a0be681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4c177526-eeca-41f7-8511-60af7b9073d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4c177526-eeca-41f7-8511-60af7b9073d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_47fba7ad-932b-46f9-ab62-d49b1dc53066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_497562b5-aa3a-4285-8184-a13ce9423fb8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_47fba7ad-932b-46f9-ab62-d49b1dc53066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5d40e681-831b-4adc-9a35-8c630f5ee346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5d40e681-831b-4adc-9a35-8c630f5ee346" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_63a1fc93-c289-422e-be90-a623ba01cc9b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e1acb062-3014-4056-baca-95352c6fe674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_FairValueHedgingMember_e1acb062-3014-4056-baca-95352c6fe674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3ba943a9-f0de-4859-af07-3545c98862a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_CashFlowHedgingMember_3ba943a9-f0de-4859-af07-3545c98862a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e415782c-ef77-4877-83f4-0244957471f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_006d385a-01e9-4183-a42d-6b075d164e5c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e415782c-ef77-4877-83f4-0244957471f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_416f7d68-2dea-454a-a3e7-401d9d373cf8" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edc39c85-631e-48b9-ba7b-810bf437e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edc39c85-631e-48b9-ba7b-810bf437e38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_69e31b05-c631-4ba2-b404-8ee4fe0b0af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_69e31b05-c631-4ba2-b404-8ee4fe0b0af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94e7a13-b4b5-4e6c-ac39-6b9b7c1cdb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4383b1f4-e575-453b-bb3e-201f7b50915c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94e7a13-b4b5-4e6c-ac39-6b9b7c1cdb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ccb2570-fe53-4609-9784-1ddc73fdfee0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a368f75a-f378-474e-88ac-0def74d69a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_InterestRateContractMember_a368f75a-f378-474e-88ac-0def74d69a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_84dc3642-2ccd-4780-bf62-d02539524a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_84dc3642-2ccd-4780-bf62-d02539524a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e33850ed-8ef1-4b77-b2d5-d5ff4adfb48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7519686c-5b59-4a27-b974-d92765d254e0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e33850ed-8ef1-4b77-b2d5-d5ff4adfb48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e5c3e445-635c-4378-b153-9d20b00ec57e" xlink:to="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5013a31-ac90-4feb-8347-9659dffc7c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f5013a31-ac90-4feb-8347-9659dffc7c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_99549191-2d29-4132-99fa-18a598ddeef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_67076dd4-d35c-461c-9b15-522a5df0b095" xlink:to="loc_us-gaap_NondesignatedMember_99549191-2d29-4132-99fa-18a598ddeef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dfaa65ed-9a27-45e7-9785-af008c9a70a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_511d6b24-1fc2-4940-9e99-2ad2de7433d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_511d6b24-1fc2-4940-9e99-2ad2de7433d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dbf6975c-c930-4fa6-b7f8-7d131721aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dbf6975c-c930-4fa6-b7f8-7d131721aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6dee3ad-f775-4eb5-8db6-81d96d5bd988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4a24350-599c-476d-8ae6-e579ce89dbba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6dee3ad-f775-4eb5-8db6-81d96d5bd988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7016d36c-486f-42d6-89da-b2d853b6096d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_aaaf41f3-0742-455c-b784-891f63404bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_aaaf41f3-0742-455c-b784-891f63404bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_e5450af5-ec32-4969-bd7a-025eb1ee98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_e5450af5-ec32-4969-bd7a-025eb1ee98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9226e936-88d5-438f-b459-2fc3c6b2a8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_9226e936-88d5-438f-b459-2fc3c6b2a8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4447ccda-2155-4362-9461-73132fa7b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4447ccda-2155-4362-9461-73132fa7b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7ca6b840-b68c-41df-8ad5-e7c3c23bcd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7ca6b840-b68c-41df-8ad5-e7c3c23bcd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e278c257-6c2a-4f99-a8a5-c1d834f0fe07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c4d8549-8c4e-4a6c-80ad-6f6f4bbcabcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e278c257-6c2a-4f99-a8a5-c1d834f0fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bbc21d7c-e0a7-46e4-85e4-c69076b183f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d9efedbf-c420-4846-928d-04f644b23d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bbc21d7c-e0a7-46e4-85e4-c69076b183f8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d9efedbf-c420-4846-928d-04f644b23d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a630ad73-d7aa-4625-bef1-8c7282fbbc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a630ad73-d7aa-4625-bef1-8c7282fbbc8e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7df4ad41-990a-4bf0-b76a-d311d5f9827c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_807707ac-40ab-462b-8271-0f1de9e8b5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_807707ac-40ab-462b-8271-0f1de9e8b5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fd229f20-8115-4e62-ab33-c51e2e9d4490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dff78820-9128-4719-80c8-1f8edf79ddb1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_fd229f20-8115-4e62-ab33-c51e2e9d4490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_762d3aec-9716-4feb-930c-731564426acd" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0b767dbd-129d-4a6f-9eae-e9cc01b2474c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0b767dbd-129d-4a6f-9eae-e9cc01b2474c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f583cf7b-8912-4d8c-85b9-f7634e0cb2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f583cf7b-8912-4d8c-85b9-f7634e0cb2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_92e9dc0b-7738-4d3d-a72b-4b6a973ef548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_92e9dc0b-7738-4d3d-a72b-4b6a973ef548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e769f023-9c33-4835-9a9d-a591808f9bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e769f023-9c33-4835-9a9d-a591808f9bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1f1428d2-6ff2-4d1b-abc4-e2742f8b6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1f1428d2-6ff2-4d1b-abc4-e2742f8b6c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_01f5db0c-57f9-4530-ac90-9c2dd46c358f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_32af6cad-0908-4c74-bd32-f28fbfc36c8f" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_01f5db0c-57f9-4530-ac90-9c2dd46c358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78c136ca-b149-49dc-a82c-d97e96320ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78c136ca-b149-49dc-a82c-d97e96320ed4" xlink:to="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f7489a85-1a62-4afb-b4bf-a3a0838949e0" xlink:to="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_81707ac1-4dbe-4fa9-9220-7720ef274c25" xlink:href="lly-20230331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmgalityPatentLitigationMember_81707ac1-4dbe-4fa9-9220-7720ef274c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2018RulingMember_008dd0be-127a-46f8-91c2-e80ab8725308" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2018RulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmployeeLitigationJuly2018RulingMember_008dd0be-127a-46f8-91c2-e80ab8725308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationJuly2019RulingMember_15a5da4e-1f37-4c82-8065-0864a630fb06" xlink:href="lly-20230331.xsd#lly_EmployeeLitigationJuly2019RulingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c2da0456-da5c-4228-bb56-863e72e52a3d" xlink:to="loc_lly_EmployeeLitigationJuly2019RulingMember_15a5da4e-1f37-4c82-8065-0864a630fb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_150cab1b-6f42-455c-b624-811bb11f03c2" xlink:to="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_aa2f359e-133b-495b-ae45-6ae76d10d7f6" xlink:href="lly-20230331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4dbbd109-0da4-43cd-a6df-f7cf6218e4f0" xlink:to="loc_lly_HumalogHumulinAndForteoMember_aa2f359e-133b-495b-ae45-6ae76d10d7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ea7da7bc-9081-4ff1-9b4f-7b6a5ef85c7c" xlink:to="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_3863edab-5a52-4a1e-b602-0e9f662eea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_e21f36d1-524c-49de-9a0a-95db4f0e88b5" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_3863edab-5a52-4a1e-b602-0e9f662eea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cc76c872-c920-4828-946b-ef54b3127811" xlink:to="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_6236c618-580b-4f6a-aee7-5c5008942a37" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_accf0def-85d7-47a2-9f66-7b0ee5005dce" xlink:to="loc_country_BR_6236c618-580b-4f6a-aee7-5c5008942a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6308271c-b4ac-4bd8-9e40-26733a51db36" xlink:to="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_c213e37d-3f6b-4034-99f6-4e5a5873640e" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_lly_LossContingencyNumberOfPatents_c213e37d-3f6b-4034-99f6-4e5a5873640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9259ec69-9749-4f4b-a386-544416e71972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9259ec69-9749-4f4b-a386-544416e71972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_05a19b2c-e474-451c-b762-1d573b8ea437" xlink:href="lly-20230331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_05a19b2c-e474-451c-b762-1d573b8ea437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a14e0867-4c28-4945-84a3-249febb4fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d17fb638-f835-4397-97a1-538d68fc726b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a14e0867-4c28-4945-84a3-249febb4fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a6d44f91-0201-493b-af5d-e1abaade7c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6d44f91-0201-493b-af5d-e1abaade7c29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_74cca149-be2e-40c0-8d0f-15203a1d2d25" xlink:to="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5c844653-9ef7-4c37-93e0-9de14db77f7d" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d5b40580-6102-41d3-869d-301ccf466af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d5b40580-6102-41d3-869d-301ccf466af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a99d825f-eb73-40b7-b933-6fc862ee5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a99d825f-eb73-40b7-b933-6fc862ee5d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_21c249a1-e7f5-4b2f-a808-6b0f56d3ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_21c249a1-e7f5-4b2f-a808-6b0f56d3ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_93c33577-c005-4586-ac25-0f173264cd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ca67e517-c359-4c3b-9dfc-7f802ac91fea" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_93c33577-c005-4586-ac25-0f173264cd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12bef405-c231-445e-b769-199c2d0f3d60" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b850212-bb28-4c49-9704-65d87623902a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75040237-6993-4a4f-a751-9f5781b390db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75040237-6993-4a4f-a751-9f5781b390db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_81d22e0a-9f1e-49f2-a7dd-b29eca8c6a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_81d22e0a-9f1e-49f2-a7dd-b29eca8c6a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_38e2f124-1b27-4af5-ae52-574d07945b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_38e2f124-1b27-4af5-ae52-574d07945b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c7b32037-3d89-4caf-a38d-2dbcdb5ee347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c7b32037-3d89-4caf-a38d-2dbcdb5ee347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a92f248-341d-4dfa-8dbe-8755fe23814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c5adce6e-fe39-44ef-afc6-544f7190ef6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a92f248-341d-4dfa-8dbe-8755fe23814a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0f384e75-5d19-4d16-b175-c7ca7d1054f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0f384e75-5d19-4d16-b175-c7ca7d1054f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82509cb7-a0ae-493b-8083-058b8371d03a" xlink:to="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2ec066f6-2f4d-46b6-89c9-bda675dc030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_2ec066f6-2f4d-46b6-89c9-bda675dc030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c4e7ffb4-3195-4423-a7c6-f6d6cd702b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_c4e7ffb4-3195-4423-a7c6-f6d6cd702b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ad23e79a-5085-469b-8120-94948d5104a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ad23e79a-5085-469b-8120-94948d5104a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_ecb0f3ce-71d2-4597-b381-e14efc5ee049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0376cc5-4143-4ab1-b3d8-1b15ca393b90" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_ecb0f3ce-71d2-4597-b381-e14efc5ee049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e9fe66d4-a633-4861-af64-4fbc2f34bcb5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_e7c0b245-856f-4c75-a4a2-29db3077050d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b66b14f4-1553-40b6-bd32-1ff9969ce1c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_e7c0b245-856f-4c75-a4a2-29db3077050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a3df5c49-377d-417c-a8bd-206651f7c90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a3df5c49-377d-417c-a8bd-206651f7c90c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe2f8ab2-7a2f-4061-818d-aac2acb0099e" xlink:to="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_f3b0ca2e-5de6-4b62-a1fa-04353e60e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_f3b0ca2e-5de6-4b62-a1fa-04353e60e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_83fd4868-1dd1-4593-933a-bad223ea6150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_96fb3ebc-f3d9-45c9-a456-ac3ecb2b7663" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_83fd4868-1dd1-4593-933a-bad223ea6150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_648fb5df-8a11-47b5-8925-c4b60014d417" xlink:href="lly-20230331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1022df68-9b9e-4f99-b22d-a31b23661582" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_648fb5df-8a11-47b5-8925-c4b60014d417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1e902a4a-9035-4218-9652-e45c10885f49" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_e427d6e4-675b-411c-a3b6-fc3aebcfdf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_31db406d-abec-478b-b49b-8d764735aa46" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_e427d6e4-675b-411c-a3b6-fc3aebcfdf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1eefc67d-eaea-4d8b-9ad4-619fafb3d783" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c040524a-81e1-4d32-a96d-3ace7adf4cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c040524a-81e1-4d32-a96d-3ace7adf4cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7796aee3-6762-4f6b-bba6-8d415b822c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7796aee3-6762-4f6b-bba6-8d415b822c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3079b3b-770f-48c3-9a3f-fcadf06cc484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3079b3b-770f-48c3-9a3f-fcadf06cc484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dbcf35d7-88bf-4be8-9c40-7f806929380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_227c0611-c1f9-4e41-8729-216524e1ddd2" xlink:to="loc_us-gaap_ProfitLoss_dbcf35d7-88bf-4be8-9c40-7f806929380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20230331.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_170eabc8-bea1-4c54-81a2-9a6dd4b375cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_InterestExpense_170eabc8-bea1-4c54-81a2-9a6dd4b375cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_459b6dc9-47ae-4c5c-9163-677037308019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_459b6dc9-47ae-4c5c-9163-677037308019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bcf28dd0-5377-49d7-a0b4-960008adb610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bcf28dd0-5377-49d7-a0b4-960008adb610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_37da8d26-906f-4243-ae47-a09f1116d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_37da8d26-906f-4243-ae47-a09f1116d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_436bea20-096a-4e3f-84f7-1572a97a8501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_436bea20-096a-4e3f-84f7-1572a97a8501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7499043d-4a11-4bc9-bf79-e4b6ce769c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_507f3de8-fd36-4370-b646-60d8d2a9d23b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7499043d-4a11-4bc9-bf79-e4b6ce769c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774739568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-6351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,272,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1700NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774576752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 6,960.0<span></span>
</td>
<td class="nump">$ 7,810.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,626.7<span></span>
</td>
<td class="nump">2,072.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,985.1<span></span>
</td>
<td class="nump">1,610.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">1,749.2<span></span>
</td>
<td class="nump">1,557.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">165.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense (Note 10)</a></td>
<td class="num">(35.7)<span></span>
</td>
<td class="nump">350.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">5,430.3<span></span>
</td>
<td class="nump">5,756.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,529.7<span></span>
</td>
<td class="nump">2,053.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 6)</a></td>
<td class="nump">184.8<span></span>
</td>
<td class="nump">150.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,344.9<span></span>
</td>
<td class="nump">$ 1,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">901.0<span></span>
</td>
<td class="nump">903.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">903.3<span></span>
</td>
<td class="nump">906.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Sales, Operating Expenses, And Other-net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776203984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,344.9<span></span>
</td>
<td class="nump">$ 1,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax (Note 9)</a></td>
<td class="nump">67.3<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,412.2<span></span>
</td>
<td class="nump">$ 2,020.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664778313520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 5)</a></td>
<td class="nump">$ 3,545.9<span></span>
</td>
<td class="nump">$ 2,067.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 5)</a></td>
<td class="nump">123.4<span></span>
</td>
<td class="nump">144.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $14.0 (2023) and $16.0 (2022)</a></td>
<td class="nump">7,526.2<span></span>
</td>
<td class="nump">6,896.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,495.9<span></span>
</td>
<td class="nump">1,662.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,544.8<span></span>
</td>
<td class="nump">4,309.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,575.2<span></span>
</td>
<td class="nump">2,954.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,811.4<span></span>
</td>
<td class="nump">18,034.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 5)</a></td>
<td class="nump">2,750.4<span></span>
</td>
<td class="nump">2,901.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,073.1<span></span>
</td>
<td class="nump">4,073.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">7,087.1<span></span>
</td>
<td class="nump">7,206.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">3,406.7<span></span>
</td>
<td class="nump">2,792.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $10,486.0 (2023) and $10,233.4 (2022)</a></td>
<td class="nump">10,546.2<span></span>
</td>
<td class="nump">10,144.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,488.1<span></span>
</td>
<td class="nump">4,337.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">53,163.0<span></span>
</td>
<td class="nump">49,489.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1,501.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,015.9<span></span>
</td>
<td class="nump">1,930.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">739.7<span></span>
</td>
<td class="nump">1,059.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">9,529.5<span></span>
</td>
<td class="nump">8,784.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,017.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,528.3<span></span>
</td>
<td class="nump">475.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,193.5<span></span>
</td>
<td class="nump">2,370.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,010.0<span></span>
</td>
<td class="nump">17,138.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">18,880.5<span></span>
</td>
<td class="nump">14,737.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 7)</a></td>
<td class="nump">1,313.0<span></span>
</td>
<td class="nump">1,305.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,842.1<span></span>
</td>
<td class="nump">3,709.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,822.5<span></span>
</td>
<td class="nump">1,824.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">25,858.1<span></span>
</td>
<td class="nump">21,576.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">593.5<span></span>
</td>
<td class="nump">594.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,793.1<span></span>
</td>
<td class="nump">6,921.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">10,639.3<span></span>
</td>
<td class="nump">10,042.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 9)</a></td>
<td class="num">(3,777.3)<span></span>
</td>
<td class="num">(3,844.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(45.0)<span></span>
</td>
<td class="num">(50.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders' equity</a></td>
<td class="nump">11,190.4<span></span>
</td>
<td class="nump">10,649.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">104.5<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,294.9<span></span>
</td>
<td class="nump">10,775.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 53,163.0<span></span>
</td>
<td class="nump">$ 49,489.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Rebates And Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774589264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Receivables, Net, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 10,486.0<span></span>
</td>
<td class="nump">$ 10,233.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664773457504">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th" colspan="2"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596.3<span></span>
</td>
<td class="nump">$ 6,833.4<span></span>
</td>
<td class="nump">$ 8,958.5<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (4,343.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 175.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 117.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,496.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="num">(278.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">6,656.3<span></span>
</td>
<td class="nump">9,369.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(4,225.3)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">131.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,775.4<span></span>
</td>
<td class="nump">$ 594.1<span></span>
</td>
<td class="nump">6,921.4<span></span>
</td>
<td class="nump">10,042.6<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,844.6)<span></span>
</td>
<td class="num">$ (50.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">125.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,299)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(748.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="num">(259.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(31.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,294.9<span></span>
</td>
<td class="nump">$ 593.5<span></span>
</td>
<td class="nump">$ 6,793.1<span></span>
</td>
<td class="nump">$ 10,639.3<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (3,777.3)<span></span>
</td>
<td class="num">$ (45.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 104.5<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of March&#160;31, 2023, there was $2.50 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777976528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776131168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,344.9<span></span>
</td>
<td class="nump">$ 1,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">362.3<span></span>
</td>
<td class="nump">435.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(559.4)<span></span>
</td>
<td class="num">(506.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment losses</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">426.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">165.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="nump">164.1<span></span>
</td>
<td class="num">(34.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other operating activities, net</a></td>
<td class="nump">168.3<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">1,730.6<span></span>
</td>
<td class="nump">2,523.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(668.5)<span></span>
</td>
<td class="num">(365.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of and distributions from noncurrent investments</a></td>
<td class="nump">281.9<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(116.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PurchasesOfInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(235.0)<span></span>
</td>
<td class="num">(515.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="nump">40.3<span></span>
</td>
<td class="num">(133.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="num">(688.8)<span></span>
</td>
<td class="num">(1,037.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(1,017.2)<span></span>
</td>
<td class="num">(885.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(1,498.0)<span></span>
</td>
<td class="nump">499.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">3,958.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(710.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(750.0)<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(281.0)<span></span>
</td>
<td class="num">(282.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by (Used for) Financing Activities</a></td>
<td class="nump">412.3<span></span>
</td>
<td class="num">(2,878.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,478.9<span></span>
</td>
<td class="num">(1,359.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at January&#160;1</a></td>
<td class="nump">2,067.0<span></span>
</td>
<td class="nump">3,818.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at March 31</a></td>
<td class="nump">$ 3,545.9<span></span>
</td>
<td class="nump">$ 2,459.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasesOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasesOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664959564352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. We issued our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D includes the initial costs and development milestones incurred related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div>Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. Development milestone payments related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, were previously included in cash flows from operating activities in the consolidated condensed statements of cash flows and are now included in purchases of IPR&amp;D in cash flows from investing activities. The reclassification resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $23.8&#160;million for the three months ended March 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776833008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,238.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">721.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three months ended March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March&#160;31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,547.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">429.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,977.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,075.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,115.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,190.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">753.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">602.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,356.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">527.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">275.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">673.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780224000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we completed the acquisition of Akouos, Inc. (Akouos). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;D when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D charges of $105.0 million and $165.6 million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 5 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the three months ended March&#160;31, 2023 were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we acquired a Priority Review Voucher from BioMarin Pharmaceutical Inc. for $110.0&#160;million. We recognized no other significant acquired IPR&amp;D charges during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events - Divestitures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of the olanzapine portfolio, including Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to Cheplapharm Arzneimittel GmbH. Under the terms of the agreement, we will receive $1.05&#160;billion in cash upon successful closing of the transaction and an additional $305&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive milestone payments of up to $50&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Amphastar Pharmaceuticals, Inc. Under the terms of the agreement, we will receive $500&#160;million in cash upon successful closing of the transaction and an additional $125&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive sales-based milestone payments of up to $450&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These transactions are subject to customary closing conditions and regulatory approval.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we completed the acquisition of Akouos, Inc. (Akouos). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;D when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;D charges of $105.0 million and $165.6 million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Akouos Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 5 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations attributable to Akouos for the three months ended March&#160;31, 2023 were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we acquired a Priority Review Voucher from BioMarin Pharmaceutical Inc. for $110.0&#160;million. We recognized no other significant acquired IPR&amp;D charges during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events - Divestitures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of the olanzapine portfolio, including Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to Cheplapharm Arzneimittel GmbH. Under the terms of the agreement, we will receive $1.05&#160;billion in cash upon successful closing of the transaction and an additional $305&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive milestone payments of up to $50&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into an agreement to sell the rights of Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Amphastar Pharmaceuticals, Inc. Under the terms of the agreement, we will receive $500&#160;million in cash upon successful closing of the transaction and an additional $125&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive sales-based milestone payments of up to $450&#160;million in aggregate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These transactions are subject to customary closing conditions and regulatory approval.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780264352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulins, Basaglar and Rezvoglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. Rezvoglar is included in the Basaglar product family.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to the Basaglar product family as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(126.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim generally share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for the Basaglar product family in the U.S. We record our sales of the Basaglar product family to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to the Basaglar product family:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million were capitalized as intangible assets as of March&#160;31, 2023 and December&#160;31, 2022 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera were recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $1.47 billion, primarily related to bebtelovimab, for the three months ended March&#160;31, 2022. We did not have sales of our COVID-19 antibodies during the three months ended March&#160;31, 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2023, Roche is eligible to receive up to $160.0&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div>We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2023, we are eligible to receive payments of $65.0&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the three months ended March&#160;31, 2023 and 2022, collaboration and other revenue recognized was not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780319360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Equity and Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three months ended March&#160;31, 2023 and 2022 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net losses recognized in our consolidated condensed statements of operations for equity securities were $13.7&#160;million and $425.4&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. The net gains (losses) recognized for the three months ended March&#160;31, 2023 and 2022 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had approximately $950 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">512.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 99 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2023, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,330.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">165.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">516.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">833.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,750.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we issued $750.0&#160;million of 5.000 percent fixed-rate notes due in 2026, which are callable at par after one year, $1.00&#160;billion of 4.700 percent fixed-rate notes due in 2033, $1.25&#160;billion of 4.875 percent fixed-rate notes due in 2053, and $1.00&#160;billion of 4.950 percent fixed-rate notes due in 2063, all with interest to be paid semi-annually. We used the net cash proceeds from the offering of $3.96&#160;billion for general business purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for our short-term and long-term debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,498.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,883.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,654.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,654.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,740.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,329.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,329.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Related Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. The majority of our cash is held by a few major financial institutions that have been identified as Global Systemically Important Banks (G-SIBs) by the Financial Stability Board. G-SIBs are subject to rigorous regulatory testing and oversight and must meet certain capital requirements. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer based on credit rating of our counterparty. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect significant counterparties to fail to meet their obligations given their investment grade credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $423.4 million and $422.1 million&#160;of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2023 and 2022&#160;were&#160;not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 9) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 9). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. Forward contracts generally have maturities not exceeding 12 months. At March&#160;31, 2023, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.440%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,948.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574.7</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.8</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.97 billion and $6.83&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, of which $5.58&#160;billion and $5.45 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of March&#160;31, 2023 and December&#160;31, 2022, respectively. At March&#160;31, 2023, we had outstanding cross-currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At March&#160;31, 2023, we had outstanding foreign currency forward contracts to sell 1.38 billion euro and to sell 1.82&#160;billion Chinese yuan with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&#160;31, 2023, all of our total long-term debt is at a fixed rate. We have converted approximately 12 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 9) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March&#160;31, 2023, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.00 billion, which have settlement dates ranging through 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $13.1&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three months ended March&#160;31, 2023 and 2022, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Risk-Management Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for risk management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of acquisitions of businesses. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780231920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 12.1 percent for the three months ended March&#160;31, 2023, reflecting the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit. The effective tax rate was 7.3 percent for the three months ended March&#160;31, 2022, reflecting the favorable tax impact of net investment losses on equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780259872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health (benefit) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(263.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776765808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests. The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. In April 2023, the Supreme Court of Canada denied Apotex's appeal petition, and this matter is closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP (AstraZeneca), were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi, Novo Nordisk, and AstraZeneca, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately 1.15 billion Brazilian reais (approximately $226&#160;million as of March&#160;31, 2023). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST. A mediation hearing is scheduled for May 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian reais, which ruling in June 2021 was limited in scope and the security was reduced to 100 million Brazilian reais (approximately $20&#160;million as of March&#160;31, 2023). ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s and ABL&#8217;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Average Manufacturer Price Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the District of New Jersey, 2018); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023), and Lake County, Illinois (U.S. District Court for the Northern District of Illinois, 2023). These lawsuits are at various stages in the litigation process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021, the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc.</span></div>In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. The stay was lifted in April 2023. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780284960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,874.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,062.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,844.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,826.6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,066.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,777.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,343.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,575.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,531.6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,225.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 5), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:26.827%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="30" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780277760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other&#8211;Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment losses on equity securities (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(115.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774398960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D includes the initial costs and development milestones incurred related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. Development milestone payments related to externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, were previously included in cash flows from operating activities in the consolidated condensed statements of cash flows and are now included in purchases of IPR&amp;D in cash flows from investing activities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;D when the event triggering an obligation to pay the milestone occurs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Investments in Equity and Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div>We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Description of Derivative Risk Management</a></td>
<td class="text">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 9) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 9). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 9) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780315952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,238.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">721.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March&#160;31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,547.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">429.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,977.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">248.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mounjaro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">568.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,075.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,115.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,190.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">753.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">602.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,356.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">527.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">186.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">275.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,436.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">673.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,960.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,810.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of amounts recorded for contract liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664959564352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the amounts recognized for assets acquired and liabilities assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at December 1, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to GJB2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. </span></div>(3) See Note 5 for a discussion on the estimation of the CVR liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776833008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of significant milestones and revenue recognized</a></td>
<td class="text">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to the Basaglar product family as of March&#160;31, 2023 and December&#160;31, 2022: <div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(126.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to the Basaglar product family:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774686736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of the contractual maturities of our investments in debt securities measured at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of the fair value of available-for-sale securities in an unrealized gain or loss position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">512.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of activity related to our available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value information, assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,330.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,343.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">165.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">155.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">475.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">624.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">516.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">833.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,750.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value information, liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for our short-term and long-term debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,498.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,883.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,654.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,654.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,740.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,329.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,329.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative instruments</a></td>
<td class="text">At March&#160;31, 2023, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.440%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,948.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinese yuan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574.7</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pounds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.8</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of fair value, by balance sheet grouping</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for risk management assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(91.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">228.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776792992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net pension and retiree health (benefit) cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health (benefit) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(263.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777872800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of components of other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,874.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,062.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,844.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,826.6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,066.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,777.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,343.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,575.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,531.6)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,225.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains/losses on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of reclassifications out of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:26.827%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="30" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664778448800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment losses on equity securities (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(115.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776137472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Increase in net cash provided by operating activities</a></td>
<td class="nump">$ 1,730.6<span></span>
</td>
<td class="nump">$ 2,523.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash used in investing activities</a></td>
<td class="num">$ (688.8)<span></span>
</td>
<td class="num">(1,037.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Increase in net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Increase in net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776128064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,960.0<span></span>
</td>
<td class="nump">$ 7,810.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6,238.2<span></span>
</td>
<td class="nump">7,132.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">721.8<span></span>
</td>
<td class="nump">677.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 25.1<span></span>
</td>
<td class="nump">$ 53.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777936560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Adjustments to Revenue) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774589232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 220.3<span></span>
</td>
<td class="nump">$ 219.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664768554080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,960,000,000<span></span>
</td>
<td class="nump">$ 7,810,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,436,200,000<span></span>
</td>
<td class="nump">5,174,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,523,900,000<span></span>
</td>
<td class="nump">2,635,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,190,400,000<span></span>
</td>
<td class="nump">3,388,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,075,000,000<span></span>
</td>
<td class="nump">2,276,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,115,400,000<span></span>
</td>
<td class="nump">1,111,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,977,100,000<span></span>
</td>
<td class="nump">1,741,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,547,400,000<span></span>
</td>
<td class="nump">1,313,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">429,700,000<span></span>
</td>
<td class="nump">427,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">577,500,000<span></span>
</td>
<td class="nump">419,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">329,400,000<span></span>
</td>
<td class="nump">229,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">248,100,000<span></span>
</td>
<td class="nump">189,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">568,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">536,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_MounjaroMember', window );">Mounjaro&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">32,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">460,900,000<span></span>
</td>
<td class="nump">618,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">271,600,000<span></span>
</td>
<td class="nump">368,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">189,300,000<span></span>
</td>
<td class="nump">249,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">252,000,000.0<span></span>
</td>
<td class="nump">273,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">198,800,000<span></span>
</td>
<td class="nump">190,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">53,200,000<span></span>
</td>
<td class="nump">82,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">209,300,000<span></span>
</td>
<td class="nump">191,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">135,400,000<span></span>
</td>
<td class="nump">119,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">73,900,000<span></span>
</td>
<td class="nump">72,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">145,100,000<span></span>
</td>
<td class="nump">144,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">56,000,000.0<span></span>
</td>
<td class="nump">54,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">89,200,000<span></span>
</td>
<td class="nump">90,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,356,000,000<span></span>
</td>
<td class="nump">1,353,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">753,400,000<span></span>
</td>
<td class="nump">783,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">602,600,000<span></span>
</td>
<td class="nump">569,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">750,900,000<span></span>
</td>
<td class="nump">469,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">461,100,000<span></span>
</td>
<td class="nump">301,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">289,800,000<span></span>
</td>
<td class="nump">167,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">236,800,000<span></span>
</td>
<td class="nump">230,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">100,600,000<span></span>
</td>
<td class="nump">79,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">136,100,000<span></span>
</td>
<td class="nump">151,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">129,900,000<span></span>
</td>
<td class="nump">122,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">118,800,000<span></span>
</td>
<td class="nump">109,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">11,100,000<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">58,200,000<span></span>
</td>
<td class="nump">343,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="nump">254,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">38,100,000<span></span>
</td>
<td class="nump">89,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">180,200,000<span></span>
</td>
<td class="nump">186,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">52,800,000<span></span>
</td>
<td class="nump">39,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">127,500,000<span></span>
</td>
<td class="nump">147,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">777,800,000<span></span>
</td>
<td class="nump">748,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">354,500,000<span></span>
</td>
<td class="nump">378,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">423,300,000<span></span>
</td>
<td class="nump">369,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">527,000,000.0<span></span>
</td>
<td class="nump">488,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">312,200,000<span></span>
</td>
<td class="nump">307,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">214,800,000<span></span>
</td>
<td class="nump">180,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">228,900,000<span></span>
</td>
<td class="nump">255,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">42,300,000<span></span>
</td>
<td class="nump">71,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">184,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">360,500,000<span></span>
</td>
<td class="nump">397,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">144,500,000<span></span>
</td>
<td class="nump">153,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">216,000,000.0<span></span>
</td>
<td class="nump">244,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">154,300,000<span></span>
</td>
<td class="nump">149,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">108,700,000<span></span>
</td>
<td class="nump">108,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">45,600,000<span></span>
</td>
<td class="nump">41,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">206,200,000<span></span>
</td>
<td class="nump">248,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">35,800,000<span></span>
</td>
<td class="nump">45,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">203,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">275,300,000<span></span>
</td>
<td class="nump">1,923,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">108,700,000<span></span>
</td>
<td class="nump">1,582,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="nump">340,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">122,300,000<span></span>
</td>
<td class="nump">137,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">70,700,000<span></span>
</td>
<td class="nump">70,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51,700,000<span></span>
</td>
<td class="nump">67,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">100,300,000<span></span>
</td>
<td class="nump">217,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">7,600,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">92,700,000<span></span>
</td>
<td class="nump">210,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,469,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,455,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">52,800,000<span></span>
</td>
<td class="nump">98,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">30,500,000<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 47,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_MounjaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_MounjaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664773318832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,960.0<span></span>
</td>
<td class="nump">$ 7,810.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,436.2<span></span>
</td>
<td class="nump">5,174.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,090.9<span></span>
</td>
<td class="nump">1,067.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">387.2<span></span>
</td>
<td class="nump">410.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">372.7<span></span>
</td>
<td class="nump">406.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 673.1<span></span>
</td>
<td class="nump">$ 751.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664779604992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.0<span></span>
</td>
<td class="nump">$ 165.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Olanzapine Portfolio | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds</a></td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Additional cash proceeds</a></td>
<td class="nump">305.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived', window );">Milestone payment received</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baqsimi&#174; | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Additional cash proceeds</a></td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived', window );">Milestone payment received</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember', window );">BioMarin Pharmaceutical Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember', window );">Akouos Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_OlanzapinePortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_OlanzapinePortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_BaqsimiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_BaqsimiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664773727760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,073.0<span></span>
</td>
<td class="nump">$ 4,073.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember', window );">Akouos Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 153.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">181.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">547.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(153.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">$ (66.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777653584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Asset Acquisitions) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember', window );">BioMarin Pharmaceutical Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_PaymentsForAssetAcquisitions', window );">Acquired IPR&amp;D expense</a></td>
<td class="nump">$ 110.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664778292704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details) - Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 111.2<span></span>
</td>
<td class="nump">$ 116.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">57.3<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="num">$ (126.0)<span></span>
</td>
<td class="num">$ (130.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terms or rights and obligations under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774204016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Net Product Revenue) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,960.0<span></span>
</td>
<td class="nump">$ 7,810.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">577.5<span></span>
</td>
<td class="nump">419.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">85.8<span></span>
</td>
<td class="nump">92.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 228.9<span></span>
</td>
<td class="nump">$ 255.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774185328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,960,000,000<span></span>
</td>
<td class="nump">$ 7,810,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">228,900,000<span></span>
</td>
<td class="nump">255,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,469,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations percent (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,030,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terms or rights and obligations under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664775966864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment losses on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="nump">$ 425,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded commitments to invest in venture capital funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Unfunded commitments to invest in venture capital funds, anticipated payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Percentage of nonperforming assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Accounts receivable derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1', window );">Average remaining maturity of foreign currency derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Foreign currency-denominated notes, designated as hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,580,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Losses expected to be reclassified in the next 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember', window );">Swap U.S. Dollars to Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember', window );">Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember', window );">Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps | Cash Flow Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,830,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lly_A50NotesDue2026Member', window );">5.0% Notes Due 2026 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lly_A47NotesDue2033Member', window );">4.7% Notes Due 2033 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lly_A4875NotesDue2053Member', window );">4.875% Notes Due 2053 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lly_A495NotesDue2063Member', window );">4.95% Notes Due 2063 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lly_SeniorNotesDue202620332053And2063Member', window );">Senior Notes Due 2026, 2033, 2053 And 2063 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 3,960,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A50NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A50NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A47NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A47NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A4875NotesDue2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A4875NotesDue2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A495NotesDue2063Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A495NotesDue2063Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_SeniorNotesDue202620332053And2063Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_SeniorNotesDue202620332053And2063Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664776205072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 648.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less&#160;Than 1 Year</a></td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">219.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More&#160;Than 10 Years</a></td>
<td class="nump">$ 237.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774327744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">39.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">120.5<span></span>
</td>
<td class="nump">46.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 512.4<span></span>
</td>
<td class="nump">$ 568.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774319936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Realized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664770931152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Fair Value Measurement) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 2,750.4<span></span>
</td>
<td class="nump">$ 2,901.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,343.1<span></span>
</td>
<td class="nump">657.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">123.4<span></span>
</td>
<td class="nump">144.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">516.6<span></span>
</td>
<td class="nump">478.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">833.7<span></span>
</td>
<td class="nump">781.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">2,750.4<span></span>
</td>
<td class="nump">2,901.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">145.2<span></span>
</td>
<td class="nump">146.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">214.8<span></span>
</td>
<td class="nump">213.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">155.3<span></span>
</td>
<td class="nump">149.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">204.0<span></span>
</td>
<td class="nump">398.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">624.0<span></span>
</td>
<td class="nump">683.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,343.1<span></span>
</td>
<td class="nump">657.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">163.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">232.5<span></span>
</td>
<td class="nump">235.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">165.2<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">58.2<span></span>
</td>
<td class="nump">52.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">475.6<span></span>
</td>
<td class="nump">484.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,343.1<span></span>
</td>
<td class="nump">657.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">145.2<span></span>
</td>
<td class="nump">146.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">214.8<span></span>
</td>
<td class="nump">213.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">155.3<span></span>
</td>
<td class="nump">149.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">204.0<span></span>
</td>
<td class="nump">398.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">624.0<span></span>
</td>
<td class="nump">683.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,330.2<span></span>
</td>
<td class="nump">650.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">145.2<span></span>
</td>
<td class="nump">146.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">624.0<span></span>
</td>
<td class="nump">683.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">214.8<span></span>
</td>
<td class="nump">213.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">155.3<span></span>
</td>
<td class="nump">149.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">113.8<span></span>
</td>
<td class="nump">311.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">87.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3) | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774431072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="num">$ (18,883.6)<span></span>
</td>
<td class="num">$ (14,740.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,498.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="num">(16,654.6)<span></span>
</td>
<td class="num">(12,329.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="num">(16,654.6)<span></span>
</td>
<td class="num">(12,329.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,492.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Commercial Paper | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Commercial Paper | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,492.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Commercial Paper | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664770685632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details) - Mar. 31, 2023<br> &#8364; in Millions, &#165; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>CNY (&#165;)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember', window );">Buy USD Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">$ 2,410.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,231.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euros Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,667.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">3,948.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember', window );">Buy US Dollar Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">229.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,574.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember', window );">Buy GBP Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 216.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 265.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664871338288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Effect of Risk Management) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="num">$ (61.9)<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(131.8)<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(46.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">122.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="num">(94.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="num">$ (52.8)<span></span>
</td>
<td class="num">$ (6.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664773950912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">$ (40.1)<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(71.8)<span></span>
</td>
<td class="num">(70.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign Exchange Contract | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">(40.1)<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(71.8)<span></span>
</td>
<td class="num">(70.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="num">(40.1)<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Other noncurrent liabilities</a></td>
<td class="num">(71.8)<span></span>
</td>
<td class="num">(70.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">63.7<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign Exchange Contract | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Carrying Amount | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(91.8)<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(91.8)<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(91.8)<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">228.6<span></span>
</td>
<td class="nump">246.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">58.2<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">228.6<span></span>
</td>
<td class="nump">246.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">228.6<span></span>
</td>
<td class="nump">246.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest Rate Contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">58.2<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">58.2<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">67.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Carrying Amount | Foreign Exchange Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(38.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">67.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">67.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(38.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(38.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges | Estimate of Fair Value Measurement | Foreign Exchange Contract | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777680816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664780703568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 70.4<span></span>
</td>
<td class="nump">$ 89.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">161.1<span></span>
</td>
<td class="nump">100.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(263.3)<span></span>
</td>
<td class="num">(239.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(37.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(13.2)<span></span>
</td>
<td class="num">(13.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">$ (36.5)<span></span>
</td>
<td class="num">$ (30.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664768131648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>BRL (R$) </div>
<div>patent</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>BRL (R$) </div>
<div>site </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>site </div>
<div>patent</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2018RulingMember', window );">Employee Litigation, July 2018 Ruling | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="nump">R$ 1,150<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2019RulingMember', window );">Employee Litigation, July 2019 Ruling | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">R$ 100<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2018RulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2018RulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2019RulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationJuly2019RulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664778037248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 10,775.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">76.8<span></span>
</td>
<td class="nump">$ 56.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">67.3<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">11,294.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(3,844.6)<span></span>
</td>
<td class="num">(4,343.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3,777.3)<span></span>
</td>
<td class="num">(4,225.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,874.2)<span></span>
</td>
<td class="num">(1,550.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">72.8<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(25.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">47.6<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,826.6)<span></span>
</td>
<td class="num">(1,575.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(37.1)<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="num">(21.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(18.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,062.3)<span></span>
</td>
<td class="num">(2,583.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,066.1)<span></span>
</td>
<td class="num">(2,531.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Net unrealized gains/losses on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">129.0<span></span>
</td>
<td class="num">(213.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">109.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 143.7<span></span>
</td>
<td class="num">$ (100.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664774689024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tax Effect) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="num">$ (65.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="num">(13.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Net unrealized gains/losses on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Net unrealized gains/losses on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (3.9)<span></span>
</td>
<td class="num">$ (29.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664779621056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">1,529.7<span></span>
</td>
<td class="nump">2,053.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(184.8)<span></span>
</td>
<td class="num">(150.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">74.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">29.1<span></span>
</td>
<td class="nump">87.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">$ (22.5)<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140664777903424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 102.8<span></span>
</td>
<td class="nump">$ 84.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(34.2)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment losses on equity securities (Note 5)</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">425.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(115.8)<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(59.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">$ (35.7)<span></span>
</td>
<td class="nump">$ 350.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>lly-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20230331.xsd" xlink:type="simple"/>
    <context id="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6c39e441ad84014878b856a1411f674_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if7e37ea68750472dae583b744621207e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1700NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i42ff8c3480034649af99d9e4b0f62406_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c2ab2b26eca44b79b6d178d0f021629_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i927e3b53935c4022981ef2bcccb6abdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b2d9ab3c1794f1d8b361cd95d702eb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabf9b65901614ec99ac3f7f3cf96ba0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3db0e5f4479b4590a17a13660ba7120f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaef6a6bd5dd4d8bb6af6b8e7f16c197_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7656e7caa28247f39bd611bc66416bd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95753ad64fa24dfc9db4020a919ed2e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id978959344a247b69b4db196a5f33b07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c601fdfc135468b9efa7eeeaaf2bbdc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50a04715762e44a39f3f2505d74a6ea1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2186586b7322416183b886001b72303f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3148a12fb5994593a755fff70b7d4470_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16887cea932f44c3a6088e33ecfb7490_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f8048a6c27248afac7fffd0fe38b008_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib2097ff769544728b3e0e7f64451512e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if3edace87bee46b0bf89263a4a4be3b1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c67213efc434eb9ac796a4c1a04c8da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc8dbf8ede644257a18c8621fa65c557_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic813de36efc74513bd64da94a269adfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i188c9e0e0deb45c7ac4c04ec58fafeae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib68e310320e9466d8f5ba3eb98d90284_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i637339e89f374f98959ff8ae6e6501d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i439164f165d34e9bb97df6c5e992ff8b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if684f40112064b11b340468506a32fa3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc91a78b7e994d8a828ad6accd7e7eb9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie33c470d29b348aaaf9cacc62407b9b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66f1bc66163b41baa48cbf1328b78bbc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ae9598be4a64cd69d5667e9e70ca761_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i153592c1af1f4910bf06d43f543dcc71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89e11d3a40394c318b16109c7c0fecf6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e757fc239f4499e91acfaeb16335063_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ie7699e9bf7f941dcb048f29c3aada3b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic88d6c314da94d23b9e30802e9728044_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib386950c303c4cfa991af56051f481c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i118b413e750a419a8eea249e9dec5ea8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i49f70762797b4c7eb12579a57e4a0f1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41563e4306144d7db1ae5fab5a13d025_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia45726ea3ba342708ad76343e7d8ea9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i776dd251590543c2aa2cb51a4dab931f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1de368b269ea4b33baf0dc1ce490d43c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ba05d67547242b28419ed4e7793321c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if0cc6e06de26466c90d397554c65af18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b0d2e9299804c05b2243243ee5f298f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1e3800138a064caf84059e7b7ac1f59f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88e8033ea6754341b21a71b5dd3e785c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i11dd59e0fdc74287873fca650e145c15_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f4e39b3439c480c8742d89f8399bc82_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id13290ff47804307a44e2f065e33dd7d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifac33e8897674b85a6950df08eee5bf8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a28a52e5fa34f38a6ecc947140b6edb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90a6d8bc4d434540ad95d77f973fa070_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d89a91c0fbb4dd195707004ab1a00b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4783bd0e08d47d29ab78b3d697d290f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c7662e4b8c740ebba1d408fa1765201_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i97119da1943c4d1e95f0e996e9f315be_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id3c27dd4f47b47239694dc03b4ecc6ad_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i90e4c56100484d70a675bd288c597049_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf2f9585c7204b33beb2bc33724774a0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:MounjaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id16fef32b8fb476596fe6c4d0bb25380_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i811218a96d2b41c0a71ad7a4b77e56b2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7b94ba9dd63247d5b32ffa10006a021e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id898a8a22f0e4880a5338b8467984755_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3450a514000e4564aed94e9856bd66d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2bd2ba8150f4e69a8256ef87cc94d2d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb86385cc8eb4bed91738b3eec15d109_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7d5f5c213bf74ee680df8883531a880e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i87ac73e33e864d3d85f05e179d6e0ab5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i93975c00ca0e44ba99e88b2a02696fbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41870e267fbe402dad822ec24c06b44f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39805ee81eec439aa8c2e397f5508410_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4655d36440574fbeab0c91fc7b019703_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44114472bba24a3b91861ccdbb5b23ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d1aed3d8f0c4cb293c37cdc3196c8d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1eee894daf9648e981d2c1b49f7448e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i43ff4b5d9df8493fbd95a0e88fe1cc78_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if4dc93a102494bcdb03aacc7bbba37f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if3506079381447bd842f668fa1edf8bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib67d2dd261224805ac90f2f1b66659e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2548d402f8348a19d3cdabfabed7bbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8ee45c4c43e47b6a8bf88847481e710_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if78c1dab52df4fad8c34b85682e70bf9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i93368f3f449f4b9fbf16c9329f7056bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4cc66ce8e6de454cac39d92a460a5da5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic5306573ee5f40fe87015d1bead33c79_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67961791f67f455a9e83bdd66879e1e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7827ab11ad634535a354ffe9397dee6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9800b2536c0a4887b5ab9dd03310e3d5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4913832cdf6c42bfa9d7047743a02c46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d7fe4b4cb9d4e1eb78bf2b8fc45025b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7380748fafce4bbeb79b3fb7212654a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ff8425fbfc64303ae4dd3c6a3664599_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f4e2ee8a2d34917bdcc965e7626ef0e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib56eaf4a89a44762b2ad02723519711d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i36a88ab4c21743beb4653082449b8794_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i01ec6bedcbf8431996d351090aeb835f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ec65e20bbe8429d8374bab94fff526d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32ee755aa5ec43ce8d7d5b0801744953_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36a7138a41b64af0b3d3bffc680013e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4850b75145f14e119182161edd48e156_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7eea234886e74de6bc9398e17900aabf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i00c07348838844f9927b4f1042344fc8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic54de819fdc34f43a6a60f819b305005_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia728bce450914e0ab2648a04596d1d35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67d1f99b0aa548e694ca63f72c14567a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9140b6e5e49c43dbb2dbd87cb8181bbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7070b3ba7a54482a84f745990995ccdd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia688e1f2870e4ce7ad9e8932949035dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieb82241d17ed4a128f5799c977329bf4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79547491309b4e5393994557f1671667_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5886df3058224ce1aa56b3af9d1a1dc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if65a58b1573343a39b71e05ab32cc416_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifecbc3c01d7643c3888c9bb26a95292d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i97d13f666ff449d7a621398eaa0ef2d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i74abf3ad08e8479fbc7b50f9e8bccaf1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49343f97cd6f47108d6fd5848cd54864_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i808d86cf633c44669b50bbdecdb33551_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i795c0bdc41294080907d9ea59944ead4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9df5f251db6448df818fab73530a644a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i417d453530f54ca0b2209fa1faf5306d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if29c502013aa40aeb696d62e85288626_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff009e5b94684162a6c0b8401522ef69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id944e42934f04a7f867c267ec9717aff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5231a969184a4364a058bc909f82fe8b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8cf70417fae9467fa9f5e6435d854dfd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i10d99551c34a4e858ad1c4e0502e76dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib18890600eb448588714f8ad882431ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69246a482ad44038a5cc2d5c54873ae2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib58a7cb2a4a0485d96deb76ac57931ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f65318bd79648b998f3e5df408c0412_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3213310f015747d080af9a1ff48b5ad8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i16329625fa6f44a6a1c064ac7d4ec9dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i153b28fedc304d3e8ffde2bdf7f073c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0385f2c26b2f4d3e8fb95aaa85d8bc2a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie5e0e3a0711046c39391d2d3cf445882_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9e6d1650065e4c768674409d266dca06_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i31d09044e85e405bae8df74949e8712b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e50725af9a34d7a98f04d67cb123a30_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9e7240880ac4123a3894cbb650d0172_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd4c963f8e9e4b4db60302cf2284c762_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i269467655eda495eb32d7ecade1d1990_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03b2366367f84820bf8ace8d801f1c7d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie96f23fe8818410dbe8e8a34a66455ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i957ffa2d2be34dee93676a024e802aa2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icef141b8c87343e8a397e0bf1e526680_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53c7539f3edc4efaa041fe0e65fdc6ab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i367924f0fc6a4ee6b301ed3d61eb59d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ice3f5be448854af1bc7435c75e8fd14a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icf75f8c30aff470988cc19ce904d3fe4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bf7bba33b974a30af558c8ffb0eff76_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab868bc977a9479b97ce8c1d76008a42_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53b5d56ba3c84300a4655bfc90d63682_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4da9824d115d4642b33d62110647bc25_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id1f0a7c14210458f99c56d32fab18cae_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0577f0dc20c64f89a47c8c6dea223e7e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9816923eb3343fcb3c969e22954983c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i974f97a08b2246b99fad08fcff9d907b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01b0c35171b54d0e8199472f276c3efd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d0c12862e7a4f5295df6787910e6d95_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf02a47c1f054f6cab10a1350b11ca78_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3846c71ac29e4037bc0323344ed7bf33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1943dbb4c94472d9c47d4588395f87d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c58df1da1424666b72028b96c96e821_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i948eeabb45154555a0aa21e3c99f533f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i696edc9f8e1843b28ed762a1347db26b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i703ac11468d54f86bf1f951723906604_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibeb41e587fef4c8aaeee5a0e8d565098_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7157b6266b57432189b37acac4c62b1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8f7663963954d37992ed44ffb330868_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b6109f92c24420fb119449586e2d751_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06f6d319daa54e91842b67dd9ad0ca0d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a86976547184c9aa6f46daea7912cde_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia0798771ccf6491d8bf4e3a529a99992_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0bebcb77e7cc46c4a0f6232d59204728_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2afe04177a85445183aee9c1f1a104cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0b8c13f78ef499fa5e3a82aa88d9a10_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2dd5a2af9de84cfc812225bc521e17bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icbf0b36bab2d459389f2adb7bf797fc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3508798f670645c0af6c4e615ca44088_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45a904aef68a4f45b2b86bf8b5576e30_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5103a4e13b1f49fcb43c76f4ef1e1696_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76e758f49518403ab2b0c55235561aa3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if51e24ac8e8b450599cdde81c0c8a8db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib0b13b0180da45dabb7f682f854e3394_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd283be94b6d4f30af788ea943b170d1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92ac892edbf94f62919a942916235192_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic522b3c6168f49769bd3610b3cfb9fd2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i394796b389834a5d8a4a6a52018ea5e4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibf536f227695468d8955c509d0cac28a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fbeb1df59694ca1a5121853310fe013_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8fd8ff202c66402cb6acdcfb73f456e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if4b193d99bd84b609a946006de3ff5b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ce552cbf23a4e5e87ebb11e406b4c7c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f75bb32e91f4c8c914a357a961a505e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i591aacf4b21b4fb6af4a84ef723f602d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e43da972920406cb8cec2e4ac4f504a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i546300f8490545128a0251b2fdd2206b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3357638f0d364662b153eab67fa8550f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic91090e6b25c497aa5caa5cd3b067650_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb8415110eb3486093fdd56a22adfd54_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7a092f91d8a468d8c4c31d4148a904b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if724a8d2f737491298c6d043d5a7b8fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i445c404661b9435abdfa6e32f19fa84d_I20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="iae82f601bab2473da6f28b70df983fa5_D20221201-20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AkouosAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="i7692466539d946a186b9e8a3794403e0_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:OlanzapinePortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="ic7897a00ac5944569e250a8e3e4f0b96_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:OlanzapinePortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i100bf53cad0845918532d994ef899f46_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:BaqsimiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="ie1373c2b92194421a101613e8613e0bd_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:BaqsimiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d0abcdee3334210846272da16cb8bf0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd665f0b61e04e9290ab394dc775adfc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c0be196fbee4b99986d201abe4c40cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ff485149e744b8388e86b2d61f131bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78acf8b5d08a423ab887d0babcc4c793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20238217248b408d991f048bd5cb02de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i73c97dbdad3e47c19014952cddab28fa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92837642c10f4f2d8a9378d7a850d897_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i609b231bb46d449cb0c55bf0feca2672_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5463e57189f4d458870b77c846c8470_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5cbee495f74d4bc7ac390f3934fd8dec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i103526d82f5c4005b57a6ca769c093a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i489cad1a4170481f8dc4678a75f24771_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifa643ca7a9684ef7bc9e57583e9f2c9f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f28555ca5d9421a9bb743d1916adb6c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i64cc16dbdab440cba483787915c9d53d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ab4c398ad894122bc46ff06e78555c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1477b2c322fa4d258992d89c08206da3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib07ca7f96ff047149b52aa21f1419c5d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic0f030511d7046938601479dedb444f4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1c7566c897554984865a313ce03a9329_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0134da41219f40099434bf6b0e92907f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1cac2c8384d54ca495e549787dc20271_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1879600e47a94b1ca76977132157c1f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3918b47b0546407986bcb5eb572cf16a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i51606337f7734c3486883b088d9e425b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07d8251eccdf47259566f7ce1b910246_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8dc74babfb5f48019438eb1839ff23ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c819184949c43c88caf8d26d02607fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8026bc96eb9499a97499c0c3a47904d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4a28c2c52e041b8bda2d6528cde8205_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9afb33798b944ff09e0d384619049f08_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i14fba24e65df4393afd80bbbfba657c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8f0237a8c7ae47d897c07629a4ccd158_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i837f1e72cbb14e459cf199db8d586de3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7b28da6dd9e645d398bc98f07007e279_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id276c57f9b1f4968a4c1e9e22e9ca168_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9bfc537fc2c649e6a5a5f04fa5e3eac0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i060e380eb6bd4c7b8d931a5b7fe8ee32_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c95303f9a0d4b8dbc0cd35c9ab50369_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2aee17f60b34dfaa64036bd799907ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9cdd4b1a54e04c3a9406a84414b9f579_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5575d654b61f4900b3705243433ef745_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84c516fae2e94d6dbda47e05ce423f1b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ef8ccfb7b53440397caf6f2176ec2c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd1914622ec74bfc91e9e91e6b7153e4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i954f45623ee841cbbb44ef65dc983e82_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibbdc87b2e3b847c699cc755d5929caa3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93672f2b12e14d149242b511c86a6250_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i64f02815ce424e099d024a5372594f49_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3620be0cd8f6437c993131b23aae9aa0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id4c92706e1f14b06b6f276c841acc827_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i87fe25007da841e6a6dfa7dea8abca12_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ebed6fdc46043b680d5a256576f2871_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5cb98f1aad55409684b3ba48c8c07916_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6dbc248c1574a47a024938a5536f95c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2b8cd580dcd4aa7a914f8764250a273_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19353eef79fe415d9f09bbb87f88817e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i001f8aeb21bc42778b5ba830866254e9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iefe01b19e39a4007b2c2d6fed53c9838_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55cf7db1bd84431d8151876c0779039f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b2f853a69374cc289e36b04c56dc656_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8cea0f1817514262a527599b1b82ff06_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if48d0a0094404e7283b202d1e3bddef6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie97234b19add45c8a1264d62a11227cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebfbfe46c3934f43b65aa033cc031c63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c78f11ff6a047f081fced706e82fafa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dbd154370ab46c5aa386577c6e77972_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2be3d28f17b4d53b00d099d33166a22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a551b91bdf34460b537440476918ed1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf82c4e9f9fd4a0db74790b311d892d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14330e00eca04b5aa32be284d320080f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i851cea55d9ca4dada65a5272023c5cf5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d33a84402254240a7b6fd4134d0c50d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ace9101d47e4406b2a9101fde438cc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8619a22dba4e4f568d1919d6cd7c5376_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f9a47c0173949d69d205062ba1a08a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i022f12bcdcd0432a8bf7bd1609fcd81f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i813ca92d3c304796b09a1c1b8cd503cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77fd8621adac49b9a812a1b54ce30bd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3bbe0151d1d436383b9c9a162467d10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46ca25f6912d4deaa22749065f92f810_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i800172f3d41a475b95bc904fa96bc892_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbf1513ec6fe42dc8fc97dacbcbb2f7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0f0aee5c436422aacd166802e150362_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2930663eccea45d3ab83ffbf88977505_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55dd2b5a2b18473582bd68be66d7d771_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0881c8a632db4b36a3e7ecfd7928e941_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564f1f9a74ad45f6b61966a59691288e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i489bce7d4ec7404b9664b907c028323f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i245ac866b994442fbc4b1f2c0864fe2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6856168703f140ec90f1f07f17cc591d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42aa25d783514516803c587532a3c61e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffa8c24cfa2d4bbb8bac085b94dea6e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49c245d1c06644e1b6ab489c2e9f6916_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61ecc19905f14bd28130682e968375e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e06948912d142179578cad05d244ac3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96286855c6b74d7ca6b4c49c79940a71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2035cc82b2c4f2984eefd8ae524520a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9458648cddd94b1e98f28b8ab753bc74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i463ce48ff9854c67b168581527823709_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A50NotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i5629b4e2ef53489dbf21e68abf79b47a_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A47NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="ia2aa54d93fb744f09a03b3641900a309_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A4875NotesDue2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="ied6c5f93596b48d09753ee6dac6abb6c_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A495NotesDue2063Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="ice2c8b929e4c4bc5a32d8aa02836cac1_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDue202620332053And2063Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="i35d458da5e9246b8a8c0b7b714992619_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if0331e3cce77463eab1cf2359214ff10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if485cce9601842de8e0453ea2c5bdb90_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i38c397a2da7e467c86ff6be26f9e20c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6ac66d67a45e4eb9b8df6e33b966bdeb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifeac312680b340f5b5e739bbc1e1882d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia278d7067652484dac30db72abe60a63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30ea2a3ccd6c4b00ba12b0f45309f52f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5f2344b073f45f7b33a4471dd2abba3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a314d1e73864fd780eeebcc4f2a1867_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcf771418ff145e48f59e9ff50e2c708_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6e0597d66944d53bf676c80d6b96114_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5c08ba67b1c94a638f7917eaf0032bad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id0507f641e794b5a91c61ce38a4c073c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i429677c58b714ca8a8137930ebb1264e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf306204988949a8a9f4c724f64060af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3cd20496f3d4a06a9644d09794a69a7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i260b5249d7e84893aefd8c83c3d04825_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i645e8bd9724c4c4cab525b0c0ce2038a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a44228b4f8545afb2c73892b5d2dc61_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i77245def3f8b4e7dab758e4a8bde31a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia8cd03fb09db4a7d82b3453427246d58_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i43a702b6516d4b76a6b7e939ece50067_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1c2892bae36442e8926b2ce9c0668bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c4c3a1eaec84aa68e202c8ea853063b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48e9490fbbc14d76ab189e023cf3f228_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i57e32bbc79574914bba00cdb0742b99b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58f19b8ba9ed454fa02e5160a844f996_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72a614a742164e49b4da60cae000aac8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ee17b04babc40a6ab35eccdf222fe82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib72e1ac48fd74f079d8811bbcae3d5d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37c553f14757453c942a550f354e3a74_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6789d3ab2e2e4887828f80411eaa0097_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b68c8b710bd465cb70d755bbb9d33df_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibea8c83934624a97a1dc11e68563bf6e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i332f789539594747bf8464ec5cafdb0b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib0de9c67450541c296870312132a3b92_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5442836a58a740f9a2ec6a5044876fa3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic4345c04245449db88cb19f4963073ed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6128cb3f8b34eb38e4ba315f7d53bbf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a5624b505084aa68791383a31649f60_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3441b768235345d7a17d1010afb3aa34_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb5b9b0ce2374a22a8d5ea231570946a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b75c331361d44ec829664b5a49b1365_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4ed07ce471c498fafc8e126e65bf30b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i97b86836fd2b4c638e1b4648bb0f535f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1e1b2d2ba1774f099d8109747e8c6a95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d4aaf0f785e46d39d0b337f7ca1aa83_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i33268d4bc0be4bfeb735237bbf2beaa5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3f8023d0e15487abe65174ea5fdd911_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if27a50fefdd14c2f984c86fe00f4646c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcb4d961f831495a8982fcca640793b2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i606b780fae204c2fb03456ec7d4609ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5b291e9275fa4cdea832b11022bb1650_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if17408fcf4a6444ca4350f667c9e2531_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie10c867d799d4679b141e08dc578e51f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i97f0c78f29754db2b760047cbe32a568_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5964e87d1767486d9c9f3e69ea87005f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide8899346d6d43418aa5c2c278c01334_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i13b3318a1c6d4b2989d8bd17e5d7fa8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c721984329042fa98416c00587829be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b26c90f2d0f429498c69e75f2486afb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia203e1c41a27445f9ac21572233934b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff538190e8dd49b1a7a2291adead31c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3322119f512345d8bdc5b393121fe2a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddbfbaced29242dabda4aa8d0200d534_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61271b58943e4dfe8d82e39de366487a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6961e3f6be845d49d270b23ae0eb760_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ee7bb9be4e14b0199dbb8ff375c4fd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic42c0160e96e4f31982f3ea5eddf15be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebbad1803617416b8a7575b6635bd9e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifec954c0cc0a4864a3be7c95f0bbbba3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29f5e9a727714d8e9d04fd093c69c3f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i023e643351984eaa8065abddb7c0e922_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68d6338210f24d0b8761f25b6917fedf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0289f9ec779478ca9a7d9feaa66a043_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27e470a377e24131be208163db576480_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17bd13ed9bbb44bd9b794d91b7205501_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if16b30290f524f5ba8cd96a652b77f18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0cac47e76cf444dcab2ac2c436b08b33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb9f543aacc94384a647f3a1c0667ca4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1df7036cdae24b0a97dccbbd25afe031_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b8664bea8164219ad1c5f82db48f0b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94edd79b891548bd83088ab50b487992_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id027583937064a45b5174328a3e4fd18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifed5b21a16d248339ba5818828910280_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0157807f4391408d931450405bc79b5f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1429cdab82b46a7a0ad4c4e85647f6a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d76ed1b0d8a474586570b1b99086173_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b4ab320c12a472eb82bbab75fbf501b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id56d2b03dc9949ebb50d95e71f042821_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2018RulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2018RulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ad20ef67d2f430481744471c5b56210_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i8c6d0498b5f448c7a43cd5218c9d9457_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7954361cad5e468189b61f0e148dc919_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationJuly2019RulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ea4ac837c5c446c91d4a1eadb1660df_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="if52058720702455ab18d11fcfce47593_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41c57ea452d543e989f9536150f9db93_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd425dd4dd0841579d320a37187ecdef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99e2ca758e964af8b28d95fd2e6bc9cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i653d3a81e6b14167933ef66d19e6c10c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id51d9a0f258444078ac8ef9caa739449_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i14ddf45785ed4e96a99f49ff596d8acb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7e2bb76dd4f4adab26a41f1f82d2c2b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i510af8b9f1844bed829cb00dfc685190_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0e84d8dd08244d678c234bae2809c48c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic0d4430e40014abc901dd4edd7cb49e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie00101643b4643a483d888a017ecd8ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac6c49fd39884008bd1780b0e7dd589d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9209cc4104c44020b5cca0fb5e342032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b6a9fdaf2f44f0ab06f86a366185a4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b36144f48ef40aea33af45869704e46_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea75053548e54a9383137eac2aa979bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i27e1942610fb4fe3b661fe8f47c36101_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd6d6a2a126f4ea8916e435402446e81_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie708bb24249c494bac718b7262662532_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1057b3b5f0c84df780eeb0542ab9296b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0424c9ff126d4e098f24803951d6a61e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b5badb1e9e9416281833c0e936313e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie92b4b2cc38546abbedc7e893d1b940c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib17225a13a894c18ab97a3b6bf0fb9b2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4c5514dfeeac4fd79d56e6bb4067d42e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5724b7029fb74929941da12378c70867_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2bc8829f02584de496f6271827b1daa4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id6504efffb904c0bb389e6b7ec4a995b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d8b989d89ce4af9a4cc6f268d29ee6f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12a88826d3584cfc872524cbbc7ff75c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV8zLTEtMS0xLTI0NjI2Mw_4ba14db7-b395-4984-aa34-df528612879a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV80LTEtMS0xLTI0NjI2Mw_bea165c9-98e3-492e-b740-8ef51f7edd01">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV81LTEtMS0xLTI0NjI2Mw_e045a789-23ea-475a-b88f-6f007d698076">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV82LTEtMS0xLTI0NjI2Mw_c8b5ceaf-6608-488d-9d99-636833b5af61">0000059478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV83LTEtMS0xLTI0NjI2Mw_70944b16-5c43-4904-b524-219b6c999671">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentQuarterlyReport
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV84LTEtMS0xLTI3MDkyMw_9782e2f9-109c-4e87-81bd-e9e6957f166f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80L2ZyYWc6MTMwMTMwOTVmNzFiNGZiZDkyZWUyYmVmMzY5YTdiODYvdGFibGU6N2NhY2ViYTNmNDM0NGQ5MTkyOTMwYjIxNzljMzFmMTEvdGFibGVyYW5nZTo3Y2FjZWJhM2Y0MzQ0ZDkxOTI5MzBiMjE3OWMzMWYxMV85LTEtMS0xLTI3MDkyOQ_82b01142-a55c-4ab4-bbce-9a71580520e2">false</dei:DocumentTransitionReport>
    <dei:DocumentType
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM4_bfcf660f-9088-45f4-828a-13f03a81c41e">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMTA_69633f54-4d5b-45ea-86fa-bc96eefa44be">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQy_ad6c1f5d-262f-419d-9340-c473d2cbbd9c">001-6351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM5_39eb969b-bcb7-4936-99f8-41507909f549">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ODA0N2NmY2RjNjAyNDVhY2I2ODRiODJiMGMzNDViNjEvdGFibGVyYW5nZTo4MDQ3Y2ZjZGM2MDI0NWFjYjY4NGI4MmIwYzM0NWI2MV8wLTAtMS0xLTI0NjI2Mw_245d858a-bf47-4ba5-bfc1-a8cf29f81b7e">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ODA0N2NmY2RjNjAyNDVhY2I2ODRiODJiMGMzNDViNjEvdGFibGVyYW5nZTo4MDQ3Y2ZjZGM2MDI0NWFjYjY4NGI4MmIwYzM0NWI2MV8wLTItMS0xLTI0NjI2Mw_c2ebf22a-c2d2-40f0-985d-b283c0c3dcc3">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQw_34fea546-fff5-4de9-9ffb-6b3be82c578a">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM0_45f9e6e3-face-4e61-bdaa-dd0efb32e1f3">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ0_4fb19e34-5fd4-4343-a2e8-e5172e082b8f">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM1_e2c1fe7b-a992-402c-86b3-50db2d0a501c">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM2_2b3ec243-e04f-4773-94dc-ce514208bb28">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQz_7e0ad5b3-4144-429e-8452-eab1838675d6">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTAtMS0xLTI0NjI2Mw_19610aae-6a1d-44f1-854a-cc93f1b62657">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTEtMS0xLTI0NjI2Mw_0910fe6d-706a-472a-94ad-4d325d83c1d4">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i057a6e2060974113b2103e4d65ae7465_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xLTItMS0xLTI0NjI2Mw_30ee7d80-cc7b-49c9-9541-d73e4f759123">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTAtMS0xLTI0NjI2Mw_9f2e8b68-6862-47d7-a710-15a0d07adc7d">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTEtMS0xLTI0NjI2Mw_3ea03f38-9851-436d-b212-112999a72da0">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia6c39e441ad84014878b856a1411f674_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8yLTItMS0xLTI0NjI2Mw_0a9bb5ba-85de-4e5a-a9c1-8ff33f583312">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTAtMS0xLTI0NjI2Mw_dd435779-373e-45bb-94bf-ed66ca7eea1a">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTEtMS0xLTI0NjI2Mw_9405c5a5-da61-4c4c-973b-b277a9daa8ca">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if7e37ea68750472dae583b744621207e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8zLTItMS0xLTI0NjI2Mw_bf186a3f-8eed-46a8-9eed-43a94d8b860d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTAtMS0xLTI0NjI2Mw_ca964212-0318-4b32-aa3e-eabdbb944a8a">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTEtMS0xLTI0NjI2Mw_0121b6e7-26d6-4775-a577-89354ea01f8a">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic309f12f8a1c4e91ba62903d619bc8b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV80LTItMS0xLTI0NjI2Mw_5914cdba-68ee-4567-aacb-004fc55468c7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTAtMS0xLTI0NjI2Mw_c4f20e8f-2150-48f5-8edd-b82116e8b34e">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTEtMS0xLTI0NjI2Mw_1dc59cab-4291-4ce8-afa2-41a0552ffd5e">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic41fa438dbf14546ba7f71e0e5a0a522_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV81LTItMS0xLTI0NjI2Mw_a14a080f-2767-4f7b-9f40-0c9c5e7f8802">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTAtMS0xLTI0NjI2Mw_4c35434e-a478-4b7b-ab1b-b36f224fd1f8">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTEtMS0xLTI0NjI2Mw_caf68901-bbfd-4785-ac60-b06072789838">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iad572624d16d4bd587f47c2e836247b8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV82LTItMS0xLTI0NjI2Mw_7b8831b8-55ae-4f00-926f-5889833dde7a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTAtMS0xLTI0NjI2Mw_bb3df26e-2825-4fd1-bd4c-e83f5ccd4cf9">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTEtMS0xLTI0NjI2Mw_ffe90418-7e0e-4b60-acc0-e87fa3da708e">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9122d5ecaead424fb0860fe4155affdd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV83LTItMS0xLTI0NjI2Mw_7377d5c4-e319-4835-b2aa-404621ffd4c6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTAtMS0xLTI0NjI2Mw_f4f4a117-2287-4a07-9a19-c610f623e485">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTEtMS0xLTI0NjI2Mw_80c20f8b-0e43-424a-a817-12c6f6076c69">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifff0e2241f6a49d8a34b5c7138691859_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV84LTItMS0xLTI0NjI2Mw_8e4daa6d-5fb9-4b6a-bdfd-96ca20bde5c3">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTAtMS0xLTI0NjI2Mw_efb6126e-a5fc-4d6b-b03c-31ab11d31408">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTEtMS0xLTI0NjI2Mw_4fe8dfc3-877f-49ff-83a5-d41f7c13eb12">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ideffc31528c94c228bafcd178fff9adf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV85LTItMS0xLTI0NjI2Mw_042ef758-d03d-4587-ab64-c78afb2d9ed5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0wLTEtMS0yNDYyNjM_7cfbc39a-939b-4a74-8d77-7ad4623a7890">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0xLTEtMS0yNDYyNjM_63ffe111-9f84-4395-89d6-c43291c9c2bc">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6ad56767dd8d44d5957ea53d48c19712_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMC0yLTEtMS0yNDYyNjM_f16c4a8e-a4e8-4731-bcf5-1ff232606130">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0wLTEtMS0yNDYyNjM_908d70e1-7e05-4349-8981-7435f30808cc">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0xLTEtMS0yNDYyNjM_ecd153cc-7c39-4628-a11a-221fea3bf23f">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8bcb6feedf2144cf8f10afb9e7f62dec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6NjYzMDU5YWExMmViNDhjNTkyOWQzY2U1MGJiOWJlMGUvdGFibGVyYW5nZTo2NjMwNTlhYTEyZWI0OGM1OTI5ZDNjZTUwYmI5YmUwZV8xMS0yLTEtMS0yNDYyNjM_f3a26945-b0cd-404e-90ea-70ff7b7bd69b">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDM3_9b0cbba3-587f-4689-bd59-e4201a17dc58">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ1_4e9ef0b0-9926-47e5-8d03-c5430256076d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8wLTAtMS0xLTI0NjI2Mw_9c4c50ea-7e07-489f-ab07-1467ef556af1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8xLTctMS0xLTI0NjI2Mw_e821753e-76e5-455d-b227-b1b088e2ea72">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6MTVmYTQxN2U4NDBiNDc3ZjhlODg2MWI5NzY0NTFmYzAvdGFibGVyYW5nZToxNWZhNDE3ZTg0MGI0NzdmOGU4ODYxYjk3NjQ1MWZjMF8yLTctMS0xLTI0NjI2Mw_be1da75d-2e9e-4449-ab3f-33ba46baa759">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGV4dHJlZ2lvbjoxMWI3OWRjNjM1MjE0YzJmOTUyMGUxNTYwM2M2ZTNkM18yMDQ3_9fb80416-d08a-49ed-91f8-c30c9db724dc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i42ff8c3480034649af99d9e4b0f62406_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xL2ZyYWc6MTFiNzlkYzYzNTIxNGMyZjk1MjBlMTU2MDNjNmUzZDMvdGFibGU6ZGJkYzRmOGE0MmZlNGRiNGExMmE5ZjNiYWQyMWUxOGYvdGFibGVyYW5nZTpkYmRjNGY4YTQyZmU0ZGI0YTEyYTlmM2JhZDIxZTE4Zl8xLTItMS0xLTI0NjI2Mw_8257dbbb-2e28-493b-938f-7abd4aa9cd1d"
      unitRef="shares">949272933</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMi0xLTEtMS0yNDYyNjM_7b71abc2-0516-49a9-acc6-c84837ef3d49"
      unitRef="usd">6960000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMi0zLTEtMS0yNDYyNjM_e1758cf5-d9b1-4eaf-a995-d1400510ab44"
      unitRef="usd">7810000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNC0xLTEtMS0yNDYyNjM_d877dc93-fcb5-4d28-ac9f-9ad43a9c8472"
      unitRef="usd">1626700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNC0zLTEtMS0yNDYyNjM_21aa468f-81f9-48ea-857e-d83222588254"
      unitRef="usd">2072100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNS0xLTEtMS0yNDYyNjM_b9d25593-c40c-41cf-ad0a-c38a9370cfcf"
      unitRef="usd">1985100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNS0zLTEtMS0yNDYyNjM_a8400133-bd0d-4e1c-b5d2-232e95b4eed9"
      unitRef="usd">1610100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNi0xLTEtMS0yNDYyNjM_b7993d1a-4b61-48b3-874d-a197c24dfcb9"
      unitRef="usd">1749200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNi0zLTEtMS0yNDYyNjM_aeab0a9e-72e2-4437-a7f8-7007ff706725"
      unitRef="usd">1557900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNy0xLTEtMS0yNDYyNjM_213ddecc-db78-4f71-b291-981fa5cc30dd"
      unitRef="usd">105000000.0</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfNy0zLTEtMS0yNDYyNjM_bf6b77c5-9405-489d-83a6-06d768b2908e"
      unitRef="usd">165600000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfOS0xLTEtMS0yNDYyNjM_449d44ca-5bd8-47ad-beec-05ec75001f20"
      unitRef="usd">35700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfOS0zLTEtMS0yNDYyNjM_d4409b0a-0e3b-4a05-a825-799f4f158585"
      unitRef="usd">-350700000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTAtMS0xLTEtMjQ2MjYz_dea2cdda-41c6-4735-8ab7-336f2fee06c4"
      unitRef="usd">5430300000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTAtMy0xLTEtMjQ2MjYz_7b425efa-05bf-45cb-adc6-b53478b2da65"
      unitRef="usd">5756400000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTEtMS0xLTEtMjQ2MjYz_6f4861fb-202a-466b-b72e-b17e44cb6e4c"
      unitRef="usd">1529700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTEtMy0xLTEtMjQ2MjYz_4586a835-5dd1-47f6-9d98-8c22bcb6bf95"
      unitRef="usd">2053600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTItMS0xLTEtMjQ2MjYz_e6cfb438-2b68-4564-bdb7-f01b0a3021e9"
      unitRef="usd">184800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTItMy0xLTEtMjQ2MjYz_ea34c09b-f550-4479-9afd-c0f576c3b0ac"
      unitRef="usd">150700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTMtMS0xLTEtMjQ2MjYz_d593d4e7-1d67-42fa-80b5-244b61fdb8c5"
      unitRef="usd">1344900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTMtMy0xLTEtMjQ2MjYz_17a1d23a-591c-4127-baa0-550d4b7d4a74"
      unitRef="usd">1902900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTgtMS0xLTEtMjQ2MjYz_b0a9a1dd-67f9-432c-912c-4b7885616a3a"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMTgtMy0xLTEtMjQ2MjYz_145cf2fc-d703-458a-ae5e-0b7b83d2b579"
      unitRef="usdPerShare">2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjAtMS0xLTEtMjQ2MjYz_28f1ea59-79dd-4538-9ce5-fbcaa579de8b"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjAtMy0xLTEtMjQ2MjYz_870a0df2-dcef-459a-8d9a-1e1dd287da12"
      unitRef="usdPerShare">2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjQtMS0xLTEtMjQ2MjYz_dd7b3d5e-b7ae-4f93-96d6-5b9635914cb5"
      unitRef="shares">901000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjQtMy0xLTEtMjQ2MjYz_2cb027b7-7902-446c-a85f-f7139e7a95ab"
      unitRef="shares">903700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjUtMS0xLTEtMjQ2MjYz_581bcef1-bb65-4c1b-ac35-ef284444c564"
      unitRef="shares">903300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8xOS9mcmFnOjA1ZmEwZDdkYjI5NDQzMzM5NWQ3ZTdjYzZjMzY0YjhmL3RhYmxlOmNhOTdiZDQ3OGFmYzRkYWJhNjlhNGEwZGMyMDY5MTAxL3RhYmxlcmFuZ2U6Y2E5N2JkNDc4YWZjNGRhYmE2OWE0YTBkYzIwNjkxMDFfMjUtMy0xLTEtMjQ2MjYz_f7af531a-c494-4303-a543-b9852779940b"
      unitRef="shares">906400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMi0xLTEtMS0yNDYyNjM_d593d4e7-1d67-42fa-80b5-244b61fdb8c5"
      unitRef="usd">1344900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMi0zLTEtMS0yNDYyNjM_17a1d23a-591c-4127-baa0-550d4b7d4a74"
      unitRef="usd">1902900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMy0xLTEtMS0yNDYyNjM_431c0852-4d8d-4fd8-8553-fd3980b86916"
      unitRef="usd">67300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfMy0zLTEtMS0yNDYyNjM_f104c56b-f1c8-4383-89b5-8ab68a9f337a"
      unitRef="usd">117800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfNC0xLTEtMS0yNDYyNjM_71bb4432-e33e-4260-a000-aa140db02a72"
      unitRef="usd">1412200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yMi9mcmFnOjhhNmNjYjA4ZTFkNDQ3ZDVhODJiYjNiYTc3NDQzN2Q1L3RhYmxlOjY2YTQ3MTE4NGY1MDQ5ZTFhNDU3NjFkNDBmOTFiZjQyL3RhYmxlcmFuZ2U6NjZhNDcxMTg0ZjUwNDllMWE0NTc2MWQ0MGY5MWJmNDJfNC0zLTEtMS0yNDYyNjM_74071ba7-dd74-491c-9e80-1cfacca616fe"
      unitRef="usd">2020700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMy0xLTEtMS0yNDYyNjM_341139b8-4030-492b-a969-fe8dd4412c1f"
      unitRef="usd">3545900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMy0zLTEtMS0yNDYyNjM_4ea3b86a-a56c-413a-9ef1-448148b1e18b"
      unitRef="usd">2067000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNC0xLTEtMS0yNDYyNjM_f2057217-8061-46c6-a039-0a5f18310c1a"
      unitRef="usd">123400000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNC0zLTEtMS0yNDYyNjM_43ba1f34-6b11-48fe-b553-4a8e0c4d041d"
      unitRef="usd">144800000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0wLTEtMS0yNDYyNjMvdGV4dHJlZ2lvbjpkOGQyNmYyMzkxZTk0OTVkYWI2ZGIzMjUzZmI2NTgzMl80Nw_c75c96f6-189c-4825-bcc7-177f2141b20b"
      unitRef="usd">14000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0wLTEtMS0yNDYyNjMvdGV4dHJlZ2lvbjpkOGQyNmYyMzkxZTk0OTVkYWI2ZGIzMjUzZmI2NTgzMl82MA_9060ae71-c8e9-4022-a800-601c3979a22e"
      unitRef="usd">16000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0xLTEtMS0yNDYyNjM_72a21dfa-c0fe-4e8c-8b2c-a8bc2fae16b2"
      unitRef="usd">7526200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNS0zLTEtMS0yNDYyNjM_5d71f6ff-3cc3-4b83-b890-4ebcdb578ff1"
      unitRef="usd">6896000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNi0xLTEtMS0yNDYyNjM_d1c4bc1b-1dbc-47f7-9c4c-b2d818a4697f"
      unitRef="usd">1495900000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNi0zLTEtMS0yNDYyNjM_ac47af60-3e69-48b3-a7fd-d5f934a25ab5"
      unitRef="usd">1662900000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNy0xLTEtMS0yNDYyNjM_84450690-0c3c-436e-9886-62d3791d52e0"
      unitRef="usd">4544800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNy0zLTEtMS0yNDYyNjM_26c571e5-7db4-4f90-bfac-26573bfaac15"
      unitRef="usd">4309700000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOC0xLTEtMS0yNDYyNjM_264446b4-73ff-4e0b-8da1-99bd9e45a537"
      unitRef="usd">3575200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOC0zLTEtMS0yNDYyNjM_5f8f4f08-61ad-4ada-83d7-89fd8fee4238"
      unitRef="usd">2954100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOS0xLTEtMS0yNDYyNjM_8b01cde4-e06b-4946-ae68-c5d6782f2c01"
      unitRef="usd">20811400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfOS0zLTEtMS0yNDYyNjM_c59f5dea-69ea-4f67-81e4-19f7cad757e6"
      unitRef="usd">18034500000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTAtMS0xLTEtMjQ2MjYz_e068b5ac-d11f-472c-ad01-1181b2c55182"
      unitRef="usd">2750400000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTAtMy0xLTEtMjQ2MjYz_22548887-ad8f-476a-a253-4e3d71d73cc0"
      unitRef="usd">2901800000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTEtMS0xLTEtMjQ2MjYz_709e1125-7ec4-4875-bf12-5fa7ccdd7d11"
      unitRef="usd">4073100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTEtMy0xLTEtMjQ2MjYz_28b737d0-18fb-4727-a4ba-45f3408d7b04"
      unitRef="usd">4073000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTItMS0xLTEtMjQ2MjYz_0e900319-4dc3-4bbc-9f34-c0d7a11b1bd7"
      unitRef="usd">7087100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTItMy0xLTEtMjQ2MjYz_2af41bc4-f4e2-41f8-baeb-a4ad49a2ccc7"
      unitRef="usd">7206600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTMtMS0xLTEtMjQ2MjYz_066f41c8-08c6-4f8b-904e-a2fa80a764cf"
      unitRef="usd">3406700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTMtMy0xLTEtMjQ2MjYz_d80e2f67-7f61-411f-a93d-ccc010c35322"
      unitRef="usd">2792900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMC0xLTEtMjQ2MjYzL3RleHRyZWdpb246NTM4NmJiYjNhMjU2NGRiOTg4MDIxNTVlOWJmMGM2NjBfNjM_bc3fc5c1-8f07-4642-8a3c-41d3d8667938"
      unitRef="usd">10486000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMC0xLTEtMjQ2MjYzL3RleHRyZWdpb246NTM4NmJiYjNhMjU2NGRiOTg4MDIxNTVlOWJmMGM2NjBfNzU_1ca5a11d-9050-4064-8bd9-dc8a464f9c8d"
      unitRef="usd">10233400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMS0xLTEtMjQ2MjYz_14bc75a8-93be-4923-af0a-f37fd12bcc3f"
      unitRef="usd">10546200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTQtMy0xLTEtMjQ2MjYz_2a98d60c-40bd-459c-ab74-da82ad89b80d"
      unitRef="usd">10144000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTUtMS0xLTEtMjQ2MjYz_76966e60-f532-403c-9861-1708e7f63819"
      unitRef="usd">4488100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTUtMy0xLTEtMjQ2MjYz_4dc796e9-cdb5-48a7-b767-419678dd97b1"
      unitRef="usd">4337000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTYtMS0xLTEtMjQ2MjYz_ca00794e-0cab-49bb-9be0-9cbfb4b2700f"
      unitRef="usd">53163000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTYtMy0xLTEtMjQ2MjYz_1a30b059-6b34-4b1a-b7b8-0158dcf6e74d"
      unitRef="usd">49489800000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTktMS0xLTEtMjQ2MjYz_46f7f080-58b6-4cc3-a7e2-124ce3b087ae"
      unitRef="usd">3100000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMTktMy0xLTEtMjQ2MjYz_70803f64-645e-4450-8009-32891444ade2"
      unitRef="usd">1501100000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjAtMS0xLTEtMjQ2MjYz_f5f282c2-2acd-406b-8079-a8859156e4e1"
      unitRef="usd">2015900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjAtMy0xLTEtMjQ2MjYz_6bb79a39-3932-49e5-96e7-3c487ef69657"
      unitRef="usd">1930600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjEtMS0xLTEtMjQ2MjYz_4116fd9d-ea92-46de-9397-1f85b1b87c47"
      unitRef="usd">739700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjEtMy0xLTEtMjQ2MjYz_1b941a70-cae2-4da3-8d72-81ad40aa81fa"
      unitRef="usd">1059800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjItMS0xLTEtMjQ2MjYz_cf10fdc8-9a2f-4485-82fb-119d1c5f83f4"
      unitRef="usd">9529500000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjItMy0xLTEtMjQ2MjYz_51916739-c9d0-4bf9-8ea0-fa6657c93029"
      unitRef="usd">8784100000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjMtMS0xLTEtMjQ2MjYz_4f473932-9190-432a-baba-2813de8ee23e"
      unitRef="usd">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjMtMy0xLTEtMjQ2MjYz_0f92ca19-c93a-4de2-9cc5-7ae1466abab2"
      unitRef="usd">1017200000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjQtMS0xLTEtMjQ2MjYz_124de0e1-c9b0-4d7c-b879-09a642da88eb"
      unitRef="usd">1528300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjQtMy0xLTEtMjQ2MjYz_28c0d9e5-4d54-4bc1-ad5f-294e4638ccc3"
      unitRef="usd">475100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjUtMS0xLTEtMjQ2MjYz_0ab75143-c67c-4f43-acb9-8f74462a2d0d"
      unitRef="usd">2193500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjUtMy0xLTEtMjQ2MjYz_7f1d78ca-ec53-4033-87b0-c798d37cde09"
      unitRef="usd">2370300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjYtMS0xLTEtMjQ2MjYz_9dcc427b-9e68-4641-82a3-8c0e94a7e003"
      unitRef="usd">16010000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjYtMy0xLTEtMjQ2MjYz_042077c3-a9f6-4478-b16a-8dd207913397"
      unitRef="usd">17138200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjgtMS0xLTEtMjQ2MjYz_be6bd450-74d1-40ee-a9b9-c6de949bba67"
      unitRef="usd">18880500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjgtMy0xLTEtMjQ2MjYz_47321fe3-026b-48a4-8a03-620438c15621"
      unitRef="usd">14737500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjktMS0xLTEtMjQ2MjYz_c6ca8285-a194-4083-90f5-acd3d1e02d4d"
      unitRef="usd">1313000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMjktMy0xLTEtMjQ2MjYz_9f693368-bd1a-4f20-b478-4320ca35772e"
      unitRef="usd">1305100000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzAtMS0xLTEtMjQ2MjYz_b7a73c0f-00d3-41d3-a3c1-4a1481cffe5f"
      unitRef="usd">3842100000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzAtMy0xLTEtMjQ2MjYz_6a5216ce-9b8a-4d4a-9601-3668a2eb645b"
      unitRef="usd">3709600000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzItMS0xLTEtMjQ2MjYz_33abc0a0-d561-436a-b321-6a1e6048a684"
      unitRef="usd">1822500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzItMy0xLTEtMjQ2MjYz_0753a8d9-6813-4493-8fd3-4fb2ac19e658"
      unitRef="usd">1824000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzMtMS0xLTEtMjQ2MjYz_8eaed607-6aff-41b8-a4c5-d102b1788403"
      unitRef="usd">25858100000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzMtMy0xLTEtMjQ2MjYz_cca19963-cae1-4aa3-b7c5-7392efff6c46"
      unitRef="usd">21576200000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzQtMS0xLTEtMjQ2MjYz_aa6348db-59e6-4b8b-b635-36593c5cdbfb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzQtMy0xLTEtMjQ2MjYz_84d8127c-0401-47ee-bd88-7d42161e355a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzYtMS0xLTEtMjQ2MjYz_f8ee7b3d-2cd0-4888-aefe-9a0e1ed7c653"
      unitRef="usd">593500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzYtMy0xLTEtMjQ2MjYz_16bdbbcd-69bd-4475-ba97-00f4125b6476"
      unitRef="usd">594100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzctMS0xLTEtMjQ2MjYz_6b561e73-f2c6-4098-8294-56619860883c"
      unitRef="usd">6793100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzctMy0xLTEtMjQ2MjYz_088254fc-e1ef-4a43-8a15-56327f4206e3"
      unitRef="usd">6921400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzgtMS0xLTEtMjQ2MjYz_cb980380-591e-4154-9822-9ac0a5d2f6e0"
      unitRef="usd">10639300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzgtMy0xLTEtMjQ2MjYz_cb16c103-e91c-448b-b5a4-f2f08edb3199"
      unitRef="usd">10042600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzktMS0xLTEtMjQ2MjYz_711d0919-34b7-48d8-a580-14812d0ea1d2"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfMzktMy0xLTEtMjQ2MjYz_7cc4a2a3-cedd-4db8-b3cf-de208890f760"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDAtMS0xLTEtMjQ2MjYz_968c77d4-a5ee-4c64-87ed-89eeb6042f58"
      unitRef="usd">-3777300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDAtMy0xLTEtMjQ2MjYz_107c4d27-3c39-4aba-84c7-f6207aa7ee40"
      unitRef="usd">-3844600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDEtMS0xLTEtMjQ2MjYz_363f02e9-a92a-4ffe-bc4d-6979f368b685"
      unitRef="usd">45000000.0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDEtMy0xLTEtMjQ2MjYz_36d2e0ea-e9ba-46e7-bd1e-390b6843492b"
      unitRef="usd">50500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDItMS0xLTEtMjQ2MjYz_4bdf6bb9-f969-4349-8a58-875e1f90d657"
      unitRef="usd">11190400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDItMy0xLTEtMjQ2MjYz_f249bcdc-c6b9-4501-add4-6b34dc1637ca"
      unitRef="usd">10649800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDMtMS0xLTEtMjQ2MjYz_9a6c9131-794a-4209-8d1d-0a49f213e7e7"
      unitRef="usd">104500000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDMtMy0xLTEtMjQ2MjYz_fb797967-4485-4714-b99b-d29ed246315f"
      unitRef="usd">125600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDQtMS0xLTEtMjQ2MjYz_1da68fc5-5347-4fa5-9334-b19ade40e41a"
      unitRef="usd">11294900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDQtMy0xLTEtMjQ2MjYz_39b0c1d8-f8cb-4c39-bd7e-39162960f342"
      unitRef="usd">10775400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDUtMS0xLTEtMjQ2MjYz_aa3054ca-3f5d-4385-8eca-d15c7684ee0f"
      unitRef="usd">53163000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yNS9mcmFnOmFhYjVlYWE2ZjgzODQwZWM4OGU5ZThhMDQxYzFhMTIzL3RhYmxlOmNhMjQ3MGZkMTI2MjRjZjdhMmY0N2U1YTAxZDQ2NDYxL3RhYmxlcmFuZ2U6Y2EyNDcwZmQxMjYyNGNmN2EyZjQ3ZTVhMDFkNDY0NjFfNDUtMy0xLTEtMjQ2MjYz_d19e29dc-8f7f-4d66-9501-9f175f83176f"
      unitRef="usd">49489800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xLTEtMS0yNDYyNjM_788a7be3-49ad-4a9b-8177-8ab03b92389f"
      unitRef="shares">954116000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0zLTEtMS0yNDYyNjM_6fac41c9-0b7e-47fe-b985-afde23838f4f"
      unitRef="usd">596300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b2d9ab3c1794f1d8b361cd95d702eb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy01LTEtMS0yNDYyNjM_22294fc6-2e9a-43c3-af65-99e3d443b4f6"
      unitRef="usd">6833400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf9b65901614ec99ac3f7f3cf96ba0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy03LTEtMS0yNDYyNjM_de1befc8-9cc0-4f49-8845-e6c5dc267f86"
      unitRef="usd">8958500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3db0e5f4479b4590a17a13660ba7120f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy05LTEtMS0yNDYyNjM_bc260d35-5241-4066-b9cd-3a20de8a06a5"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaef6a6bd5dd4d8bb6af6b8e7f16c197_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMS0xLTEtMjQ2MjYz_5ecec8f8-136e-4965-a078-6be6e5de478a"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7656e7caa28247f39bd611bc66416bd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673"
      unitRef="shares">463000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7656e7caa28247f39bd611bc66416bd7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95753ad64fa24dfc9db4020a919ed2e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNy0xLTEtMjQ2MjYz_3e7c5275-4244-4eac-859d-d3898e7fbbae"
      unitRef="usd">175600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNC03LTEtMS0yNDYyNjM_bec454cb-9dfa-4f46-a23d-cd758b50ceb9"
      unitRef="usd">1902900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNC0xNy0xLTEtMjQ2MjYz_f1e7d27b-ffb9-4132-93d7-e1b6f7ed5617"
      unitRef="usd">-36600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9c601fdfc135468b9efa7eeeaaf2bbdc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfNS0xMS0xLTEtMjQ2MjYz_d62a331c-8844-492e-8b93-a75058ead15b"
      unitRef="usd">117800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xLTEtMS0yNDYyNjM_1f816b57-d65d-4cb6-8d72-50b059630207"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0zLTEtMS0yNDYyNjM_43626a72-2ffe-47fa-a2e9-4edf53ceb99c"
      unitRef="usd">3500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC03LTEtMS0yNDYyNjM_87026b9f-0b47-4d62-ba32-d3f7ce95214b"
      unitRef="usd">1496500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2"
      unitRef="usd">-1500000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0"
      unitRef="shares">5607000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3"
      unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMS0xLTEtMjQ2MjYz_a775202d-4838-4fca-add6-3e5cc1ef7348"
      unitRef="shares">2096000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ice75a6bb3af34d868a06de9b5e108df9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMy0xLTEtMjQ2MjYz_2b33ce06-d3bb-4b5c-afcf-3388be7f2841"
      unitRef="usd">1300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtNS0xLTEtMjQ2MjYz_b14b3af3-35bb-4e66-b5eb-1cea49b13f70"
      unitRef="usd">-278100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020"
      unitRef="shares">-13000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6194321ca8574cdfa85d1688462e5742_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a"
      unitRef="usd">2200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a52ef1b5b84497b9ec8b31a96873f90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTEtNS0xLTEtMjQ2MjYz_1398406b-8aa1-496a-8086-806bf0f6da80"
      unitRef="usd">101000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="id978959344a247b69b4db196a5f33b07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTMtNy0xLTEtMjQ2MjYz_e1435be1-4812-4bb7-94be-06f030e0265c"
      unitRef="usd">-4500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i43a17a6d0b354d1aa053265a3c1e5007_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTMtMTctMS0xLTI0NjI2Mw_eb8c3bd0-ca03-4355-a459-f55cfd03b36e"
      unitRef="usd">7800000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i50a04715762e44a39f3f2505d74a6ea1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMS0xLTEtMjQ2MjYz_3e3e6429-faa2-4ae1-a1b0-c473c2c742d9"
      unitRef="shares">950605000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50a04715762e44a39f3f2505d74a6ea1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMy0xLTEtMjQ2MjYz_a45a66fd-97f2-410d-8540-f55665e36f45"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2186586b7322416183b886001b72303f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtNS0xLTEtMjQ2MjYz_b977e204-b892-4282-9e51-4a4e28db0c5a"
      unitRef="usd">6656300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3148a12fb5994593a755fff70b7d4470_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtNy0xLTEtMjQ2MjYz_2d68e6d0-6e59-4c81-865f-a8957ef33861"
      unitRef="usd">9369400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16887cea932f44c3a6088e33ecfb7490_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtOS0xLTEtMjQ2MjYz_ddc3237d-bd23-493c-9667-74b96dabe760"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f8048a6c27248afac7fffd0fe38b008_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTEtMS0xLTI0NjI2Mw_1f60487c-e214-4df1-8325-cd40b52455d8"
      unitRef="usd">-4225300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib2097ff769544728b3e0e7f64451512e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2097ff769544728b3e0e7f64451512e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3edace87bee46b0bf89263a4a4be3b1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTctMS0xLTI0NjI2Mw_77e913b7-69a3-4dcd-8345-da4a010d72ad"
      unitRef="usd">131200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c67213efc434eb9ac796a4c1a04c8da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMS0xLTEtMjQ2MjYz_29471574-c48a-4c86-a226-2662ab8b5216"
      unitRef="shares">950632000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c67213efc434eb9ac796a4c1a04c8da_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMy0xLTEtMjQ2MjYz_18f45a21-d29f-4804-9977-4fec647e3e86"
      unitRef="usd">594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc8dbf8ede644257a18c8621fa65c557_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtNS0xLTEtMjQ2MjYz_d56962df-07dc-4f5e-a0ab-da90e2f519ef"
      unitRef="usd">6921400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic813de36efc74513bd64da94a269adfe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtNy0xLTEtMjQ2MjYz_aad3d355-5599-48f1-9770-8e741a78af5a"
      unitRef="usd">10042600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i188c9e0e0deb45c7ac4c04ec58fafeae_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtOS0xLTEtMjQ2MjYz_076e4922-95a1-488b-af18-b51567230d55"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib68e310320e9466d8f5ba3eb98d90284_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTEtMS0xLTI0NjI2Mw_52012914-e3ae-4faf-8561-ca004d88d99f"
      unitRef="usd">-3844600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606"
      unitRef="shares">450000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc26ae3210374c3091d7fa7aa02ec20f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622"
      unitRef="usd">-50500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i637339e89f374f98959ff8ae6e6501d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTctMS0xLTI0NjI2Mw_81ff4ff1-edfd-4ad6-a64d-7441252e88ff"
      unitRef="usd">125600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTctNy0xLTEtMjQ2MjYz_ac9e5e50-5edf-4244-bc9b-0b35bdba40ba"
      unitRef="usd">1344900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTctMTctMS0xLTI0NjI2Mw_1613c1aa-8a7b-4e54-852f-a0089caa2b5d"
      unitRef="usd">10000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i439164f165d34e9bb97df6c5e992ff8b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTgtMTEtMS0xLTI0NjI2Mw_68e57724-9011-4854-88c4-8f5b242b5808"
      unitRef="usd">67300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMS0xLTEtMjQ2MjYz_f04c4be6-f203-4fc6-8a7d-f3f5f5f68158"
      unitRef="shares">2299000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMy0xLTEtMjQ2MjYz_c3a255b4-458b-404c-a9a6-aca995cc285e"
      unitRef="usd">1400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtNy0xLTEtMjQ2MjYz_4ad1acb4-b5a7-4ff8-bcaa-535bf74338a2"
      unitRef="usd">748600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2"
      unitRef="shares">2299000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf"
      unitRef="usd">-750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271"
      unitRef="shares">2299000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMS0xLTEtMjQ2MjYz_1bc5b45c-40be-4c7d-80fd-1edc256e54d4"
      unitRef="shares">1336000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if8eb35a1976a4fda94db120a91b4a44e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMy0xLTEtMjQ2MjYz_6b51c4e2-2321-4e17-860c-7ab6093ec0c0"
      unitRef="usd">800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItNS0xLTEtMjQ2MjYz_d7319568-0c3b-4638-a582-e7135d42b747"
      unitRef="usd">-259500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6"
      unitRef="shares">-48000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978"
      unitRef="usd">8800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie0b879d9117143c993a7f0cff9be961a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjMtNS0xLTEtMjQ2MjYz_f4171d19-0669-4819-a386-c1bff24424a4"
      unitRef="usd">131200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i9dc4325f3a49469eb34ce8b20b3beaea_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtNy0xLTEtMjQ2MjYz_11fa4709-2198-431a-bf09-340837237a89"
      unitRef="usd">-400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if684f40112064b11b340468506a32fa3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtMTUtMS0xLTI0NjI2Mw_b5fcb825-25eb-4c3c-a678-6818d0849108"
      unitRef="usd">3300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib66d4fbd238b4b88a2bf75b8a98c06c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjQtMTctMS0xLTI0NjI2Mw_0d5bf8b9-5945-4292-9b9b-0fffeadee1ad"
      unitRef="usd">31100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMS0xLTEtMjQ2MjYz_82c11aaa-d1af-4555-84cc-e9cdc7e64e9f"
      unitRef="shares">949669000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9579489f8d3040789b3f0aceb9c9f8eb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMy0xLTEtMjQ2MjYz_8371939d-a520-40a2-a240-5baaa1bec655"
      unitRef="usd">593500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc91a78b7e994d8a828ad6accd7e7eb9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtNS0xLTEtMjQ2MjYz_d4d2eb97-886f-4156-9de3-682b69ec1fa0"
      unitRef="usd">6793100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie33c470d29b348aaaf9cacc62407b9b1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtNy0xLTEtMjQ2MjYz_77f5a716-e638-49c3-9a88-b8e9ad25dc53"
      unitRef="usd">10639300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66f1bc66163b41baa48cbf1328b78bbc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtOS0xLTEtMjQ2MjYz_62a20c12-20b4-4d66-98fe-0cfad6cf52b3"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ae9598be4a64cd69d5667e9e70ca761_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTEtMS0xLTI0NjI2Mw_12ff479e-a9f1-4133-869c-bb9915703ea0"
      unitRef="usd">-3777300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i153592c1af1f4910bf06d43f543dcc71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f"
      unitRef="shares">402000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i153592c1af1f4910bf06d43f543dcc71_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5"
      unitRef="usd">-45000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89e11d3a40394c318b16109c7c0fecf6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTctMS0xLTI0NjI2Mw_73e00f8a-8fb7-4206-9a85-0abe1195be5c"
      unitRef="usd">104500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMTI2_62140bf1-54af-4617-829d-72564082bc91"
      unitRef="usd">2500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6e757fc239f4499e91acfaeb16335063_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMTQ5_8b558f14-6334-41d3-a565-122e863b8e37"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMy0xLTEtMS0yNDYyNjM_1cb1196f-b2a7-476a-ad77-9fff48b28189"
      unitRef="usd">1344900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMy0zLTEtMS0yNDYyNjM_fd0af7f2-d0eb-4326-9599-26af0bab2156"
      unitRef="usd">1902900000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNi0xLTEtMS0yNDYyNjM_78bb8f7e-706f-4889-88b6-0be6743ff430"
      unitRef="usd">362300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNi0zLTEtMS0yNDYyNjM_a64d330d-fb2d-435c-872e-53b20137d6f9"
      unitRef="usd">435700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNy0xLTEtMS0yNDYyNjM_73069978-78c8-41af-b7b8-80622f2b8aea"
      unitRef="usd">559400000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNy0zLTEtMS0yNDYyNjM_c225658b-78c8-463c-9dfb-84e0c435f472"
      unitRef="usd">506600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfOS0xLTEtMS0yNDYyNjM_f861715e-7cb3-4ed1-82a1-0e91f0d663b4"
      unitRef="usd">131200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfOS0zLTEtMS0yNDYyNjM_faa7a6ca-3c4a-4f94-b26c-65098180fdbd"
      unitRef="usd">101000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTEtMS0xLTEtMjQ2MjYz_61d8122b-780f-4db9-89e2-b8cc9b41b29a"
      unitRef="usd">-14200000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTEtMy0xLTEtMjQ2MjYz_a7347b8a-f80c-4dca-803e-00ca486ecb96"
      unitRef="usd">-426100000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTItMS0xLTEtMjQ2MjYz_b2c8f983-8368-425e-877d-6acfec10f1bd"
      unitRef="usd">105000000.0</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTItMy0xLTEtMjQ2MjYz_d446b70b-f1de-4b62-ba2e-572e092d8089"
      unitRef="usd">165600000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTMtMS0xLTEtMjQ2MjYz_093a8526-d222-41d8-b34c-3c49344a6406"
      unitRef="usd">-164100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTMtMy0xLTEtMjQ2MjYz_c4b1900c-dfeb-4bc6-ac96-fe17795922d0"
      unitRef="usd">34300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTQtMS0xLTEtMjQ2MjYz_8047e388-04d0-4f7c-9719-68a84bf9a8ba"
      unitRef="usd">168300000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTQtMy0xLTEtMjQ2MjYz_b29713b0-ce66-4d91-92b3-d072b73c29f2"
      unitRef="usd">32600000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTUtMS0xLTEtMjQ2MjYz_c27c3855-f29e-4753-b684-7a05707d70a1"
      unitRef="usd">1730600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTUtMy0xLTEtMjQ2MjYz_57a195ff-02cc-4de3-b719-a956495077e2"
      unitRef="usd">2523000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTctMS0xLTEtMjQ2MjYz_75d520d2-e6bc-414a-9ad0-b5dc6ec73b11"
      unitRef="usd">668500000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTctMy0xLTEtMjQ2MjYz_5f07ba16-f660-4215-b4ab-3be7a1d85bf4"
      unitRef="usd">365400000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTgtMS0xLTEtMjQ2MjYz_502b2ef7-9f88-4335-a4e2-1a02e4983a38"
      unitRef="usd">61500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTgtMy0xLTEtMjQ2MjYz_387fd437-ffbe-4b68-91c6-fc9cb5c943b0"
      unitRef="usd">26700000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTktMS0xLTEtMjQ2MjYz_d4f7a058-ce42-4865-8d67-28d7ab97efed"
      unitRef="usd">23000000.0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMTktMy0xLTEtMjQ2MjYz_9530eda6-8c39-4a71-8fc9-ea56ac72ed36"
      unitRef="usd">14600000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjAtMS0xLTEtMjQ2MjYz_ce512557-582a-484f-88d6-7b7f18732aa1"
      unitRef="usd">281900000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjAtMy0xLTEtMjQ2MjYz_aeeb598f-2338-42d6-a3aa-f7088b1b9aa5"
      unitRef="usd">81400000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjEtMS0xLTEtMjQ2MjYz_b4e62995-c80e-46da-bb02-951254778733"
      unitRef="usd">146000000.0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjEtMy0xLTEtMjQ2MjYz_2a4333d3-b872-4709-b828-5d90c0ff82c7"
      unitRef="usd">116700000</us-gaap:PaymentsToAcquireOtherInvestments>
    <lly:PurchasesOfInProcessResearchAndDevelopment
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjQtMS0xLTEtMjQ2MjYz_94aebea1-ab55-4d8b-84b6-c9f870cc8aeb"
      unitRef="usd">235000000.0</lly:PurchasesOfInProcessResearchAndDevelopment>
    <lly:PurchasesOfInProcessResearchAndDevelopment
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjQtMy0xLTEtMjQ2MjYz_0dc6ef2e-1766-4e93-8b08-8b41338fb3db"
      unitRef="usd">515600000</lly:PurchasesOfInProcessResearchAndDevelopment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjUtMS0xLTEtMjQ2MjYz_f5afc049-0334-4e59-8ee6-787370371a2c"
      unitRef="usd">-40300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjUtMy0xLTEtMjQ2MjYz_0ae4af4f-94d3-4131-a384-67309fbaae4f"
      unitRef="usd">133400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjYtMS0xLTEtMjQ2MjYz_112d89e0-a568-4848-9bb1-aba8bc158c89"
      unitRef="usd">-688800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjYtMy0xLTEtMjQ2MjYz_f047cdf3-bfed-4fdc-bdd9-ccfd5fdbbbf3"
      unitRef="usd">-1037600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjgtMS0xLTEtMjQ2MjYz_f073194e-3894-427f-aa5e-37bb83bba768"
      unitRef="usd">1017200000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjgtMy0xLTEtMjQ2MjYz_0ac262a1-884f-4ca4-804a-099465e850b5"
      unitRef="usd">885500000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjktMS0xLTEtMjQ2MjYz_cea8427c-93a5-49ac-9957-dbf774a7765d"
      unitRef="usd">-1498000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMjktMy0xLTEtMjQ2MjYz_cd1a3b88-7b68-4fa0-aef4-d016ace23aeb"
      unitRef="usd">499700000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzAtMS0xLTEtMjQ2MjYz_7456ef5a-fe04-484a-a683-502c9b78d2a7"
      unitRef="usd">3958500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzAtMy0xLTEtMjQ2MjYz_8d6c2e70-4b83-4014-8b45-2e7739c5ab5b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzEtMS0xLTEtMjQ2MjYz_a2297274-6135-4405-a42b-ca82a06f483b"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzEtMy0xLTEtMjQ2MjYz_1601a976-5109-4095-9c15-b7be2cb57218"
      unitRef="usd">710100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzItMS0xLTEtMjQ2MjYz_5c56a282-53bf-484a-a95d-349a875d7443"
      unitRef="usd">750000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzItMy0xLTEtMjQ2MjYz_38166322-fa38-4744-b245-eaf2e1d77247"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzQtMS0xLTEtMjQ2MjYz_06de43ab-4f09-4cdc-a543-2e8f3ef491d4"
      unitRef="usd">-281000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzQtMy0xLTEtMjQ2MjYz_518bbd47-ca4b-4004-a170-bb491a65ed42"
      unitRef="usd">-282400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzUtMS0xLTEtMjQ2MjYz_23b50dce-4887-4e93-b996-11049a2612e6"
      unitRef="usd">412300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzUtMy0xLTEtMjQ2MjYz_a42cbdc0-3350-449f-b230-2087dc485930"
      unitRef="usd">-2878300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzYtMS0xLTEtMjQ2MjYz_1f7ada39-7963-4743-a990-37a20911977a"
      unitRef="usd">24800000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzYtMy0xLTEtMjQ2MjYz_ede130d2-8e6e-4c92-a311-1a2985751ac8"
      unitRef="usd">33600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzgtMS0xLTEtMjQ2MjYz_5f9bb384-c384-4247-99db-a78c57df9829"
      unitRef="usd">1478900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzgtMy0xLTEtMjQ2MjYz_70d3b02d-85d9-410a-8cca-c538a5b0e9ab"
      unitRef="usd">-1359300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzktMS0xLTEtMjQ2MjYz_c766b674-199e-4172-8e0a-0387bdc85165"
      unitRef="usd">2067000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie7699e9bf7f941dcb048f29c3aada3b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfMzktMy0xLTEtMjQ2MjYz_06607aca-f1b6-4c3b-ac89-9739368ef35e"
      unitRef="usd">3818500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNDAtMS0xLTEtMjQ2MjYz_3daf9465-9abc-4774-8be2-902bb6144c31"
      unitRef="usd">3545900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic88d6c314da94d23b9e30802e9728044_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8zNC9mcmFnOjkzODZmZjM5MjJkYTQ0ODFhZTVlMDM1NmVmZTE0NmFmL3RhYmxlOjc5OWVhMTc2ZGU3ZTQ1YThiYjdiNTA2Y2FkZWM4ZjA0L3RhYmxlcmFuZ2U6Nzk5ZWExNzZkZTdlNDVhOGJiN2I1MDZjYWRlYzhmMDRfNDAtMy0xLTEtMjQ2MjYz_2d9b117b-9d86-49cf-8151-4adbcfd3f2a8"
      unitRef="usd">2459200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDE2OQ_4d8ccd0e-4cc2-4f68-9451-f016ec87add5">Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/lly-20221231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Form 10-K&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the year ended December&#160;31, 2022. We issued our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D includes the initial costs and development milestones incurred related to externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. Development milestone payments related to externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, were previously included in cash flows from operating activities in the consolidated condensed statements of cash flows and are now included in purchases of IPR&amp;amp;D in cash flows from investing activities. The reclassification resulted in an increase to net cash provided by operating activities and net cash used in investing activities of $23.8&#160;million for the three months ended March 31, 2022.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDE2NA_2f45f1f4-9e51-48d4-83b9-9ec5bf299af1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense, and fees paid to contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D includes the initial costs and development milestones incurred related to externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNQ_de891727-b040-410a-808b-4693400f6c97">ReclassificationsCertain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. Development milestone payments related to externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, were previously included in cash flows from operating activities in the consolidated condensed statements of cash flows and are now included in purchases of IPR&amp;amp;D in cash flows from investing activities.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib386950c303c4cfa991af56051f481c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNA_381e0f0c-43b2-429e-ae4f-48261dfe27c0"
      unitRef="usd">23800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib386950c303c4cfa991af56051f481c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80MC9mcmFnOmJlNTY1YTVmMDQwNDRhODM4NmMwZDljN2RiYWI1YjRhL3RleHRyZWdpb246YmU1NjVhNWYwNDA0NGE4Mzg2YzBkOWM3ZGJhYjViNGFfNDM5ODA0NjUyMTIyNA_422bc3d2-080e-4a50-9ecc-ea94a50af223"
      unitRef="usd">23800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzcwMA_7ea1bef3-783c-44a4-9d3b-e75ec8b59297">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,238.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;721.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three months ended March&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,547.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;429.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,977.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;329.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;577.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;536.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;568.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,075.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,115.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,190.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;180.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;753.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;602.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,356.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;527.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;354.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,455.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;275.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,436.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,436.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,090.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;387.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;673.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzY5NQ_c8f17dcd-049a-4b4d-aa46-d11f1f6ff801">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,238.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;721.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,547.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;429.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,977.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;329.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;248.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;577.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Mounjaro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;536.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;568.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;460.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,075.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,115.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,190.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;127.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;180.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;753.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;602.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,356.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;527.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;186.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;354.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;206.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,455.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;275.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,436.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,436.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,090.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;387.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;673.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,960.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,810.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i118b413e750a419a8eea249e9dec5ea8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMi0xLTEtMS0yNDYyNjM_25bcd39b-25ac-43ef-8ce6-efa0ae234c6c"
      unitRef="usd">6238200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49f70762797b4c7eb12579a57e4a0f1f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMi0zLTEtMS0yNDYyNjM_b4bbc33d-8686-42d7-a427-4e3957733c6c"
      unitRef="usd">7132900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41563e4306144d7db1ae5fab5a13d025_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMy0xLTEtMS0yNDYyNjM_364c9fc0-37b6-427d-a523-cdafbcf27bfc"
      unitRef="usd">721800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia45726ea3ba342708ad76343e7d8ea9a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfMy0zLTEtMS0yNDYyNjM_acaddd68-be75-4433-a6c4-d882f29fd810"
      unitRef="usd">677100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfNC0xLTEtMS0yNDYyNjM_4e9c6d69-5c4c-42de-aaab-8a2b6e7cbb10"
      unitRef="usd">6960000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOmI4MmI3Y2NmNGU0ZDRiZDQ4MzZiOTRiYWNmNDhmYzdlL3RhYmxlcmFuZ2U6YjgyYjdjY2Y0ZTRkNGJkNDgzNmI5NGJhY2Y0OGZjN2VfNC0zLTEtMS0yNDYyNjM_3f6a212d-bae7-4c34-a834-bbe80896f748"
      unitRef="usd">7810000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i776dd251590543c2aa2cb51a4dab931f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMjM3_38a499d2-eb89-4a59-8795-789769e7e70e"
      unitRef="usd">25100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1de368b269ea4b33baf0dc1ce490d43c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfNTQ5NzU1ODE3Njk2_300409f4-1fe4-4d10-a97f-5459f9d8a217"
      unitRef="usd">53200000</us-gaap:Revenues>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i8ba05d67547242b28419ed4e7793321c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMTQ3Mw_2b2acf87-a275-492c-bfef-bde55fb58e2d"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="if0cc6e06de26466c90d397554c65af18_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMTQ3Mw_73cb78ae-4328-42eb-8b9d-5123c6e00b30"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RleHRyZWdpb246NGJlMjhlZGQxNjY4NDFjMjhiODJjMThjYzcwMzY3MjRfMzY5Ng_0da280c4-6741-441c-99eb-9ae218a6ab08">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjdhYTQ3N2RhZjQyNTRlOWJhNjYwMWUwODZhYTU5YjIyL3RhYmxlcmFuZ2U6N2FhNDc3ZGFmNDI1NGU5YmE2NjAxZTA4NmFhNTliMjJfMS0xLTEtMS0yNDYyNjM_c1b22cc7-acb2-4901-a1a4-c390614e9f21"
      unitRef="usd">220300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjdhYTQ3N2RhZjQyNTRlOWJhNjYwMWUwODZhYTU5YjIyL3RhYmxlcmFuZ2U6N2FhNDc3ZGFmNDI1NGU5YmE2NjAxZTA4NmFhNTliMjJfMS0zLTEtMS0yNDYyNjM_dafa893e-946a-4f1f-ac7a-5cea7ffef3f5"
      unitRef="usd">219200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i1b0d2e9299804c05b2243243ee5f298f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0xLTEtMS0yNDYyNjM_91bd3301-19e3-47fa-b0af-5930dd810c78"
      unitRef="usd">1547400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e3800138a064caf84059e7b7ac1f59f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0yLTEtMS0yNDYyNjM_0d6e8cab-e316-450d-9583-fcae6a22f5fb"
      unitRef="usd">429700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88e8033ea6754341b21a71b5dd3e785c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS0zLTEtMS0yNDYyNjM_47861f79-cb3f-4203-b4ea-cc5f773abaf6"
      unitRef="usd">1977100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11dd59e0fdc74287873fca650e145c15_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS01LTEtMS0yNDYyNjM_ad1c42ac-fcc3-4377-83c0-9a6461f643fd"
      unitRef="usd">1313900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f4e39b3439c480c8742d89f8399bc82_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS02LTEtMS0yNDYyNjM_a64ec98a-5e48-46ce-b554-04e9502ae609"
      unitRef="usd">427400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id13290ff47804307a44e2f065e33dd7d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNS03LTEtMS0yNDYyNjM_e293b33e-875d-4329-a1f7-0eee1a234f51"
      unitRef="usd">1741300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifac33e8897674b85a6950df08eee5bf8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0xLTEtMS0yNDYyNjM_7a4f1b5f-23a4-49b1-846a-8ec7f02b939e"
      unitRef="usd">329400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a28a52e5fa34f38a6ecc947140b6edb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0yLTEtMS0yNDYyNjM_7f4e4454-5c4e-4064-bf27-84d5d15a24e1"
      unitRef="usd">248100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi0zLTEtMS0yNDYyNjM_9e453744-0f16-4d42-b455-2a333f27de56"
      unitRef="usd">577500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90a6d8bc4d434540ad95d77f973fa070_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi01LTEtMS0yNDYyNjM_9ca06592-571a-407a-9013-013a2723132a"
      unitRef="usd">229800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d89a91c0fbb4dd195707004ab1a00b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi02LTEtMS0yNDYyNjM_96db241f-d392-4b42-9c87-79391384b9b8"
      unitRef="usd">189700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNi03LTEtMS0yNDYyNjM_d56e4fa9-e4a9-46e5-89e4-4f3cf62afa31"
      unitRef="usd">419400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4783bd0e08d47d29ab78b3d697d290f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0xLTEtMS0yNjI2MzA_7dcbc679-3cd6-4d5f-baf9-a39c03a9043d"
      unitRef="usd">536400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c7662e4b8c740ebba1d408fa1765201_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0yLTEtMS0yNjI2MzA_2e2387b7-322d-47ed-a89c-2d876542e2e1"
      unitRef="usd">32000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97119da1943c4d1e95f0e996e9f315be_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0zLTEtMS0yNjI2MzA_fbfd47e2-c779-45d4-a86e-a30cf2ee8110"
      unitRef="usd">568500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3c27dd4f47b47239694dc03b4ecc6ad_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy01LTEtMS0yNjI2MzA_4839194a-8849-4db9-a634-10ec16e24087"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90e4c56100484d70a675bd288c597049_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy02LTEtMS0yNjI2MzA_48807874-5904-43e5-8edb-54ca7d4cb540"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf2f9585c7204b33beb2bc33724774a0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy03LTEtMS0yNjI2MzA_a1b5c104-e84c-4ae0-b188-26b7270ae6e2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id16fef32b8fb476596fe6c4d0bb25380_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0xLTEtMS0yNDYyNjM_9af69c5f-6ae4-4861-a3f2-c02c12af93eb"
      unitRef="usd">271600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i811218a96d2b41c0a71ad7a4b77e56b2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0yLTEtMS0yNDYyNjM_2633197c-00f8-4c6b-b8c5-141db2f2c484"
      unitRef="usd">189300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b94ba9dd63247d5b32ffa10006a021e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy0zLTEtMS0yNDYyNjM_37d569ba-6277-4e32-a78c-c7be40cad9a4"
      unitRef="usd">460900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id898a8a22f0e4880a5338b8467984755_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy01LTEtMS0yNDYyNjM_1f92bd7c-48f7-45c1-be66-56349fef00c3"
      unitRef="usd">368900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3450a514000e4564aed94e9856bd66d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy02LTEtMS0yNDYyNjM_a4d14368-8a84-4d7c-8d3a-093826e46cd2"
      unitRef="usd">249300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2bd2ba8150f4e69a8256ef87cc94d2d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNy03LTEtMS0yNDYyNjM_cad1b61f-cf0d-4563-b05a-e7cda99a015c"
      unitRef="usd">618200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb86385cc8eb4bed91738b3eec15d109_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0xLTEtMS0yNDYyNjM_bda70036-53fe-444a-959e-bf43c8c75afd"
      unitRef="usd">198800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d5f5c213bf74ee680df8883531a880e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0yLTEtMS0yNDYyNjM_03df56a2-3fbc-4c47-96df-6272a1edde26"
      unitRef="usd">53200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87ac73e33e864d3d85f05e179d6e0ab5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC0zLTEtMS0yNDYyNjM_f1922377-d703-4160-8713-ea75042b7110"
      unitRef="usd">252000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93975c00ca0e44ba99e88b2a02696fbb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC01LTEtMS0yNDYyNjM_7d83d022-02c9-4fc5-8faa-8fb6fad10e60"
      unitRef="usd">190400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41870e267fbe402dad822ec24c06b44f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC02LTEtMS0yNDYyNjM_138664e6-e6d7-4ee2-b2e5-ef61bcab0fbf"
      unitRef="usd">82800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39805ee81eec439aa8c2e397f5508410_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOC03LTEtMS0yNDYyNjM_190cf235-7e69-41a6-9f4d-aad939944e12"
      unitRef="usd">273200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4655d36440574fbeab0c91fc7b019703_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0xLTEtMS0yNDYyNjM_38f92685-72b5-4d2e-8ca4-17b7cfaf438e"
      unitRef="usd">135400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44114472bba24a3b91861ccdbb5b23ed_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0yLTEtMS0yNDYyNjM_8e0bf244-69b8-4ccc-babc-be5b451bbbd2"
      unitRef="usd">73900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS0zLTEtMS0yNDYyNjM_9f3ac19a-040a-4f01-a141-9eab10f9514d"
      unitRef="usd">209300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d1aed3d8f0c4cb293c37cdc3196c8d8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS01LTEtMS0yNDYyNjM_51492cfe-3a50-425c-bf6f-32ac44a8be2e"
      unitRef="usd">119300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eee894daf9648e981d2c1b49f7448e5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS02LTEtMS0yNDYyNjM_fc60ed39-ce2a-4791-99ec-85be7f0bdea6"
      unitRef="usd">72200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfOS03LTEtMS0yNDYyNjM_62d820c8-b9e1-4212-9602-4b275f323165"
      unitRef="usd">191500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43ff4b5d9df8493fbd95a0e88fe1cc78_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMS0xLTEtMjQ2MjYz_efbf96a7-31a9-443e-8d6a-24451de60840"
      unitRef="usd">56000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4dc93a102494bcdb03aacc7bbba37f8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMi0xLTEtMjQ2MjYz_c9832a14-b3d7-4fd3-ab7b-43c5a69dbf58"
      unitRef="usd">89200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3506079381447bd842f668fa1edf8bc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtMy0xLTEtMjQ2MjYz_8bbb8e98-db84-424b-84f1-b20ba24bd64a"
      unitRef="usd">145100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib67d2dd261224805ac90f2f1b66659e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNS0xLTEtMjQ2MjYz_6e33b2af-205f-4a2f-b1b2-8766ea718787"
      unitRef="usd">54300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2548d402f8348a19d3cdabfabed7bbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNi0xLTEtMjQ2MjYz_2b766747-0a8e-4ad6-821c-5d73d69f2b0b"
      unitRef="usd">90200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8ee45c4c43e47b6a8bf88847481e710_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTEtNy0xLTEtMjQ2MjYz_c10d61cd-8e58-41d2-bd61-4ac7482bfd12"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if78c1dab52df4fad8c34b85682e70bf9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMS0xLTEtMjQ2MjYz_f344aafc-3fb1-4628-b863-07ad5b422f93"
      unitRef="usd">3075000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93368f3f449f4b9fbf16c9329f7056bc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMi0xLTEtMjQ2MjYz_e7d512cc-722f-45bd-b648-f53c1c78b174"
      unitRef="usd">1115400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cc66ce8e6de454cac39d92a460a5da5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItMy0xLTEtMjQ2MjYz_21b57dbe-29f5-4234-9eda-8d954429e108"
      unitRef="usd">4190400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5306573ee5f40fe87015d1bead33c79_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNS0xLTEtMjQ2MjYz_235cf968-2d6a-4611-84de-8cee5abd0b88"
      unitRef="usd">2276600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67961791f67f455a9e83bdd66879e1e3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNi0xLTEtMjQ2MjYz_633ec603-f07c-4c8e-a720-205fb1c78f0c"
      unitRef="usd">1111600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7827ab11ad634535a354ffe9397dee6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTItNy0xLTEtMjQ2MjYz_7ec90077-5c47-4cf8-b189-85b10e791253"
      unitRef="usd">3388200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9800b2536c0a4887b5ab9dd03310e3d5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMS0xLTEtMjQ2MjYz_382857e1-8114-44cf-b17e-1d90c08b9c8a"
      unitRef="usd">461100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4913832cdf6c42bfa9d7047743a02c46_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMi0xLTEtMjQ2MjYz_ba4f63a1-1a27-473c-a52a-ef2814690ce2"
      unitRef="usd">289800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d7fe4b4cb9d4e1eb78bf2b8fc45025b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtMy0xLTEtMjQ2MjYz_f64be617-b3d3-4162-81c2-b507ca9ecc05"
      unitRef="usd">750900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7380748fafce4bbeb79b3fb7212654a4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNS0xLTEtMjQ2MjYz_4fef8c67-2e87-4942-a68f-c529843c968f"
      unitRef="usd">301500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ff8425fbfc64303ae4dd3c6a3664599_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNi0xLTEtMjQ2MjYz_34192a5f-809d-446c-a8f2-443939a0865b"
      unitRef="usd">167900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f4e2ee8a2d34917bdcc965e7626ef0e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTUtNy0xLTEtMjQ2MjYz_b80155a0-fab3-4fc8-8a48-a7c5b7ec0996"
      unitRef="usd">469400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib56eaf4a89a44762b2ad02723519711d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMS0xLTEtMjQ2MjYz_5ba0b9fd-3532-4d45-b8a8-918e6a9930a0"
      unitRef="usd">100600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36a88ab4c21743beb4653082449b8794_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMi0xLTEtMjQ2MjYz_ed991db9-a915-4fce-aa98-08230c171b7b"
      unitRef="usd">136100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01ec6bedcbf8431996d351090aeb835f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtMy0xLTEtMjQ2MjYz_6f7ece45-2497-4d7b-afc6-d88a1094cd1e"
      unitRef="usd">236800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ec65e20bbe8429d8374bab94fff526d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNS0xLTEtMjQ2MjYz_5a838db2-e3d3-4097-b7d6-a1222a724d17"
      unitRef="usd">79200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32ee755aa5ec43ce8d7d5b0801744953_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNi0xLTEtMjQ2MjYz_ad9cffde-721f-44d7-aae0-be65316ca4ef"
      unitRef="usd">151100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36a7138a41b64af0b3d3bffc680013e2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTYtNy0xLTEtMjQ2MjYz_42b815bf-d196-4a91-bb37-afdf6f20c657"
      unitRef="usd">230300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4850b75145f14e119182161edd48e156_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMS0xLTEtMjQ2MjYz_7efb9b0e-3850-4eeb-bff2-2ad4f94cc932"
      unitRef="usd">118800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7eea234886e74de6bc9398e17900aabf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMi0xLTEtMjQ2MjYz_8f9ff7c5-1fa3-40df-a577-dfd9693145cc"
      unitRef="usd">11100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00c07348838844f9927b4f1042344fc8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctMy0xLTEtMjQ2MjYz_28317433-e828-4d29-818b-e208ef410cac"
      unitRef="usd">129900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic54de819fdc34f43a6a60f819b305005_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNS0xLTEtMjQ2MjYz_c53e426f-299c-4538-9ebd-8c8ff0a29766"
      unitRef="usd">109700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia728bce450914e0ab2648a04596d1d35_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNi0xLTEtMjQ2MjYz_4ba53b70-ac87-447e-8359-83dca26f4277"
      unitRef="usd">13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67d1f99b0aa548e694ca63f72c14567a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTctNy0xLTEtMjQ2MjYz_638431ea-be67-4973-85b0-c03935d60e7d"
      unitRef="usd">122700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9140b6e5e49c43dbb2dbd87cb8181bbd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMS0xLTEtMjQ2MjYz_24ef3ba8-8060-487a-adf4-a3a173b327a4"
      unitRef="usd">20100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7070b3ba7a54482a84f745990995ccdd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMi0xLTEtMjQ2MjYz_21ad0c41-da9a-4df1-8d55-1390db9250e6"
      unitRef="usd">38100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia688e1f2870e4ce7ad9e8932949035dc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtMy0xLTEtMjQ2MjYz_f0223546-1476-4ba6-af7b-89d14811d2fa"
      unitRef="usd">58200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb82241d17ed4a128f5799c977329bf4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNS0xLTEtMjQ2MjYz_5d372309-d5f8-442f-b8f4-3e6ee25873a0"
      unitRef="usd">254300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79547491309b4e5393994557f1671667_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNi0xLTEtMjQ2MjYz_bdf64f9e-8329-4066-bbb1-d1eb4e70470d"
      unitRef="usd">89700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5886df3058224ce1aa56b3af9d1a1dc3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMTgtNy0xLTEtMjQ2MjYz_c2b5084d-556a-483d-9268-8dc774419e3a"
      unitRef="usd">343900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if65a58b1573343a39b71e05ab32cc416_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMS0xLTEtMjQ2MjYz_7be5e06a-337c-4ea5-8dba-f0f6288b01c7"
      unitRef="usd">52800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifecbc3c01d7643c3888c9bb26a95292d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMi0xLTEtMjQ2MjYz_9423e3b1-4cdc-4f47-94c6-d4ef67a1edc7"
      unitRef="usd">127500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97d13f666ff449d7a621398eaa0ef2d1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtMy0xLTEtMjQ2MjYz_9d3466c0-a6ee-4e49-817d-597f164b37d3"
      unitRef="usd">180200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74abf3ad08e8479fbc7b50f9e8bccaf1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNS0xLTEtMjQ2MjYz_1257459e-806f-40cb-9705-a5bd82c7520c"
      unitRef="usd">39000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49343f97cd6f47108d6fd5848cd54864_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNi0xLTEtMjQ2MjYz_53906c9a-1a2f-4b49-80a8-6cdba5ff56ed"
      unitRef="usd">147500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i808d86cf633c44669b50bbdecdb33551_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjAtNy0xLTEtMjQ2MjYz_b7d2b8e1-dca4-4363-bfb5-4a82a6f85eb9"
      unitRef="usd">186700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i795c0bdc41294080907d9ea59944ead4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMS0xLTEtMjQ2MjYz_8495d9a6-529c-4a58-b00c-3beb030b279a"
      unitRef="usd">753400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9df5f251db6448df818fab73530a644a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMi0xLTEtMjQ2MjYz_fc8eebe3-2aab-4c56-9f1b-f120f7d9f418"
      unitRef="usd">602600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i417d453530f54ca0b2209fa1faf5306d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtMy0xLTEtMjQ2MjYz_7fc262ee-6acd-4334-b105-be3be78a9342"
      unitRef="usd">1356000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if29c502013aa40aeb696d62e85288626_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNS0xLTEtMjQ2MjYz_5b460de1-d453-4dc7-8efa-ceffd915e058"
      unitRef="usd">783700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff009e5b94684162a6c0b8401522ef69_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNi0xLTEtMjQ2MjYz_d159cf1c-d751-49a4-8a8c-d08b9d82065e"
      unitRef="usd">569200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id944e42934f04a7f867c267ec9717aff_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjEtNy0xLTEtMjQ2MjYz_86f1f8ad-b0f0-46dd-ba6a-9aedd5567669"
      unitRef="usd">1353000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5231a969184a4364a058bc909f82fe8b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMS0xLTEtMjQ2MjYz_608e1a61-9200-4506-aa07-5fa90f1c9de6"
      unitRef="usd">312200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cf70417fae9467fa9f5e6435d854dfd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMi0xLTEtMjQ2MjYz_b1eef842-5aa5-42b2-8499-bc720eee452a"
      unitRef="usd">214800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10d99551c34a4e858ad1c4e0502e76dc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtMy0xLTEtMjQ2MjYz_7c13d3d3-d9aa-471b-8475-dfd1c09abebf"
      unitRef="usd">527000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib18890600eb448588714f8ad882431ea_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNS0xLTEtMjQ2MjYz_8406ff0e-7c2a-4d27-b0e9-9c89bca77550"
      unitRef="usd">307200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69246a482ad44038a5cc2d5c54873ae2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNi0xLTEtMjQ2MjYz_75ed85bd-44e4-49b9-bb3f-9308f79556bc"
      unitRef="usd">180800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib58a7cb2a4a0485d96deb76ac57931ab_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjQtNy0xLTEtMjQ2MjYz_4e21eb01-2a78-4223-8fe0-aedb01f5db66"
      unitRef="usd">488100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f65318bd79648b998f3e5df408c0412_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMS0xLTEtMjQ2MjYz_f5460905-16a2-4811-9b3d-e459f0387de3"
      unitRef="usd">42300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3213310f015747d080af9a1ff48b5ad8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMi0xLTEtMjQ2MjYz_eaac88ea-875e-4c5b-9e17-9d68edf44e13"
      unitRef="usd">186500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtMy0xLTEtMjQ2MjYz_88bd67c2-172b-409d-a6fd-e4d07376a1e4"
      unitRef="usd">228900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16329625fa6f44a6a1c064ac7d4ec9dc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNS0xLTEtMjQ2MjYz_cd26a57d-024c-45e0-911f-55c3a49e3a42"
      unitRef="usd">71300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i153b28fedc304d3e8ffde2bdf7f073c5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNi0xLTEtMjQ2MjYz_1dc437dd-c214-464c-ac13-138bdf579a4d"
      unitRef="usd">184300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjUtNy0xLTEtMjQ2MjYz_bb7172ff-48cd-4d93-87a9-48088e92bc32"
      unitRef="usd">255600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0385f2c26b2f4d3e8fb95aaa85d8bc2a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMS0xLTEtMjQ2MjYz_2ac4a9da-40f3-4f02-a901-3108f394b63f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5e0e3a0711046c39391d2d3cf445882_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMi0xLTEtMjQ2MjYz_da1fe737-acc4-445f-a9be-cadb2c0c5c15"
      unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e6d1650065e4c768674409d266dca06_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtMy0xLTEtMjQ2MjYz_47e8caa2-ecd4-41b9-b587-108fce0418e7"
      unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31d09044e85e405bae8df74949e8712b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNS0xLTEtMjQ2MjYz_14438f4c-40fb-42a0-b464-b1b81eee6c43"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e50725af9a34d7a98f04d67cb123a30_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNi0xLTEtMjQ2MjYz_9b9188c4-c746-427b-8665-60859ebbda69"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9e7240880ac4123a3894cbb650d0172_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjYtNy0xLTEtMjQ2MjYz_0728483a-77c2-4e59-8974-ebd05ede5631"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd4c963f8e9e4b4db60302cf2284c762_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMS0xLTEtMjQ2MjYz_2db73657-dce6-4b24-81a9-c538172ee262"
      unitRef="usd">354500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i269467655eda495eb32d7ecade1d1990_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMi0xLTEtMjQ2MjYz_2b2202aa-e24b-40c1-8638-ad71ffb00ced"
      unitRef="usd">423300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03b2366367f84820bf8ace8d801f1c7d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctMy0xLTEtMjQ2MjYz_78c2ae4d-d768-45b8-ba66-6b81a58a034d"
      unitRef="usd">777800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie96f23fe8818410dbe8e8a34a66455ee_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNS0xLTEtMjQ2MjYz_abef739f-1f3e-407b-9026-507f8e36b915"
      unitRef="usd">378500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i957ffa2d2be34dee93676a024e802aa2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNi0xLTEtMjQ2MjYz_feb61b3a-039b-418b-be5b-c58fe54fd878"
      unitRef="usd">369600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icef141b8c87343e8a397e0bf1e526680_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMjctNy0xLTEtMjQ2MjYz_8bed7b88-2e74-4e81-8799-f1e843695348"
      unitRef="usd">748100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53c7539f3edc4efaa041fe0e65fdc6ab_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMS0xLTEtMjQ2MjYz_3731e66c-b7a1-4900-aebd-3661905c6b7f"
      unitRef="usd">108700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i367924f0fc6a4ee6b301ed3d61eb59d9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMi0xLTEtMjQ2MjYz_bdb79d14-902d-4f27-943b-b68b040e290f"
      unitRef="usd">45600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice3f5be448854af1bc7435c75e8fd14a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtMy0xLTEtMjQ2MjYz_827cc052-9570-48b0-8ef5-843daf9e28b7"
      unitRef="usd">154300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf75f8c30aff470988cc19ce904d3fe4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNS0xLTEtMjQ2MjYz_b0e03b28-9fd7-4965-b3ad-cb126a7f2ee3"
      unitRef="usd">108300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bf7bba33b974a30af558c8ffb0eff76_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNi0xLTEtMjQ2MjYz_a1564aec-e044-4f86-bd55-ffe88835f20c"
      unitRef="usd">41000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab868bc977a9479b97ce8c1d76008a42_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzAtNy0xLTEtMjQ2MjYz_f459abdb-7676-4091-b4c6-ac58052415a6"
      unitRef="usd">149300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53b5d56ba3c84300a4655bfc90d63682_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMS0xLTEtMjQ2MjYz_4c997dc8-d727-4427-954d-337c7585a749"
      unitRef="usd">35800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4da9824d115d4642b33d62110647bc25_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMi0xLTEtMjQ2MjYz_e76b7996-6ad6-4196-b5b3-aec90c9b6257"
      unitRef="usd">170400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1f0a7c14210458f99c56d32fab18cae_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtMy0xLTEtMjQ2MjYz_9abccb3f-54bb-4ad8-bfd4-4675e84b6445"
      unitRef="usd">206200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0577f0dc20c64f89a47c8c6dea223e7e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNS0xLTEtMjQ2MjYz_70c46110-63a5-4252-bbf1-fa8c5a10fa3e"
      unitRef="usd">45100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9816923eb3343fcb3c969e22954983c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNi0xLTEtMjQ2MjYz_a6a50c64-eced-4bca-b863-24249fd14d34"
      unitRef="usd">203400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i974f97a08b2246b99fad08fcff9d907b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzQtNy0xLTEtMjQ2MjYz_e11645b3-351e-4ae5-889e-51425cdd20fb"
      unitRef="usd">248400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01b0c35171b54d0e8199472f276c3efd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMS0xLTEtMjQ2MjYz_45078688-8d95-4bf1-ac02-40a1c50bf478"
      unitRef="usd">144500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d0c12862e7a4f5295df6787910e6d95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMi0xLTEtMjQ2MjYz_e6d7744b-02f4-4705-a246-8e76e95c5344"
      unitRef="usd">216000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf02a47c1f054f6cab10a1350b11ca78_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtMy0xLTEtMjQ2MjYz_8fa2722d-cafc-4d0f-b496-ebd19e6d1d7b"
      unitRef="usd">360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3846c71ac29e4037bc0323344ed7bf33_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNS0xLTEtMjQ2MjYz_aab88bf3-7d2f-4937-883c-32e3f55adf9d"
      unitRef="usd">153400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1943dbb4c94472d9c47d4588395f87d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNi0xLTEtMjQ2MjYz_174ec021-e1eb-4343-9264-4d32d09397e5"
      unitRef="usd">244400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c58df1da1424666b72028b96c96e821_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfMzUtNy0xLTEtMjQ2MjYz_408a52c4-ceb4-4ce1-9028-f0489755a968"
      unitRef="usd">397700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i948eeabb45154555a0aa21e3c99f533f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMS0xLTEtMjQ2MjYz_746f0d85-057f-4ff9-ae91-8c3ebe6f84b2"
      unitRef="usd">70700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i696edc9f8e1843b28ed762a1347db26b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMi0xLTEtMjQ2MjYz_f9314ee1-7542-4030-839e-bc4bfbe03236"
      unitRef="usd">51700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i703ac11468d54f86bf1f951723906604_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtMy0xLTEtMjQ2MjYz_00e0f158-71f9-45b3-9e66-09cf69fc60f4"
      unitRef="usd">122300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibeb41e587fef4c8aaeee5a0e8d565098_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNS0xLTEtMjQ2MjYz_827892fb-94f5-4b14-b152-0e388527307b"
      unitRef="usd">70200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7157b6266b57432189b37acac4c62b1d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNi0xLTEtMjQ2MjYz_4bbc7460-0eda-43d2-802b-b22f71a3d875"
      unitRef="usd">67300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8f7663963954d37992ed44ffb330868_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDAtNy0xLTEtMjQ2MjYz_2a3c1cf9-bc1f-414c-b0b7-be05642793de"
      unitRef="usd">137400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b6109f92c24420fb119449586e2d751_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMS0xLTEtMjQ2MjYz_0964be4e-6138-4029-9548-1bf58b47aff3"
      unitRef="usd">7600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06f6d319daa54e91842b67dd9ad0ca0d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMi0xLTEtMjQ2MjYz_85c658bf-1e30-4acc-83ed-b2fe37d1bbe3"
      unitRef="usd">92700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a86976547184c9aa6f46daea7912cde_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtMy0xLTEtMjQ2MjYz_d8c6892d-6d44-4e8b-b171-8048dc682515"
      unitRef="usd">100300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0798771ccf6491d8bf4e3a529a99992_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNS0xLTEtMjQ2MjYz_4a13dcee-1e6e-4d72-8ca5-5ffcbe0a5286"
      unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bebcb77e7cc46c4a0f6232d59204728_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNi0xLTEtMjQ2MjYz_89789ade-bcac-4073-bf13-b2da6ed5f6f6"
      unitRef="usd">210800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2afe04177a85445183aee9c1f1a104cf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDEtNy0xLTEtMjQ2MjYz_bdc340bd-fb25-4f39-a132-9dac30791e67"
      unitRef="usd">217700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0b8c13f78ef499fa5e3a82aa88d9a10_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMS0xLTEtMjYwMDQ5_5eff7fb4-9b57-4108-91c5-40aed2e6fc2f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dd5a2af9de84cfc812225bc521e17bd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMi0xLTEtMjYwMDQ5_2607743a-f17e-4b70-a489-90d2d75512db"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMy0xLTEtMjYwMDQ5_80a5dfb5-0969-489a-bbbd-911f64c3d22b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbf0b36bab2d459389f2adb7bf797fc3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNS0xLTEtMjYwMDQ5_c06335c3-2540-4784-9f58-cb144794bdf8"
      unitRef="usd">1455200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3508798f670645c0af6c4e615ca44088_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNi0xLTEtMjYwMDQ5_760afdf2-316e-4ea8-81fe-ad800edb53c0"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNy0xLTEtMjYwMDQ5_82b8383e-2440-4a9d-b12a-d10afb102b11"
      unitRef="usd">1469800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45a904aef68a4f45b2b86bf8b5576e30_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMS0xLTEtMjQ2MjYz_02b03305-1037-4ad7-b245-02dd000fd17f"
      unitRef="usd">30500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5103a4e13b1f49fcb43c76f4ef1e1696_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMi0xLTEtMjQ2MjYz_ade5b4b5-6174-4d29-8320-de19911eede3"
      unitRef="usd">22200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76e758f49518403ab2b0c55235561aa3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItMy0xLTEtMjQ2MjYz_eeec99d1-19be-49cd-bcf7-3886899c5675"
      unitRef="usd">52800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if51e24ac8e8b450599cdde81c0c8a8db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNS0xLTEtMjQ2MjYz_394543f7-1648-474d-9bd4-5a4b630841d3"
      unitRef="usd">50100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0b13b0180da45dabb7f682f854e3394_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNi0xLTEtMjQ2MjYz_217a33e0-f1ea-4041-817f-cfbd3e758b8f"
      unitRef="usd">47800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd283be94b6d4f30af788ea943b170d1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDItNy0xLTEtMjQ2MjYz_b4c5953a-2ef2-495d-b998-89797c21ed4a"
      unitRef="usd">98100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92ac892edbf94f62919a942916235192_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMS0xLTEtMjQ2MjYz_3225636e-7a9b-4783-9207-e6607559b913"
      unitRef="usd">108700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic522b3c6168f49769bd3610b3cfb9fd2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMi0xLTEtMjQ2MjYz_76a4e0a2-eb32-4cf5-aeef-a87cd0e7b4b8"
      unitRef="usd">166600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i394796b389834a5d8a4a6a52018ea5e4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtMy0xLTEtMjQ2MjYz_7e12d57a-9345-4d53-ad7d-098275aaf4af"
      unitRef="usd">275300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf536f227695468d8955c509d0cac28a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNS0xLTEtMjQ2MjYz_bd41a722-7d38-4868-a656-483acb558b0f"
      unitRef="usd">1582400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fbeb1df59694ca1a5121853310fe013_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNi0xLTEtMjQ2MjYz_d044435f-49af-4026-86ba-f4bac0e63e6e"
      unitRef="usd">340600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fd8ff202c66402cb6acdcfb73f456e0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDMtNy0xLTEtMjQ2MjYz_3c4d2003-22d1-4165-ab50-ce115638e684"
      unitRef="usd">1923000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMS0xLTEtMjQ2MjYz_ef5e269d-9a55-40b0-80a7-2be2614970bd"
      unitRef="usd">4436200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4b193d99bd84b609a946006de3ff5b5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMi0xLTEtMjQ2MjYz_8e9984e0-9689-4c28-afc5-0f35ae05a7ec"
      unitRef="usd">2523900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtMy0xLTEtMjQ2MjYz_05afefe8-b62c-4249-bcf0-cc72a3a3cdbb"
      unitRef="usd">6960000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNS0xLTEtMjQ2MjYz_129288ed-9f93-4b49-b90f-0d9f2d71d58e"
      unitRef="usd">5174600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ce552cbf23a4e5e87ebb11e406b4c7c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNi0xLTEtMjQ2MjYz_4c6a9d5d-92e6-4d94-b8ad-03d2a081d220"
      unitRef="usd">2635400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjRhN2NhYWM0OTYxNDRiYzBiODg4YmYyYjVmZGRjMGM2L3RhYmxlcmFuZ2U6NGE3Y2FhYzQ5NjE0NGJjMGI4ODhiZjJiNWZkZGMwYzZfNDQtNy0xLTEtMjQ2MjYz_59ea5ba3-491d-42c9-be30-1d5f114d3b32"
      unitRef="usd">7810000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06a10e1d5abc49289a9fe54374fa475a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfMy0xLTEtMS0yNDYyNjM_0b564e47-c010-4508-b09a-020e27d83bfe"
      unitRef="usd">4436200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i437ea91717a74f0d8fd3686b134a4241_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfMy0zLTEtMS0yNDYyNjM_0580a056-1f86-4f1c-b7f1-1b8b544ccc10"
      unitRef="usd">5174600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f75bb32e91f4c8c914a357a961a505e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNC0xLTEtMS0yNDYyNjM_51ae4351-1c81-4463-bb7c-1e6b85b3b95f"
      unitRef="usd">1090900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i591aacf4b21b4fb6af4a84ef723f602d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNC0zLTEtMS0yNDYyNjM_00eed427-fd5a-40da-8e93-813b7f67a1e7"
      unitRef="usd">1067300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e43da972920406cb8cec2e4ac4f504a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNS0xLTEtMS0yNDYyNjM_43f294c3-c35d-4707-955c-cbc2402cb8b5"
      unitRef="usd">387200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i546300f8490545128a0251b2fdd2206b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNS0zLTEtMS0yNDYyNjM_925cccb0-aca9-4f42-bebb-c1c327f350e4"
      unitRef="usd">410200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3357638f0d364662b153eab67fa8550f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNi0xLTEtMS0yNDYyNjM_34d6cdf2-fce9-4b69-8345-9f5b9c46d8d7"
      unitRef="usd">372700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic91090e6b25c497aa5caa5cd3b067650_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNi0zLTEtMS0yNDYyNjM_4d46fc37-3629-4a39-ba3e-18bd33955b47"
      unitRef="usd">406500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb8415110eb3486093fdd56a22adfd54_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNy0xLTEtMS0yNDYyNjM_0ab621ba-ceb8-4c4e-872e-97d327e1f69e"
      unitRef="usd">673100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7a092f91d8a468d8c4c31d4148a904b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfNy0zLTEtMS0yNDYyNjM_495a071a-ba57-4a41-93c9-5a4374715b87"
      unitRef="usd">751500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfOC0xLTEtMS0yNDYyNjM_9fb19e9a-fc78-4884-8abd-2d14fa316327"
      unitRef="usd">6960000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80My9mcmFnOjRiZTI4ZWRkMTY2ODQxYzI4YjgyYzE4Y2M3MDM2NzI0L3RhYmxlOjE5MzU0MDA5YWMzYjQ4NWViYmZhODhmYjU3MGJmMTMwL3RhYmxlcmFuZ2U6MTkzNTQwMDlhYzNiNDg1ZWJiZmE4OGZiNTcwYmYxMzBfOC0zLTEtMS0yNDYyNjM_72ea520a-73ca-456c-be0b-3316af327e38"
      unitRef="usd">7810000000</us-gaap:Revenues>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ2MA_d7dbed87-bb25-4271-9cfd-4754ed9a86f4">Acquisitions and Divestitures&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we completed the acquisition of Akouos, Inc. (Akouos). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;amp;D when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D charges of $105.0 million and $165.6 million for the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of a Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Akouos Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 5 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Akouos for the three months ended March&#160;31, 2023 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we acquired a Priority Review Voucher from BioMarin Pharmaceutical Inc. for $110.0&#160;million. We recognized no other significant acquired IPR&amp;amp;D charges during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events - Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we entered into an agreement to sell the rights of the olanzapine portfolio, including Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to Cheplapharm Arzneimittel GmbH. Under the terms of the agreement, we will receive $1.05&#160;billion in cash upon successful closing of the transaction and an additional $305&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive milestone payments of up to $50&#160;million in aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we entered into an agreement to sell the rights of Baqsimi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to Amphastar Pharmaceuticals, Inc. Under the terms of the agreement, we will receive $500&#160;million in cash upon successful closing of the transaction and an additional $125&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive sales-based milestone payments of up to $450&#160;million in aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These transactions are subject to customary closing conditions and regulatory approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ2MA_f4ba9f19-899a-4d84-94c6-3b5e9ccaa7d2">Acquisitions and Divestitures&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we completed the acquisition of Akouos, Inc. (Akouos). This transaction, as further discussed below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;amp;D when the event triggering an obligation to pay the milestone occurs. We recognized acquired IPR&amp;amp;D charges of $105.0 million and $165.6 million for the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of a Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Akouos Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we acquired all shares of Akouos for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2&#160;million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122&#160;million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions. The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Akouos information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 5 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations attributable to Akouos for the three months ended March&#160;31, 2023 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we acquired a Priority Review Voucher from BioMarin Pharmaceutical Inc. for $110.0&#160;million. We recognized no other significant acquired IPR&amp;amp;D charges during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events - Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we entered into an agreement to sell the rights of the olanzapine portfolio, including Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to Cheplapharm Arzneimittel GmbH. Under the terms of the agreement, we will receive $1.05&#160;billion in cash upon successful closing of the transaction and an additional $305&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive milestone payments of up to $50&#160;million in aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we entered into an agreement to sell the rights of Baqsimi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to Amphastar Pharmaceuticals, Inc. Under the terms of the agreement, we will receive $500&#160;million in cash upon successful closing of the transaction and an additional $125&#160;million in cash upon the one year anniversary of closing. We are also eligible to receive sales-based milestone payments of up to $450&#160;million in aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These transactions are subject to customary closing conditions and regulatory approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNjQ1Mw_7d93ec18-f7ad-4508-8b47-2c88e41522d3">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed as acquired IPR&amp;amp;D when the event triggering an obligation to pay the milestone occurs.</us-gaap:BusinessCombinationsPolicy>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTc1NQ_213ddecc-db78-4f71-b291-981fa5cc30dd"
      unitRef="usd">105000000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MDE1MA_bf6b77c5-9405-489d-83a6-06d768b2908e"
      unitRef="usd">165600000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE4NQ_3db0b52f-541f-4f71-aaf6-db5762971662"
      unitRef="usdPerShare">12.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTYzNDQyMg_d106f938-d187-4eea-a770-9fbba8083b2e"
      unitRef="usd">327200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE5Nw_57dc7a8f-e4a5-4a9f-933f-c71e780f732e"
      unitRef="right">1000000</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTY0MjE5MA_fc2de477-3109-4153-971d-0f6527a6f52f"
      unitRef="usdPerShare">3000000.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="if724a8d2f737491298c6d043d5a7b8fb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfMTA5OTUxMTYzNDYyOA_3373c9f7-95f2-42da-8b7d-3c592920cd74"
      unitRef="usd">122000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUyNTUzMw_1e15164b-d309-4c2d-a4ca-623c2cba5c63">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at December 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to GJB2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 5 for a discussion on the estimation of the CVR liability.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMS0xLTEtMS0yNDg0MTg_f395ffba-c466-40a0-8bbc-8d442212cdc9"
      unitRef="usd">153200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMi0xLTEtMS0yNDg0MTg_1d647dad-51e3-494f-91c8-a804c626e38c"
      unitRef="usd">184000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMy0xLTEtMS0yNDg0MTg_c244c065-3da4-4291-a8ef-234a31b65d59"
      unitRef="usd">181200000</us-gaap:Goodwill>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfNS0xLTEtMS0yNDg0MTg_24af5b4f-f46a-4564-940a-bdf419a1660a"
      unitRef="usd">28900000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfNi0xLTEtMS0yNDg0MTg_5f51910a-4ba0-49b6-bb6d-94903aee81a9"
      unitRef="usd">547300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="iae82f601bab2473da6f28b70df983fa5_D20221201-20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfOC0xLTEtMS0yNDg0MTg_6c355424-d455-44f5-84b2-c4d0e1d86d20"
      unitRef="usd">153200000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i445c404661b9435abdfa6e32f19fa84d_I20221201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfOS0xLTEtMS0yNDg0MTg_d37bacc5-d968-421c-b32a-3f65df41b575"
      unitRef="usd">66900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i901b71b7118b4a0cb2d23959947046e0_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RhYmxlOjllMWNkOTY5MzQwMDQ4NmFhNGYwZWQ5ZGE5NGVhM2FlL3RhYmxlcmFuZ2U6OWUxY2Q5NjkzNDAwNDg2YWE0ZjBlZDlkYTk0ZWEzYWVfMTAtMS0xLTEtMjUwODQ1_0e5373a4-af43-4530-bc2c-4b68d270f053"
      unitRef="usd">327200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:PaymentsForAssetAcquisitions
      contextRef="i7692466539d946a186b9e8a3794403e0_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNTQ5NzU1ODI5OTEz_936c4f8e-faaf-4274-bb39-87eaf072cb91"
      unitRef="usd">110000000</lly:PaymentsForAssetAcquisitions>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzUxNw_c067d827-3c8b-45e1-9550-9a47c43ac528"
      unitRef="usd">1050000000.00</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ic7897a00ac5944569e250a8e3e4f0b96_I20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzUzMg_0e2d5465-fc8c-45e7-9b23-b3a6fb0ce5d8"
      unitRef="usd">305000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived
      contextRef="ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU0Ng_8601f4df-bdb8-481e-ac63-1a562b97e722"
      unitRef="usd">50000000</lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i100bf53cad0845918532d994ef899f46_D20230401-20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU1OQ_a4b19c74-49b0-4f65-8496-9e3239b1ffbf"
      unitRef="usd">500000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ie1373c2b92194421a101613e8613e0bd_I20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU3Mw_c61ec6ea-3019-4b74-bf73-247912a1f2d2"
      unitRef="usd">125000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived
      contextRef="i100bf53cad0845918532d994ef899f46_D20230401-20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF80OS9mcmFnOjQ2ZjQ4ZTFjNDAzNzQxZTk5NjM3ZDFjNjhiMDdkMWVjL3RleHRyZWdpb246NDZmNDhlMWM0MDM3NDFlOTk2MzdkMWM2OGIwN2QxZWNfNDM5ODA0NjUzNzU4Nw_43f9ff71-a6c6-4d81-91f8-33238b873bbb"
      unitRef="usd">450000000</lly:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTA0MjY_f30a8934-a80b-47d8-b00b-7b91d42722b1">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as our basal insulins, Basaglar and Rezvoglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. Rezvoglar is included in the Basaglar product family.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration, which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to the Basaglar product family as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(126.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Jardiance product family, we and Boehringer Ingelheim generally share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for the Basaglar product family in the U.S. We record our sales of the Basaglar product family to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to the Basaglar product family:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;577.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $330.0 million were capitalized as intangible assets as of March&#160;31, 2023 and December&#160;31, 2022 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us in potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera were recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $1.47 billion, primarily related to bebtelovimab, for the three months ended March&#160;31, 2022. We did not have sales of our COVID-19 antibodies during the three months ended March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2023, Roche is eligible to receive up to $160.0&#160;million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2023, we are eligible to receive payments of $65.0&#160;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25&#160;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. During the three months ended March&#160;31, 2023 and 2022, collaboration and other revenue recognized was not material.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTA0Mjc_60de8424-e408-4794-9d3c-062309864f2b">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to the Basaglar product family as of March&#160;31, 2023 and December&#160;31, 2022: &lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(126.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to the Basaglar product family:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;577.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMi0xLTEtMS0yNDYyNjM_dc63b064-af2f-4343-a61a-d65157c5ebbc"
      unitRef="usd">111200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7d0abcdee3334210846272da16cb8bf0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMi0yLTEtMS0yNDYyNjM_2a2a4281-8ea9-41f0-a4f1-387c835903c5"
      unitRef="usd">116200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ibd665f0b61e04e9290ab394dc775adfc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMy0xLTEtMS0yNDYyNjM_ddb3c83c-f0c1-475c-bdcb-f96090f2b16e"
      unitRef="usd">57300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9c0be196fbee4b99986d201abe4c40cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfMy0yLTEtMS0yNDYyNjM_ffb224d1-ce4c-4849-bede-d341625d3bc5"
      unitRef="usd">63500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7ff485149e744b8388e86b2d61f131bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfNC0xLTEtMS0yNDYyNjM_813bb5cc-89ad-430d-9353-edb39f3557cf"
      unitRef="usd">-126000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i78acf8b5d08a423ab887d0babcc4c793_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjJkYjBjNTA2ZmQyMDQ5MjJhYTk5ZDNlZTdmZGYzN2E3L3RhYmxlcmFuZ2U6MmRiMGM1MDZmZDIwNDkyMmFhOTlkM2VlN2ZkZjM3YTdfNC0yLTEtMS0yNDYyNjM_c7565f60-31f8-4f56-910d-8f6401b79b63"
      unitRef="usd">-130600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="iba2e92b1b2db4b2aad7f820ee591f4fc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMi0xLTEtMS0yNDYyNjM_9e453744-0f16-4d42-b455-2a333f27de56"
      unitRef="usd">577500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d3cd7a9033f497da8fadd8455fe662a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMi0zLTEtMS0yNDYyNjM_d56e4fa9-e4a9-46e5-89e4-4f3cf62afa31"
      unitRef="usd">419400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9a50bbf4eec4cad9c39acb73f9e6df0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMy0xLTEtMS0yNDYyNjM_9f3ac19a-040a-4f01-a141-9eab10f9514d"
      unitRef="usd">209300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia32d2eaa3d4f46568a8b69118be52b98_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfMy0zLTEtMS0yNDYyNjM_62d820c8-b9e1-4212-9602-4b275f323165"
      unitRef="usd">191500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20238217248b408d991f048bd5cb02de_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfNC0xLTEtMS0yNDYyNjM_91300226-67b6-4d69-b8cb-e75a9114c13f"
      unitRef="usd">85800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73c97dbdad3e47c19014952cddab28fa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjlhYTU2Mzg0NTI1ZDQ5YzVhNDVhZmRlMjZiNTA2ZDU1L3RhYmxlcmFuZ2U6OWFhNTYzODQ1MjVkNDljNWE0NWFmZGUyNmI1MDZkNTVfNC0zLTEtMS0yNDYyNjM_cb5bf639-54e7-4e93-a006-a05b7c328088"
      unitRef="usd">92000000.0</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="i92837642c10f4f2d8a9378d7a850d897_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNDY2MQ_b5337318-2bbd-4dcc-92b2-c455b802ec09"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i609b231bb46d449cb0c55bf0feca2672_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTE2Nw_9ab4e743-1164-4fb8-aa42-defbd5df967c"
      unitRef="usd">330000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic5463e57189f4d458870b77c846c8470_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTE2Nw_c785c441-f44d-4c3d-a519-624a3b06cd44"
      unitRef="usd">330000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i5cbee495f74d4bc7ac390f3934fd8dec_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTUxNw_9b1ae04f-dd22-4b8f-a3c1-f9c28eb03eae"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i8afc04328f534b809fc6d392b624cefc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjM3ZWFkM2Q0OWI3NDQxZmE4NzA1ZTU0OTNiYmZmMTU2L3RhYmxlcmFuZ2U6MzdlYWQzZDQ5Yjc0NDFmYTg3MDVlNTQ5M2JiZmYxNTZfMi0xLTEtMS0yNDYyNjM_88bd67c2-172b-409d-a6fd-e4d07376a1e4"
      unitRef="usd">228900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d005eb6dfbb4e9abda602a13b7be14a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RhYmxlOjM3ZWFkM2Q0OWI3NDQxZmE4NzA1ZTU0OTNiYmZmMTU2L3RhYmxlcmFuZ2U6MzdlYWQzZDQ5Yjc0NDFmYTg3MDVlNTQ5M2JiZmYxNTZfMi0zLTEtMS0yNDYyNjM_bb7172ff-48cd-4d93-87a9-48088e92bc32"
      unitRef="usd">255600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9aa31683ad6344588c6ea7a75cd89bb6_D20220101-20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNTQ5NzU1ODI1OTA2_ff54c655-df4f-4b9f-be08-9d3b240838e8"
      unitRef="usd">1470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4d6edf1b8cf46f29ca03fed22e98dc0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfNDM5ODA0NjUyMzM2OQ_3d55d78b-61da-4f2c-ac03-a3b2414dae4c"
      unitRef="usd">0</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i103526d82f5c4005b57a6ca769c093a5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfOTI5Ng_325cc008-68e7-435f-8156-ebbdd9af6907"
      unitRef="usd">160000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i489cad1a4170481f8dc4678a75f24771_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfOTQwMA_21ad027f-5894-4fb9-89aa-e04af5045fb9"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ifa643ca7a9684ef7bc9e57583e9f2c9f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTAwMTM_c7834dfe-5109-428d-88c7-6bf4ebface67"
      unitRef="usd">65000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7f28555ca5d9421a9bb743d1916adb6c_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF81Mi9mcmFnOmRkYmI3OWVmMzM1MTQyZTZiNDZlM2JjN2IxYzI2NDE3L3RleHRyZWdpb246ZGRiYjc5ZWYzMzUxNDJlNmI0NmUzYmM3YjFjMjY0MTdfMTAxMTE_e17b2c84-824d-4a31-b372-a1e96f7cc6ff"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3ODc_f06653ab-231e-4327-81d8-594c35cd6f47">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Equity and Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three months ended March&#160;31, 2023 and 2022 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net losses recognized in our consolidated condensed statements of operations for equity securities were $13.7&#160;million and $425.4&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. The net gains (losses) recognized for the three months ended March&#160;31, 2023 and 2022 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we had approximately $950 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;512.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 99 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2023, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value of Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,330.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;157.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;165.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;90.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;475.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;516.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;833.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,750.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;484.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,901.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we issued $750.0&#160;million of 5.000 percent fixed-rate notes due in 2026, which are callable at par after one year, $1.00&#160;billion of 4.700 percent fixed-rate notes due in 2033, $1.25&#160;billion of 4.875 percent fixed-rate notes due in 2053, and $1.00&#160;billion of 4.950 percent fixed-rate notes due in 2063, all with interest to be paid semi-annually. We used the net cash proceeds from the offering of $3.96&#160;billion for general business purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for our short-term and long-term debt:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,498.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,883.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,654.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,654.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,740.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk Management and Related Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. The majority of our cash is held by a few major financial institutions that have been identified as Global Systemically Important Banks (G-SIBs) by the Financial Stability Board. G-SIBs are subject to rigorous regulatory testing and oversight and must meet certain capital requirements. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer based on credit rating of our counterparty. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect significant counterparties to fail to meet their obligations given their investment grade credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $423.4 million and $422.1 million&#160;of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2023 and 2022&#160;were&#160;not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 9) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 9). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. Forward contracts generally have maturities not exceeding 12 months. At March&#160;31, 2023, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,948.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chinese yuan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;British pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts. Our foreign currency-denominated notes had carrying amounts of $6.97 billion and $6.83&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, of which $5.58&#160;billion and $5.45 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of March&#160;31, 2023 and December&#160;31, 2022, respectively. At March&#160;31, 2023, we had outstanding cross-currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments. At March&#160;31, 2023, we had outstanding foreign currency forward contracts to sell 1.38 billion euro and to sell 1.82&#160;billion Chinese yuan with settlement dates ranging through 2023, which have been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&#160;31, 2023, all of our total long-term debt is at a fixed rate. We have converted approximately 12 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 9) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March&#160;31, 2023, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.00 billion, which have settlement dates ranging through 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(131.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(46.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12&#160;months, we expect to reclassify $13.1&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the three months ended March&#160;31, 2023 and 2022, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value of Risk-Management Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for risk management assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of acquisitions of businesses. The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE2OQ_2983c6ae-7384-480c-8443-28e5612cc6c1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors.We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss). We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1Mjc4_68e10cae-f071-4d81-be0a-57c97e0a1818"
      unitRef="usd">-13700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTA5OTUxMTY2NjA3MQ_204c1a91-3ef9-493d-b815-9a1e9a73f4dd"
      unitRef="usd">-425400000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1NzI4_a36fd1be-9fbf-418a-9ad0-51e6e61f1325"
      unitRef="usd">950000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM1ODQ4_d4ada807-6bb3-45bd-a43a-ce21f764ff97">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3MA_9eaac882-35b7-4cee-9a1c-5d61751c86e1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi0xLTEtMS0yNDg5NzI_35238c3a-cc8a-4255-b2a5-592308bd6cc5"
      unitRef="usd">648100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi0zLTEtMS0yNDg5NzI_2caf6d8f-3392-40c6-ad62-5d06591c7eb9"
      unitRef="usd">76000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi01LTEtMS0yNDg5NzI_75f7155a-7ed1-4d8b-a146-cd5423985d6b"
      unitRef="usd">219400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi03LTEtMS0yNDg5NzI_7accc03c-ef49-49f1-9bdb-27bb715ff53a"
      unitRef="usd">115500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjE2ZDJmOTY4MzEyYTQwYWE4OTQ4MzY2NTNlNTJiZjI2L3RhYmxlcmFuZ2U6MTZkMmY5NjgzMTJhNDBhYTg5NDgzNjY1M2U1MmJmMjZfMi05LTEtMS0yNDg5NzI_d82d3175-9b8e-429c-84cc-c8d48dfd796f"
      unitRef="usd">237200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3MQ_3034751f-7d8b-46bd-989b-faa0d1b1c81d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;512.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMS0xLTEtMS0yNDg5NzI_4fe24878-551a-43b9-9790-7dccfa4f335d"
      unitRef="usd">1800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMS0zLTEtMS0yNDg5NzI_d73dfa97-9815-411a-916c-03b449bb904f"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMi0xLTEtMS0yNDg5NzI_2bf512e9-2782-4eb9-ba08-965f43b57f15"
      unitRef="usd">39000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMi0zLTEtMS0yNDg5NzI_babae84a-4c56-40a5-88dc-2fb6ec5df0f0"
      unitRef="usd">49200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMy0xLTEtMS0yNDg5NzI_3e852ea8-1c82-4859-8b93-cda15c86f8b5"
      unitRef="usd">120500000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfMy0zLTEtMS0yNDg5NzI_afa08fc5-6749-4fed-a65c-cfe22c51d08b"
      unitRef="usd">46800000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfNC0xLTEtMS0yNDg5NzI_eeea00f7-4593-4fdc-82d8-e53fb5e259bf"
      unitRef="usd">512400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjUxZjY1NjYxZWQ0ZjQ1MTE4NjhhZjIyNTg2NDRkZjgwL3RhYmxlcmFuZ2U6NTFmNjU2NjFlZDRmNDUxMTg2OGFmMjI1ODY0NGRmODBfNC0zLTEtMS0yNDg5NzI_42dc2392-2de4-4cba-87b7-eb26090e81be"
      unitRef="usd">568700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODM4OTQ4_310db327-7d3b-46ee-a08c-e390755e4201"
      unitRef="number">0.99</lly:DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Mg_5e851e93-7172-4502-8623-acab54bffbf1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMi0xLTEtMS0yNDg5NzI_4dc10da9-586e-4509-ac04-1dbf36f54856"
      unitRef="usd">27600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMi0zLTEtMS0yNDg5NzI_c92cd937-8e20-4860-857d-8e470140e26a"
      unitRef="usd">35200000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMy0xLTEtMS0yNDg5NzI_fa9dced4-859f-4c8f-b67b-c89ebeec956e"
      unitRef="usd">200000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfMy0zLTEtMS0yNDg5NzI_13b1b197-cd5c-4b4e-9ff5-7ab2e6cecb2d"
      unitRef="usd">100000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfNC0xLTEtMS0yNDg5NzI_2f13c0a5-00bc-4fe2-bab8-6f03c2dc6639"
      unitRef="usd">700000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjI3YmE5NjA4ODMzYzQzYzI5YTg1NzI0YTc2NzY3NGUwL3RhYmxlcmFuZ2U6MjdiYTk2MDg4MzNjNDNjMjlhODU3MjRhNzY3Njc0ZTBfNC0zLTEtMS0yNDg5NzI_259ce67e-2204-4f6a-bd2a-d2007e9ce5c4"
      unitRef="usd">800000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Mw_0455110f-d5e5-43e4-be97-c9aeaa3b0d89">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,330.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,343.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;157.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;165.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;155.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;113.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;90.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;475.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;624.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;516.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;833.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,750.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;657.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;484.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;781.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,901.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0xLTEtMS0yNDg5OTI_6a7a271f-a1db-48d2-b567-a455411d453c"
      unitRef="usd">2343100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i64cc16dbdab440cba483787915c9d53d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0zLTEtMS0yNDg5OTI_91e81f69-14cb-4ef4-af21-9ed185effad2"
      unitRef="usd">2343100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy01LTEtMS0yNDg5OTI_eba791b9-ed4f-4aa4-a488-082388ee53b6"
      unitRef="usd">2330200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy03LTEtMS0yNDg5OTI_183fe6e7-93ab-4ebb-96da-c7adbe0a848f"
      unitRef="usd">12900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy05LTEtMS0yNDg5OTI_43fb6de9-b9f0-4063-b6d8-c7a6b1cb28f9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0f030511d7046938601479dedb444f4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMy0xMS0xLTEtMjQ4OTky_354a8ae1-25f2-4111-bfbb-ebaa9e8e2efa"
      unitRef="usd">2343100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1c7566c897554984865a313ce03a9329_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0xLTEtMS0yNDg5OTI_230e90c5-16ef-4527-b66a-4756d5028118"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0134da41219f40099434bf6b0e92907f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0zLTEtMS0yNDg5OTI_1c7f14b1-2f24-4b5f-ad99-12668c068f90"
      unitRef="usd">23500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1cac2c8384d54ca495e549787dc20271_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi01LTEtMS0yNDg5OTI_4080ce1f-2ef8-49cf-a6e4-440634040a7f"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1879600e47a94b1ca76977132157c1f5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi03LTEtMS0yNDg5OTI_a47b612b-fa4f-450a-8430-6db36d4dbf0c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi05LTEtMS0yNDg5OTI_5bbe459a-6319-42fe-840b-79060aa4dc7c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3918b47b0546407986bcb5eb572cf16a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNi0xMS0xLTEtMjQ4OTky_ef741514-7ca1-4bf8-b4ef-0246bba527f9"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i51606337f7734c3486883b088d9e425b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0xLTEtMS0yNDg5OTI_7077f164-9df1-48ab-ae60-29903cb9e29e"
      unitRef="usd">50100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i07d8251eccdf47259566f7ce1b910246_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0zLTEtMS0yNDg5OTI_f9e697e0-5607-45f8-9289-918ebfdb643e"
      unitRef="usd">50200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8dc74babfb5f48019438eb1839ff23ad_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy01LTEtMS0yNDg5OTI_4db966fe-f7bd-4acf-b942-fc2c6c000214"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0c819184949c43c88caf8d26d02607fc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy03LTEtMS0yNDg5OTI_c3cbc17e-3682-4b36-8d98-d84c88e52ec1"
      unitRef="usd">50100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib8026bc96eb9499a97499c0c3a47904d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy05LTEtMS0yNDg5OTI_5f2064bd-5923-462b-b0fb-ca0a0f0c831b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia4a28c2c52e041b8bda2d6528cde8205_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNy0xMS0xLTEtMjQ4OTky_0cd65073-f999-498b-a096-462ee8eb1556"
      unitRef="usd">50100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9afb33798b944ff09e0d384619049f08_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0xLTEtMS0yNDg5OTI_5d8522e2-7beb-4451-a664-ea4994d4939e"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i14fba24e65df4393afd80bbbfba657c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0zLTEtMS0yNDg5OTI_86a7575d-a92f-4a1c-b1e1-98a190abc66c"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f0237a8c7ae47d897c07629a4ccd158_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS01LTEtMS0yNDg5OTI_20505bfb-8623-4be5-b042-477ffbf50912"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i837f1e72cbb14e459cf199db8d586de3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS03LTEtMS0yNDg5OTI_e67d80c4-6504-4116-9805-586a248a37c8"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS05LTEtMS0yNDg5OTI_8ff53ec5-98ee-4b1d-995d-5908fdd87ea2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfOS0xMS0xLTEtMjQ4OTky_42e22831-8cef-45ea-a885-816886c30a0a"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7b28da6dd9e645d398bc98f07007e279_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMS0xLTEtMjQ4OTky_796e38b3-8dbc-47ca-aa80-8893936a232e"
      unitRef="usd">47400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id276c57f9b1f4968a4c1e9e22e9ca168_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMy0xLTEtMjQ4OTky_7f9b095a-2e9b-4f7a-9c08-9f503fa82ed4"
      unitRef="usd">47400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9bfc537fc2c649e6a5a5f04fa5e3eac0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtNS0xLTEtMjQ4OTky_e7d37e33-cc4f-413e-8583-855295b99be5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i060e380eb6bd4c7b8d931a5b7fe8ee32_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtNy0xLTEtMjQ4OTky_ce91d36b-319f-46e8-8e5d-793eebd63158"
      unitRef="usd">28000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0c95303f9a0d4b8dbc0cd35c9ab50369_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtOS0xLTEtMjQ4OTky_d95f2a61-3379-4ece-9ed1-d2f69fc68f80"
      unitRef="usd">19400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib2aee17f60b34dfaa64036bd799907ea_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTAtMTEtMS0xLTI0ODk5Mg_070762a7-980f-42c0-a647-df3b9c8c5fc2"
      unitRef="usd">47400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTItMS0xLTEtMjQ4OTky_88951dc8-5101-48a1-9f3b-6ad0c19f3a29"
      unitRef="usd">123400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1c7566c897554984865a313ce03a9329_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMS0xLTEtMjQ4OTky_33f34bfb-e466-4d14-8330-c37f4d4e842e"
      unitRef="usd">145200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0134da41219f40099434bf6b0e92907f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMy0xLTEtMjQ4OTky_d767ef7b-511e-40bf-a17d-f844ecbaf8f6"
      unitRef="usd">157500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1cac2c8384d54ca495e549787dc20271_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtNS0xLTEtMjQ4OTky_da0857fb-f1f0-4957-9174-2051e95814a1"
      unitRef="usd">145200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1879600e47a94b1ca76977132157c1f5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtNy0xLTEtMjQ4OTky_99035c10-e39e-4a09-82e7-47f23d3bee35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="idec58ba79a3d4e3cb3a8f144084eb37e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtOS0xLTEtMjQ4OTky_a5c82405-c6e6-4d81-9b3d-082a00a8b39e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3918b47b0546407986bcb5eb572cf16a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTUtMTEtMS0xLTI0ODk5Mg_05a75c24-7baf-412d-a8e1-9d781c8df9f1"
      unitRef="usd">145200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i51606337f7734c3486883b088d9e425b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMS0xLTEtMjQ4OTky_398f2c21-afd2-41e1-8eaf-a4398c77287c"
      unitRef="usd">214800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i07d8251eccdf47259566f7ce1b910246_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMy0xLTEtMjQ4OTky_05247952-63e8-42ed-93be-5a10a9ab5128"
      unitRef="usd">232500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8dc74babfb5f48019438eb1839ff23ad_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctNS0xLTEtMjQ4OTky_2e28d213-fba3-46d9-9053-78662cacd800"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0c819184949c43c88caf8d26d02607fc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctNy0xLTEtMjQ4OTky_e2db395d-eb18-4ff5-af14-11f4586d674d"
      unitRef="usd">214800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib8026bc96eb9499a97499c0c3a47904d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctOS0xLTEtMjQ4OTky_4fcecd7e-bb2b-4a33-9194-e43575e1b855"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia4a28c2c52e041b8bda2d6528cde8205_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTctMTEtMS0xLTI0ODk5Mg_164d9b5f-fc19-493b-bd6b-925373257bae"
      unitRef="usd">214800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9cdd4b1a54e04c3a9406a84414b9f579_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMS0xLTEtMjQ4OTky_c0933550-4aff-4147-a847-96a8d41c735f"
      unitRef="usd">155300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5575d654b61f4900b3705243433ef745_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMy0xLTEtMjQ4OTky_fb2165e7-0dc9-434e-a5da-77f8f0275f3b"
      unitRef="usd">165200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i84c516fae2e94d6dbda47e05ce423f1b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtNS0xLTEtMjQ4OTky_1f514da8-b3e2-48f7-93cc-1c0d9cd27419"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3ef8ccfb7b53440397caf6f2176ec2c9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtNy0xLTEtMjQ4OTky_06cf22d1-20a8-4f77-adba-a8002ed318ab"
      unitRef="usd">155300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd1914622ec74bfc91e9e91e6b7153e4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtOS0xLTEtMjQ4OTky_a934e2a5-7cbe-42c0-981d-3f67ea790992"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i954f45623ee841cbbb44ef65dc983e82_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTgtMTEtMS0xLTI0ODk5Mg_06bc770d-b842-47c9-b253-24664981f833"
      unitRef="usd">155300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9afb33798b944ff09e0d384619049f08_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMS0xLTEtMjQ4OTky_04c8acb5-50fc-4700-8316-6af3f0985dd2"
      unitRef="usd">56800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i14fba24e65df4393afd80bbbfba657c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMy0xLTEtMjQ4OTky_01227cb6-4076-4903-b847-f1df310b0ed0"
      unitRef="usd">58200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8f0237a8c7ae47d897c07629a4ccd158_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktNS0xLTEtMjQ4OTky_834a9687-f0f4-42fc-8738-f1a419bec20d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i837f1e72cbb14e459cf199db8d586de3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktNy0xLTEtMjQ4OTky_e520304f-d4ad-4029-9215-2697079c5f7e"
      unitRef="usd">56800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8ce5ab0e6ba74233ae10fa932ca3ab3c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktOS0xLTEtMjQ4OTky_183c6a70-90e6-4804-811f-8d5902862d36"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iac0e417e4d5e49e4b80b3faab9670b0e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMTktMTEtMS0xLTI0ODk5Mg_0cd3c036-b2b5-4389-b2a9-ce3cf244fb76"
      unitRef="usd">56800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibbdc87b2e3b847c699cc755d5929caa3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMS0xLTEtMjQ4OTky_6afea0e4-af14-4a57-a67d-89a20b6c9100"
      unitRef="usd">204000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i93672f2b12e14d149242b511c86a6250_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMy0xLTEtMjQ4OTky_89a96509-8bf8-40ed-92b7-778a19c6b1a0"
      unitRef="usd">22700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i64f02815ce424e099d024a5372594f49_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtNS0xLTEtMjQ4OTky_a8789259-2cbd-40c3-9ead-3d5e03b17e62"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3620be0cd8f6437c993131b23aae9aa0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtNy0xLTEtMjQ4OTky_1e6fe78b-1e69-4aff-aa61-92bfb71fcf54"
      unitRef="usd">113800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id4c92706e1f14b06b6f276c841acc827_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtOS0xLTEtMjQ4OTky_3de3ae38-1a7b-4ff4-a381-69932eb9e53f"
      unitRef="usd">90200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i87fe25007da841e6a6dfa7dea8abca12_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjAtMTEtMS0xLTI0ODk5Mg_9caf7b94-15fc-4829-bd68-076c81ea0693"
      unitRef="usd">204000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8ebed6fdc46043b680d5a256576f2871_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMS0xLTEtMjQ4OTky_a3a556c7-7957-4d7c-91d2-b5d36be10a33"
      unitRef="usd">624000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5cb98f1aad55409684b3ba48c8c07916_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMy0xLTEtMjQ4OTky_84bf1d33-c1cb-47d3-a56e-d483103e2864"
      unitRef="usd">475600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if6dbc248c1574a47a024938a5536f95c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtNS0xLTEtMjQ4OTky_354cbd04-bf50-4a56-afc6-8b51c44b33e2"
      unitRef="usd">624000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib2b8cd580dcd4aa7a914f8764250a273_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtNy0xLTEtMjQ4OTky_78704e1f-f393-46ba-ac76-1124cc6691a0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i19353eef79fe415d9f09bbb87f88817e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtOS0xLTEtMjQ4OTky_1fd1a29a-2e98-4d26-ab1d-2fbf3b65632c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i001f8aeb21bc42778b5ba830866254e9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjEtMTEtMS0xLTI0ODk5Mg_415c3eab-d9d9-47a4-81d5-2e60f89fb82e"
      unitRef="usd">624000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjItMS0xLTEtMjQ4OTky_32761728-d153-4225-bcd9-28dd9a6be25a"
      unitRef="usd">516600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjMtMS0xLTEtMjQ4OTky_cdd37972-85c8-4b10-b6f5-4d940e8c0b68"
      unitRef="usd">833700000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjQtMS0xLTEtMjQ4OTky_818886c1-4b7f-4ee3-b89b-99299c61312b"
      unitRef="usd">2750400000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMS0xLTEtMjQ4OTky_8c50135d-3b3f-4117-86dc-c02fa3045e2e"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i55cf7db1bd84431d8151876c0779039f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMy0xLTEtMjQ4OTky_2e4ea817-f40c-4d66-a5af-85c56bdcae19"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctNS0xLTEtMjQ4OTky_0cc9cb7d-541c-4b00-9bcd-808d6b9e8a91"
      unitRef="usd">650400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctNy0xLTEtMjQ4OTky_a7dea9f6-aece-42e8-a95a-2e9d43cce624"
      unitRef="usd">7000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctOS0xLTEtMjQ4OTky_1dd32a57-7e23-4871-8e01-5889c8c20f20"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMjctMTEtMS0xLTI0ODk5Mg_d6388fe0-9887-4787-83fc-3a8b09d84c80"
      unitRef="usd">657400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMS0xLTEtMjQ4OTky_0cc98dcd-155f-4998-837a-fb2474ded131"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if48d0a0094404e7283b202d1e3bddef6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMy0xLTEtMjQ4OTky_34454e77-ffc5-43ae-a5c6-e5a00eb7d601"
      unitRef="usd">31100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie97234b19add45c8a1264d62a11227cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtNS0xLTEtMjQ4OTky_e897232d-f858-4b3d-9a5e-6555d4b544b7"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iebfbfe46c3934f43b65aa033cc031c63_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtNy0xLTEtMjQ4OTky_3454f8ab-2e47-4457-9199-ae7268846820"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1c78f11ff6a047f081fced706e82fafa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtOS0xLTEtMjQ4OTky_1d02783a-f55f-450e-9cc0-91142f36a3c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5dbd154370ab46c5aa386577c6e77972_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzAtMTEtMS0xLTI0ODk5Mg_35c00278-37ea-44c9-ae43-a36f2c804ea4"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMS0xLTEtMjQ4OTky_b4a585b4-d278-4ca2-ae4a-1442cb3bffa6"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMy0xLTEtMjQ4OTky_8ea80b7d-56e5-4851-bb69-a9debcb417a6"
      unitRef="usd">53500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtNS0xLTEtMjQ4OTky_b03770b8-060a-4ba9-b301-2cd589600e9c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia2be3d28f17b4d53b00d099d33166a22_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtNy0xLTEtMjQ4OTky_5c9f8aca-2435-4f8a-911f-fe574317769e"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8a551b91bdf34460b537440476918ed1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtOS0xLTEtMjQ4OTky_4559fa6c-7dec-4dc5-8a4b-e1a5223033df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icf82c4e9f9fd4a0db74790b311d892d9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzEtMTEtMS0xLTI0ODk5Mg_1c298bee-c710-4e18-a9e7-19187d5c200d"
      unitRef="usd">53400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i14330e00eca04b5aa32be284d320080f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMS0xLTEtMjQ4OTky_d0a11a51-1b31-4b2f-9fa0-95d9a7f64cf3"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i851cea55d9ca4dada65a5272023c5cf5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMy0xLTEtMjQ4OTky_89b1bbad-fdac-43dd-b99a-27bbe8e8dadc"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6d33a84402254240a7b6fd4134d0c50d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtNS0xLTEtMjQ4OTky_2d181ed8-5b2d-4b70-acc2-1e4fa297f48a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5ace9101d47e4406b2a9101fde438cc6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtNy0xLTEtMjQ4OTky_13dbbc7d-b5e8-4e25-b757-569a445b0587"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8619a22dba4e4f568d1919d6cd7c5376_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtOS0xLTEtMjQ4OTky_d1026a88-4938-4668-8533-4da8952fda44"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f9a47c0173949d69d205062ba1a08a1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzMtMTEtMS0xLTI0ODk5Mg_e044b540-fd31-491e-bc50-6f8bbff1b681"
      unitRef="usd">2000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i022f12bcdcd0432a8bf7bd1609fcd81f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMS0xLTEtMjQ4OTky_2cc579bf-716f-4570-a862-f84a8308e334"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i813ca92d3c304796b09a1c1b8cd503cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMy0xLTEtMjQ4OTky_ee164d1b-e391-43a3-933f-688a0c4d4910"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i77fd8621adac49b9a812a1b54ce30bd6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtNS0xLTEtMjQ4OTky_7d74cb23-c464-4614-8247-dfe4fa7e9ee2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if3bbe0151d1d436383b9c9a162467d10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtNy0xLTEtMjQ4OTky_2fa21e1c-d561-4375-8a9c-7195353e4e24"
      unitRef="usd">39100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i46ca25f6912d4deaa22749065f92f810_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtOS0xLTEtMjQ4OTky_05c7e9db-d78d-4d55-8690-25f1c4ae3afd"
      unitRef="usd">19500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i800172f3d41a475b95bc904fa96bc892_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzQtMTEtMS0xLTI0ODk5Mg_bde93499-7a00-471f-8ad0-9c591a3850f0"
      unitRef="usd">58600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzYtMS0xLTEtMjQ4OTky_5971f044-383d-475f-873b-293e3fe9500c"
      unitRef="usd">144800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2ddb8f2a4f5141ae8f29cfd3c327bdd1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMS0xLTEtMjQ4OTky_0e7e0f33-bbd8-43e6-8f7d-ca50623f3fd9"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if48d0a0094404e7283b202d1e3bddef6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMy0xLTEtMjQ4OTky_a7bda349-3d7b-4769-8bbd-1fb5b63629c2"
      unitRef="usd">163200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie97234b19add45c8a1264d62a11227cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktNS0xLTEtMjQ4OTky_716a8031-16b4-4cdf-8b40-8f3202d84541"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iebfbfe46c3934f43b65aa033cc031c63_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktNy0xLTEtMjQ4OTky_569be551-ddc1-4522-b4c1-a865b5b38088"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1c78f11ff6a047f081fced706e82fafa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktOS0xLTEtMjQ4OTky_427a3772-7999-4f85-8cd6-3f634a293778"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5dbd154370ab46c5aa386577c6e77972_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfMzktMTEtMS0xLTI0ODk5Mg_e69a2ebe-ec26-4f23-b153-b796ebd9d154"
      unitRef="usd">146400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id98d1ef2e41541d79ebf9c6e26b2a6e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMS0xLTEtMjQ4OTky_f3c492dc-5caf-4515-9fb3-00690edb8046"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib381004c3e2c4be39b1e5a2a43c1ad3a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMy0xLTEtMjQ4OTky_11d58875-4dd2-40dc-a076-6d38405d21c4"
      unitRef="usd">235800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8f88414bab394ef39d85cf5ac0b4ac2d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtNS0xLTEtMjQ4OTky_afdf95b7-4617-443b-9ece-41c8af87beab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia2be3d28f17b4d53b00d099d33166a22_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtNy0xLTEtMjQ4OTky_8da06ba3-7513-4054-8e71-cadb137c8bae"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8a551b91bdf34460b537440476918ed1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtOS0xLTEtMjQ4OTky_47b57eb8-d27f-4b51-9f69-6c050327ae54"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icf82c4e9f9fd4a0db74790b311d892d9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDAtMTEtMS0xLTI0ODk5Mg_2f4c8888-95ac-44c1-9183-109607e4c2f9"
      unitRef="usd">213900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifbf1513ec6fe42dc8fc97dacbcbb2f7b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMS0xLTEtMjQ4OTky_179c2a4d-795e-4dfa-b0d5-1baa7477262b"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if0f0aee5c436422aacd166802e150362_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMy0xLTEtMjQ4OTky_796c97a3-1036-4fa6-92f5-ff17a3b676eb"
      unitRef="usd">161500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2930663eccea45d3ab83ffbf88977505_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtNS0xLTEtMjQ4OTky_14ccc746-ed10-45d1-9095-6cd67163a46a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i55dd2b5a2b18473582bd68be66d7d771_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtNy0xLTEtMjQ4OTky_38c3e58d-a01d-4877-bb50-2f2259442e3c"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0881c8a632db4b36a3e7ecfd7928e941_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtOS0xLTEtMjQ4OTky_f63529eb-9b70-4eb9-b377-cc629f18af8e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i564f1f9a74ad45f6b61966a59691288e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDEtMTEtMS0xLTI0ODk5Mg_4c8a99f0-763b-4a6b-bb26-e1e01b261b93"
      unitRef="usd">149200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i14330e00eca04b5aa32be284d320080f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMS0xLTEtMjQ4OTky_d95a9bfa-325b-4652-9afd-bc83569fd180"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i851cea55d9ca4dada65a5272023c5cf5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMy0xLTEtMjQ4OTky_85981be8-88d2-495d-a629-aff3fd04aca7"
      unitRef="usd">52500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6d33a84402254240a7b6fd4134d0c50d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItNS0xLTEtMjQ4OTky_37ce99f3-1f69-439b-9b01-d565ef0f2259"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5ace9101d47e4406b2a9101fde438cc6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItNy0xLTEtMjQ4OTky_f3884780-93a5-4cfd-9b29-9fa49959721c"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8619a22dba4e4f568d1919d6cd7c5376_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItOS0xLTEtMjQ4OTky_c2f0b2bc-c052-4787-bc3c-6d2f76c8ec76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3f9a47c0173949d69d205062ba1a08a1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDItMTEtMS0xLTI0ODk5Mg_d465224a-9004-43f3-88ae-96e311b92918"
      unitRef="usd">50600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i489bce7d4ec7404b9664b907c028323f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMS0xLTEtMjQ4OTky_7f0820be-a09c-451c-8070-fae4e6530d18"
      unitRef="usd">398600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i245ac866b994442fbc4b1f2c0864fe2f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMy0xLTEtMjQ4OTky_8780fb51-70c1-4e4f-b3a7-db4268ff8167"
      unitRef="usd">34500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6856168703f140ec90f1f07f17cc591d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtNS0xLTEtMjQ4OTky_22c3ed55-1575-4671-969c-a4440445a268"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i42aa25d783514516803c587532a3c61e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtNy0xLTEtMjQ4OTky_4ddc181f-c8e3-43fe-99b6-dcfc3af86fb7"
      unitRef="usd">311000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iffa8c24cfa2d4bbb8bac085b94dea6e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtOS0xLTEtMjQ4OTky_f3154b17-fc4e-4322-84be-6e86ff6112af"
      unitRef="usd">87600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i49c245d1c06644e1b6ab489c2e9f6916_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDMtMTEtMS0xLTI0ODk5Mg_f6345c95-c68c-4d10-bef5-46b9661c278e"
      unitRef="usd">398600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i61ecc19905f14bd28130682e968375e7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMS0xLTEtMjQ4OTky_630f192a-831a-4a8a-86e2-7ded3263c1d2"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1e06948912d142179578cad05d244ac3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMy0xLTEtMjQ4OTky_1cbd3fb1-1221-45b1-b3f9-54aee05be743"
      unitRef="usd">484700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i96286855c6b74d7ca6b4c49c79940a71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtNS0xLTEtMjQ4OTky_165d53c5-83f7-4bae-97ee-8c78120b229c"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia2035cc82b2c4f2984eefd8ae524520a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtNy0xLTEtMjQ4OTky_0bf6ebfe-0863-45e3-9430-e49a6d87ccc8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9458648cddd94b1e98f28b8ab753bc74_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtOS0xLTEtMjQ4OTky_9280fb00-a9e3-4dcd-815f-f6bc12f8a971"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i463ce48ff9854c67b168581527823709_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDQtMTEtMS0xLTI0ODk5Mg_74adf8bb-b645-418e-82d1-9bd1fd3d27ab"
      unitRef="usd">683600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDUtMS0xLTEtMjQ4OTky_c9ca9d54-c176-42d7-8352-87e0848747c6"
      unitRef="usd">478400000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDYtMS0xLTEtMjQ4OTky_be4aaf13-260d-4480-a884-a486f318be41"
      unitRef="usd">781100000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOmU3MWRiNmEzMTcyYjRkYmRiN2NjNmE2MDkwM2M0Y2IwL3RhYmxlcmFuZ2U6ZTcxZGI2YTMxNzJiNGRiZGI3Y2M2YTYwOTAzYzRjYjBfNDctMS0xLTEtMjQ4OTky_9c910f37-853e-4259-9502-979132dff09d"
      unitRef="usd">2901800000</us-gaap:LongTermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDQyMQ_c063b326-f9fa-4809-8df8-a72f14dc59bb"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e1d9b47b9e544db9c86bcf1fbf9fad0_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDUyNg_6b6164a2-4c99-460c-84e5-ef8d79076463"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5629b4e2ef53489dbf21e68abf79b47a_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkwMA_c5f8f883-325c-42b8-aeb1-8cabd1f3d662"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5629b4e2ef53489dbf21e68abf79b47a_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkxNA_bcb04d59-a6a2-4ca3-bc17-09c9f01bc2e2"
      unitRef="number">0.047</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia2aa54d93fb744f09a03b3641900a309_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkxNg_40b1717f-76c1-46da-981e-a88b1518f31b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2aa54d93fb744f09a03b3641900a309_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkzMA_beb631c2-76ed-4060-a714-2c6c3bb7de6d"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ied6c5f93596b48d09753ee6dac6abb6c_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODkzMg_f6635c74-8268-4493-98f4-b64aabbd75c9"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied6c5f93596b48d09753ee6dac6abb6c_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMzg0ODI5MDczODk0Ng_4fd12cde-461b-4d5f-baed-3a2cb6cdbbc0"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ice2c8b929e4c4bc5a32d8aa02836cac1_D20230201-20230228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1NDUyOQ_5e64ff77-898b-4af4-ae6c-0d1eeb9e2d2b"
      unitRef="usd">3960000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3NA_41d4afba-1c7d-4c9c-9498-3096b6f73df2">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for our short-term and long-term debt:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,498.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,492.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,883.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,654.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,654.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,740.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,329.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CommercialPaper
      contextRef="i35d458da5e9246b8a8c0b7b714992619_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy0xLTEtMS0yNDkwMTU_039e6efb-c969-45e9-81a6-b838b84b42c5"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="if0331e3cce77463eab1cf2359214ff10_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy0zLTEtMS0yNDkwMTU_edda695e-5d55-4a25-a857-fed920478238"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="if485cce9601842de8e0453ea2c5bdb90_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy01LTEtMS0yNDkwMTU_1635ef6b-c332-4e08-a3be-fe3d68791d77"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i38c397a2da7e467c86ff6be26f9e20c9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy03LTEtMS0yNDkwMTU_5daa58ff-6ac0-4156-b966-0909ae9caceb"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i6ac66d67a45e4eb9b8df6e33b966bdeb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfMy05LTEtMS0yNDkwMTU_f936ddbb-aac7-43a3-aaa3-624c95e2949b"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ifeac312680b340f5b5e739bbc1e1882d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC0xLTEtMS0yNDkwMTU_84e23506-74be-41b3-a53d-468a562a2529"
      unitRef="usd">1498000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ia278d7067652484dac30db72abe60a63_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC0zLTEtMS0yNDkwMTU_692d43d9-51b1-4a93-b88f-abb4da4d3f53"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i30ea2a3ccd6c4b00ba12b0f45309f52f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC01LTEtMS0yNDkwMTU_33cd2fa0-8a29-4a2f-b660-af53ba9ab95b"
      unitRef="usd">1492000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="id5f2344b073f45f7b33a4471dd2abba3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC03LTEtMS0yNDkwMTU_ce1070c1-e0f8-4a3f-8bdf-974311fc1816"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i4a314d1e73864fd780eeebcc4f2a1867_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNC05LTEtMS0yNDkwMTU_a9ebc1ab-d281-41fd-bc95-ab71e1b17cf2"
      unitRef="usd">1492000000</us-gaap:CommercialPaper>
    <us-gaap:LongTermDebt
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi0xLTEtMS0yNDkwMTU_a91ea593-739b-4c3c-8aee-f36657462783"
      unitRef="usd">18883600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi0zLTEtMS0yNDkwMTU_2c9d484d-42f7-4761-8c02-e584daac586f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi01LTEtMS0yNDkwMTU_292fe32e-994c-49df-8f05-a314c307307e"
      unitRef="usd">16654600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi03LTEtMS0yNDkwMTU_f163c540-a421-4700-aafb-6645be9c8122"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic0f030511d7046938601479dedb444f4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNi05LTEtMS0yNDkwMTU_1971e2b0-8743-4205-9be5-6f4af4a0851a"
      unitRef="usd">16654600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy0xLTEtMS0yNDkwMTU_5ab4de92-b6cc-4b0d-b724-9eb067f55fb8"
      unitRef="usd">14740600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy0zLTEtMS0yNDkwMTU_2a9443e4-3100-4808-8ea4-d300a3f67145"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy01LTEtMS0yNDkwMTU_6c829aa0-6949-4d26-9201-15af3233fc0a"
      unitRef="usd">12329300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy03LTEtMS0yNDkwMTU_c7040140-6520-437d-a875-3f926a6df2d5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjk3ZGZlNDc1ZDdkMTRhODY5MjE2NGNiOTM5NjU2NjU0L3RhYmxlcmFuZ2U6OTdkZmU0NzVkN2QxNGE4NjkyMTY0Y2I5Mzk2NTY2NTRfNy05LTEtMS0yNDkwMTU_e0f8a4f9-4740-4ba8-be28-fad9c909cb28"
      unitRef="usd">12329300000</us-gaap:LongTermDebt>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQzNzIw_6e691f1a-0e6e-4a74-9994-6c140c549da6"
      unitRef="usd">423400000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQzNzI4_fd0aac6b-4711-422a-b23e-df7f5d36ece2"
      unitRef="usd">422100000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY4MTI_a97e7815-2a54-4f0b-b2a5-9ea237d3ab7e">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 9) and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 9). Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Chinese yuan, Japanese yen, and Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 9) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNjA0NzMxMzk5MjA3MQ_a5b65101-92a7-4305-85ef-0bc363e70300">P12M</us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3NQ_d7ee457c-4b2d-4f42-81be-a4c4b3d8b432">At March&#160;31, 2023, we had outstanding foreign currency forward commitments as follows, all of which have settlement dates within 180 days:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,231.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,948.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chinese yuan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;British pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDY2OA_1a67a6f2-f0ef-46e3-82cb-d3de77182265">P180D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ibcf771418ff145e48f59e9ff50e2c708_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfMy0xLTEtMS0yNDkxNTk_6b22d046-5494-48f8-a001-66523771f213"
      unitRef="usd">2410500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ibcf771418ff145e48f59e9ff50e2c708_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfMy00LTEtMS0yNDkxNjc_95a4be32-104b-4e5f-83a0-c65d16d36ab4"
      unitRef="eur">2231400000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="if6e0597d66944d53bf676c80d6b96114_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNC0xLTEtMS0yNDkxNjM_b32684c4-a549-4924-8ecf-7f7b878501ac"
      unitRef="eur">3667400000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if6e0597d66944d53bf676c80d6b96114_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNC00LTEtMS0yNDkxNjc_9dedbc9f-ccd2-4492-9752-7122b3d85b0d"
      unitRef="usd">3948600000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i5c08ba67b1c94a638f7917eaf0032bad_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNS0xLTEtMS0yNDkxNjM_bb7a863a-a2b1-45d5-b502-b2fe9c28de4a"
      unitRef="usd">229800000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i5c08ba67b1c94a638f7917eaf0032bad_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfNS00LTEtMS0yNDkxNjc_4c17cb3f-7630-4d80-ad61-d78e7651e24e"
      unitRef="cny">1574700000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="id0507f641e794b5a91c61ce38a4c073c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfOC0xLTEtMS0yNDkxNjM_4a91ae63-7662-4f79-b6c1-5410d18a53fd"
      unitRef="gbp">216700000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id0507f641e794b5a91c61ce38a4c073c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjMxMjIzMzAxMTliNTQzNDg5ZWQ4ZTc4OWRmYzdjZWUyL3RhYmxlcmFuZ2U6MzEyMjMzMDExOWI1NDM0ODllZDhlNzg5ZGZjN2NlZTJfOC00LTEtMS0yNDkxNjc_c598b0d0-4869-4300-8968-c51ed8af5757"
      unitRef="usd">265800000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:LongTermDebt
      contextRef="i429677c58b714ca8a8137930ebb1264e_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDkwMA_49b34ee7-aaa5-44a5-9b97-f8f1bcb88b2a"
      unitRef="usd">6970000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icf306204988949a8a9f4c724f64060af_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDkwNw_660e2c89-6556-46aa-95c1-33d1c7216d0a"
      unitRef="usd">6830000000</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDk1MA_bf833284-9ca2-4131-b086-3209d3914373"
      unitRef="usd">5580000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i927e3b53935c4022981ef2bcccb6abdc_I20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDk1Nw_dd3db809-b4a9-4f36-8feb-5fa317c32882"
      unitRef="usd">5450000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ia3cd20496f3d4a06a9644d09794a69a7_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTE4Mg_603399f3-af93-446b-842f-44bee6c1289b"
      unitRef="usd">1020000000.00</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i260b5249d7e84893aefd8c83c3d04825_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTIxOQ_c52907d6-fdbc-422e-b743-096906052710"
      unitRef="usd">1000000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i645e8bd9724c4c4cab525b0c0ce2038a_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTYzMw_9d414124-c0c5-4ee0-9b39-d2b04b8bebde"
      unitRef="eur">1380000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2a44228b4f8545afb2c73892b5d2dc61_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNDM5ODA0NjU1MjEwMg_9a7a6698-3d46-4f48-9fa3-fdb8ce750750"
      unitRef="cny">1820000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNzIxOQ_1ff36b91-b7af-4444-97db-dbb8cd98912f"
      unitRef="number">0.12</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i77245def3f8b4e7dab758e4a8bde31a4_I20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNzkyOA_f7c22b5b-c4d8-4e92-9db7-02578205cd46"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Ng_4a6e21ef-b9ed-4557-af5d-2414672819d2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ia8cd03fb09db4a7d82b3453427246d58_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfMy0xLTEtMS0yNDkwNjg_1e13c79f-ea14-4ba1-a97e-58dac4e18972"
      unitRef="usd">-35300000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i43a702b6516d4b76a6b7e939ece50067_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfMy0zLTEtMS0yNDkwNjg_6b94db2f-8579-4fd9-b557-5166d25b4532"
      unitRef="usd">94600000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNC0xLTEtMS0yNDkwNjg_5ce3d405-d0d5-4554-a48f-9dc3263f60f7"
      unitRef="usd">35300000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNC0zLTEtMS0yNDkwNjg_375b451f-f20e-45b8-aa46-ea26bdd40881"
      unitRef="usd">-94600000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i98ec36c2c92c4c72abcc7ca1d36a61be_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNi0xLTEtMS0yNDkwNjg_837181f1-6bf6-4426-8a3a-011f562b695f"
      unitRef="usd">3800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if03a2316709a4a2bb8ae62d2576e9eb5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNi0zLTEtMS0yNDkwNjg_cb871313-1efe-428a-b056-6cff128f8cdc"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib1c2892bae36442e8926b2ce9c0668bc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNy0xLTEtMS0yNDkwNjg_0a179fe5-c16c-424e-8885-f0faba44ed3b"
      unitRef="usd">-12900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6c4c3a1eaec84aa68e202c8ea853063b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfNy0zLTEtMS0yNDkwNjg_4a7953ca-915e-436d-903a-4e0f2e8c39ff"
      unitRef="usd">8300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i48e9490fbbc14d76ab189e023cf3f228_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOC0xLTEtMS0yNDkwNjg_248f9949-a6e6-4c5e-b843-0f3e07af1444"
      unitRef="usd">52800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i57e32bbc79574914bba00cdb0742b99b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOC0zLTEtMS0yNDkwNjg_6d30f046-26c7-4aef-adce-cb10c939af24"
      unitRef="usd">6100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOS0xLTEtMS0yNTA4NzQ_51a0de66-b62d-405f-b67d-5679e4330c88"
      unitRef="usd">61900000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjljYTIxYjdhMDk1MTQwN2ZhMDhhODU2ZmQ3ZTAyMTQ3L3RhYmxlcmFuZ2U6OWNhMjFiN2EwOTUxNDA3ZmEwOGE4NTZmZDdlMDIxNDdfOS0zLTEtMS0yNTA4NzQ_8ec008c8-43a0-4cbf-92c8-38bf2d44c699"
      unitRef="usd">-6300000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Nw_63950ee7-177b-4c4f-b520-b1bb7e2762f2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(131.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(46.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODE3ODE3Nw_feb7f011-7972-424a-8c7d-c89b73898459">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(131.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(46.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i58f19b8ba9ed454fa02e5160a844f996_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfMy0xLTEtMS0yNDkwNjg_d5b40e10-ef48-4046-ae48-db08ea2cb43e"
      unitRef="usd">-131800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i72a614a742164e49b4da60cae000aac8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfMy0zLTEtMS0yNDkwNjg_8b718573-7f8c-4dda-82cf-577553017d06"
      unitRef="usd">54400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNC0xLTEtMS0yNDkwNjg_fdcd6ecd-8c88-4181-ace4-09b658bc8bc3"
      unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNC0zLTEtMS0yNDkwNjg_f9ecbe74-0efa-40f4-af69-5e2cf985f3a0"
      unitRef="usd">10800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0ee17b04babc40a6ab35eccdf222fe82_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNS0xLTEtMS0yNDkwNjg_12c7f8cc-91aa-42f9-9363-fc6a9f256d44"
      unitRef="usd">-46100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib72e1ac48fd74f079d8811bbcae3d5d7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNS0zLTEtMS0yNDkwNjg_3d31281f-c600-4f04-8819-31be7e7bc29e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i37c553f14757453c942a550f354e3a74_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNy0xLTEtMS0yNDkwNjg_e9a10372-d2ff-489c-b703-a66d8cdca8be"
      unitRef="usd">23800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6789d3ab2e2e4887828f80411eaa0097_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfNy0zLTEtMS0yNDkwNjg_a8293adb-bfa4-4777-9036-6acb85846b91"
      unitRef="usd">122500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6fdb0ae5ab6d44fda348910ff54cac46_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfOC0xLTEtMS0yNDkwNjg_03c18d2b-6ce1-4d28-a209-9068e2c57dd2"
      unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2869fd82667d42aa97f66f0f5f6417f1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjVhZDFkZDNmOTQ2NTRiYWVhODY5Y2E4YzkyMzVmMTMyL3RhYmxlcmFuZ2U6NWFkMWRkM2Y5NDY1NGJhZWE4NjljYThjOTIzNWYxMzJfOC0zLTEtMS0yNDkwNjg_417938e7-601e-4260-af23-ce9d66b575f3"
      unitRef="usd">17100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i9c2ab2b26eca44b79b6d178d0f021629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfNTQ5NzU1ODQ4ODM2_5953462b-ebbd-4056-bc35-7d54344489a6"
      unitRef="usd">-13100000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3NzY_7f40eb10-60cd-4d0e-89aa-5bb8c588b53d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes certain fair value information at March&#160;31, 2023 and December&#160;31, 2022 for risk management assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(91.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;228.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;58.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;63.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(32.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RleHRyZWdpb246NDliMDIyZjU0ZGI1NGQ3M2FjMjJhMGE5MGRjMjFlMGFfMTY3ODI_85bd923c-76a8-4ea6-8e57-fb09a17ed5d4"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi0xLTEtMS0yNDYyNjM_9673821c-6b86-430b-bd77-9a03b51c5104"
      unitRef="usd">2700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi0zLTEtMS0yNDYyNjM_26c26960-8f75-4d2e-a4b5-a4381f0eaf37"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi01LTEtMS0yNDYyNjM_00647f36-3958-432f-9482-8382dbab6d23"
      unitRef="usd">2700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi03LTEtMS0yNDYyNjM_632a67c2-cd9c-4cfe-aa9f-af279e4dd46e"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNi05LTEtMS0yNDYyNjM_217deff5-f30e-4549-b17b-c06e9cc93fee"
      unitRef="usd">2700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy0xLTEtMS0yNDYyNjM_86bceabf-660c-4837-b36a-5086827511de"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy0zLTEtMS0yNDYyNjM_9de38d7f-458c-44ba-9f8f-2a4dbd23d768"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy01LTEtMS0yNDYyNjM_c62a1e96-14f2-475e-a220-141fbfa36df6"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy03LTEtMS0yNDYyNjM_16160975-b2ad-4944-9481-ff00b591d177"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNy05LTEtMS0yNDYyNjM_2dda236a-58d5-45dc-877e-d6e95c6b9db4"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5b68c8b710bd465cb70d755bbb9d33df_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC0xLTEtMS0yNDYyNjM_128fc141-8656-4555-82ae-f9277cb0a635"
      unitRef="usd">91800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibea8c83934624a97a1dc11e68563bf6e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC0zLTEtMS0yNDYyNjM_1a437efa-113a-46c3-9561-27e25114779a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iabe34e8d76ff4ff39a04e6ebcfe4f03d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC01LTEtMS0yNDYyNjM_b8e9622b-acc2-4299-beb2-dc4095a92c18"
      unitRef="usd">91800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7dfa84895cab4faa83cbdcaf91b6e417_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC03LTEtMS0yNDYyNjM_5d6c5206-c9cc-4865-aa59-2041d2638429"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i332f789539594747bf8464ec5cafdb0b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfOC05LTEtMS0yNDYyNjM_896c1e54-d938-4c2f-95c5-848fe5eaaa82"
      unitRef="usd">91800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib0de9c67450541c296870312132a3b92_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItMS0xLTEtMjQ2MjYz_dec38967-f996-448a-a24e-90870766bf63"
      unitRef="usd">228600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5442836a58a740f9a2ec6a5044876fa3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItMy0xLTEtMjQ2MjYz_370849ab-86db-45ea-8578-6b4ccb700cb2"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic4345c04245449db88cb19f4963073ed_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItNS0xLTEtMjQ2MjYz_4ef2af5b-c80d-45e7-8381-eb452ceb464a"
      unitRef="usd">228600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib6128cb3f8b34eb38e4ba315f7d53bbf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItNy0xLTEtMjQ2MjYz_53aa8512-622e-493f-ab7e-169733b86a89"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7a5624b505084aa68791383a31649f60_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTItOS0xLTEtMjQ2MjYz_12efeabd-c308-4bfa-b70a-f5124958d058"
      unitRef="usd">228600000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3441b768235345d7a17d1010afb3aa34_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtMS0xLTEtMjQ2MjYz_7aa46533-6933-426d-8b2b-ef238b92b3bf"
      unitRef="usd">55600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifb5b9b0ce2374a22a8d5ea231570946a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtMy0xLTEtMjQ2MjYz_9b0b85fb-c278-466e-8fa1-ab1a08162dde"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6b75c331361d44ec829664b5a49b1365_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtNS0xLTEtMjQ2MjYz_7d8f2806-6bd4-4a08-b7bf-246e65ca8aa6"
      unitRef="usd">55600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia4ed07ce471c498fafc8e126e65bf30b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtNy0xLTEtMjQ2MjYz_6c79e4cc-cf48-4002-8874-cc03487fde4b"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i97b86836fd2b4c638e1b4648bb0f535f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMTUtOS0xLTEtMjQ2MjYz_5289684f-9144-49fb-a893-71b743c50a8a"
      unitRef="usd">55600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1e1b2d2ba1774f099d8109747e8c6a95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtMS0xLTEtMjQ2MjYz_570d7905-eafd-4b11-ac3c-95f1630979b6"
      unitRef="usd">58200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9d4aaf0f785e46d39d0b337f7ca1aa83_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtMy0xLTEtMjQ2MjYz_c26778a5-f61f-4cc0-8f18-84ad34303ff3"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i33268d4bc0be4bfeb735237bbf2beaa5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtNS0xLTEtMjQ2MjYz_bbeb3dc6-567c-45c9-8a07-3afea1d7b1b0"
      unitRef="usd">58200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if3f8023d0e15487abe65174ea5fdd911_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtNy0xLTEtMjQ2MjYz_6540669b-d47e-4872-a36e-18209f131377"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if27a50fefdd14c2f984c86fe00f4646c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjAtOS0xLTEtMjQ2MjYz_1c0d085b-7390-4c3e-bb8f-06d24e85055d"
      unitRef="usd">58200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibcb4d961f831495a8982fcca640793b2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtMS0xLTEtMjQ2MjYz_4dbe8af3-a2eb-4541-8626-e32fa51bddbb"
      unitRef="usd">900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i606b780fae204c2fb03456ec7d4609ba_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtMy0xLTEtMjQ2MjYz_7a5df109-a643-416f-9d08-8a6545893ae7"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtNS0xLTEtMjQ2MjYz_6a80d80e-61d4-4c63-9270-8e260825e8d9"
      unitRef="usd">900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5b291e9275fa4cdea832b11022bb1650_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtNy0xLTEtMjQ2MjYz_9c55bcfd-b854-411a-882e-5f9c1781bd9a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="if17408fcf4a6444ca4350f667c9e2531_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjMtOS0xLTEtMjQ2MjYz_68a80549-ffe7-47da-a9ea-af693feb64a9"
      unitRef="usd">900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibcb4d961f831495a8982fcca640793b2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtMS0xLTEtMjQ2MjYz_e4f26b58-e547-4749-9c5b-a526eb52f5a7"
      unitRef="usd">13100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i606b780fae204c2fb03456ec7d4609ba_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtMy0xLTEtMjQ2MjYz_cfb09373-b8dd-49dc-a915-6a5774985783"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2dfae6dc3c5e421bbb4f3603ee9be8b3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtNS0xLTEtMjQ2MjYz_5cab6f8c-eedd-4d5a-bb3a-d8e386d755f8"
      unitRef="usd">13100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5b291e9275fa4cdea832b11022bb1650_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtNy0xLTEtMjQ2MjYz_0c4cf8f1-a500-4f38-9839-ef813fcc44b2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if17408fcf4a6444ca4350f667c9e2531_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjQtOS0xLTEtMjQ2MjYz_767f1404-f66c-4764-ba69-a1e72d6cc70b"
      unitRef="usd">13100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie10c867d799d4679b141e08dc578e51f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtMS0xLTEtMjQ2MjYz_901152c8-ca70-4114-adda-b8041d071998"
      unitRef="usd">63700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i97f0c78f29754db2b760047cbe32a568_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtMy0xLTEtMjQ2MjYz_bfcafe73-315c-4560-9004-cff0dec3c18d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5964e87d1767486d9c9f3e69ea87005f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtNS0xLTEtMjQ2MjYz_ffb18762-e826-4872-a7a1-e91491203dab"
      unitRef="usd">63700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ide8899346d6d43418aa5c2c278c01334_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtNy0xLTEtMjQ2MjYz_65b71b9e-c1ea-4461-9c27-90b7d08e409b"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjYtOS0xLTEtMjQ2MjYz_8c4dd5e2-dad1-4fee-9b86-4c278f3ecd6b"
      unitRef="usd">63700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie10c867d799d4679b141e08dc578e51f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctMS0xLTEtMjQ2MjYz_ddd87874-5306-4bb5-9c7d-fbf57fc5bcba"
      unitRef="usd">32000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i97f0c78f29754db2b760047cbe32a568_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctMy0xLTEtMjQ2MjYz_a4d50a10-4398-4bd3-b9c8-25dd0dede6da"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5964e87d1767486d9c9f3e69ea87005f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctNS0xLTEtMjQ2MjYz_ad0aba7d-2e73-464f-9a1b-ea80488c4102"
      unitRef="usd">32000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ide8899346d6d43418aa5c2c278c01334_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctNy0xLTEtMjQ2MjYz_0bb15ea4-aa40-42ab-9650-2370c332e774"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0723274d0cf649f5a2ded1f032e2b7c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMjctOS0xLTEtMjQ2MjYz_2a1e9563-8c6f-4ec7-bde9-b11b23919117"
      unitRef="usd">32000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtMS0xLTEtMjQ2MjYz_e0757b39-4e4d-4cf4-84c1-9c3d53630ca7"
      unitRef="usd">40100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtMy0xLTEtMjQ2MjYz_7e64cb73-a064-4112-bcb0-5cbb71299709"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtNS0xLTEtMjQ2MjYz_66823487-a58f-42af-bc27-7731ba1416ce"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtNy0xLTEtMjQ2MjYz_5120f66a-a395-472c-b05c-d2338a640128"
      unitRef="usd">40100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ic0f030511d7046938601479dedb444f4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzEtOS0xLTEtMjQ2MjYz_3dad7303-2a93-4961-b8ac-a06d9cd5385f"
      unitRef="usd">40100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItMS0xLTEtMjQ2MjYz_f4aed0dd-c0d9-46b1-99b0-c8a785a26c96"
      unitRef="usd">71800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0ab4c398ad894122bc46ff06e78555c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItMy0xLTEtMjQ2MjYz_da91ef20-cd00-4c57-aadf-061757d57152"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1477b2c322fa4d258992d89c08206da3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItNS0xLTEtMjQ2MjYz_c3622c0b-23ea-4be5-bf39-2201d8c337c3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib07ca7f96ff047149b52aa21f1419c5d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItNy0xLTEtMjQ2MjYz_1119d6f7-dd19-4e6a-a2a4-b9ae19787297"
      unitRef="usd">71800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic0f030511d7046938601479dedb444f4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfMzItOS0xLTEtMjQ2MjYz_3215b0af-8809-46e0-bf37-b06597797fb0"
      unitRef="usd">71800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i13b3318a1c6d4b2989d8bd17e5d7fa8d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtMS0xLTEtMjQ2MjYz_92e74eb6-4024-404f-ac68-e53f1f286aef"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9c721984329042fa98416c00587829be_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtMy0xLTEtMjQ2MjYz_72797242-21c1-4972-bddf-f28e23376363"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7b26c90f2d0f429498c69e75f2486afb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtNS0xLTEtMjQ2MjYz_2c8b9bf1-7ab3-4d33-8ff2-acb6616ee373"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia203e1c41a27445f9ac21572233934b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtNy0xLTEtMjQ2MjYz_5d313091-4e84-4a7c-81df-b1acc6eacfcb"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iff538190e8dd49b1a7a2291adead31c0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDAtOS0xLTEtMjQ2MjYz_684741d5-565f-4ef6-b54a-7196b146564a"
      unitRef="usd">134300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3322119f512345d8bdc5b393121fe2a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMS0xLTEtMjQ5ODIy_4efcb5c7-4c71-49aa-8d76-519aabe6dced"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMy0xLTEtMjQ5ODI5_c08b841c-8d2a-4d13-b39a-d7d5815e9974"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="iddbfbaced29242dabda4aa8d0200d534_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNS0xLTEtMjQ5ODM2_5518489f-d7a6-45ee-b5b0-6c3f3559d4ac"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i61271b58943e4dfe8d82e39de366487a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNy0xLTEtMjQ5ODQz_3bc60411-06b4-4d85-bf04-e390e7b39357"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic6961e3f6be845d49d270b23ae0eb760_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItOS0xLTEtMjQ5ODUw_2035b4b2-b747-42c0-b4b6-d1a845c9bd1a"
      unitRef="usd">162900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3322119f512345d8bdc5b393121fe2a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMS0xLTEtMjQ2MjYz_ab3af688-58fb-4907-8a2e-8f319f1c17e6"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie5ab57cab68d4cf0ab106fdbc2e4e367_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItMy0xLTEtMjQ2MjYz_7520e533-9832-40b1-a0ac-8ddcd073d148"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iddbfbaced29242dabda4aa8d0200d534_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNS0xLTEtMjQ2MjYz_8aa6c950-32f5-4e75-b8df-841395d762a2"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i61271b58943e4dfe8d82e39de366487a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItNy0xLTEtMjQ2MjYz_687a70f2-b9af-4e88-8c32-c03003a4bea5"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic6961e3f6be845d49d270b23ae0eb760_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDItOS0xLTEtMjQ2MjYz_170357b1-994f-495d-90dd-e1b08d02642c"
      unitRef="usd">246000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6ee7bb9be4e14b0199dbb8ff375c4fd5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtMS0xLTEtMjQ2MjYz_a693ada3-5367-4b1f-8352-3bdf37d77a80"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic42c0160e96e4f31982f3ea5eddf15be_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtMy0xLTEtMjQ2MjYz_867a2360-10ae-4e38-abb6-63f70ea86240"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="iebbad1803617416b8a7575b6635bd9e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtNS0xLTEtMjQ2MjYz_a7115869-dee7-4939-ac72-f61ad28b0b3f"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifec954c0cc0a4864a3be7c95f0bbbba3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtNy0xLTEtMjQ2MjYz_f303438c-6360-4bb4-a487-695af1d21b4c"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i29f5e9a727714d8e9d04fd093c69c3f9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNDUtOS0xLTEtMjQ2MjYz_24421d03-07d1-4e1d-b7d0-5a54053d5f83"
      unitRef="usd">67600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i023e643351984eaa8065abddb7c0e922_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtMS0xLTEtMjQ2MjYz_3841fb26-7d67-414f-8bc3-3a75bb632e54"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i68d6338210f24d0b8761f25b6917fedf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtMy0xLTEtMjQ2MjYz_10a99407-38a3-4eeb-a5bc-5039de0b47c4"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic0289f9ec779478ca9a7d9feaa66a043_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtNS0xLTEtMjQ2MjYz_775dabf9-8c12-470f-9d7d-58df0d71691a"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i27e470a377e24131be208163db576480_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtNy0xLTEtMjQ2MjYz_dddd7789-45db-495d-9eda-15d97d660ae9"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i17bd13ed9bbb44bd9b794d91b7205501_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTAtOS0xLTEtMjQ2MjYz_8ce18a44-cf6d-4bf4-b877-236fb72b077e"
      unitRef="usd">53100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if16b30290f524f5ba8cd96a652b77f18_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMS0xLTEtMjcwNzE3_3ee3f829-6afd-4df2-a603-f2ba60872150"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0cac47e76cf444dcab2ac2c436b08b33_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMy0xLTEtMjcwNzI3_dbbf3e8d-f4dc-40a6-9634-8495db3c9810"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibb9f543aacc94384a647f3a1c0667ca4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNS0xLTEtMjcwNzM1_b5651f91-225e-4292-b8ed-6ed5f50992b3"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1df7036cdae24b0a97dccbbd25afe031_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNy0xLTEtMjcwNzQ0_fb9d3677-b9ca-4d70-8457-b13bac5d6e5d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2b8664bea8164219ad1c5f82db48f0b3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtOS0xLTEtMjcwNzUy_af525a58-2699-4b6d-a3f8-b926467ab0ab"
      unitRef="usd">38300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i94edd79b891548bd83088ab50b487992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtMS0xLTEtMjQ2MjYz_31d26ed1-0e03-42a4-a489-6c710744bdea"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id027583937064a45b5174328a3e4fd18_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtMy0xLTEtMjQ2MjYz_befa0eda-d803-48e7-8bae-348d30bb9cb8"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtNS0xLTEtMjQ2MjYz_804cda63-870a-462b-a402-fffdf2d4255f"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifed5b21a16d248339ba5818828910280_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtNy0xLTEtMjQ2MjYz_b90cd925-ef47-45a7-b75e-826746b07778"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTMtOS0xLTEtMjQ2MjYz_980244e2-0640-4a85-b13f-79584d312849"
      unitRef="usd">26600000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i94edd79b891548bd83088ab50b487992_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMS0xLTEtMjQ2MjYz_3e0e2dda-4fca-4bed-b41a-c6c7c5c653df"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id027583937064a45b5174328a3e4fd18_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtMy0xLTEtMjQ2MjYz_3c0d856b-a4ae-4a26-9844-bd488e899dbf"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i366dccb46abb4e8bbaff9cadcd0fe40c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNS0xLTEtMjQ2MjYz_158e86e1-7c54-4938-b60f-baf6c3584b60"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ifed5b21a16d248339ba5818828910280_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtNy0xLTEtMjQ2MjYz_729f157c-6b6e-420e-ab50-ddbff94b0b63"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5da89e98bd5b4bfeb01c03d7644f2a71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTQtOS0xLTEtMjQ2MjYz_42908900-4800-4415-880c-c78b6064120c"
      unitRef="usd">21500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtMS0xLTEtMjQ2MjYz_6e0e0889-4b69-4f33-90c5-6aa9068162ad"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtMy0xLTEtMjQ2MjYz_137ce972-79a4-4d6b-9c51-70b8caffe488"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtNS0xLTEtMjQ2MjYz_0a2b7966-3f4d-4acc-8014-fc1cc03593e0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtNy0xLTEtMjQ2MjYz_6e067a5e-fb26-4dba-afad-ccd73b9ca90c"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTYtOS0xLTEtMjQ2MjYz_5368229f-701f-46ae-a526-09743a0047fd"
      unitRef="usd">39500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iefe01b19e39a4007b2c2d6fed53c9838_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctMS0xLTEtMjQ2MjYz_c63bbcb9-6beb-4ab7-b83e-4f88edaf2630"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4108ea1ab1ce40eeb2c82f037b7443b5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctMy0xLTEtMjQ2MjYz_348243fa-0a3e-4b3f-b5ba-af4c127abac8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3b2f853a69374cc289e36b04c56dc656_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctNS0xLTEtMjQ2MjYz_c077228a-3c08-41ce-83c0-03b3c987544b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5711ab457fe44e7f8c656a2c72ae9cc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctNy0xLTEtMjQ2MjYz_79e89781-578f-4885-9424-e8c6b9aeae11"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8cea0f1817514262a527599b1b82ff06_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82MS9mcmFnOjQ5YjAyMmY1NGRiNTRkNzNhYzIyYTBhOTBkYzIxZTBhL3RhYmxlOjcyOTliMTlkOTYxOTQzYTQ4YWY2ODhiZmM2NTkxY2RlL3RhYmxlcmFuZ2U6NzI5OWIxOWQ5NjE5NDNhNDhhZjY4OGJmYzY1OTFjZGVfNTctOS0xLTEtMjQ2MjYz_279cb2f3-d85a-4c43-b297-46045c6c9548"
      unitRef="usd">70600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfMTMyMA_8f3b0702-b234-4bb4-bebc-875af7fba4c6">Income Taxes &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was 12.1 percent for the three months ended March&#160;31, 2023, reflecting the tax impact of the new Puerto Rico tax regime, partially offset by a net discrete tax benefit. The effective tax rate was 7.3 percent for the three months ended March&#160;31, 2022, reflecting the favorable tax impact of net investment losses on equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing. While it is reasonably possible that the Internal Revenue Service examination of these tax years could conclude within the next 12 months, final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings. As a result, an estimate of the range of reasonably possible changes in unrecognized tax benefits cannot be made.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfNTY_ba3d01c2-4fbc-4132-84cc-c7a6463e2e29"
      unitRef="number">0.121</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82NC9mcmFnOjVjNDY1NzU5NzFmYzQ0OWJhN2FlMTZhM2E2ZGUxZWZkL3RleHRyZWdpb246NWM0NjU3NTk3MWZjNDQ5YmE3YWUxNmEzYTZkZTFlZmRfNzA5_b4e440fe-e003-4f5a-acb7-10b171854710"
      unitRef="number">0.073</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RleHRyZWdpb246NGQ4ZmM3ZWY1NjFmNDI0ODg4NDY3ZjM4ODRlNmQ5NjFfMTI5_c7b6d44e-b862-414b-893a-da25edf0f6ac">Retirement Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health (benefit) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;161.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(263.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RleHRyZWdpb246NGQ4ZmM3ZWY1NjFmNDI0ODg4NDY3ZjM4ODRlNmQ5NjFfMTMw_73cc4a83-5ea3-4d65-a768-7a3152cf5df1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health (benefit) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;161.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(263.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNC0xLTEtMS0yNDYyNjM_40ea8486-65df-479f-a177-5876613823d6"
      unitRef="usd">70400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNC0zLTEtMS0yNDYyNjM_123dcdd6-bc34-46fd-9249-4994f197724f"
      unitRef="usd">89100000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNS0xLTEtMS0yNDYyNjM_f5db5caf-db9d-4c17-bb69-d86b412ba9c7"
      unitRef="usd">161100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNS0zLTEtMS0yNDYyNjM_d4abe731-eeb0-4bfc-8482-0bc3185ccebe"
      unitRef="usd">100500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNi0xLTEtMS0yNDYyNjM_aa6cb807-b013-4559-8bb5-6b63edccfa94"
      unitRef="usd">263300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNi0zLTEtMS0yNDYyNjM_26670d48-76d8-41e0-adf4-5e7e5ded88c3"
      unitRef="usd">239500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNy0xLTEtMS0yNDYyNjM_b36e1dba-9a95-4008-b290-198e78f4845d"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfNy0zLTEtMS0yNDYyNjM_dd2c1c6b-9d7a-4f47-b21b-7221a16590e9"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfOC0xLTEtMS0yNDYyNjM_45b0ab06-dff9-4076-a24b-1dc425c61469"
      unitRef="usd">-30000000.0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfOC0zLTEtMS0yNDYyNjM_b442789c-60e4-4ffb-a4e5-22b6cf6fedb4"
      unitRef="usd">-87000000.0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0157807f4391408d931450405bc79b5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfMTAtMS0xLTEtMjQ2MjYz_99f23b2e-35d2-41c8-976c-0700fd99d6b2"
      unitRef="usd">-1200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i81d13d43162d4f7b8b80063bf011eada_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOmU2NWE4ZGM4MDE4YTQ2ZGRiYjg4ZmI3ZjE2OTM0OTM4L3RhYmxlcmFuZ2U6ZTY1YThkYzgwMThhNDZkZGJiODhmYjdmMTY5MzQ5MzhfMTAtMy0xLTEtMjQ2MjYz_e66c5dae-63b9-42ad-914b-e50a55247a86"
      unitRef="usd">37800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNC0xLTEtMS0yNDYyNjM_4ce8edaa-b858-40fd-b3f3-486dfc74404b"
      unitRef="usd">7700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNC0zLTEtMS0yNDYyNjM_87f6c44c-7291-496b-87ae-30b9ea4cb9b1"
      unitRef="usd">11200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNS0xLTEtMS0yNDYyNjM_d8db39e5-6627-4e3c-9921-c2b73c0f8e4d"
      unitRef="usd">15400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNS0zLTEtMS0yNDYyNjM_b8e340ce-6a98-4233-b583-fc4383e29c78"
      unitRef="usd">9400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNi0xLTEtMS0yNDYyNjM_54248396-6923-4db1-807e-2c3d61d078dd"
      unitRef="usd">45500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNi0zLTEtMS0yNDYyNjM_f8c58660-e1be-451e-bcd0-cef2e5e9498b"
      unitRef="usd">37900000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNy0xLTEtMS0yNDYyNjM_7f2ee86a-b0c1-4cd0-87f9-480ff17608c7"
      unitRef="usd">-13200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfNy0zLTEtMS0yNDYyNjM_4c4b5fad-d6b3-4d18-ba97-eb164afa7d6c"
      unitRef="usd">-13700000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfOC0xLTEtMS0yNDYyNjM_0e30fcbb-83c1-426b-93ec-d1be05504738"
      unitRef="usd">900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfOC0zLTEtMS0yNDYyNjM_2fc461c0-4f30-483d-a858-310cbb2cd6d1"
      unitRef="usd">-200000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if7ac7b89bd5347d2a00b7991af20dd7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfMTAtMS0xLTEtMjQ2MjYz_60f9c9ae-0dd2-4b46-9706-4d818cff7fb6"
      unitRef="usd">-36500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i77ebcd3a839f4360af3965274b39a2b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF82Ny9mcmFnOjRkOGZjN2VmNTYxZjQyNDg4ODQ2N2YzODg0ZTZkOTYxL3RhYmxlOjI5YzEyNzRlNDAxODRlZjE5MTQwYzM3OWRmZDFjYTk3L3RhYmxlcmFuZ2U6MjljMTI3NGU0MDE4NGVmMTkxNDBjMzc5ZGZkMWNhOTdfMTAtMy0xLTEtMjQ2MjYz_e2d99514-aefb-4f25-b489-d3360b5971d2"
      unitRef="usd">-30800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfMjU5OTk_14711df5-2173-4190-8780-0be39cd7acca">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta (pemetrexed)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was protected by a patent through June 2021. A number of legal proceedings that were initiated prior to patent expiration are ongoing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a named defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in three different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following a trial, in November 2022, a jury returned a verdict in favor of Teva. The parties have filed post-trial motions on which the court will rule and then enter final judgment in the case. We intend to appeal the jury verdict if necessary. Pursuant to agreement by the parties, the award, if any, will not become due until completion of the appeal process. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. We challenged these two patents by filing requests for Inter Partes Review with the Patent Trial and Appeal Board (PTAB) and in October 2022, the PTAB granted our requests. The corresponding district court litigation is stayed while this PTAB proceeding is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim, our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court for the District of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trademark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021. In August 2022, the Court dismissed the appeal and in October 2022, Apotex appealed the decision. In April 2023, the Supreme Court of Canada denied Apotex's appeal petition, and this matter is closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies and HHS's Administrative Dispute Resolution regulations. We seek a declaratory judgment that the defendants violated the Administrative Procedure Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we amended our complaint to bring claims related to HRSA's determination and filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties filed notices of appeal related to the court's summary judgment order. In October 2022, the U.S. Court of Appeals for the Seventh Circuit held oral argument. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP (AstraZeneca), were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi, Novo Nordisk, and AstraZeneca, filed a motion to dismiss the lawsuit, which was granted in September 2022. In October 2022, the plaintiffs filed a motion for leave to amend their complaint. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Branchburg Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions including health coverage for a class of individuals and certain of their children. In July 2018, the appeals court (TRT) generally affirmed our appeal of the Labor Court's ruling, which included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately 1.15 billion Brazilian reais (approximately $226&#160;million as of March&#160;31, 2023). In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements, which were allowed to proceed in June 2021; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST. A mediation hearing is scheduled for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019 and September 2020, the LPA filed applications in the Labor Court for enforcement of certain remedies granted by the TRT in its July 2018 decision, requested restrictions on Lilly Brasil&#x2019;s assets in Brazil, and required Lilly Brasil and Antibi&#xf3;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian reais, which ruling in June 2021 was limited in scope and the security was reduced to 100 million Brazilian reais (approximately $20&#160;million as of March&#160;31, 2023). ABL and LPA appealed the June 2021 Labor Court ruling to the TST, which appeal is under review. The Labor Court is currently assessing the status of Lilly Brasil&#x2019;s and ABL&#x2019;s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant is expected. These matters are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lilly Brasil is also named in various pending lawsuits filed in the Labor Court by individual former employees making related claims. These individual lawsuits are at various stages in the litigation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Puerto Rico Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits. The trial began in May 2022; however, the Municipality filed a new motion requesting the CFI to award damages. The request was denied by the CFI in our favor and the Municipality filed for revision at the AP, which we opposed, staying the case. In February 2023, the AP denied the Municipality's motion for revision. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Manufacturer Price Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Following a trial in August 2022, the jury returned a verdict in favor of the plaintiff. The case is proceeding with post-trial motions after which the court will enter final judgment in the case. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in two lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively, for certain patient support programs related to our products Humalog, Humulin, and Forteo. The Texas state court action has been stayed. The New Jersey state court action was dismissed with prejudice pending an ongoing appeal before the Appellate Division of the New Jersey Superior Court. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, along with Sanofi, Novo Nordisk, and in some matters certain pharmacy benefit managers, have been named in lawsuits related to insulin pricing that assert various theories, including consumer protection, fraud, false advertising, unjust enrichment, civil conspiracy, federal and state RICO statutes, deceptive trade practices, and unfair competition claims. These lawsuits include In re. Insulin Pricing Litigation, a putative consumer class action (U.S. District Court for the District of New Jersey, 2017); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. District Court for the District of New Jersey, 2018); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a putative class action brought by direct purchasers of insulin (U.S. District Court for the District of New Jersey, 2020), and suits brought by the State of Minnesota (U.S. District Court for the District of New Jersey, 2018), State of Kentucky (Franklin County Circuit Court, 2019), State of Mississippi (U.S. District Court for the Southern District of Mississippi, 2021), State of Arkansas (U.S. District Court for the Eastern District of Arkansas, 2022), County of Albany, New York (U.S. District Court for the Northern District of New York, 2022), State of Montana (U.S. District Court for the District of Montana, 2022), State of Kansas (U.S. District Court for the District of Kansas, 2022), State of Illinois (U.S. District Court for the Northern District of Illinois, 2022), State of California (Los Angeles County Superior Court, 2023), Jackson County, Missouri in a putative class action on behalf of Missouri counties and municipalities (Jackson County Circuit Court, 2023), the Government of Puerto Rico (Court of First Instance Superior Court, San Juan, 2023), and Lake County, Illinois (U.S. District Court for the Northern District of Illinois, 2023). These lawsuits are at various stages in the litigation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the pricing and sale of our insulin and other products, we have been subject to various investigations and received subpoenas, civil investigative demand requests, information requests, interrogatories, and other inquiries from various governmental entities. These include subpoenas from the New York and Vermont Attorney General Offices, civil investigative demands from the Washington, New Mexico, Colorado, Louisiana, Texas and Ohio Attorney General Offices, the U.S. Department of Justice and the U.S. Federal Trade Commission, as well as information requests from the Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada Attorney General Offices. In January 2022, the Michigan Attorney General filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the Attorney General has authority to investigate Lilly's sale of insulin under the MCPA. The court authorized the proposed investigation and the issuance of civil investigative subpoenas. In April 2022, the parties entered into a stipulation providing that the State of Michigan will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved. In July 2022, the court dismissed the case in its entirety. The Michigan Attorney General filed a notice of appeal to the Michigan Court of Appeals, which remains pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received similar requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021, the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are cooperating with all of the aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc.&lt;/span&gt;&lt;/div&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. In October 2021, the court issued a summary judgment decision in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which were denied. We filed supplemental summary judgment motions. In November 2022, the court stayed proceedings so the parties can pursue mediation. The stay was lifted in April 2023. A trial date has not been set. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. This matter is ongoing</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNDM5ODA0NjU4NTY4MQ_73d9b8ed-c956-4fbb-9c30-a4ab0703898d">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="id1429cdab82b46a7a0ad4c4e85647f6a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODY5MDgz_923ee39f-9d1e-4a38-b4af-081554c63dbc"
      unitRef="patent">3</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="i8d76ed1b0d8a474586570b1b99086173_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODY5NzY3_b867b1ab-2429-463f-ac24-b940bdc07fb1"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="i8d76ed1b0d8a474586570b1b99086173_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4Mzkx_b867b1ab-2429-463f-ac24-b940bdc07fb1"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="i4b4ab320c12a472eb82bbab75fbf501b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODczOTkz_b0f0c300-6bfa-4ae7-b8e4-ceb408e2580a"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id56d2b03dc9949ebb50d95e71f042821_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODc5MDM4_f19db2e6-fa99-495a-9f45-4072d6d37fdc"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4Mzk2_af40b3ac-8c80-45df-b8ef-2dc8b19a14bc"
      unitRef="brl">1150000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i08c473efe1574d6cb311fd5b27a4d15e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODc5Mjk0_d16c9722-82b5-44ce-b08c-347cbd564beb"
      unitRef="usd">226000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3ad20ef67d2f430481744471c5b56210_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODgwMzI1_db7de391-aca0-4756-b1c9-4b5d5b53548d"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i8c6d0498b5f448c7a43cd5218c9d9457_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODgwNDI1_401052c7-0886-4cd6-99b7-e18a0305c92a"
      unitRef="brl">100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7954361cad5e468189b61f0e148dc919_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODkxMjQz_d41658fa-1111-43db-bb34-302a821033ee"
      unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3ea4ac837c5c446c91d4a1eadb1660df_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83MC9mcmFnOmViNzMxOWRkOGU1YTQyYWZhMGIyZGQwNjJkYWNlY2E3L3RleHRyZWdpb246ZWI3MzE5ZGQ4ZTVhNDJhZmEwYjJkZDA2MmRhY2VjYTdfNTQ5NzU1ODg4NDE1_4f68740d-77c7-4200-b95e-8d1e37644687"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIyOQ_a7b8e3a2-e4d5-4239-a2b6-caefb739fca6">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,874.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,062.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,844.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,826.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,066.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;143.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,777.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,575.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,531.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,225.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gains/losses on available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gains/losses on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (expense) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 5), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIzNA_331bdd02-7b8f-4001-82fc-9879c6fa471a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,874.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,062.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,844.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,826.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,066.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;143.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,777.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Available-For-Sale&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains (Losses) on Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,575.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,531.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,225.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gains/losses on available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gains/losses on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (expense) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if52058720702455ab18d11fcfce47593_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0xLTEtMS0yNDYyNjM_fbd33dca-c172-4aef-a32e-c326f4128c51"
      unitRef="usd">-1874200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41c57ea452d543e989f9536150f9db93_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0zLTEtMS0yNDYyNjM_305fe970-923d-419c-a64f-fe50e1162c41"
      unitRef="usd">-37100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd425dd4dd0841579d320a37187ecdef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi01LTEtMS0yNDYyNjM_f8815283-4f7e-403a-97f8-91327b190ec9"
      unitRef="usd">-2062300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99e2ca758e964af8b28d95fd2e6bc9cc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi03LTEtMS0yNDYyNjM_e8068f08-04c5-4dfa-a48c-1eb605f63cd1"
      unitRef="usd">129000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i653d3a81e6b14167933ef66d19e6c10c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfMi0xMS0xLTEtMjQ2MjYz_8af349cb-670b-4ac8-88a7-4ab1e73f5d45"
      unitRef="usd">-3844600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0xLTEtMS0yNDYyNjM_aec1ebbf-ce04-4ab5-ae59-97f2a592be49"
      unitRef="usd">72800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0zLTEtMS0yNDYyNjM_c1820e0e-adf4-438c-97c8-a75ecedee2cf"
      unitRef="usd">8100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC01LTEtMS0yNDYyNjM_e019aae9-dbf2-4d77-92cb-a321bc7fa835"
      unitRef="usd">-16800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC03LTEtMS0yNDYyNjM_e53c020f-3e67-4372-b32c-aa7bec994115"
      unitRef="usd">12700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNC0xMS0xLTEtMjQ2MjYz_27095175-6492-485e-83af-607be5c8bb61"
      unitRef="usd">76800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0xLTEtMS0yNDYyNjM_5db5f05c-fa4e-426f-9143-fa47f8384036"
      unitRef="usd">25200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0zLTEtMS0yNDYyNjM_de8d3bc1-188a-4c3b-b830-44eea47ea72c"
      unitRef="usd">-700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS01LTEtMS0yNDYyNjM_dbe3711f-a9d9-42cf-bda6-38372dbbdf46"
      unitRef="usd">-13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS03LTEtMS0yNDYyNjM_3c55ab5c-b99b-4ea9-98c1-165f9120d26e"
      unitRef="usd">-2000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNS0xMS0xLTEtMjQ2MjYz_37b44e5f-c489-422d-8f4f-3e84a1991577"
      unitRef="usd">9500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0xLTEtMS0yNDYyNjM_b4d9252c-594a-4b40-bc16-9c62422efce6"
      unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0zLTEtMS0yNDYyNjM_cafa7c7f-afe1-44a6-b831-dfb44b585733"
      unitRef="usd">8800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi01LTEtMS0yNDYyNjM_f460fa4f-7913-4974-8530-b3cb2a46d278"
      unitRef="usd">-3800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi03LTEtMS0yNDYyNjM_bfbc55df-c1b1-4219-90cf-def78c57d2dd"
      unitRef="usd">14700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfNi0xMS0xLTEtMjQ2MjYz_79cdabf4-8ad4-48a2-aed0-e4a7440cd230"
      unitRef="usd">67300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id51d9a0f258444078ac8ef9caa739449_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0xLTEtMS0yNDYyNjM_342762e1-f0e1-4dd5-9eff-c0b09465d54a"
      unitRef="usd">-1826600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14ddf45785ed4e96a99f49ff596d8acb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0zLTEtMS0yNDYyNjM_e5b1709a-f231-469e-aa16-854604da31f4"
      unitRef="usd">-28300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7e2bb76dd4f4adab26a41f1f82d2c2b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC01LTEtMS0yNDYyNjM_11f02dbc-d3bd-43b7-b1f1-82eb4265fff1"
      unitRef="usd">-2066100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i510af8b9f1844bed829cb00dfc685190_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC03LTEtMS0yNDYyNjM_9d7631cf-03af-4326-9b85-896cfa894517"
      unitRef="usd">143700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e84d8dd08244d678c234bae2809c48c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjVjOTZlNzJiMjU1NzQzYzhiYTMxZmFkZjk5OGJlMDZiL3RhYmxlcmFuZ2U6NWM5NmU3MmIyNTU3NDNjOGJhMzFmYWRmOTk4YmUwNmJfOC0xMS0xLTEtMjQ2MjYz_94c6cd00-8cd2-4c6c-9b94-d5550f705cb2"
      unitRef="usd">-3777300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0d4430e40014abc901dd4edd7cb49e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0xLTEtMS0yNDYyNjM_1e06843d-e9da-4fb8-8d42-c6983426401b"
      unitRef="usd">-1550200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie00101643b4643a483d888a017ecd8ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0zLTEtMS0yNDYyNjM_bcd653eb-43bc-4b2d-92dd-d0f23a465bd7"
      unitRef="usd">3700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac6c49fd39884008bd1780b0e7dd589d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi01LTEtMS0yNDYyNjM_cb921d19-3da5-4bac-b170-2c7ba14e647f"
      unitRef="usd">-2583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9209cc4104c44020b5cca0fb5e342032_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi03LTEtMS0yNDYyNjM_d9172682-81cc-442a-93c1-4d7f16967787"
      unitRef="usd">-213000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b6a9fdaf2f44f0ab06f86a366185a4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfMi0xMS0xLTEtMjQ2MjYz_9f0446df-2b6b-4d42-bd21-4498b9e6720e"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0xLTEtMS0yNDYyNjM_c8116f28-e4b9-4164-b8ad-8396482b544e"
      unitRef="usd">-25000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0zLTEtMS0yNDYyNjM_8e16cb38-5a86-41ee-a6f6-401079b9b577"
      unitRef="usd">-21300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC01LTEtMS0yNDYyNjM_f7b4151b-a0ac-48ca-9695-29b67ee7ea4b"
      unitRef="usd">-6600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC03LTEtMS0yNDYyNjM_46b5b740-cd0e-4e54-a44b-b707894a23c4"
      unitRef="usd">109400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNC0xMS0xLTEtMjQ2MjYz_98be98d5-595d-474e-94e4-22e9cf581cda"
      unitRef="usd">56500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0xLTEtMS0yNDYyNjM_8295dbe3-a364-4793-9aa9-cb63e9943384"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0zLTEtMS0yNDYyNjM_0ecaddc5-efd9-4a35-8c0a-c691edae0a75"
      unitRef="usd">500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS01LTEtMS0yNDYyNjM_92b5e539-c095-4f8b-a7bf-053dd29cc97e"
      unitRef="usd">-58600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS03LTEtMS0yNDYyNjM_5abd4d61-4464-4f28-8cac-b828f35020d7"
      unitRef="usd">-3200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNS0xMS0xLTEtMjQ2MjYz_4008b540-757c-46e9-9975-ad00e5b9d575"
      unitRef="usd">-61300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0xLTEtMS0yNDYyNjM_de534b5a-b09d-4891-a8dd-464481893de6"
      unitRef="usd">-25000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0zLTEtMS0yNDYyNjM_ae2a481b-35f0-44e1-bc1c-c39e0921ab6c"
      unitRef="usd">-21800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi01LTEtMS0yNDYyNjM_137fd90c-dfc3-486a-9073-9ded0ff07af3"
      unitRef="usd">52000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi03LTEtMS0yNDYyNjM_03bcf180-730e-4d7a-a61f-7bd11535eb10"
      unitRef="usd">112600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfNi0xMS0xLTEtMjQ2MjYz_e945a31e-8d2f-4a6f-a948-149d2cb9153d"
      unitRef="usd">117800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27e1942610fb4fe3b661fe8f47c36101_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0xLTEtMS0yNDYyNjM_6b4777f0-141e-475c-9287-70e04ad3ceb0"
      unitRef="usd">-1575200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd6d6a2a126f4ea8916e435402446e81_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0zLTEtMS0yNDYyNjM_ee6a013d-6e70-4c16-9fc9-cbc925be375c"
      unitRef="usd">-18100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie708bb24249c494bac718b7262662532_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC01LTEtMS0yNDYyNjM_e3c909d3-67ae-44db-b57d-422d065df1eb"
      unitRef="usd">-2531600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1057b3b5f0c84df780eeb0542ab9296b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC03LTEtMS0yNDYyNjM_6722183c-94f0-4f8f-8f50-47e079fb64f9"
      unitRef="usd">-100400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0424c9ff126d4e098f24803951d6a61e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOmY3NTI4NGNiMWU1ZjQ3OTI4ZGNiMDk4YWE5N2M1M2U0L3RhYmxlcmFuZ2U6Zjc1Mjg0Y2IxZTVmNDc5MjhkY2IwOThhYTk3YzUzZTRfOC0xMS0xLTEtMjQ2MjYz_10b50b90-9ef3-4190-acb4-e31c991ba68f"
      unitRef="usd">-4225300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ib495b1145e52494b89d9ffea450579fd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMi0xLTEtMS0yNDYyNjM_7edf5690-6848-439c-b133-5b30892b9c67"
      unitRef="usd">-46500000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ida69be7d68c046dda31bd21d1ee97540_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMi0zLTEtMS0yNDYyNjM_f151828a-fef1-4220-9fe1-bb984b0609b7"
      unitRef="usd">13700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i53eee16a0c6b466daa3254a9d2030107_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMy0xLTEtMS0yNDYyNjM_25111455-2a92-4bd2-83c0-107cc5aceeb7"
      unitRef="usd">2600000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6b36144f48ef40aea33af45869704e46_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfMy0zLTEtMS0yNDYyNjM_9be6e241-11a6-4898-8a0d-7a6bd7fa666d"
      unitRef="usd">-6700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i26726a4aeedd4a99b14cff62f533eb55_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNC0xLTEtMS0yNDYyNjM_56e96ab1-e42e-40f8-b5a9-4539c99603e2"
      unitRef="usd">4000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6b1c441af8b9495bb3d71c7cf5d1c646_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNC0zLTEtMS0yNDYyNjM_904c8826-c5cd-4476-8026-873cdc355304"
      unitRef="usd">28400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i37050817f4aa4295bb353f26657f45b3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNS0xLTEtMS0yNDYyNjM_36122c70-8e8b-478d-bc76-6d5531a5724d"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iea75053548e54a9383137eac2aa979bf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNS0zLTEtMS0yNDYyNjM_5f324c9e-99a5-4b10-a7fb-4700b4275809"
      unitRef="usd">29900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNi0xLTEtMS0yNDYyNjM_02a2cea7-7278-4c25-b012-f809182ed8b5"
      unitRef="usd">-36000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjU5ZjYzMGYzNmM3NTRmZGRhYWMxYTYzZjRhZDNjYTAwL3RhYmxlcmFuZ2U6NTlmNjMwZjM2Yzc1NGZkZGFhYzFhNjNmNGFkM2NhMDBfNi0zLTEtMS0yNDYyNjM_829048df-68c7-432f-8adf-ede009a6719a"
      unitRef="usd">65300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RleHRyZWdpb246MjI4Zjg5MjE2MzlmNGZhYWI1NTgzMzBhYWQ4NWU5MWNfMTIzMg_a303452f-e3ec-4cfd-ae30-3dc82932bc35">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0b5badb1e9e9416281833c0e936313e3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNC0yLTEtMS0yNDYyNjM_f0681a5b-ae0e-4901-a048-fa5ab3d76f34"
      unitRef="usd">-12600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie92b4b2cc38546abbedc7e893d1b940c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNC00LTEtMS0yNDYyNjM_006c5280-2972-4964-a555-5b99ced0f9b3"
      unitRef="usd">-13000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib17225a13a894c18ab97a3b6bf0fb9b2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNS0yLTEtMS0yNDYyNjM_908c6035-13fa-4fda-8552-d7fcb8d83f72"
      unitRef="usd">29100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4c5514dfeeac4fd79d56e6bb4067d42e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNS00LTEtMS0yNDYyNjM_9a9e209c-b340-409a-baf1-5bb40318a762"
      unitRef="usd">87200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNi0yLTEtMS0yNDYyNjM_5ab7df07-572e-45c0-b712-ee60934c12b2"
      unitRef="usd">16500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNi00LTEtMS0yNDYyNjM_29de0064-f1e9-4fde-ab26-aaa6292d539a"
      unitRef="usd">74200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNy0yLTEtMS0yNDYyNjM_400f4a41-87cf-49c8-a621-d358b004d4da"
      unitRef="usd">3500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfNy00LTEtMS0yNDYyNjM_6c565b56-cdfe-4397-aed9-dfc60596e077"
      unitRef="usd">15600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i5724b7029fb74929941da12378c70867_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfOC0yLTEtMS0yNDYyNjM_4b654cef-8cfd-4041-9e24-9ef82688cbc7"
      unitRef="usd">13000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50dee3e9f06f4e81ad5768b1bb4d9f8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfOC00LTEtMS0yNDYyNjM_bd984eb1-a429-476f-a120-7d140460672d"
      unitRef="usd">58600000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bc8829f02584de496f6271827b1daa4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTAtMi0xLTEtMjQ2MjYz_64fd1cf4-b64a-4edf-8953-4542993050a7"
      unitRef="usd">-22500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id6504efffb904c0bb389e6b7ec4a995b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTAtNC0xLTEtMjQ2MjYz_87835f14-f282-4359-965b-e5fdeec5f6ec"
      unitRef="usd">2700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i0d8b989d89ce4af9a4cc6f268d29ee6f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTItMi0xLTEtMjQ2MjYz_cc6f5835-d356-4aed-b1a1-545dbd91d917"
      unitRef="usd">-9500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a88826d3584cfc872524cbbc7ff75c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83My9mcmFnOjIyOGY4OTIxNjM5ZjRmYWFiNTU4MzMwYWFkODVlOTFjL3RhYmxlOjg2NDBlZjUwMmIxNzRlNzNhNDE4MTU3ZDhkMmIwNjcwL3RhYmxlcmFuZ2U6ODY0MGVmNTAyYjE3NGU3M2E0MTgxNTdkOGQyYjA2NzBfMTItNC0xLTEtMjQ2MjYz_46ebb571-0149-4757-aaf4-50244afc0b37"
      unitRef="usd">61300000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RleHRyZWdpb246NDA2MTk3NDRlYzIxNGY5ZmIzOTUxZjg1YjI5MDg2ZThfMTAw_bfdde9d8-1018-491b-90b6-6a6e7daefd0e">Other&#x2013;Net, (Income) Expense&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(34.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment losses on equity securities (Note 5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(115.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RleHRyZWdpb246NDA2MTk3NDRlYzIxNGY5ZmIzOTUxZjg1YjI5MDg2ZThfMTAy_1f9cba1c-b419-4223-b1e6-ec5effe64f76">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(34.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment losses on equity securities (Note 5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(115.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMi0xLTEtMS0yNDYyNjM_27387715-c210-4a1e-b64f-3a3e7574fe2b"
      unitRef="usd">102800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMi0zLTEtMS0yNDYyNjM_d02a2129-58ad-4bb8-8bd6-9bac61b0634e"
      unitRef="usd">84900000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMy0xLTEtMS0yNDYyNjM_443d4661-990e-4533-b825-b3e9adc45697"
      unitRef="usd">34200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfMy0zLTEtMS0yNDYyNjM_17e082b6-9a67-465c-83b5-f8ddf96e6acb"
      unitRef="usd">7000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNC0xLTEtMS0yNDYyNjM_e8742930-8b24-4c07-a315-33278d3c189a"
      unitRef="usd">-13700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNC0zLTEtMS0yNDYyNjM_db37c3f7-baf1-4379-bc2d-8a73ddccc74c"
      unitRef="usd">-425400000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNS0xLTEtMS0yNDYyNjM_b5c60530-e29d-4b5f-a0fc-8804a3ae55b7"
      unitRef="usd">-115800000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNS0zLTEtMS0yNDYyNjM_6d722b9f-34ab-43a5-9272-57bce1b0e8d8"
      unitRef="usd">-93300000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNy0xLTEtMS0yNDYyNjM_c18d5fcc-c517-40e9-b0e5-f1193258361f"
      unitRef="usd">2200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfNy0zLTEtMS0yNDYyNjM_9d6d5c0b-9520-44ab-a523-e4c68dc1df27"
      unitRef="usd">59300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfOC0xLTEtMS0yNDYyNjM_0bd18910-ff17-4eeb-b2e5-34958ede46bc"
      unitRef="usd">35700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id13c9c6b838744e8b2c37e9044b59722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF83OS9mcmFnOjQwNjE5NzQ0ZWMyMTRmOWZiMzk1MWY4NWIyOTA4NmU4L3RhYmxlOmY5NmM4NjljNzc4YjQ4N2Y5MDJhNmJkMTAzOTdhMTU3L3RhYmxlcmFuZ2U6Zjk2Yzg2OWM3NzhiNDg3ZjkwMmE2YmQxMDM5N2ExNTdfOC0zLTEtMS0yNDYyNjM_0a87fa2a-6f75-4c56-8d77-4a88068474ca"
      unitRef="usd">-350700000</us-gaap:NonoperatingIncomeExpense>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of March&#160;31, 2023, there was $2.50 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTUtMS0xLTI0NjI2Mw_77338d56-8ac0-43c1-b8ab-b7acfda6452c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTMtMS0xLTI0NjI2Mw_1bbf2a04-4306-4745-aabd-cafcf828687f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xMy0xLTEtMjQ2MjYz_b2e04891-045d-4880-b9bd-25cdb35cd4c0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTMtMS0xLTI0NjI2Mw_ae2f59fc-1490-44a1-9f98-361fe3914271"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTMtMS0xLTI0NjI2Mw_d6737b0d-d517-4ec4-9b4d-346785872020"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjEtMTUtMS0xLTI0NjI2Mw_b61a98a7-f6a0-4c2a-92ad-6feb8ce1ea44"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTUtMS0xLTI0NjI2Mw_e4a72e19-658f-425c-b867-f0d4b0884622"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xNS0xLTEtMjQ2MjYz_83fd2c9f-9169-4527-b777-27e36ef6b5d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTYtMTMtMS0xLTI0NjI2Mw_eb30290c-b21f-4e21-866f-28c757f1a606"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTUtMS0xLTI0NjI2Mw_6b241e4e-9c6f-4b3e-9c03-41773c7af2cf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTMtMS0xLTI0NjI2Mw_7df6e5fe-f374-453d-99dd-b910a9826da6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTAtMTUtMS0xLTI0NjI2Mw_6f4a421f-fd0f-445a-8d37-5ed723418d8a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjItMTUtMS0xLTI0NjI2Mw_e4a64773-2c23-4151-86ad-19a08a6c0978"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjUtMTUtMS0xLTI0NjI2Mw_a8bb82f8-3429-45bc-94d1-9e70c8f997a5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMjAtMTMtMS0xLTI0NjI2Mw_885637c7-66f0-42a9-adb9-a6288f996bd2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMTQtMTMtMS0xLTI0NjI2Mw_175107ea-7e52-48da-a039-9156ba409e1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfMy0xMy0xLTEtMjQ2MjYz_77a958ec-244c-43c2-946b-da0af471f673"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xNS0xLTEtMjQ2MjYz_0cdc8baf-a267-4eaa-9bf7-aed19b0aaea2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOS0xNS0xLTEtMjQ2MjYz_17c55127-d642-44f9-8ed8-e01710aa58d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RhYmxlOjQwOTkwODBmNzExMzQzYzViMThmM2E3Mzg4N2NjNDdjL3RhYmxlcmFuZ2U6NDA5OTA4MGY3MTEzNDNjNWIxOGYzYTczODg3Y2M0N2NfOC0xMy0xLTEtMjQ2MjYz_e7bd530c-a580-42fc-a516-e4e001118c5d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmJjYzM4YzNmNzgyYzQ1NDVhZDlkYzhjN2YxMDg3MTA0L3NlYzpiY2MzOGMzZjc4MmM0NTQ1YWQ5ZGM4YzdmMTA4NzEwNF8yOC9mcmFnOjQzMjY2NGM1Y2YzYzRlOTQ4MTM5NTYwZDU1NDkyMmZiL3RleHRyZWdpb246NDMyNjY0YzVjZjNjNGU5NDgxMzk1NjBkNTU0OTIyZmJfMjYy_188e300a-0626-4f3f-9eba-d0c5f5d0fc66"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  97YM6M,8>ZSD)   I3P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6<;7/BO!6&_XJ&SM-YGIE-\+MAFV2&>).6*9ME-VD[::<?'*P$S]H6E4U>
M_GTE0Q#.RD?&2/MA X1SQ;<LG5RV@\]>"/U9+C&NT&N>%>7Y8%E5J\_#8;E8
MXCPN3\D*%^P[CX3F<<6>TJ=AN:(X3NJB/!LZEA4,\S@M!A=G]6MS>G%&UE66
M%GA.4;G.\YB^7>*,O)P/[,'["S_2IV7%7QA>G*WB)WR+JW^LYI0]&^XH29KC
MHDQ)@2A^/!],[,_1R.,%]3O^F>*7<N\QXE$>"/G)GTR3\X'%MPAG>%%Q1,R^
M/.,(9QDGL>WXWQ8ZV/U,7KC_^)U^78=G81[B$D<D^U>:5,OSP6B $OP8K[/J
M!WGY&]X&\CEO0;*R_A^];-[K>0.T6)<5R;?%; ORM-A\C5^W [%7X(Q:"IQM
M@?.AP&[[">ZVP*V#;K:LCO4EKN*+,TI>$.7O9C3^H!Z;NIJE20N^&V\KRKZ;
MLKKJ(B+/F*(YVV/H!)7+F.+R;%@Q,/_V<+&%7&X@3@O$15])42U+=%4D.&G6
M#]D&[;;*>=^J2P<$?HWI*7+M3\BQ'%>R/1%</EFQ<L>3E3<VQ]T-DEOSW!;>
M%[)8LZE;H6FQ63A\ OYGQMZ%IA7.R__*AFR#].1(OCH_EZMX@<\';/F5F#[C
MP<6?_V0'UE]D>37!&NF]77H/HHOT=V\K+$L*E]O6R7=9)+"J9R1_%\GO%FF.
M:4H2/F\16S[2=#!I-U-;IRI8WS-GL,L9@%MW551I]8:NTPRCFW7^@*DL(<RP
M+/LD<'U;E@VL[)DMW&4+NV3[@9_2LJ(QVYDW<2[=@PK.;(IFT]GL'DUNOJ#H
MV]?YY.9>%A;$] P[VH4==0D[+1:$K@BM.] G=%NQ.8L(11%9%Q5]8U\3Z0C
M\.F-+"Y8TS/N>!=WW"7N7?R*I@E;I^ECNMATW?99#!-=_\3R0FOL6[*L8&W/
MK+8E?@5;7=).DH31RT_O#U#]"^9;(=VC"N0LS3(^'3:3!:.(#:)TV"(8U#?[
MGG[8!V6/^#,VH^_(2R'-#>.F19+&1;PB62KSF @N[YO6$6F=@]+N%O"<DN>T
M6,AW-<R4KUZXJ&]0(4PV:"2_!)V3LHHS].]TU=JC%$0O<$:^-*D)-[*%'-FP
MWM03=L*.H-J#P0#7#J6Q3/B1+03)AKUF1A9L?\V7I(#,00%QPN"$'4]*6RY<
MVC>?$".[DQE%:TJY!_[ K%%6:?%4+\FU_!@()MY+CYPBN*IO3B%)=B=+FO+V
MOSEDYJ(;OP>7YH2);3E-Z)$M_,CN)$C<=)D.L:[Z1.B;-!W,F<64'0I/%@O,
M0 R3;)#2Q"8,R1:*9'=RI-L\SC)TN2[9MTOYO(4YCW%6ROI6!-?US.<(*W(Z
M6=%5CND37YA_981JR;ILOHH+Z:Y5 %N#PG5]@PH%<CHIT.T2LQT)Q8,Q[?%,
M.(\CG,?IY#PL6,[\_;8BBY],?.HS3>C;NF)>P)RM>)(FUB0QVW'8T/R:QD]O
M/E^,O;$3.F.7';@_RT(*WW%@.YGDN$CJ,PK762S/ @/:]YX)O7&$WC@=3_Y<
MIR4W@GL<4W3-7I2V&@6L]6R>"==QA.LX'<\&;3-N3PJUIX1QWZ6G2N"BOAF%
M[SC=?(?%I"PB.T["K^CO6-YH5">$V#]_[(4C:4X3ON,(WW%@.WD7NOWI"IW=
M4^!.3FSGQ)7O4!/"XPCA<6!1^;Z.*7.Z[&WKKM)P,**B:WG+,2$VCA ;!Q:2
M.QH795J?[0&B]90:N*YG-E=(C0L[R/YO0?1[0="*S<_G.%OC/Z37$#29R?8B
M@@G/<87GN+:!JRB:Y&4[ B94R!4JY,(J=)=6&4;D$=G.[P]_H%N\6%/6E:6Y
M8=)A\RB":7US[UT^@^6&K>BD/K9^RQ]()HT+ V8SZ1EYN*IO+.%&+JPS[_L/
M7;TNEG'!CAO;KD H0#?WMU?2?":\R!5>Y,(B$R)[./H-W9"*J7JRQOP2E^P4
MW"7,.7B1FC E5YB2&QAH4YJL9SL")AS*%0[EPM)S2)N"25UG4 1S^B86,N7"
M)M2A02E.&\WN6X*9<"E7N)0+>] !+0H&M;8H$S[E"9_R8)^R3P/'_S#! NG?
M*&@U*5VT9FIA4IX!D_*TFI0N6G,$A$EYVDQ*0>HZ@R*8TS>Q<"CO6(=2 'B+
MD@<S\L=%>W]=I,NB%*"V%@67]<TG+,I37 0[M3].,%=V1>P2YAR\0$U8E"<L
MRC-@49Y6B])%:XZ L"A/FT4I2%UG4 1S^B86%N4=:U$* &M1+<%,6)0G+,K3
M95$*4&N+,F%1OK H'[8HZ]??@=)SGI<PY] %JHO63"TLRC=@4;Y6B])%:XZ
ML"A?FT4I2%UG4 1S^B86%N4?:U$* &]1\F F+,H7%N7KLB@%J*U%P65]\^W]
MP39L4=:I;UD?)ICL6N(ES#EX@9JP*%]8E&_ HGRM%J6+UAP!85&^-HM2D+K.
MH CF]$TL+,H_UJ(4 -ZBY,%,6)0O+,K795$*4&N+,F%1@;"H +:HX#0,?]OP
M&I-,>CX*9AVZ2'71FLF%204&3"K0:E*Z:,T1$"85:#,I!>F0613!K+ZIA4T%
MQ]J4 L!;E3R8"9L*A$T%NFQ* 6IK57!9WWS"I@+8IB0G/3VI3<&<@Q>ID<_"
M[7T8SH!-!5IM2A>M.0+"I@)M-J4@=9U!$<SIFUC85'"L32D K$6U!#-A4X&P
MJ4"732E K2W*A$V%PJ9"U96]\*.N>V-9/)ASZ +516NF%B85&C"I4*M)Z:(U
M1T"85*C-I!2DKC,H@CE]$PN+"H^U* 6 MZCQ1)K,A$:%0J-"71JE +7U*+BL
M;SZA4:%*HWZY,"/]G/PES#EXA9K0J%!H5&A HT*M&J6+UAR!O3L/:-,H!:GK
M#(I@3M_$0J/"8S5* 6 ]JB68"8T*A4:%NC1* 6IM428T:B0T:J32*#?\,,$"
M:8N".8<N4%VT9FJA42,#&C72JE&Z:,T1$!HUTJ91"E+7&13!G+Z)A4:-CM4H
M!8"UJ)9@)BQJ)"QJI,NB%*"V%@67'9ION'<S,O[9W?H>;25:\%O4;.Y+MGMU
M=Q^X27WWLZ%X^^8F<E]C_M'?$F7XD95:IUQ\Z.:^;)LG%5G5MS9[(%5%\OKA
M$L<)IOP-[/N/A,W:[1/^ W9WQ[OX/U!+ P04    "  97YM6(.B[\ZH$  "2
M$0  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U876^<.!3]*Q:MJD1*
M )OO=&:D9-K5]B%ME"B[#ZM]<, S@P*8VB:3_?=K P%F,#25YB6QF7L/YU[?
MZV.SV%/VS'>$"/":9P5?&CLARBO+XO&.Y)B;M"2%_&5#68Z%G+*MQ4M&<%([
MY9F%;-NW<IP6QFI1/[MCJP6M1)86Y(X!7N4Y9O_=D(SNEP8TWA[<I]N=4 ^L
MU:+$6_) Q&-YQ^3,ZE"2-"<%3VD!&-DLC6MXM4:V<J@M_DK)G@_&0(7R1.FS
MFGQ+EH:M&)&,Q$)!8/GOA:Q)EBDDR>-G"VIT[U2.P_$;^A]U\#*8)\S)FF9_
MIXG8+8W0  G9X"H3]W3_)VD#\A1>3#->_P7[UM8V0%QQ0?/663+(TZ+YCU_;
M1 P<)([> ;4.Z-C!G7!P6@>G#K1A5H?U!0N\6C"Z!TQ92S0UJ'-3>\MHTD(M
MXX-@\M=4^HG5FA:<9FF"!4F G"1RA>3H0<@'<K4$!W0#?I2$895U#LX>"UPE
MJ;0^!Y?@\>$+./MX#O@.,\)!6H#;-,N4X07X.)PN+"')JE=:<4OLIB&&)H@Y
MX)868L?!5\DI.?2W9)!=I.@MTALT"WB+F0D<> &0C1P-G_7[W=$,':=+O%/C
M.1-XWXJ8YJ1/-/CG^HD+)LOZ7UVR&C!7#Z9Z_8J7."9+0S8S)^R%&*M/'Z!O
M?]9%>B*P@[C=+FYW#GUU3UY(41%P]IT* M"Y+M@&P:\1U#[TLO(CWUY8+\,@
MQD9!"'NC W)>1\Z;790UY4*6+GDM51O($2X20,6.L"L=3^^4BW(BL(.X_2YN
M?W915-RJT3G.B+97&_=@D&SH(]\,CM9D;(;L )E0ORI!QR[X1<EP@EF\JU<C
MD?63T5*UC(YH,"8:A=Z 04-48^9#>XIHV!$-9XG*/>*9B+387@ I5%D]4)QQ
M(G?N5'6WTBP=[7#,)W C$QW1UIAY7F!&>MI11SN:I7T=_ZQ2)G?]M+@L&8T)
MYX!-Y+SM6T?;M\UKO"$]VSL*(=)DWC-]?030[F7,GHWAAVK23Q]"!.'G@H@+
M<);6&^SY6S.WQ*&M9=ZB#VE=.MZHOC5FCF</S [9#T08_K+_]/N.EBP<L?!<
MQS:=8[8:N\#S37>"+NKIHEFZK78]$7F,)*!)-!#X5;]WM&"'58NB<7+'=LCV
MG,G:Z)46S@K:&]V:8%L&OKX*G#'3T#7#8Z(:LYDJZ)41SDOC=WEJ;Y*I)=<X
MA\.W.JX[:/Z6G<8NLM'4)@%[;83SXO@5LT)N:1S(TV!SXM.*(CRI*IX*[3#F
M7A?AO##>8)[&:B\!"<TRS ;!ZRNH@8N&R3?=T1*-K:1(3H@/[&42SNODES2K
MU#'^-^@&[Z([MIK4=-AK)0QGR^FAN3-4O!8>$.,LKK+ZEJ%.(N2=Q38KR+]=
M;"=".\Q(+\-P7H?[8FON4_HE&XML9!\?;^!892/;F=JA4*^R:%YEAQ4VPQ&-
M95*]_EB?M&9C>;(&M]N<L&U]Z><@IE4AFNM?][3[L'!=7Z>/GM_ JW7S>:"'
M:;Y6R(/;-I6WVXQL)*3<RF5Z6?,!H)D(6M9WZ"<JY(V\'NX(3@A3!O+W#96J
MTD[4"[K/,*O_ 5!+ P04    "  97YM6<O=N.[<"   T!P  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;*U5RV[;,!#\%4(-B@1(]8Z<I+: V&G1')(&
M,=(>BAYH:6T1D4B7I!_]^RXI194=V>BA%XFD=H8SN^)RN!'R114 FFRKDJN1
M4VB]O/8\E1504>6*)7#\,A>RHAJG<N&II02:6U!5>J'O)UY%&7?2H5U[E.E0
MK'3).#Q*HE951>7O,91B,W("YW7AB2T*;1:\=+BD"YB"?EX^2IQY+4O.*N"*
M"4XDS$?.37 ]24R\#?C&8*,Z8V*<S(1X,9.[?.3X1A"4D&G#0/&UA@F4I2%"
M&;\:3J?=T@"[XU?VS]8[>IE1!1-1?F>Y+D;.I4-RF--5J9_$Y@LT?BX,7R9*
M99]DT\3Z#LE62HNJ :."BO'Z3;=-'CH Y.D'A T@W ?$!P!1 XBLT5J9M75+
M-4V'4FR(--'(9@8V-Q:-;A@W59QJB5\9XG0Z$5R)DN540TYPDF.!<#35N(#%
MTHJ(.:Y7^(L4IG9K('<\$Q60TV=.5SE#W!GY0)ZGM^3TY(R<$,;)/2M+K)$:
M>AHEFHV\K)$SKN6$!^1$Y%YP72CR"97DNW@/K;7^PE=_X_ HX3V5+HF"<Q+Z
M8=2C9_+O\/"(G*A-=V3YH@-\;5X/IO7'S4QIB7_WS[[LU>QQ/[LY\==J23,8
M.4BL0*[!2=^_"Q+_8Y_U_T2VDXBX341\C#U]P ;%K.,^FS7VTF)-'UJG013'
M[M706W<-](1=^6$G;$?:12OMXJBTK[H 2;*=XM12SPD'6SE-M^3T06@@5V=]
M^NL-!AUAR<"-]M2_#0J"@7O9+SYIQ2='Q4]Z9/<I3-ZF+@Y"-]S3^#8,#X+O
M#O9$>IT&5(%<V+ZL,(<KKNNSVJZVK?_&=KR]]3%>"74'_TM3WR=X$A>,*U+"
M'"E1 J9/UCVZGFBQM&UN)C0V33LL\%H#:0+P^UQ@O9J)V:"]*-,_4$L#!!0
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M#(-V#GB^5LKN#=?I_6#/_P!02P,$%     @ &5^;5J"6M1VU"@  6V$  !@
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M*VL WV^D-$\W]@7-V>3J?U!+ P04    "  97YM6 CMI=UX'  #($0  &
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)U9;6_;.!+^*X2W6"2
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MC91 EC6(@2'-5CX#6,1N$:Z/VDF6(J=@<E$H.AD44'5HC*%'E9Y" #0DT5Z
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M6X5"SQ5*O\0B)U8PB?Y;LY:Y7PMCR:2Y]B<NDUB\E&N6,090)3F""U$MD;=
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M%N#YW&!&U!>DH/T-T=6?4$L#!!0    ( !E?FU9\,JIR>AH  *U=   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;,5<6W/;.);^*RB/:]JNDA5)E&39
MG:0J<2<SV>I+-DYW/VSM T1"$CL4J1"D'>^OWW,!"("D9#GI[GE(+%(D<'!P
M+M^Y0,_OB_*3WBA5B2_;+-<O3C95M;M^]DS'&[65>ECL5 [?K(IR*RNX+-?/
M]*Y4,J&7MMFSR6@T?[:5:7[R\CG=>U^^?%[459;FZGTI=+W=RO+AM<J*^Q<G
MXQ-[XT.ZWE1XX]G+YSNY5K>J^G7WOH2K9\TH2;I5N4Z+7)1J]>+DU?CZ]12?
MIP=^2]6]]CX+7,FR*#[AQ;ODQ<D("5*9BBL<0<*?.W6CL@P' C(^FS%/FBGQ
M1?^S'?TMK1W6LI1:W139[VE2;5Z<+$Y$HE:RSJH/Q?V_E5G/#,>+BTS3_^*>
MGXVF)R*N=55LS<M P3;-^:_\8OC@O; 8[7EA8EZ8$-T\$5'Y@ZSDR^=E<2]*
M?!I&PP^T5'H;B$MSW)3;JH1O4WBO>ODVS64>IS(3[W)=E37PN]+/GU4P-#[P
M+#;#O.9A)GN&B<1/15YMM'B3)RH)WW\&)#5T32Q=KR<'!_Q)ED,1C0=B,II$
M!\:+FG5&-%ZT;YTR+<5O,JN5^"'5<5;HNE1:_,^K):P:1.-_^];,0T[[AT1U
MN=8[&:L7)Z /6I5WZN3E/_\QGH^^/T#PM"%X>FCTXS?F*X:!SW=*5_PYS<6;
MSW5:/0B9)^('M:S$K8KK,JU28- O=2D4?YUZ+\E2@4+%19U7*A%@&T2MTWPM
MJDVIE$C2U4J5\*#8JFI3)!KT!*Q(@D^ )E8;):J'G1+%JCOVM?CG/Q:3R?S[
M-I%QL=W)'&DJ[E0I[C=IO!'W2FSDG1(Z7>?I*HTES)GF*]CF/%9B65<B+RHA
MX>6\*HLL0PI2H!GVJSJP"&7I8OH'H)351A3 "[W!MY!P6>;P,%!3"I F#725
M:E>4.!106\ @Y46NJH$X2W.@79T+]068H-6P62'8E3[F5AM9B:0@TFEU:&W3
M[ &X")2#$9#+3(D52O0=2K0>(!^V2J),(_5:A9M5P?HU4)(I#5<YS :L3$O\
M=B!V64V+@''A0[R1^9K6HL&N(3=69;$5Q1+EF^;=E2FPUCZ'2RT350)UH$>Y
MEF1L-7$3^9@F, GL2X93Z'2;9K+TB$-.XF-:;N%9K6L%:O\**.3Q<?A2Q3A#
MPFN%A]R=8_F,0KRKEUD:[Y-EP[R$=""699GBY\IC<ILL]XTE"23P_XX@ZG<0
MNN0/L.PD3SWTH*R!^WQTU\D;):+>@4IYV^%);^I4_CO[TI^QL3+_JGW]H;C/
M[V69F/7S:EOTX-"-<-+6-+OM+==[!#1; S&E)/(&0$.<U8E5XU5C_N"Y)&4@
M %N<@_H*9"NLNM [@ C:DLS4#L1:Y3!J!LZV_*0J]S[,@2.D>0)K*!\$OHVF
M![8FKHI2@Z $RS/46X5@"[EE;ZG06PKP=6#*K+.CT>'#!)0:EH]& ,"'*F$1
M0_$11@"Y<A8G$#N0)V1'D:6)1#N$-*/0)4)7<(,I@F4"I#/\(K*,M&AG]6GF
MTW$TO 2S %;3<.UT.ID-I\VMIR]I@-N-W 8DECVXY:P!/6IQQJLZ]Y?U%6P#
MRKHK J8D(H$K(QB.#@',2-%'];#[%;$KG&C 3@>D> >R\R7%IT%)3J]FHX8S
M\%*=KVHB$]1_FUK+7A@=P>VZ@UMHL&.Y2RL0-'P>3;EU;!(5+-W!\& 2LDPL
M@529)NS^I"&;IMKAP..1> "IUF1A6.Q((N2=!.4$!;\ 7EYH"9J>H)/WF!,8
M.N/L/#O@F;K&Q4E-7G4+VFC4'3QIO:TS$CPR@/1UJ3:(X._09J(AY$T^)R)Y
M!6A$@'\2MUX3Q9X9@=E[Z/=(1_GPK('1"[+B8,Y3>X=%36[1UR.QP9=D9JR5
M14/SP&"C$1:+9Q!2J.I>*;:RA/I@/&8-C+JJS8;JC5A!N*/)ZL?($=@@V#]
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M0UQMKHEE49;$'=U>:S]D.O2IRYFS\6 *:&-TWCQ#=R;]=WX,&.9+@G7]6.C
MG>F0>C9>#!8(2<X#RL[&\\%\-CUPNX_FZ>!R.L(O'8D0ED^NAE'OK0^I_@04
MY0  &V3ZP>3;^CN W%VO28!303O8_!QS2V N=;W\0\45J!LE<[EB4^)LA#Y
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M[@I M*GMU3(K"$MN1KWLDJ@4BJ3FJG^3&?_9";EOQ8%/JZRR,BZ0VT,0!I:
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MC05&@Y3(Y4 GR1M!#7'RE5NVAB -N<V"W.DT>P4&-+="<=<RML:OO\#'L21
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M.&!%M>PA%S4"C%3!(3/R<I3!NDI"M-_B*9.7:.V*\N' 7N,1[QET>-CUBT2
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M$2$6.PMXPS1SIM4(G^44-.X=T@G_CFV30TPEC*._SDB,5F\XXT!4#2B/MYO
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M5M3Q45D G9>24M8MK(/^'S+[ U!+ P04    "  97YM68%YB7PT-  "*)@
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MK)86X/V#,;Y_( 7#5Z+S_P%02P,$%     @ &5^;5KQSXAZ6 P  T@<  !D
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M>YYBP^\QC$-_0,7DPH_@E;1(BV.;L6@445\4AOX0GM^5=*5@+;?2$HA?2?R
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M*U!O\+_]PO_+3J_7Z.WY7XAUJV)-+^A6>.Y0Z)04.@<I3&'%;&VUR<R$)!/
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M<VAE970R.2YX;6RM55UOFS 4_2M73)I:*0H$TF[J"%*2=EJE5:H:=7N8]N#
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ML&QY#=)P)9&&,L,W\6R>^/I0\)5#:TYBY)5LE'KPR>=MAB/?$ @HK&=@[G>
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MWW]8KZ?C-_M?\'F]^>5QVM?_#U!+ P04    "  97YM6/KXQW[$#  !H$@
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MF36VT K69)O*9[;_':J$1IIOR5)1_*)]%>M::+D5DF456"G(:%[^DR]5(5H
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M4P;R_8I2L2^H!NI[H^!_4$L#!!0    ( !E?FU9%38SN70(  '@%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+54WT_;,!#^5ZP,(9 FDH:6(4@C
MM71HE894@=@>ICVXR;6Q\(_@<UKX[W=VVBR3:-_V$OO.=]]]9^>[;&OL"U8
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M19FMJP>EW69EF275MRLI%C+7%ZB?WV4J9M8O= .[YP5._P=02P,$%     @
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MY<I\$E': G-_*81^V=BIVWUDD[]02P,$%     @ &5^;5FGCENK  @  -0<
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MK^73W\7QC*).W[K<U(?_>T]'67_AK?=U4VZ/![<6;(O=\Y_Y'T=/* >P<."
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M(@CFX!8CGC,\ Y*$]SC.&5,%N42<\!/PD-&I"@1-9>]<9ZM<*!LJ.RPA19>
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MV/93ANV)H*OB:X I%8*FQ>$2HQEFRD#>GU.IU,H3]8%!]4')Z']02P,$%
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M0+!6UH=UUH?'9IW85^%5QM&_SW6C*_>]\%/?BQ)F_I5H*.D'>!"VE8PA.TV
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MB7)ON3Q1?%-LSSYQI7A6',:,ADSH /@_XESM3_0-ZAW^Y7]02P,$%     @
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M3M(L+K8>\(<D_ZP<N8+_J+D:VKLX>7:]!&] !1S0?47KLB,DJ3+W$H #%>%
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MD@7EN8'\?LF8>/R0=[!_P&CZ/U!+ P04    "  97YM6\ R,N_\#  !P$@
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M%TP#OTU96@*KR#(J9!G]*&F0!3(JK?&!WQN>),*W1EW'ZXWJ$V%<D!PWDOR
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M"$(;X/LEY^K0T ,4ETSS_P!02P,$%     @ &5^;5N8-E1^#!   %A@  !D
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M6DOT0[*$93W?U345A9'GPBZ(%?":BA[R\2DB'O%;^"R^/YU8Z/B%SGZ*YQ_
MVQ<1S9=_Z-'5#:&0[B[$5V@>AMMX&U$%2V09EM^^:&ATI2"6O[?IG/'HM_,P
ML\*YW- 0IHZ&EB >P9E]>(<'WJ<VD3H"JTG6+R3KV]"S5_/#NQ'!^%,"ZA2=
ML%2!CPB>]"PFH:WZ#'*40IHI['%&>GK\'JM%-6."<<\O@FID@X)L8"7[,U<T
M0O>@)U9 BCZU<<L0AI7GXH",>\,]>LTPX@5^;]!.<% 0'-@)TB=-+X$54VW<
M!HV'GN%1OS?:X]86%GB5$FK<A@6WH95;HSF.ZHBV<JS/.[8).@*K23,JI!F]
MD7ECU*5D'8'5)!L7DHV_HQ7%GG#R%.E)Q.AUH#O'S5=[W OVWO]FT  ?FCJP
M5Z[!GI7Q/.9"L;_S=W^EN2LF(!WCO&41,^.&_D'=MXJ=V[$#WQ5:7<F*F\%O
MI%UR(EW)UA%:7392RD;^]^J50]26KT&C05JBAOW*"EPG6+HG;'4:_[5ZY=FU
MYO6;W%JB<'!H8<6E3\%VH_+""2='#:J"^ON4^PW*P>@@X]*L8+M;N1&,ZV\Y
M_1ZQ$)Z%S0F_RAQCI7-TLW2$5A>O-%)X\%;F&*NE.UJVCM#JLI4>#]M-WHOL
M?(Y9;UE2:8"\M&&CE<[PH66YM%[8:E-F\U!MJ6"ZMR/])0ROV1^=FJ^NT.JR
ME?8+C]]*?UB-X-&R=816WZXH32"QF\ 7]4>.6?M8'/?P7GNT1(V&AQ9E4IHM
M8G4E&>/J*O<JO6$G<>P@=X56EZPT6H2\D=X@5L=WM&P=H=5E*^T?L=N_E_6&
MW]CG.2.DX0I;PDAC0\.M[+#&(![2C6>)0KY-5+8G65PM-K?GZ9;NWO4+?+[(
MMJA+F&S'_)J*!Y9(%,%*0WJ]H5[-1+8)G9THODGW<>^Y4CQ.#]= ER!,@+Z_
MXEP]GY@'%/\*F/T+4$L#!!0    ( !E?FU8%241$+0,  !P)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;*U636_;, S]*X0W# FPVK$=YZ-+#/1C
MPWIH5[38=AAV4!PF$69+F:0D[;\?);M>&KM9#\LAEF3RZ3U*)#W92?5+KQ -
M/!2YT%-O9<SZ- ATML*":5^N4=";A50%,S15RT"O%;*Y<RKR(.KU!D'!N/#2
MB5N[5>E$;DS.!=XJT)NB8.KQ''.YFWJA][1PQY<K8Q>"=+)F2[Q'\W5]JV@6
MU"AS7J#07 I0N)AZ9^'IQ=C:.X-O''=Z;PQ6R4S*7W9R-9]Z/4L(<\R,16#T
MV.(%YKD%(AJ_*TROWM(Z[H^?T#\Y[:1EQC1>R/P[GYO5U!MY,,<%V^3F3NX^
M8Z4GL7B9S+7[AUUI.X@\R#;:R*)R)@8%%^63/51QV',@G':'J'*(#AWZ+SC$
ME4/LA);,G*Q+9E@Z47('REH3FAVXV#AO4L.%/<5[H^@M)S^3?C$K5._>C*(P
M_'"#YCUTKD0F"^S"QP>Z*1JA<XF&\5QWX02^WE]"YVT7W@(7<,WSG$Y"3P)#
M1"Q<D%6;GI>;1B]L&L.U%&:EX:.8X_RY?T ":A71DXKSZ"C@-5,^Q.%[B'I1
MW,+GXO7NT1$Z<1W4V.'%+^#=2$%IIICA8@EE/*%3Q;,+/\YFVBBZOS_;(E<B
M]]N1;4Z?ZC7+<.I1TFI46_32=V_"0>]#F^S_!/8L"/TZ"/UCZ.F5,$BH!K 4
MWB:V1!@Y!%MOMFG8B_S1)-CNJVA:C?K^N+?W"VN/9U23FFKR.JK<G54;TQ)@
MN,?A).[[T0'3TBK9MQJV4QO4U 9'J5%.$JLMD:/2:2"76J,&JG_X>\/-(VC,
M-HH;3HN=&VD0DFX;_4&#?AC[PP/V3:-^E/C]=@'#6L#PJ( [-%RA(S]#@0MN
M8)VS]JHQ; 8Y#)/&?6@Q&\=^W,YS5/,<'>7I"B%T>%7]CES:47/[J'$36HR2
M\4L<QS7'\;\Y5L5:N&+]"KKC1O:<Q$GC[)M6<=+S#R]OL-=H"E1+UW\U9'(C
M3%FMZ]6ZQ9^YSG:P?DZMO^S4?V'*[P:JQ4LN-.2X($BB0-FDREY<3HQ<NW8V
MDX::HQNNZ/,%E36@]PM):5!-[ ;U!U'Z!U!+ P04    "  97YM6AM L9I4#
M  "H&0  #0   'AL+W-T>6QE<RYX;6S=6=%NVC 4_94H7:=6FD@A(Y 5D#:D
M2I.VJ5+[L+?*$ <L.4[FF [ZN%^I]K:OV*?L2^8;AP2H+Z)]6)N!VMCW^)Y[
M?'WMU.H@5RM.K^:4*F>9<)$/W;E2V3O/RZ=SFI"\E694:"1.94*4[LJ9EV>2
MDB@'IX1[G;.SP$L($^YH(!;)1:)R9YHNA!JZ[4YE<\SC8Z2MP5O7,7SC-*)#
M]^;D];=%JLY?.>9Y].;HZ.SF]'S7?E( IZYG)>UNDQ9C6T!S4C8QQ^  -2U<
M#T[<.XAX'S-*W;=,]KB:ZS'F%MH5_?GQ"TE]C>Q-?N_,3OS[)\); ?MIV]8U
MW9@I=##GCMUYVQMW]P_*56M?MM#2Z"$[8#M?K3T9PZF["/4]3GUOH_;*S3P:
MQ*FH][3O&H..31+JW!(^=,>$LXEDX!63A/&5,7? ,$UY*AVE#Q,MI@V6_,[
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M-:UUV1SR6?=QP.034$L! A0#%     @ &5^;5@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  97YM6
M)+RL8N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  97YM6F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !E?FU:TQA[K.0D
M "E/   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  97YM6(.B[\ZH$  "2$0  &               @(%]
M$0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ &5^;5G+W
M;CNW @  - <  !@              ("!718  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( !E?FU8MAEX[NP<  *PA   8
M  " @4H9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  9
M7YM6I-7[_7P"  #D!0  &               @($[(0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ &5^;5J"6M1VU"@  6V$  !@
M         ("![2,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( !E?FU9TFZ-R90(  % &   8              " @=@N  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  97YM6:TU"1M0&  "G'
M&               @(%S,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ &5^;5@([:7=>!P  R!$  !@              ("!?3@  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !E?FU;O+J,W"@H
M *88   9              " @1%   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ &5^;5L&^1#_F"@  ,3,  !D              ("!
M4DH  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  97YM6
M!VX\><L+  !/)   &0              @(%O50  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( !E?FU9\,JIR>AH  *U=   9
M      " @7%A  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ &5^;5B3?0J^$ P  R0<  !D              ("!(GP  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  97YM61!^?EC@#  #%!P
M&0              @('=?P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( !E?FU9$9P-;%1T  &94   9              " @4R#  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ &5^;5I4[Z\*C
M!@  0!(  !D              ("!F*   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  97YM6@9-I(K\"  !/!@  &0
M@(%RIP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !E?
MFU9@7F)?#0T  (HF   9              " @6BJ  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ &5^;5B5]>>/(!P  ,1(  !D
M         ("!K+<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  97YM6O'/B'I8#  #2!P  &0              @(&KOP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !E?FU8T2&(MK ,  - (
M   9              " @7C#  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ &5^;5FD,I&5L"P  LRX  !D              ("!6\<
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  97YM6;*_>
M"$4#  #@!P  &0              @('^T@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( !E?FU:.I:'MNP4  %80   9
M  " @7K6  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M&5^;5B5U2&?1 @  0@8  !D              ("!;-P  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  97YM6.GBQH 8#  !F"@  &0
M            @(%TWP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( !E?FU;'O:FY7P,  +4-   9              " @;'B  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ &5^;5CEVCQ:J @
M!P<  !D              ("!1^8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  97YM64#I&1RT"   ;!0  &0              @($H
MZ0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !E?FU92
MT/OXN1,  ,#8   9              " @8SK  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ &5^;5CZ^,=^Q P  :!(  !D
M     ("!?/\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M"  97YM6KA3+34X&  #/+@  &0              @(%D P$ >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !E?FU;N9\Y?[P,  $,2   9
M              " @>D) 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ &5^;5D5-C.Y= @  > 4  !D              ("!#PX! 'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  97YM6&DH8KQX#
M   9#   &0              @(&C$ $ >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( !E?FU8:3AG0B@,  + 0   9              "
M@?@3 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ &5^;
M5BG3#X1Z!0  6"H  !D              ("!N1<! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  97YM6J=LB[88*   [<   &0
M        @(%J'0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( !E?FU:X0E]4C (  #@&   9              " @2<H 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ &5^;5LJ[=*#$ @  < <
M !D              ("!ZBH! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  97YM6:>.6ZL "   U!P  &0              @('E+0$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !E?FU9G!27<
M,0\   .H   9              " @=PP 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ &5^;5L\YS68*!0  7"(  !D
M ("!1$ ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  9
M7YM61BR.Y6H$   U'0  &0              @(&%10$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( !E?FU9H-_V=A 4  .T?   9
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M970U,"YX;6Q02P$"% ,4    "  97YM6T)60JXL&  !L)   &0
M    @('@: $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M !E?FU;P#(R[_P,  ' 2   9              " @:)O 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ &5^;5N8-E1^#!   %A@  !D
M             ("!V',! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    "  97YM6!4E$1"T#   <"0  &0              @(&2> $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !E?FU:&T"QFE0,
M *@9   -              "  ?9[ 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     ^ #X Z1   !B) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>510</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>125</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited</Role>
      <ShortName>Consolidated Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Condensed Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Condensed Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity</Role>
      <ShortName>Consolidated Condensed Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Condensed Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows</Role>
      <ShortName>Consolidated Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other???Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other???Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestituresTables</Role>
      <ShortName>Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitures</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Other???Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other???Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpense</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BasisofPresentationPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenue (Adjustments to Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails</Role>
      <ShortName>Revenue (Adjustments to Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Acquisitions and Divestitures (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestituresTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestituresTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Acquisitions and Divestitures (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Divestitures (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestituresTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Net Product Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Schedule of Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Unrealized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Realized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Fair Value Measurement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails</Role>
      <ShortName>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Effect of Risk Management) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tax Effect) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Reclassification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lly-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Other???Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other???Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentQuarterlyReport, dei:DocumentTransitionReport -  lly-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="lly-20230331.htm">lly-20230331.htm</File>
    <File>lly-03312023x10qxexhibit311.htm</File>
    <File>lly-03312023x10qxexhibit312.htm</File>
    <File>lly-03312023x10qxexhibit32.htm</File>
    <File>lly-20230331.xsd</File>
    <File>lly-20230331_cal.xml</File>
    <File>lly-20230331_def.xml</File>
    <File>lly-20230331_lab.xml</File>
    <File>lly-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="936">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="59">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 936,
    "http://xbrl.sec.gov/dei/2022": 59
   },
   "contextCount": 510,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 487,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 7
   },
   "keyCustom": 21,
   "keyStandard": 224,
   "memberCustom": 71,
   "memberStandard": 54,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Acquisitions and Divestitures",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Collaborations and Other Arrangements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Retirement Benefits",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Other\u2013Net, (Income) Expense",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other\u2013Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.lilly.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Condensed Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
     "shortName": "Consolidated Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Acquisitions and Divestitures (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestituresTables",
     "shortName": "Acquisitions and Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Retirement Benefits (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Other\u2013Net, (Income) Expense (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other\u2013Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.lilly.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "ib386950c303c4cfa991af56051f481c7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i118b413e750a419a8eea249e9dec5ea8_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i8ba05d67547242b28419ed4e7793321c_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenue (Adjustments to Revenue) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
     "shortName": "Revenue (Adjustments to Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i8ba05d67547242b28419ed4e7793321c_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Unaudited)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Consolidated Condensed Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "if4b193d99bd84b609a946006de3ff5b5_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i3f75bb32e91f4c8c914a357a961a505e_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AcquiredInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Acquisitions and Divestitures (Narrative) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "ib7be43b8e3a3494a829c922cf02c7d0f_D20230401-20230430",
      "decimals": "-7",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i927e3b53935c4022981ef2bcccb6abdc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions and Divestitures (Assets Acquired and Liabilities Assumed) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i445c404661b9435abdfa6e32f19fa84d_I20221201",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7692466539d946a186b9e8a3794403e0_D20220201-20220228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Acquisitions and Divestitures (Asset Acquisitions) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
     "shortName": "Acquisitions and Divestitures (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
     "shortName": "Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i821dd7cbf61341dbbfaf914c7ef0c9ec_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
     "shortName": "Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i20238217248b408d991f048bd5cb02de_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
     "shortName": "Collaborations and Other Arrangements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i92837642c10f4f2d8a9378d7a850d897_D20230101-20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Financial Instruments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Unrealized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Realized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
     "shortName": "Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
     "shortName": "Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "ibcf771418ff145e48f59e9ff50e2c708_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
     "shortName": "Financial Instruments (Schedule of Foreign Currency Forward Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "ibcf771418ff145e48f59e9ff50e2c708_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
     "shortName": "Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i7ca7c951b1ec4ae08fc65f7ee239aa69_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.lilly.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i0157807f4391408d931450405bc79b5f_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Retirement Benefits (Components of Net Periodic (Benefit) Cost) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i0157807f4391408d931450405bc79b5f_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i4b4ab320c12a472eb82bbab75fbf501b_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unitRef": "site",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Contingencies (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i3ea4ac837c5c446c91d4a1eadb1660df_I20191031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i927e3b53935c4022981ef2bcccb6abdc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
     "shortName": "Other Comprehensive Income (Loss) (AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails",
     "shortName": "Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
     "shortName": "Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i0d8b989d89ce4af9a4cc6f268d29ee6f_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Other\u2013Net, (Income) Expense (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other\u2013Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Condensed Statements of Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
     "shortName": "Consolidated Condensed Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i718019883deb49e6ae6e5d5e8ceb0dd7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical",
     "shortName": "Consolidated Condensed Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i9c2ab2b26eca44b79b6d178d0f021629_I20230331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Condensed Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
     "shortName": "Consolidated Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.lilly.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20230331.htm",
      "contextRef": "i1ebea3ece73b46d9a72eb60d4aa77343_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 125,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes Due 2051",
        "label": "1.125% Notes Due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes Due 2061",
        "label": "1.375% Notes Due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due 2043",
        "label": "1.625% Notes Due 2043 [Member]",
        "terseLabel": "1.625% Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1700NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes Due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1700NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A47NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.7% Notes Due 2033",
        "label": "4.7% Notes Due 2033 [Member]",
        "terseLabel": "4.7% Notes Due 2033"
       }
      }
     },
     "localname": "A47NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A4875NotesDue2053Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.875% Notes Due 2053",
        "label": "4.875% Notes Due 2053 [Member]",
        "terseLabel": "4.875% Notes Due 2053"
       }
      }
     },
     "localname": "A4875NotesDue2053Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A495NotesDue2063Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Notes Due 2063",
        "label": "4.95% Notes Due 2063 [Member]",
        "terseLabel": "4.95% Notes Due 2063"
       }
      }
     },
     "localname": "A495NotesDue2063Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".500% Notes Due 2033 [Member]",
        "label": ".500% Notes Due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A50NotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.0% Notes Due 2026",
        "label": "5.0% Notes Due 2026 [Member]",
        "terseLabel": "5.0% Notes Due 2026"
       }
      }
     },
     "localname": "A50NotesDue2026Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625NotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes Due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625NotesDue2031Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition",
        "label": "Acquired In-process Research And Development",
        "terseLabel": "Acquired in-process research and development (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AkouosAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Akouos Acquisition [Member]",
        "label": "Akouos Acquisition [Member]",
        "terseLabel": "Akouos Acquisition"
       }
      }
     },
     "localname": "AkouosAcquisitionMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BaqsimiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baqsimi\u00ae",
        "label": "Baqsimi\u00ae [Member]",
        "terseLabel": "Baqsimi\u00ae"
       }
      }
     },
     "localname": "BaqsimiMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "terseLabel": "Basaglar\u00ae"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BioMarinPharmaceuticalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioMarin Pharmaceutical Inc",
        "label": "BioMarin Pharmaceutical Inc [Member]",
        "terseLabel": "BioMarin Pharmaceutical Inc"
       }
      }
     },
     "localname": "BioMarinPharmaceuticalIncMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (up to) (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Consideration transferred, number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euros Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyGBPSellUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy GBP Sell USD",
        "label": "Buy GBP Sell USD [Member]",
        "terseLabel": "Buy GBP Sell USD"
       }
      }
     },
     "localname": "BuyGBPSellUSDMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSDollarSellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US Dollar Sell Chinese Yuan",
        "label": "Buy US Dollar Sell Chinese Yuan [Member]",
        "terseLabel": "Buy US Dollar Sell Chinese Yuan"
       }
      }
     },
     "localname": "BuyUSDollarSellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsdSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy USD Sell Euro [Member]",
        "label": "Buy USD Sell Euro [Member]",
        "terseLabel": "Buy USD Sell Euro"
       }
      }
     },
     "localname": "BuyUsdSellEuroMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms or rights and obligations under collaborative arrangements.",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Potential achievements"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Sales, Operating Expenses, And Other-net",
        "label": "Cost Of Sales, Operating Expenses, And Other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Percentage of nonperforming assets"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes [Member]",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received",
        "label": "Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationMilestonePaymentsToBeReceived",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationJuly2018RulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation, July 2018 Ruling",
        "label": "Employee Litigation, July 2018 Ruling [Member]",
        "terseLabel": "Employee Litigation, July 2018 Ruling"
       }
      }
     },
     "localname": "EmployeeLitigationJuly2018RulingMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationJuly2019RulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation, July 2019 Ruling",
        "label": "Employee Litigation, July 2019 Ruling [Member]",
        "terseLabel": "Employee Litigation, July 2019 Ruling"
       }
      }
     },
     "localname": "EmployeeLitigationJuly2019RulingMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Unfunded commitments to invest in venture capital funds, anticipated payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Hedged Fixed Rate Debt"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "terseLabel": "Jardiance"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Capitalized As Intangible Assets",
        "label": "Milestone Payments, Capitalized As Intangible Assets [Member]",
        "terseLabel": "Milestone Payments, Capitalized as Intangible Assets"
       }
      }
     },
     "localname": "MilestonePaymentsCapitalizedAsIntangibleAssetsMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MounjaroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mounjaro [Member]",
        "label": "Mounjaro [Member]",
        "terseLabel": "Mounjaro\u00ae"
       }
      }
     },
     "localname": "MounjaroMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlanzapinePortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olanzapine Portfolio",
        "label": "Olanzapine Portfolio [Member]",
        "terseLabel": "Olanzapine Portfolio"
       }
      }
     },
     "localname": "OlanzapinePortfolioMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes [Member]",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities, noncurrent investments"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Acquired IPR&amp;D expense"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PurchasesOfInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchases of In-process Research And Development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasesOfInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Rebates And Discounts",
        "label": "Sales Rebates And Discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Chinese Yuan",
        "label": "Sell Chinese Yuan [Member]",
        "terseLabel": "Sell Chinese Yuan"
       }
      }
     },
     "localname": "SellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sell Euro [Member]",
        "label": "Sell Euro [Member]",
        "terseLabel": "Sell Euro"
       }
      }
     },
     "localname": "SellEuroMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SeniorNotesDue202620332053And2063Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2026, 2033, 2053 And 2063",
        "label": "Senior Notes Due 2026, 2033, 2053 And 2063 [Member]",
        "terseLabel": "Senior Notes Due 2026, 2033, 2053 And 2063"
       }
      }
     },
     "localname": "SeniorNotesDue202620332053And2063Member",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to U.S. Dollars"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapU.S.DollarsToEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap U.S. Dollars To Euro [Member]",
        "label": "Swap U.S. Dollars To Euro [Member]",
        "terseLabel": "Swap U.S. Dollars to Euro"
       }
      }
     },
     "localname": "SwapU.S.DollarsToEuroMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "terseLabel": "Trajenta"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member]",
        "label": "Trulicity [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20230331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r283",
      "r541",
      "r595",
      "r617",
      "r660",
      "r661",
      "r666",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r283",
      "r541",
      "r595",
      "r617",
      "r660",
      "r661",
      "r666",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r189",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r263",
      "r301",
      "r302",
      "r453",
      "r484",
      "r485",
      "r486",
      "r487",
      "r507",
      "r508",
      "r509",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r189",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r263",
      "r301",
      "r302",
      "r453",
      "r484",
      "r485",
      "r486",
      "r487",
      "r507",
      "r508",
      "r509",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Reclassification, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r284",
      "r285",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r596",
      "r618",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r284",
      "r285",
      "r568",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r596",
      "r618",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $14.0 (2023) and $16.0 (2022)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r9",
      "r165",
      "r178"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r33",
      "r39",
      "r122",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans",
        "verboseLabel": "Amortization of retirement benefit items"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r32",
      "r39",
      "r122",
      "r224",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r34",
      "r39",
      "r122",
      "r224",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r78",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r31",
      "r39",
      "r122",
      "r224",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r217",
      "r224",
      "r474",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net unrealized gains/losses on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net unrealized gains/losses on available-for-sale securities",
        "verboseLabel": "Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r38",
      "r39",
      "r207",
      "r553",
      "r563",
      "r567"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 9)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r122",
      "r509",
      "r558",
      "r559",
      "r631",
      "r632",
      "r633",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r642",
      "r643",
      "r644",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r208",
      "r289",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r122",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r602",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r162",
      "r177",
      "r200",
      "r234",
      "r273",
      "r277",
      "r281",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r470",
      "r475",
      "r495",
      "r616",
      "r663",
      "r664",
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r193",
      "r210",
      "r234",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r470",
      "r475",
      "r495",
      "r616",
      "r663",
      "r664",
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r73",
      "r293",
      "r550"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r73",
      "r292",
      "r549"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r73",
      "r294",
      "r551"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More\u00a0Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r73",
      "r291",
      "r548"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less\u00a0Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r70",
      "r290",
      "r309",
      "r543"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r68",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r68",
      "r196",
      "r309"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "verboseLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Average Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Average remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r463",
      "r606",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r107",
      "r108",
      "r463",
      "r606",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r112",
      "r113",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r112",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r64",
      "r195",
      "r581"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents (Note 5)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r59",
      "r64",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at March 31",
        "periodStartLabel": "Cash and cash equivalents at January\u00a01"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r156"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r66",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r66",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r234",
      "r257",
      "r258",
      "r260",
      "r262",
      "r265",
      "r266",
      "r299",
      "r320",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r495",
      "r580",
      "r626",
      "r639",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r4",
      "r163",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "negatedTerseLabel": "Short-term commercial paper borrowings"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r171",
      "r184"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r315",
      "r316",
      "r569",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r642",
      "r643",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r221",
      "r223",
      "r230",
      "r545",
      "r555"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r50",
      "r229",
      "r544",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of amounts recorded for contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r354",
      "r355",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r602",
      "r604",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r44",
      "r541"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r668",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r164",
      "r166",
      "r175",
      "r238",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r506",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r157",
      "r159",
      "r329",
      "r506",
      "r591",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r22",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r238",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r506",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r297",
      "r310",
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r370",
      "r408",
      "r429",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Recognized actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r370",
      "r409",
      "r430",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r370",
      "r407",
      "r428",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r370",
      "r374",
      "r406",
      "r427",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r404",
      "r425",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r372",
      "r405",
      "r426",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r62",
      "r271"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r133",
      "r135",
      "r139",
      "r140",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r131",
      "r133",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedTerseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r126",
      "r131",
      "r132",
      "r142",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Description of Derivative Risk Management"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r364",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Additional cash proceeds"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r606",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r231",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r255",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r486",
      "r487",
      "r546",
      "r556",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r231",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r486",
      "r487",
      "r546",
      "r556",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r188",
      "r224",
      "r225",
      "r226",
      "r239",
      "r240",
      "r241",
      "r243",
      "r250",
      "r253",
      "r264",
      "r300",
      "r353",
      "r442",
      "r443",
      "r444",
      "r452",
      "r453",
      "r485",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r509",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r74",
      "r274",
      "r628"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r201",
      "r492",
      "r583"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r652"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment losses on equity securities (Note 5)",
        "negatedNetLabel": "Net investment losses on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r337",
      "r494",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r488",
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value information, assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r146",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of fair value, by balance sheet grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r337",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r489",
      "r514",
      "r515",
      "r516",
      "r591",
      "r592",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r146",
      "r150",
      "r337",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r337",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r337",
      "r395",
      "r400",
      "r489",
      "r514",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r337",
      "r395",
      "r400",
      "r489",
      "r515",
      "r591",
      "r592",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r337",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r489",
      "r516",
      "r591",
      "r592",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Unfunded commitments to invest in venture capital funds"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value information, liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r337",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r514",
      "r515",
      "r516",
      "r591",
      "r592",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Investments in Equity and Debt Securities"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r345",
      "r351",
      "r483",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r588",
      "r649",
      "r650",
      "r651",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r584",
      "r602",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r133",
      "r138"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r47",
      "r69",
      "r625"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Net investment losses"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Schedule of activity related to our available-for-sale securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r198",
      "r314",
      "r542",
      "r589",
      "r616",
      "r655",
      "r656"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r131",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r161",
      "r172",
      "r186",
      "r273",
      "r276",
      "r280",
      "r282",
      "r547",
      "r587"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r606",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r235",
      "r449",
      "r450",
      "r451",
      "r454",
      "r456",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r236",
      "r252",
      "r253",
      "r272",
      "r447",
      "r455",
      "r458",
      "r557"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedNetLabel": "Tax benefit",
        "terseLabel": "Income taxes (Note 6)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r158",
      "r174",
      "r227",
      "r270",
      "r505"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedTerseLabel": "Losses expected to be reclassified in the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r584",
      "r602",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r209",
      "r582",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r46",
      "r269"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of the contractual maturities of our investments in debt securities measured at fair value"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r168",
      "r182",
      "r616",
      "r641",
      "r653",
      "r679"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r194",
      "r234",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r471",
      "r475",
      "r476",
      "r495",
      "r616",
      "r663",
      "r686",
      "r687"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r7",
      "r8",
      "r234",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r471",
      "r475",
      "r476",
      "r495",
      "r663",
      "r686",
      "r687"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r7",
      "r166",
      "r179",
      "r336",
      "r346",
      "r591",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "negatedTerseLabel": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Investments (Note 5)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r317",
      "r318",
      "r319",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r317",
      "r318",
      "r319",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r657",
      "r658",
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r317",
      "r318",
      "r319",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r28",
      "r167",
      "r181",
      "r234",
      "r299",
      "r320",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r495"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r646",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by (Used for) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Increase in net cash used in investing activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Increase in net cash provided by operating activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r43",
      "r63",
      "r173",
      "r185",
      "r192",
      "r219",
      "r222",
      "r226",
      "r234",
      "r242",
      "r244",
      "r245",
      "r247",
      "r248",
      "r252",
      "r253",
      "r259",
      "r273",
      "r276",
      "r280",
      "r282",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r487",
      "r495",
      "r587",
      "r663"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r117",
      "r353",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2013net, (income) expense (Note 10)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]",
        "terseLabel": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]",
        "terseLabel": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofForeignCurrencyForwardCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r225",
      "r497",
      "r499",
      "r503",
      "r631"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r212",
      "r216",
      "r477",
      "r478",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r216",
      "r218",
      "r479"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r87",
      "r220",
      "r223",
      "r229",
      "r497",
      "r502",
      "r503",
      "r544",
      "r554",
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r220",
      "r223"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income, net of tax (Note 9)",
        "verboseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeUnaudited",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r37",
      "r224",
      "r229",
      "r447",
      "r457",
      "r459",
      "r497",
      "r500",
      "r503",
      "r544",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Benefit (expense) for income taxes allocated to other comprehensive income (loss) items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r648",
      "r654",
      "r668",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other\u2013Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r94",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r634",
      "r635"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r394",
      "r400",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r435",
      "r436",
      "r437",
      "r441",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r368",
      "r369",
      "r391",
      "r604"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "terseLabel": "Accrued retirement benefits (Note 7)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r93",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r440",
      "r604",
      "r605",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash proceeds"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r637",
      "r638"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sales of and distributions from noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r192",
      "r219",
      "r222",
      "r232",
      "r234",
      "r242",
      "r252",
      "r253",
      "r273",
      "r276",
      "r280",
      "r282",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r469",
      "r472",
      "r473",
      "r487",
      "r495",
      "r547",
      "r587",
      "r612",
      "r613",
      "r633",
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r79",
      "r183",
      "r552",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $10,486.0 (2023) and $10,233.4 (2022)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Receivables, Net, Current [Abstract]"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r225",
      "r497",
      "r501",
      "r503",
      "r631"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification [Line Items]",
        "terseLabel": "Reclassification [Line Items]"
       }
      }
     },
     "localname": "ReclassificationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of reclassifications out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationTable": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification [Table]",
        "terseLabel": "Reclassification [Table]"
       }
      }
     },
     "localname": "ReclassificationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r103",
      "r187",
      "r688"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r88",
      "r180",
      "r562",
      "r567",
      "r616"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r188",
      "r239",
      "r240",
      "r241",
      "r243",
      "r250",
      "r253",
      "r300",
      "r442",
      "r443",
      "r444",
      "r452",
      "r453",
      "r485",
      "r558",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r93",
      "r94",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r93",
      "r94",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r228",
      "r234",
      "r267",
      "r268",
      "r275",
      "r278",
      "r279",
      "r283",
      "r284",
      "r286",
      "r299",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r495",
      "r547",
      "r663"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r39",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of components of other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r66",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of significant milestones and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r136",
      "r139",
      "r141",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of derivative instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effects of risk-management instruments were recognized in other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of net pension and retiree health (benefit) cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of the amounts recognized for assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r169",
      "r170",
      "r176",
      "r629"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments (Note 5)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r234",
      "r257",
      "r258",
      "r260",
      "r262",
      "r265",
      "r266",
      "r299",
      "r320",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r495",
      "r580",
      "r626",
      "r639",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r87",
      "r188",
      "r224",
      "r225",
      "r226",
      "r239",
      "r240",
      "r241",
      "r243",
      "r250",
      "r253",
      "r264",
      "r300",
      "r353",
      "r442",
      "r443",
      "r444",
      "r452",
      "r453",
      "r485",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r509",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r264",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r10",
      "r11",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r10",
      "r11",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r88",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r67",
      "r616",
      "r641",
      "r653",
      "r679"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r118",
      "r123",
      "r188",
      "r189",
      "r225",
      "r239",
      "r240",
      "r241",
      "r243",
      "r250",
      "r300",
      "r353",
      "r442",
      "r443",
      "r444",
      "r452",
      "r453",
      "r485",
      "r497",
      "r498",
      "r503",
      "r509",
      "r559",
      "r560",
      "r641",
      "r653",
      "r679"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Accounts receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r345",
      "r351",
      "r483",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r649",
      "r650",
      "r651",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r680"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Foreign currency-denominated notes, designated as hedge"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r27",
      "r90",
      "r91"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r11",
      "r87",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r11",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r11",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r87",
      "r88",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r669",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r585",
      "r602",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of the fair value of available-for-sale securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r256",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0000059478-23-000162-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-23-000162-xbrl.zip
M4$L#!!0    ( !E?FU:TJ4X*! @  %PI   ?    ;&QY+3 S,S$R,#(S>#$P
M<7AE>&AI8FET,S$Q+FAT;>U::V_;.!;]OK^"XV+;%/!+L9V'G09(DPPF0+?M
M9KWH[J<%)5(V$4K4D)0=SZ_?0U*.[=AIW33;.(,-4-<2R<M+WL-S[I5U\LO%
MI_/AOS]?DK'-)/G\S_<?KLY)K=%J?>F<MUH7PPORV_!O'TBWV8[(4-/<""M4
M3F6K=?FQ1FIC:XM^JS6=3IO33E/I46MXW7*FNBVIE.%-9EGM],3=P2>G[/0O
M)[\T&N1")67&<TL2S:GEC)1&Y"/RA7%S0QJ-JM>Y*F9:C,:6[+?W.^2+TC=B
M0D.[%5;RT[F=DU:X/FGY24YBQ6:G)TQ,B&#O:B+NQ5$G[G5[:7+0C;K)T=%A
MQ/>[G>.(=MM1?/2?"$ZVT#V,,78F^;M:)O+&F+OY^]W]YF&OL(.I8';<C]KM
MO]9\U].35.46\VF,#U^#F75C5(]@SZJB?US86A@X;TR45+K_JNW_!JZED=),
MR%G_S9D65+ZI&VQ]PW MTM!LQ!\<?L E?SD-;AYBM!0YG[L=[3M'+__UV]7[
MJR'I1,V(7)>2DZA#&U%WC[XEYUQ;D8J$NK 2E9(+.A&,7(ODQM3)^9@*72>?
M-3>"89OKA.8,=P5/R>4M3THK)IQ\2F& Z]4-V(VEGU]>#Z]^O3H_&UY]^OB/
MY_6PN]'#J_H/;'F=)#Y^,V+'U+Y^U3L:;+G&04$9PY%K2)["E2/<L?S6-D3N
M)NTWW)V?N@]1<^[YSYIS=0N.FP>';LE79$RQP9I/!)^"F.Q8&%P52EN"$_*K
MTAF)VHV_N[-R*07Y(*2<A1BIK*#Y#%$X?K%1V-^1*+RG!GN/_<YFY"974\G9
MB-=7@L$4-R17D!#,0$6.&,Q(F5M=<O@-4?'Z@BA1DN'*^4E2FN"6)BH3EE@5
M^JUUR'G"C:%ZYKID](9CWB6;!O<8G,&4THL3YG =$J$A1NB68S@\85R3Z5@D
M8V)*][$8/^6:5T;< C)A)%3+">!4V#$6: J>> >=W0*N*89E3C",D7BVO TO
M&FV=74<;)ZG($4\'C47\ B4K-.NE=I&GX(:@HR)/9,E@$QA9"E8=^!(:=%$@
MQ Z=#K52+N!71=[<FQH(9S[OJKL>I40'8$X!&'XZX_U)J!F35*JIF0-2\Y$P
M%DF;)=3=#'[#R_H2KLS<F35O7S2TNCL"K>%*'-Z8"C:5;+LCKX*4[YFW/CQ7
MA&KN@8# BAC)&@)&.- 72V'&;H3KEH'Q'.NY:R9,(I4I,<YQH58R(*+0*N$,
MMPW9 P 8!Z)"E"]ODS'-1YR<@69<1FA"2MC;X\&+J,?"5;C$7%SG 8G./G%<
MM 30 !CGR]83I2L3I9C(K?,^;-'#R?'C,YM>]]FA2-\^-Q2CR"WY AGER,7%
MR]&W05-W2IG0TFP_Q$E6S & :J8@@JK4, "ZF0CC20R]>.[MN+1U07_+%*JY
MI!Y1E0HN4%&OZ-4U"E A?#%*"N;K2%/&R)L%U<(M0 2M]J2>.TNE<?KISZ#Q
M8NLI#X4J'$(%Z0<5%%!.2DD=4V-9WHF%#F-$4/7E9 3?8NXZ@DPQGK/'D^<.
M(#;>2<1N34)KP-V>OK;&+S"/HLW!DAJ54\?3U #2+OES6*6:S7$#) L:"RGL
MS"GSIFG=*?(0\^BYJ\4W)1]!#FZK!16E+H!>XS.))%&:>0=\&CGB.1($7YTD
M"2_<Z7!=D"('H.(4B0*,_**AFCP[5(/.7TZH+#T#N3CR-$4:AT(]1R&QGHXA
M#=B"2\/EYMS,8Q(#P8,F9("Q*NW#<V_#]O2N-W?I;?KMXH/$\\39'S,>]@#^
M>$BY"5XJK-BSPZIBP!"W]?B[8K=*K7S+/7A]!^,Y!59)4FH7WR6Y6[&7*6-Q
M)W%%2PJ?8.+W$CK)=3 PIN9.QAWA> QRYIG8.UVQY PE\PV7565]KW_]!];Q
M8XC;@8*E]W(+%O_ C,V16E^P@B.I9>0L",+1RW?H^5H."+\H,D"KM+D33W\#
MQK),6,OY1MJ-%839M3 !G_SP/4 4+&<<B^)_EX'.CP#_O11PV8.^S!-?:[_]
M?RWR!+QV)I'3(,?R/SW $5<R)H(C\)7PW=4$4TYOG)*%',=KF<_._&.\^1.0
M[X)3E;Z',GL#+U&&@8;?T=(&Z%79'#H#14BZZD%(#534E!DP@.T)3ULJNM[X
MF.C%J^2NU EG$,-4X_S7$5ON^0KH\(]6*QC5@TR)?*+DA#NMRNFH>D*L*XKC
M62'5C*-U.E:!U.@*2 &J'U3;YEJDM]ZZH<C@V4<^)=<*WC^PB<=;Q>WUJ^B@
MO16']3RBK*]OJM88>.>Z 5<E+0SOS[\,H "%I+.^R/V,?M"@LA4K:U7FS TF
M3DF00#2HQ-[V/8)#<_7K:N^PV>T=N!]8K<8_-I^X^NVUZ7][;5FVWG;<;!\>
M/=C:;D8/MGW-:J=Y?'3\Y%:/.LV#3F<KLRV_#V$OL-NFH/F[6J<V'U =B?Y^
M<4NB.2>$S76G9&W#5?&S2,+_3'Z!([BJF=5Z[Y9R\-BE!-C\U-6<H6Z69/^P
M[E])6%E2%::Y'_-AU1'Z:NC:Q//8^M8\7=>7#:+WLZ]#Z-$+^5X(;4?#1ULM
MZAX-/[RFF"8W(ZW*G#4JUU+_-]CQJ+U^U3T<&/^Y_)+#IE/S!+"OA,G)%OH2
M_TR8S)?VIX3%,R[X283A?XV(/V/0=S^NCWMI["[R+9\X;DA+[[V*5ZCP+F(_
M_%(TX6LOYRW.B4\^VXLA-,9A*>W#0Y9VU3VYX+KVC3?]JL_PWJ%_ _+TOU!+
M P04    "  97YM6E$Y!30 (  !B*0  'P   &QL>2TP,S,Q,C R,W@Q,'%X
M97AH:6)I=#,Q,BYH=&WM6FMOVS@6_;Z_@N-BVQ3PV\[+20.D28HQT&T['>]V
M]]."%J]L(K2H(2D[GE^_AZ0<.['3NFV0QV '&#<2R<M+WL-S[I5T_,OYQ[/!
M?SY=L+&;*/;IGV_?]\]8I=9H?.F<-1KG@W/VZ^ ?[UFWWFRQ@>&9E4[JC*M&
MX^)#A57&SN6]1F,VF]5GG;HVH\;@<\.;ZC:4UI;JPHG*R;&_@U_BXN1OQ[_4
M:NQ<)\6$,L<20]R18(65V8A]$60O6:U6]CK3^=S(T=BQ=K/=85^TN913'MN=
M=(I.%G:.&_'ZN!$F.1YJ,3\Y%G+*I'A3D:)-)(;-I+TO.MUF,CP0G4/!N^EA
MM]DDD73^VX*3#72/8ZR;*WI3F<BL-B8_?Z_;KN_OYNYH)H4;]UK-YM\KH>O)
M<:HSA_D,QL<_HYEU8]R,8,_IO-?JYJX21RY:$ZVTZ;UHAO^.?$LMY1.IYKU7
MIT9R]:IJL?<U2T:FL=G*/PF.P*=P.8M^[F.TDADM_&ZUO:<7__ZU_[8_8)U6
MO<T^%XI8J\-KK>X.?\W.R#B9RH3[N#*=LM.,.W9JQY>4\3]EE5U<45(X.27V
M+YD0^V3(2N%#QS/!SL:24O9.9CQ+X";[F,(4F9M[L7D7#A]X$\XN/@_Z[_IG
MIX/^QP^_/ZZ'W8T>]JOWLOE5EH28SID;<_?RQ>[!T9:K/<JY$#B'-44IG#K
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M [K($6*/3H]:I9;P*R-O;TT-A(N0C%5]CT*A S"G 8PPG0W^)-R.6:KTS"X
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MWO*XA&RSN1S"AS@SA;M[R,K.^D<59"K?^-ZO_(U?'X;O($_^!U!+ P04
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MI)H+1B=L<V/[Y6 =RSI&GS_.B,9D8VZ.&:8 _9?P6NDI1&'C(V1*^\B^EES
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MJ;XZF"Q&A>)JZ*8#R,R-M(,T.CT4H><[<FN Z5I7JJ\.GYS;Q6$KGZ. %V9
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MHDO#EZCYK@.R1&Y4/?NJR]\NNA;_/\T9X9PXH?A48H3(D:1X<XDE!E7PVR[
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M&'$94X+6IG\Q>;4>.2LI0^7*.8W*D5'DK$/(;,39U.]O= 'J$F$TV^[73!#
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MOO+0GXET><]_0:28:A?0E9-1@-QU,ZJ3(L4#4<C^,IK$^0J0^X].]F</?I5
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MVF(+84T:\M[)<7W!MNNEUO/=F4^?Z",^?KAJWY6*Q9YZZ6@U"N1!A)W3*JY
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M.I^AU8-NWL]#K[9UZ@Y-^R#4-EP_-9IHQE]:+OB^$SL-<>T_%_(IL[!J <B
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MGF\3(P[@L9*8&:Z],HQ;X21A*M-$"5T1A2GK+9] %"*/W! B$:5*(FZP1-J
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MJLV2CI'H=VJWP$*UOO$[:@7!3\.$AP:1*B$]4$B*#E>2:;62O"3BK)NV.2@
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MC(P>>1$UXX8*8XL2IEDVA>)Z\Q=%GV^ZDA:+VOU.-W\D49E?1VENB,IHB,\
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M(W68I&,%5Q4AB[A]8IG.JUIF[)D;7E1ASZRP9XP!.:&C\,&@3,,_/&9 ?@A
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MN,E3,@OP;A@0$YVRN'002&=!(N:XDB%F.A,R\13-\#(6>YAOGK+5.FYVSD*
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MELF><_#7,N14YB5BAH()DZ3G$D"(; HE2RIY$U/)7_=.3]O#?,Y;\T&_AF_
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MV)!BP<<UQL>IRFH;6,B<-T(8 ]9C(@B,1XQT5)Q8I6W*A8,$;V).MZ:[E16
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M8@%Z\Y):KN%KM4"7F>:E5NL[,70&APV6(7)F'>(I^V ^>&0%9XA&G5A,W)#
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M>AA7IP.O:Y,]+TT.DJ9>;UC;,%V0Z<' ]B^J%M"VE6R[/T;#^O-PPZO!C@V
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MS,F?%_M'>Q<'?_P3HC9$484<YGA4C86U0UP:!EB1I#=J,M2=J \*)P>:6O'
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M&0DH#<6V&0F+S4QEV7U0WLYM22:SPG.#<1S817C8[F4;R'@M_Z?N;9GS!'.
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MQLAH$B/"Q2+#*Y+A;Y,RG%P"TRA2Y!5H8RX"!QF6$10Q]HG&J G!H(BE7L>
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M>1:S)-MJ/9E5GR-S.F1;>$@9#?G'<JOJ;!NB^JADDAE155$THXTC]C->".)
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MJ&1MN:27*'>T7A;WT,NB?W5RHW6SN,DR7#E=9)0FR#*QW,%K1'0ZN1#E*OI
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M%6U"<4%K:[):)<9NY/*9N?#+8G09:+BY9H(K6UN,6A8D4&@M4Z)54Y*P9>]
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M'/<.I%O25W23^JHK1ILKNF ;#C1GS[K>/" :9\NK)@? )]6BO5LD7->;/'V
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MAN,OTPK .![\BHF :KR0-[XC:7E=3C=P;O_^?42V_9=')C5G^:07)#TO:B9
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M@5G,'8\XLB# L)0U2.6=SB9N/97"7\H7;?#7X*_!W^W!7P6]*?[MX6&#OYO
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MNR[/+*=+>BB?D62/.])L[<=\4JEV,1S3SY./]?,?2?#+,)%\TOOJ;Z>LT<I
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MO_RA- 074#"IBV0@A&"QD 5(GF_PZ%!B"2W&=Y91GWW7]*JF15IK[CYQ-4J
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M@1$+2<[BT7B+G&G#+0--UI"7SC.R;C&6' VH"4:TTNV&$3?$")>3A1ABB;J
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M$56KAVDPV&!PKG 8DW8Q6!]4!E0IJN"* . .,"J[]O8I#0;7#H,+3/Z@DY/
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M!8@6ZZ!S5K(.H+$H%0-G!7/(!=/.^>22Y$5^HUE" Z,&1O<-1BYAX$4X8;4
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M&J/4^&CU#3Z*74 I^(I#6Z=ZN L<//=<X[Q*Z8WS.C)C(\V4,\U7OF?Q>K(
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MA5D4.%I=Q [L1E&^ D"]^-]184&I-P&HAY4D5_T\@_9-7@'#O_#,4N_" /1
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MAJ5I,%1GP:E=!(\L?!.>/;&S5V#]NC-3]2_<30@;1&MAJ[Z;86=4;()TN%:
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M&HA[MU>,ZXG5X%E&$0R6)H\-6J$F3\B\'U8)6K4#T6 ]OCJ!9AP"V^N'\UX
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M"_5C]JX!KE<=XEBCZ4_.$(NK!.,2I>:R-,99%;M%M^L&/3SO[*<E82I)XW]
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M>:JLM$:8W--8Y#3FW_)DXQ'WY5?CX(H]T)U(/J_CMO;04 Z'RTT%:5&GG4J
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M5C\B.#;X=Q/\.Y_'OR1.O9-Y3"1++.%4&J(R[HEW:>PHS9CA@'])OD4;\&O
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M,.7^?+4-ICP>IBPX;ZUV24ZI)[!:2& ,QA-M5482D>3,:FT]!\9 DS4.<VU
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MQID+4$>F%6.[)J1W>.-?PDJZGHET?S/L@!.*=5LF=??;A6^^DTS2.(; Y[O
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MT+D;!>+&&0"SEQD[9_\ZNS9.3?;1&7&<J_;)]WS+I4F"?3FI<W;$%98_.W;
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MAY:\ET-+I#-L.^3TQ[PO69I_7.FU^!K*VPF=X4P]$BEY+CK'I=A-M/1$/<]
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MV(=O #,!:^(9OG'*(\ K+ZS )P S=]T9+'T8B@B?[/J 2X I /GO\/@IL"M
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M?EH([<O?6JU:IV.L_+E>6_W;0X\U@&5VNQL]]N'?6HW5+SV:Q?8:ZSYVS02
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M5@^U ^(3 #DE .2ZJN7R;6Q?R$FNXALVIP1<PXE5EAH6)GLZYEK1\S 4*L<
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MB"JZ6JLKNDX'OCV#_XRCB?OC_P]02P,$%     @ &5^;5L=AT+4 $0  )[L
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MSL#_*](,I;:]^70Q833PESF;^!*RH)% ,I).B2 (0BJ0(RLB!:V+28U-SU<
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MU5;%%N&4Y44FLD?HJW!9D5$RZ("1$Y]#(H/E36,&W !E%Q:8[Y,%+2:_W8J
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M=2[D)9;I'/-YNXBWLS#O;ZA#,\$E= F2]X9B/%WKFK,#&X2B>$]FYUJ;DR;
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M'MM9/7->M ) 0&871;I)RIFN7W\"E*@+14F;W-BD+MF]2BE1\L:'^&(#$8%
MQ+_^SS].QM]]Q=E\-)W\]7OQ __^.YRD:1Y-CO_Z_6^??F;^^__Y;__R+__Z
M_S#V?UY^^.6[U]-T>H*3Q7>O9@@+S-_]/EI\_NX_,\[_\5V934^^^\_I[!^C
MK\#8ORW_T:OIEV^ST?'GQ7>22[7^V]E?2K3!H@],J9R8MDDP'SDP;M&EH%'J
MH/[?X[]X;:U5DGX)&)G&'%@$S5FQG&>.)3N#RX>.1Y-__*5^B3#'[VARD_GR
MQ[]^_WFQ^/*7'W_\_????_@CSL8_3&?'/TK.U8^KO_[^_,__N/'WOZOE7XL0
MPH_+WU[\Z7RTZ0_IL>+'__/K+Q_39SP!-IK,%S!)EP/0\'EQ\0^OHC$_GOV2
M_G0^^LM\^>]_F298+.FY=PK?W?H7]2>V^C-6/V)",B5^^&.>O_^W?_GNNS/)
MP2S-IF/\@.6[\V]_^_#F)M+19/%C'IW\>/XW/\)X3(B73UA\^X)__7X^.ODR
MQM5GGV=8;D6_FG(%92J<_U&?]F-O3)\)R"R=1F3T*4ZJ@C?$N.GI_3%?/(ME
M+' Z7C1$?//93?%.3V#44L W'MT [?)![ 1/(LY:0KWVW"LX5R#7$=9'CD?C
M\;<?TO3DQR6V5U-:A-_#,=Z/B_X=JXLI5V>O[_^X_+=7QB:21Y-173=^H1_/
M'U"'V@$%_K' 2<;\_7>C_-?O1S$+3-XI:0MJ+"$&!3J)6)P.26 \NGQ,Q;-"
M-)ZF:T\=UW5M>D'$&"*.EY\>91P=K3::-Y,RG9W ^43PS0)/YD?)1.VX*BQK
M!4QG< QB 29E]M&%6(1U-\F<KY1CCNF'X^G7'VD<8E3*^DT5J3RC\Y[1SZ3<
M;U:?Z&^/@O!2( 86B$RF(Q86I>3,NT#;'$U/06@RBSK:==27VO%BML)__IKL
M^![5S7\ ]A;3!L([8X;@?__==)9Q]M?O>0L2W^-L-,T_3?)KLH2.K K5)!',
M26G(DG&:>>LX2PB"7A*3E&W#YK5AGQ"MNXOS)K^B#[\_31:CQ;>?1V-\>UIE
M<600HY).LARL9=KH2#,3D=GB#7>%@PVY%[7K(SX!5GL)\2:ALC^A'_!X-%_,
M8+)X"R=X9"+'4% P\*(PK6DI\5H[%J(&KTN4V9@&I%X?]<D0VT.8-\E5_<E]
M0T[K[,MTMISDQP6M(*^FIY/%[-NK:29X&&(J1;,<03+MA&;!&=HVDB]:^&BS
MT0VXOA/$DZ&^G:AO:H+NKPF?X(\WF68^*J,SO_E\_7'::4'["*EH2DQ+[IGW
M7K!B1"*;P2-M-@UTX);AGPS[+<1[DW?3G_<7.<]P/C__3YVN.+):&:E3#7AX
MVG,25PP*&8G (1=K2\D.&G"^8>@GPW=?L=[DVC;C^A5]^V[V:?K[Y B$Y]E"
M839J6G:4\@Q0$$(3>$E6@'8M=O,; S\UGG<4Z4V673.6EUO,N]G[V?3K:)+P
MJ- LI2OD[X7@F2Y.D _H+#,A:T=J",FG=E2OC?[4^.XCW)ND^V:DOY_.%S#^
M_T9?ED:%ES:[["63165215IP?-+(""L:K85*LE^\Y_:QGQKANPOV)MVA#]UU
MI7DQ0UCBR%Q)D0 9\DC^0XSD/P@)K!1NR7I,A8R(7@1?'>T)4+JS\#:$2GK%
MPNKAU/C]Y^EDY>:3#1A4R9XEK:O5GQR+#FOPQAA!:#BJ?K&2]1&? )N]A+B!
MT5[1KX^83F>D7D+&3Z/%F+8$RW.V(;.2HJA@:(V(B8P!JT :$ZSVO!>CZR,^
M 49["7$#H[W"7Y]F4,_S/WX[B=/Q470%I<J&154=-1<SBRE;5H(5 A2W0O7S
M@Z\-]P2XW%U\&XCL%>I::=5/?Z3/,#G&9>@M&H\)#6<I"P(40#-0X)FDI2,&
M:<@=Z[=U;AKU"=#:6Y@;V&T0OGIU.IO15#_@E^EL4=6.#/33^9'/:"P6P80E
M9=,:.?,2!'-&B.QSUAA] PMX\^A/@.UFPMW >H/@U9O) F>0%J.O^!H6<([S
M*)@<BT;#$GJR[!P9=:$@,)%!>ZDL(,0F<>M-HS\9UAL(=P/K#<)8]71L]HH<
M\./I[-N1<$%%CXJ1YTU&G]"&UAXN:*8^NR1LS- B6'EMT"?#\>ZBW$!M@]C5
MQQ,8CU^>SFEZ\_F1(DWCEOPR0Y8]T^" ^2R &=!6N9A4L2U6[VN#/AEJ=Q?E
M!FH;1*A^.L'9,6T>?YM-?U]\?C4]^0(34CD3C#(JL&QI2=&:-A*P)3%KDG 6
MM<VZQ5*]<? G0W5_T6Z@O%>4ZEP%/^-X? ''":^=,*R (@W,0I-S'CTS 8P2
MQDMLDCAP=<PG0_#.@MR0$=(K;G5N#TY/3NH9]C3]X^-GF.'\W>FBYFI7?^^H
M).W!6M(X0,\T+2P, #7+2&JG<TPBMLCZN0O#D^&]F: WZ$&O:-<+FG"ND_YY
M#(0$,PJ+@0'GF>E8;R,@-V1&: PJT??8+S9R;;@GP.[NXMM 9*\@UVIZ/X_F
M"<;_%V'V,WU",TLB)1,<<S('II-3->96F$IUC8E2 5GR?2B]9> G0&X+D6Z@
MN5<([#JFLY31,U3."L1L2-MJP$;KH%C,$ID0U7K04'CNYS[=.O23HWI7L6X@
MNT5$C'#-8/QFDO&/_X7?CB1W*3J5&62I:<\PCOD$B9F(AD=>O#2JQ;Y\?=@G
M0')_<6X@N%?PZSP4<[G K+*_G:-M7P7+R%FG*2KR\J)5BA7IA (,+MO2[SSX
MEI&? ,U-A+J!Z5X!K]5,__<IS!8X&W\[B\$>29/0F>)8=ISV$D<+C?>D?3Y;
MC;3R<,O[$7W+P$^ YQ8BW4!SK^#7Q16=&4SF2X&>@S+6< O), FT@Y"A;V@;
M<<BB2%YIM)R'?A&PVT9^0D3W$NH&IGO%PC;,]!/$,1[YY 4'YUA,)9$3X!4+
MOIZC:=!>Q)A]V7#1LM_=O.7(#9F^<I]YC_SV$N6F.U#?G=U4_4L:3^>8__K]
M8G:*EQ].)PO\8_'3&.O8?_U^CL<G-TY]NNO$Z9P= WPY6B84U@>]&L-\_JXL
M??X7?XQ(/ %L-C8S$>J-+A]CC=PFEGP121L3"MRU!!28QR59YR.=:0>.%_/5
M)Y=J<B^8AKIRQSWS>W5G!YJG0XB[X06Z%;"K>%XO%\Y.B([6+KXW4H2;:%KN
M"[?=VK_DOS%=TT%DO1\M*.1=@,F>9<MES3 .+"JR47(1*F:=T8F[TLD>,OO7
M:B <D/QM1#P$Z<M@[Q+7BU^7QM(1Y*QEX98YJ\DF55J0ZU&#"H[(,@IUL7<%
M9W8B_0:*_9F"K;A9I[J?8!M>@Q^/OQV]<,*_G2YP_OH4_^-T@J*.> ZK6CS1
MF\A<"8)I-)+Y%&B'4ZJ@=NAX7+NC<:.JQ3U#/%HR6XJNX<N[A"5^L-)<!28)
MF#T'IJ/T!LB\E0)ILD*1MU&C^\X)Z7R.1;G2A=.[!GG<K#837\/[[TM@\@=Q
M'9B27/%S8%P[Q<%[ICPG\Q.R92'3CT9+E,ESP:WHPNM=@SQN7IN)K^'5]R6P
M*^I&B,0Y(E^D-! # RCU4D^LR<KD5+B< MD3Y$ZH3HOOQJ<_;B;["ZSAG?4E
M(L/Y%43J'%$4M,Q+!<QRK\D@#-4@+((5H;/FI&XFF"X4;GSZXZ:PO\ :7C\_
M4ZH?G+M8'6!R"K-OM*&KU<(?ZR4!Y12SH!S3B3;T4(QER*409*QQCK;3ZWCG
M,(^;U(8B;'CA_&Q3O[9FZ)7":6V%TR:Q(&HYFV+)0D/Z8GDIX)(MH71:9#<_
M_G&SV4!D#2^4GT%R5Y<-'5:*!3XHB)P)V@,($OE0(67-N* 5A*O"A?:=6-SX
M^$?.8G^1-;PA?@9)7%4LL]J_=28SVY3(K(5:>T33_JUM8"X9#&"UX=B-Q8V/
M?^0L]A=9PXO?9Y"4NP+)7EAA0BD7%:?U@-,6+A'(\17D ALCH[<B\>PZL;CQ
M\8^<Q?XBN_WF][_^N":37^C'':N83N;3\2C7RM#T?<;)'/-%V',^+3_]]^EH
M\>TZI(XU3KL]N7\%U!UFL%8?E1CU*9L RH#.%LCQ%QZ%LT(6+] ?=1VDT4G<
M+Q<GE&0&@XMD(*/0P+3 S*)1A1D0.N9D0TAW95OT.H*[0-$WO/QFDF8(<WR-
M9_]]<Y97_'DZ)JV>GXGNPW0\_GDZ^QUF^2@E74JL>Y4K9';P7%A (Y@O21A1
MR2IWY>OO,NDM(>Y_;>JI&^N!Z2$I:1BUOAY'OY*-_F8^/\5\!$Y&P75F-I3S
MV[]1"L54=";+9$@$=V46[GY*<0/*_C5B4 HWGF/TD_\ YU:?ZL1/9]^6P,XQ
M+N$=91ZY=EXRS([\3ZX2 TZ;+<\*?8&L5'/%N!7,TU:--APTC)]?KICK4R:Q
MC$_K!9;W]3(Y$;!8S$;Q=%%S.CY-WTXG-<.&Y$Q//%Y>0<;YXLCX'*4IM+:2
M=4 6&]F" 8RL=5-=/:W34%IK4AOD3UOM#L!NP[. U2S>SZ9EM/AE.I\?A:A3
M]O2VN!AI-P^UU$Q1CHFZF4.,)>!=%6]WT;/+T9^VKNPHY88'!RLD[Q:?<59O
M4\[P<\U!^8JU-N\)5FQO<?&N?((_-JKO>UA60. YUX1%8"!<KIG"D7FG$XLY
M<U.T(-?EKCO+NRA)3\A/6[/VR6?#0Y"->_?9KOT!%Z,9679:U!O;UC!9Z@F;
M#8;%B(%%KCR7$7PJK9.^;D?SM)6H$0L-CU$V(CO']&HZ7_R*B\_3_.*D5A$_
M0J[11$DZK+"<Z7 P,M3;I,F#MX;KN^YK]M:46W ](YUIP4S#XYL[]/I%(BE4
MQ3:\9(\YLEK?A6DA%0NY=H11Q:L,*@O7>B.[ \XSTI4>/#0\&]H([>\P/L45
MLDME/A*:2X&UPK&N!?P*N+I)AEH!UV .,J(>="NZ!=<S4IH6S#0\D[KF YY%
MHEZ?SJKGM[P&?:;B/YU\&4^_(2[_Z/WI+'TFB;T?PX2<@*KG@NQ_SVM@P@$G
MN918T[A3\!IE7L\$:./2;P_U:>O8/OAK63[Y'MS+M^16V$>YEBFT/+-ZZ8QI
M4R]P)P[U/%$E:2&).]N9--2ZNX$^2YUKR%W+\LY=4"]?EY>$-%='E+S0Y46U
M(U,PBYH=*37W3$,L#'2*3#JG92C2!MGZ L?V*)^OKC5@K675Z=O#JLL0QY%)
M*3D9 W,:R1%-@?9\IS2+.2J!-E@5!EF\;D)Y!BK34_XMBUC?=P!H8DX<M6=&
MU@TX\D06H/',HE<B^:*";^W'=3J ;7F6J!SG(: C89?J/ =RJ(-++$0/JMBL
M@[CK?OR 9XD'.Q2SCD<5:\%E:V@_5))H#T'6IC-*"$>TY[M:ISZ40[$>*3IG
M%\%EUE"BT:3OD5[+;!0#$SWC4ME4HK1N@&7Q*H*A2R@,E'[20XP/KFS"F3+6
M77PZJ<E@R_O!]'9(R&0K&E_+TKM<KP/26Y)M\06U1)+24(JQ"="^RR>T(/HV
MG>DM\ $R4=8PG6>/=@$U4/V$C8 .7$*A/W'3H:2^-Y4P.1N+SM.J:073,M:F
MRO0N 7T&7-(KT#P*L$=5Z%I/84^:L(VP!RNKL#1<SM._R332*,E<%DB+H"Y@
M60BUI;:-%D.R0N2[*A3W-)</E5??@)S;\Q%WD.P ":HO<EX*$<;O893?3%[!
ME]$"QJNL?U,"N4F6V1AES?I7+$9=>V];$(&GJ)J_]'<">@HJT$[B [SY'W!!
M\\/\$\PFY'W,5Z@@&IX"V3M)(-.&>Q8Q+7NP!["6ECQL_?IO1O(4%*"!C ?(
M.OTT.YTO?I[.7N*$I+IX5U9!Y14^ [08!9IH(4.8Z2AIEX."3 :%M4-O@CL[
MB^P63;@;TU/0AJ9R'R#3\T5*IR>GXWJ!Z+:DL55Y"LZ#E,$Q)7)AFD?+O%>>
M65)K;YW/SLK6FT57<$]!4X9A8H!DT0U!P'-@SALL67&6P-=Z[M:QH))F7)-O
MG:V*?/T2]! 1R:>C$FTD/4""YN8@YCDV5$H0B!J P_,NPF D9YX+BR4(&>ZL
MG[^+%MR%YRDH0C-YWYJ,V>[J[DN8C^;3\IX0TN27QX>OJTDTGE\'T>FV[AT/
MZWM!MRO.M3NYTGIE3'!69*&3<=Z%Y(7WT0OZ6.FC.Y[;UWA/]2+XJ(S26KU@
M+0J/J .M!IELB"3(MG0ILFC0HA<@N&I]1^-6,+V7%ER\@OGG][/IUQ%)_>6W
MW^9(;M2[+SB#VFGS16V_2%SC_*C8X!,WEO;!>MI31.VV2=NB,8+6/ZGMW<WP
M=EIH.J/;_[+31C]N+#W#\#% K.,6I&\F7VFMO(Y4\4QXP+!</7#-BZQ%*Q3#
M+'U16%>@/6G.!G1/7'/Z\C%(6.3Z_,\.A3*(XM 4QFM#.9VX8UZ#8DYR3* "
MT/\&7E7W>I8ZC!;TE^VA3U;GLP7-8KXZ(UB>"5BHJ09.,=)7LKFD%V1ND<(6
MD D@"9%U)]V@9U_1"_KI4B<V#'NHT](&'$[;R++AR[\&Y=Q*[P)FFZ/1[@0?
MXBBT-QV;:>TAR\$)5B+(:+.L#04]>4NTH('7G':>(*)76=INE6L>!K&W'&P.
MR^LV(FS.Y]=1G?D[\J]&T]E9XNKZ\O0B_]?I?%$!7]0H"SHF61@6+YDVCEQO
M&X'9C!&*$ZY8UX3S'<#MS]IK0.9TGTS<ZB*TBU70)'!RBA]/3TY@]FU:SG^F
M:4R/)Z-_8MX]<M'YT7WC&+O-82VJH2.DD"*2^^:T#Q#0>*><!>\@&0]'G4?I
M9XF_'LWA^'B&QTOU>;<:YM(4M2D&CZ!KN<':X,)P!HHG)D.VRJ'36;6^U7L?
MIO[>Q_)Y-#?)E0_<LI)SII<C!!; <H;)BJ(Q: ZM$WI78^_?YVS*]$VG8P>1
M#A"2N&629_:SLE(X%<G+A66XQ-5N]-(QBT8)1^LA+ZVS+^["LR\W<U#BFPG\
M(3B=[V?3?)H6[V8?<?9UE'!IQB'MR-[%P*RIV6@I>>:3SJP4U J3,R%W.H:]
MQY;9-/:AW,]VI$X;"K>Q97N.9_YBDL\1S<\MM"Z@&KJDMP+9OVO:GZ.;A#<2
M\-[8=U!,LHG<ME#;9D>;F-<^,V]\=)D'JUTGH^!AL7Z'W[HGTK>1ZP AYW-@
MYVY1R,EC#LAJ7R:F@R(<P /+,8<DE!7H.SFH6Y@"UP#LUPEM1,K-:FH[2K1Q
M.[-7TS%],ITM=RN8G&7SG.]9Y^AR+KF4+,BZX:XZW:*VH>!,UBJE6MK:X. >
M_[+;2(^9V %D.<39T?0;C!??5ME\UNIZ",J,<Y*1I:IIGN1O!&E#,,6KD%O7
MA+D&X#'SW5^BM^;--H\870:VYHOI^6>]8T5W/;11E*@S[O5*]*H$F[FQ(H$6
MN@3/(UG7V24)P1E[U.'Y/2^M?(;),;Z9O$BI%A$;38Y_FB]&)["XXCGJI)2A
M_S$3K*R]FP+SI5Z0UF@R9%]2;+V-=H#59R\Y%^&53L_U$/W3E&2*LQ,:X48<
M[G9 [\GCJL4=0[$Q12BUFJ-E6M0>L1$CRRK(DJQ+"G*'S6< : =HK=%8JZ[N
M78?F;H!XUL?T&?/I&-^5VZ&>N>4Z%*Y=* RDJ2WLK6/>1D%K=P[.@8_0/);9
M&=R^(EU#*=>P;#R$R-?%A<R_X?1X!E\^CQ*,SR]C6O"A" 9 YH367+-H%6>H
MM,@F>YM3B\2+6P$<[,+Z,%Q/6\N\<5SDXYDN785T<9OZ?E -HV*W ME_5*P1
M4=.AI+PW%;"&"QTE9QQBJDX&*;DRR(H-G,>$(>1._7@>%O5WA,;VR?PVPFW(
M^')-FWT[^NWC$6V(3A4?F(NI]NHD!)';VA093 Q:*L7OHG>.Z8?CZ=<?SY]X
MQO#Y#Y<$7XZW7]>YD>"GO:0V1$>D6W>GE]\^T3.6VEH\)NL5V:ZUCH(&BPRB
M4+5$EQ"\F*1EZT*G77 ]S;U],&8&N*5\Q_SI"1>]#^_'.%#UFB[X#E/,ICV[
MG=6G)S5#%#CI@E4$;656@LDH[/D)0>VXP[V7&ET4D/87+!I:?>XI@/,PM&<;
M1@;0FH\P7G:X.)U-:D3[Q7@\_1TFZ?*FOA?H I?$JS!,*U$S)0$9!A\2"(4J
M-B_/?3>DAQ0OVY7']9A&0Q+VET!Z/4/E(CLR?CL_(>E]--!U@$;'!#O-9^W(
MP,94N C K5':HXBD%@B84O+2<JV/MAQKX,32X"WI#P*3KI!I90!H84N1%6%D
M01-$;MXN9F^)I<XG>EOJY7"O:X]N6=?PH%GPM7JX-$6$UM5P'W!BZ39,WYI8
MNHU(]YU8*GT!ODQZA=H<'&KQ8^V G 89;,R0E6S=&O)1));V(;Z9P!]">'UC
MBE4M9B"L5,R@)+4./#((I-&9TP:>!5>F6_&6IY)8NA6I]R66;B/<O:46=@'U
MC!)+M^*H4X[A+@+>'_M22,.E9CYXP;0MM=NC"$R"=19Y[0G0R9UY6*QOFU@Z
M .E;R+4AV37CX/6(?EY<^$HAHQ:E>.:T"4SG(&NK ,Z*H14,)2='S-SC?MQ\
MZD/),-M*S-,F,FJ<)_II=CH>I=%%IEL,VA=A/0L!]5EN1^!@&*+148ODRGKO
MP8UTK3UV?WSUE>ZTC6@:OU/_ ;,\JA&(50#"!.TB&B:7W>/18&VXH1E*%Q0W
MAA=YGT^_X;&/DJ4^HFEX>%"A_#H]G?P7S*8K?1$I:5^+(SI2%9UY9@&!3#EM
ML@2GN"VR TG7G_HH.>HAF(;51BN2?S\]@?'T>%4.5SJ/1@5F02'IBO#,^^08
MK_&B&!R:U&5ONO;01TG0[F)I6-KS' @MNJL"DZHXKI.&>N&FVD7*L@C9,BM2
ME!*,L+9TX^?RH8^5GQW%TK#N9@7R$LA9'</L8DN, 4L2Y.B0S:IM[;S%-3*G
M2/YHA(Y)=R#H^E,?)4,]!'-K.<S=*%K>3EF;528=*>@3,]5$U;Z^T462VL02
MBD#4$+HL=!L>_2C)ZBNBFXSMW ]\"6>2IK3ZKNQ,+-P7E["VC5M>*#+,YV 8
MST6[E+.EKUW(NO;4Q^XQ]9!18UO\[SC[)TY&*V/&I.B31,Y4%O2FA^A8=."9
MJ:$Y#HZKV&4)O/[4_;Y5?60[;2*8QA2]^C:#DW_":KM,B8:K*I>+(7,&,ZE<
M"LR!*R)9:R7O<M7DVD,?)4&[BZ6QH_33+(X6IW^< RDVDV^&CM'>R)G6I9;P
M4Z0MP4LNT-7$T0[\7'OHH^1G=[$T]I)>C$<GBY6>Y!@T9#+_D\^U6I:HC56!
MO %32&>0=MW4)2)T]9F/DIV=A=+815H:+^MSXB5;B8G5*NXT)P=D;D*NN2_9
M6:5D25U>H0V/?I14]1518Z?IS<G)Z>0J%HF 054L)?NZ]$9&GK9A(3@)Z+F+
M'CK0M?[<QV[C]9)3XRWJ$XP7_USUN8@FI4SC\@CTLJ>220UIN^00G3*YB)"[
MA"&N/'*_;U4_N4[["Z6Q>?=N?'HR@HMRCD447I(43 BE:*.L7B#7M%2$4NI9
MFO38A9[K3WVD#/403>,7:+D&WYB7L#;[HFI]YEHH2P;.P()FH6@@N].G*'S7
MC>IPRU];RGH+JK'U]Q9/9]-Y&N'EH8H ZPUFS7*2@7PY3VB\+PPRMQF5QQR[
MO&(WG_S8MZR>LFK,W$\GQS"^/+#,GFQ2K4RM6D)(%"@6A4N,K*H(ODA52B?'
MZMI3]_N6]97OM(EP6N]?]8W?,#-E48I4)"M1U'Y:T;& .3!,064EK);8Y<#P
MEL<_6N):B&N(S>U\-?DTO>RLFISFP2AR!E6]&@=>,2]L9H*VVE""$WJ]Z]CM
M#-Y\_&-?+%M(K;$S_?-TML!5Q%);+H*H;9)-W<%K["7&Q%E6L0!'0Y:N[<#>
MU6?NV7UN(>!I ^FTCN>.:.5>'=30FL&%\H[Q4F^ !9=9T*2'-CF1B[51N2X!
M]ZO/?-PL[2R=QHOBJW=_?_-:A!>3Q2A.\^CB9 UET>0KNAITR03)UL8]WK)H
M:+D&$X1<;W:QF;#-CW_DW#6066,C\NH45SMM(#".7GWG<KW.3V^]]P LF:R=
MX"X5V_GX^$ E/X<@KZ>D&FYE=]?EL-H5IQ22]AADNG!+\RN6)0B1BQP5V$ZW
MRAY;N:)!;E:T$7/#I?>>0AX=0#VW"D5;$=6M3LT.4MY;A2+O)6W^=?.0Y-]J
MG9!<KOJ="-D!!@C=;N(]+.IWJE#4GOEMA#M,A2+EC2;@G E?NW#KNN74ENP>
M L]91P%WUF9_K!6*MA+\S0I%VTAM@*NS;VL=SI5CI:0TT22F@B?\9'0P[Z1G
M1?-$CI72!5I?C+XR_&/FLZ\T;WTA]U>;X=H2-4,8KDC#;2,-7:VATPS7RC;D
MDK01 B+77.>4002;$RBKA*S5U.\MVW#;H /7;^"H"PH=&" :4MV<6(Q&L>3!
M9"<A&[^G;DJ_-*_?H)*)/,O 7*X'OB S"\D7%FTMP.TU4=.\JOS#K=^P#=.W
MUF_81J1[K]]0)"=LG&:DR"FVSC"/J)F0X(VD-U/&3G4MGUK]AC[$-Q/X0ZC?
M<+N534MV+CE[IC#6X)6(+&@3F4/M;+8RRO6,P><0;]B&WD[QAFW$O#=GLPNH
MYQ9OV(JH3E[G+E+>FPJ $*[J- NJ%++DO6?!V,P4SZB-%E'+3D;0PZ)^IWA#
M>^:W$>XP\0;'M?'*%H:R5GDF0"Q RHQSS"5$#@KN"B<]UGC#5H*_&6_81FH-
M3;TZIY].9],OJZ0)'RRF'"-#"U +.SL6,2,3F6M)T_ EMRBX<G7,Q\Q@+_D-
M\/[]Q_LC8[E5I@A6,BZ[$"H6! ;&9<$BHPYFO:!*C_?O/]X_9O9VE%K#PYD5
M@E=OCPSZVLW<,1"AIBO1-A"$%@R-TL9P+4!",]Y>O7T*O&TIM2$.PG^>SG!T
M/'FU1'1Y/F^U=@JE9H'7FRDN%@:EABQ]4*ZD()7ODBITQQ"/F;^6TKOUE+Q=
MC/9%^N_3T7SYC#E,\NO15YPO1HO3&<[?PJRV??S:HZ_>-D_O&XO=>29K\5=0
M.7H74--+IK/U'KU+JAC-E0@>[=$V _4+4KT\G8\F.)]?&?$R&&.\L<[*PHSC
MBFEC$ZD4%^19AQ2-MM:*3HV8M@A2W86GUYW+^KP9YC>3][-IH@$^X!Q)[3^_
M(/'B5QQ/OYPLFZ]%55(BRU$9SIDNQ3 /)=)WGEY5#4EYU6'EZ3C<_B.OS?B^
M=G=S .$.$)#=,/>/GV&&[V>CA$><:^X26H;9UIXL13)OM&<V!"A%2)YY&5[9
M+P$] =UH+_@!6@*\AV_+7J:?IN=JO$)+:RTNWI57,/^\4O C!(%>2\6\EXYI
MH32#K#P3%HOA(,AL:GV8O V^)Z0S@]'2."UW!>O5]"2.)LO0]"O:M4?TY.4/
MGV8PF1><$<RWIU66!'VZ[*I L_L[C$_QP^CX\V)^% L("SPSG3.9XA82\T5S
M)HT/21D',73)XVV%YPFHTL'H:>PI;1#,)HPO<E[^#L;+=?4]SI:+[)$/F7L5
M \MD;9+H(C# 2#X>.)5<L,G9+@6/^J%X8NJT!RH:YB^OB^3ZRW"._MIK\8*<
M#/ITN0)_J-^]*^].%^0(X7PYRW^G61YQF3)MSYK%I'5M0\?)=S6")<@VY)@X
M>3D#64QM9O $E/(!4-NXG,=JX_]Y.GM!N_WBJB]\!-)I4S/^HZHB@EP(%Y<L
M>2<A)F^@TR9YUQA/0"F:BK%A_<0+VZYZB9CG/Y,HKL0VWI5+&^^(:ZV-](%)
MF4@#HS0,0$BRZV("GJ22V#H?J@.L)Z <0Y'0L&KCE8R/+],YC/\VFYY^>3-)
MX]-,"QI]FI9+VRGF=U_.5[5K2]R1C#8K&Q+C2I-<+.VS08?,E#1)61Z5-ZT[
MT^^*]0EIU%[HNJEFOE\[A<Z8?QV-Z2693O#2-7V)'S AO3SYR$6TQ7B:@ZDG
MT!YK/;F"S&!64=AZVS!TV)E:X7D":G4P>FZJ6.C==_*B_>\&,<U??KORTUD^
M6Y9!EZC(X@H026#9,G(/ HL>!&J%QJ_?">W?B')+C/O*&1ULO1J4E$/GD-XA
MO67N5(C9%,=I!J$F3/J<Z84PC@FT.8FBC+5WG9<W"G<_C);<0]!_?PA\:QH&
M"'YO@G465%TU>NT"<*!.W/>".TP;[B94=E"/_CP<1&%BTD!^0V!%.54+F=2W
M1"461:VWJPPMU'LX--Z'HMS3</LP>K*-^!O7D7GQC^GI]"JT5=&47*P40;#@
MR;+7W-;;';X0CY8[GI5,G2I0W_+X!V'I]B%AVE:" QR<KP>0SI*OA2@ZE5HN
M6)6S^F"^=AV22@4>7%9*MSXOWX3C65@/O0EH>.AY&Z;5W8D.J :R%S8C.HR1
MT)^Q>U2@A[@', MN02<<EERT8"H6S71QB0&@88(V/*%R\+JYD[%/);C' -B7
M#FPCY<9;_LO1]%>8C2;O/\/L!!*>+FINZYM)6A7:4ARA1,U09\-TEI9Y7FV=
MPCT$"S+D+IT4[QEF_R9 "R:FPXAQF)O,EU&X5V.8ST>% %[JM(T(5B"3LFYM
M*M8R$R60;9M0@K&%EP$N,]\%Z5E8!2UI:9BRT@'>:O/J ' @6^%><(<Q&YI2
MVEU=>O Q@#%Q/U"7=;U5I @HO3HZ.DZ>D>$L&AU4BB*BE$]#8>XQ,0ZK+]O0
M,+2>G/V F5;>;Q]AC&^GBXW'1*M+,M[& D4%)G7-<#%),*\R3<4:%WDH2F"G
MLFV[JM"6> ]2HZ4E_7<IUY#<#6 .D5TV/<&+:^DO85P;9'_\C&023O)E[E^=
MPW@ZK[=V7GZ[-N'YW4>9\^6[6R(4BV3EI5SOPII DM4%6"S!.A0A>-$ZUWP_
M,WL6QMD#5)(!,DJW OP63E8!TBZP]V'Y=8=\&'OP(6K172OYP"HPM!&Q!7S-
M0^#)&U;;<3&-0=7^GIZ!*4):[92+G:H^/U;-O<<P?<**NPWSS5NSP>2?\(7V
MKO?3V:),QQ?M@!&M%K!LK>V1:>[(T$=.@C!9*R=S)OET"+3=.L"![<^AZ)FV
MEFU#<W,9&(3_GH].1JL>:":X#$DRFS3Y<)QC[8%&/RJ=C.;26.S2WNW:0Y\^
ML;O+<(#MYN-IG.-_G]*2^--7^O*)_MER(:M%( +HS,BU(5.3RZICJ38ZT!"X
M V76TT?[Y_MMAO(LK/,6-#2\]W('K)6OW0'80 ;SK: .8Q(WH>Y^=>@A]_TL
M&^< <S%*9=J<.!)*+8QFP4&IES5(_[V&)/+C5HA[+,W]ZL,VXAY>#R[2@\!&
M2]N9<9(,%*.00%ED5E@3@C#HP\";QZ%LB49$W4W_#E*^U0S<2UFEY>GT?%4=
M@7[YRPCB:$Q_N_S=Z0GF00HN;3'N@*68=IW]6I$F%RR9%U)&@5R7( &%#X4+
M;F1M#Y;O*M*T!80!RS>Y%&7PWC-1<TQU34 ,*DCF0<4BB[:86I^2#5&^:?W9
M5ZXX?\ T/9Z,_HGY3:87=51&U3*\+OT7FZ2_K!XRR3_1GWR%<;TM1-+2X'3*
MS$703$N!S#LP3&*62?!$K_Y0TAIF1@\B,78W;>QPN_U0U ]8EZK%[-Y,%C Y
M'EW\\;).X*?/,/G;=)I_IS7T*%I>TY"!>1\ETXH<ZN!#8I9\:%4D.=?:/6 ]
MOW>"?ZK]'A1C -/V @=:97D-\2BG[2K9+=1VN-:AUL6)TCII] GJSD[B'+XV
MUL[ZN]37L[^[\LNWN#B"XG*$VH@J6)I@X+$VN;+,)!NSS1YEC/?8M'L#^P04
M[&$2.T#^XHZ37+UX&R=;IZ4-]^ -,J6]8N1C9.;)(66&UEU5#(E<Z(>Q =\W
ME2>@S0^)[ 'R,ZY62:R%7J[([2@+3J9M &:73; =9 8B!D8O6PDY)V?OK'2_
MBQ[> ><)Z5(KH0]PP-#4D;JH+[;ZW;<CGE6(0D<6LB!UER8PT+2"!^Z=4"JC
MR7LH"==R2D](+Q\2^4-4%=NF8FQ!Y[64F9$-4>@]5,"B-XK%0C(L6=;.IHT5
M]1$7\NVC=8/1,D#!L:W/H!T*7J)5+#L1F4[UD,F*FI,L4:844)O6.;J/LDQ/
M'P4:E)2'7J9'\62RC<CXLF0^.%I=E2,YQBPD^?5>Q-8M;Q][F9ZMZ.]8IF<;
M&@Y2=:4+P#_+]&Q-Y=;E5W;AX2 *PY7-V23+$B^U9#Y7]=Y.8B6A,QJ )]7:
M^WM<97J&U9-MQ+^G,CT\8%3))2*. ],%%0M(4X](5I=2H(I?,XD?>YF>K4CH
M4*9G&PD^@ R1J[\?+A]DTRA#9W_<.[.U7(_LI"C%6BZU(^L 0P8>?+":>QZ#
M@WMS/38-.&!FA[ B)ZTB\P7)39+9,8A:L.!XR<K&C#!4"+EE9L>]=<JC#3PD
MY$S!LE\"#RP2.TQ*2_]G+ 3H4CGL$95[WX;9SN7>MQ'C'LJ'G9GI)==D*A^8
M\EB[JI3((JW&K'CK:?DE2**U ;(1R(/PCW>AO9UX'XH3O+%@4BC:924S*[IV
ML^102#39,\L](*@4DANZAM0AW=\&['8I)K>-E/=7/ZP+JN=:3&XKQKH5$MM%
MW/M3AI1HE2Q%,Z-K0G^B#<PGKQ@HBS9EPXMJ';)_Z,7D!M"!;:2\[V)RA2?!
MR0\'E)(V24W;I3&9Y4*[9E:>F^ Z6(./I9C<5DQL4TQN"S'NP4M]-1V3'DS/
M[WN2<W66$'2E2]5%9P=RK<Y:];V"+Z,%C.NYY>Z.:Z.!^_JR0\Q_S;T-O"0!
M-H,0H&U$7V0Q1FKZ,$(RZJ@1AIZY*I<@ON+5L5],\MOI)-WRZV4'1TA+Y)<&
M=2RQ^$P&4B[ULC"I.@.PA:4<5::7 MM;C2WQ]UE&;\-QULB2P+R+X]'Q&=5G
MGUWYX(BD@\Z!8\Z41)9E;4BO):_'==QDT%F)+@VP>X'8_Q)\,-V[NG#OC[@!
MG/S+8[H&LCQS<B0O/CJGF4<OSZR;",8RIX0F#P=1-N\DT'X6^PHO'%R#'X@B
M'#J6,9\M:FN]?)H6[V8?<?9UE/#\/,D%CT8PORS\G.NKR4MF]'JB\-&2W=ZI
M)QT-<$63Z:=++;YM[,,?W1]&%:8-*6GHZUS!4^=_CFA^<8)\/ZAM8A[=].4F
MD/V&.MIP=)/P1@+>&_L8O=4(D@5CZ\IK/8LJ%D+HDB6$VJE.734>%NNWQ#;V
M2/HV<FT<UO@/F.51K7YV[G]GAS(4 S2O6K>FF,B"T\@2N=[)Y\*=[W*HM?;8
M_=G,#04];2.EQD6W:-?Y+]I\X.6;5<VHX)051C$9)*DCQLP@%<6*25([7X+O
MU,!H_;F/G;)><FH=.X0Y'(]A=M$PP4H>?6)2%S(3: 9D)JC(R'@UA"LEGG0'
MQJX_];'SU4-& _0/JK5:WI4KQMYRY;?"*:?(H -2)::]0P8\D"-BLW:62R==
M:NSS;03RS$WF=B0-T7GJAC!@\_S/%;T+W*%.$;>#>ICCQ08DKY\M[8&A(0X>
MMX4=$V@(BHEER(U+S[RSAO$H(6FC>%&MT[ >A$+=<U3Y /1I"V(:&R(WVI"_
MQJ\XGGZIW\,D?\#CTW']Y]^NG9^<'ZF<GM1?TH*^,JB<B24ZP6K)4MKI27!!
M661<%"NS3)(V[ YF3$M,!S@>'9+\Z0-@[D$<LK[%Q;G%^8&F/3G%(0]6;QUL
M^,/4;O-<.T"-G'R94B Y<F1L]I!!)&?10BF88Y<#U%O'?4"'IM('JR0(AE \
M*2TY<2$X7KUO&[PPLKC6I:$>PJ'I"LLY,;15Y:"RUL X$4UR*([%4#)+2/"%
MEB+[UK?85V,_\J//;31H?9/?2?R/XR33B61MA,"$J.F:GF030L@,,&IIHK(^
M#'=-^%F?9/91R ,KPH,]R<Q%D*V.P+RJ 06;38U$R6KJ2!><#/;/D\S&JG#?
M2>8VE.SM+*L+J&=TDKD51YT.M781\-[83Y"L0X],H31,NZ)8*+5_2G44)&H0
MNE.#Q8?%^K8GF>U)WT:N0Y]DVJB=$JGF)=>4,ZM8%+2YQFP4.4]8".+C/<G<
M2M!WG61N(:7F[8.NG?@4'K2-I(>HE"(DB8PAPL:<PB"YLZ;$TH&OAWDJMBM=
M/634^/6Z<9ZJ(7CMK&7"N\)TLLC )B3-X;ED,(:O7_-]5.?.NS+62TZ-2]R^
M&Y^>T,N^ZA'!,Y1LDV,HT9*3X0L#D\BRBT$E;3P8>U_T[.93'SM?/61T:UG7
MO89&:[RYVO.#AD37!]E#*/3.>:V%0(L ZT4P4INLK1!!*V' A<BQIIWK+B'0
M]?$>4.C3*\M#3I:94"]%%1D8^5^\5H[*"C@Z;5H?Y3V$T.>VUP[>D\M,OSJR
M,1C06;!B<NTK3VMOR$$PZZL@=<X>18=U;H>A'WF =!L]V_5NR"XD-38\^UUE
M*4XY6F (> ZZ;C29@1.:J>"ML^0XB?67\<\[2 ?0LW[$#9"_<7&"H,E*!RT"
MJ]5["(=T#$!S9GBP6J,)4;:N+?)$#G!VT9M>XA\@/VR 8&TV5D>A+?/.D<'K
M)3)O=& RQ"3)_A$1_KR*]N 4\L"*<.@#G+OSL=#9Y UDENI%/RV,8%&@J%FB
M163/,S>=XK-_9MKNIAR=,FVW(>D!)$1V@?MGIFTODGMF1N["T -0+ NH=<J<
M)4U@=0G(HB<#0R;K%=1VKO;/3-M#Z-,VQ QA\4^_P7CQ[<7Q#,\0XNQD!4UX
MY[W79#1$)&=$*5XKWACF5<E1<^.Q>5?D.^ \@KS9;:A<-_T;\= X#'$CI?=*
MZNZ+^7I+Q'.\293:]M,PHY%V\4P;>"C",EUSAY...K@UY[%;TG6'L9^FDNR%
MB:'3^#\"?? 2R&A?J;4%&4T(S$E"J W/Y.1Z8,G0VJNU%"'97=1D?:!GI!.]
M9-SX8.^NVP OKMX&6$'5#F4RAJ&,RU/^R(*,];XREU[)H%.G+I1;#ON,E*.A
M_!LVB[PU\4=;PSU&R1S-F;:^K)@O(;$0:=?S,2G0G4*0SSM)<A>/N@DE#5>3
MNP_5NX!Z1DF26W'4*5]N%P'O+4E2TC*8" +#Z#G3@;X$ZS*+M4ED-#X%SA\?
MZ]LF2;8G?1NY-K8<U[)=1-%!>>58%K7'" C'0HC+1FC)A5(/9+MX$P\S(V@K
M,=^>$;2-C%H?5+_[^YO7(KR8+$9QFD>X,EN, &G0"X8"@&E:'IBWTK("B,%I
MH4WIDMIZR^,?.W\MI-;XM?L%XVSTC]$_3T\@GJ/QDD>5368I65*K2'Y$3(E,
M&>1*BWJ-;+T9[48.;S[YL=/74U8-;:.,(T)S#..?2)46WY:[ 2W_Y//7'J"U
M*K5.*C#R% +CEKYZ+PHW=UTOFF/ZX7CZ]4=Z]-F62-]<[H8;!GSFYG)?"AHZ
M4Q7*&8IS!>^"HX-Q?+]*7!UUOY9P;_%/&\JNX9I\ P\7AAM.NWJ,=EG0+;#
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MH_D_SN(79#,N.[8)5(;IS#F+(D9FP))PHJ-/6D>T[\)SJ#AV [9O73AZ2GV
M=>,2VRM2N1FDJV<[7; -%'&^"]=A LSM6+Q5/1I1L&\U*5G[!*Z>_M;*.CQ9
M!L989LB7B,5H;WWKYIK[5X][8L2'T8YM)-]0*^J-])>GWWZ;YX\X'O]T.INN
MDN-M$1&X9 $4,'(@Z;M8BXV[HBV/W!9<2_;<>/U_T[/W;T6VD_RTH=@:NA/G
M>"J0"NBW^>OI> RK8WA(W$5 P[(1DM7>*BR@TLP*Q2$(ZUP-'73A<O, 3X?0
M!@(<X.7\> :F GOUF>S@.?[?4YBL<BS0"F?!,?!9UAK*FI$1'!F*XJ/V) JC
M.[ZH=XWS=#AN)\Z&R8OGV/[V\OU2_3Z^/H<3R//D1F5F>.+56*6EQ ;.O,H$
MC1O0'KJQN_[HIT-H+Z'=F@NRKXCW3Z5@6DQ+-3%^A0D<+_W$H<+<=X\V;&Q[
MBYFN!;1-2=Q'RZ5.7!MN@G"E\,"S*"XIS/<$M.\>^/"-[2]C&SHX8V4T]<(:
MF0^2-AHOO&8@5,*@I2IQL)OW+2;09_F[/!C#?(POXGRY1!S)@BYF>IF3-<AT
ME8N7(!CI1$1Z LKU4^:-*^#FIQ_P3'#O^G)UU6P@ZR$NI'V&R3%Y7;_1?&$\
M^B?FOY%(?YG.Y^\F2Z"YSOK-Y#IZ<>1+4:BPL,@]22%K6NH%D%,F8H)DG1?-
MFWGL"'5_^M:*Y?4\WSU0-$0*^!VPKT&E5^S*%B*.;/)2.!)3*5:SVK*&WBTP
MS#G)-?"<I<M[5*V[L#YIW6I&4F.;_17,/_\\GOY^70H\!7+WBR>+$VOG$P06
MN,@,(^FY%IQLW2YE-#<^_+EN6?TE/<1972WK^6IZ\F6&GVMXL<8,R1K&JK37
M *\TF81TK3C?2RS3&7Z"/XZ<XC1]@<P'33,AAX6^P]H!-X04++FEH74:0#OT
M^UU[&JC"ID*]^^=Q (V\LF1>3^/9%-:>OYV2&S2GOX)ZM7Q^<W$]0E_(_9:"
M62OK??+:NT$XS^HA.>@B:(UM?>[<> K/<<%\"-K0>*?=B/C*ZS@]GE23X<B6
M)&SACN4$DFF5(HO +1.  7A$ZT7IL/=V'.XY*M=0; Q5(?^6=?TM+MY,ON)\
MF=-X;7$_6\S7EW@29%W?=2(M-](RQ 2U9X1CW@AZ(S@4%P-W*K<^(FT_B^>H
MM@]$)QI6\]_9>KE[,JY$<)!94#(RLJ@"@V@ERSI$D9-1W+8N\]-T G_J]B$T
MH6%C@I9B/4OY"IA%ME +ZR/2^ZD,BV2+L^(YV3..1VD':P?=%_S>*]D>7(D/
MP_M#2>P\M[I7AGAE>IEX)#GM)#HRVDH,T\[6UC$N,)Z]*>"0V]1:A3<C.7A1
M@OUJQ;0Y.P,X_3=1K7(..^ :*.WS-DR'2?ELP=N]JM!#Z/M4"LXY:I')=5=2
M,0TNT[(L)',AD ]< -MW#]BO,MR3X+E/7=A&UH,D^]X1SEF5^9-.),F!R5"7
M0ZS775):9CSQK(6/ 5I78>P :_]6?!L.;^3\MB5@@%-WVB7S!<IS2)$'G12]
M 5D7SW2.G'GKZ87(JJA8C).I]<WM#3">B [T%?"@EP VY+A+2 A!%Y9,K=K%
M>6(Q!L$B"A6*L\&O9Y0^R=M##\/@;,;4 )4V[TSH[(+MSQM'6[.XS9V272C8
M]XTC!S)(I-<"A.,UM3ZPH$UF!;T J8+4T+K*T..Z<328=FPC^<:7&LXRQ7X>
M_8'YPWF3]]7]&5Y*44FR>LN::6^1>:EHG\T$1V:>,E]3AXVG=[<.\,"RWK?B
M8-I:@ ,8DV\F"YSA?%%1K>:[:G.+PJ=H!3/<"/*O,BER29:)4D0P625A6V=I
MWH[F">A!8Y$/D74YJ\<.YQD'=\!T+G$GLR3CVI9:X\RS4&UC BPS!C*/3/,D
MRV[0GI":#$'& #;E>9[*3W^D93;H&C@O4/#L,W/1DP B$LPL!,/B8LJIE%2:
M'^3<!>@)Z4<[P0^0QW%57S_^#E]6E_5<,#H99,'6#A6@L58! 1:-<N1(9X T
MY)9RB>0)Z4$#4=^:XK"O.W77+WI=[=T^T+6Z>P<<]F;==O-=NURG0W:95$0[
M+W21&+F+,46N"];^M?==KKMW[,,G ?QR<2S-D\[D+P7FDZ[7$VQBGD-FMMBB
M:=80TV E2P]YO^[FJG&&AD9*2Y-@<00 18NB&'=:,FT,V8K.:^:#*%9IKF-J
M773O=C2//8=G&SV[ISC9_]_>M2VW=2S7]_Q+)W._O*1*TI%SSBF7J+*=9U3/
M36)"$0H *F*^/CT (5(D 6(#,QLDH1?;LEW8:WKUS/1MNO?EJ&NSNCNR>7>#
M+6NE&18-.9*[J;SQ$.K\129T#CQG[YIOK6UX?FE0 YZZ!@/O8+NCXEX(DWV=
MH.Z2!B5=@:"T!U&BC"8(=*5UYND)2+\TJ0U;71,0*TFM=5PI96-,"(+75+XT
M@NQ?P\%*+D7!ZL/TOLM^'4--V.G@2[Z]FM>F+_-WTR_A?)7DK2X4K9W T3_-
MS^D[N++/;WK&KI';B"8XQ2 8%T'Q5, A*7ZVI.Y"DB=L6R<K]D=[RJHW$L<=
M:OGW0#[)PKHHM 43ZZNLXCV@PSKS-3FI"BN9M7XZN@?,7_K8C]5G77UO&3=)
MDKB4JQ%ED<A<\'3\!T'RE*%.'&P=WC_QZOM#5/4XO#^7ZONM[QK?7M_4A_V1
M+Y:;=?[Y_.MJ:J9$7J*7$,5R"$OM^)@] S1T8R#C,?HQ&BX_C?3E%U,-TJH=
MBJD:L]NOD/LNK/6 W1V ]2WO?PCJ^118M6;V\9KO1K2,JC>,T19R&H'Q[.O0
M"PE(.PE,8%8G;E1N/KEK9'W9H^+J:.HRA(V>$[QN$*X+B3C&P,@WEXPK4$P;
M"!@1O)9:Q-K'V+:N GX<R=&JP ^E:I-AM;^<>_3<N_,J^!84:;-7$CT4ELB
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M*)$<BE)KKIZ);A[+%AU3/QJIYA[D#IW3=O.OZU\"SO.__\O_ U!+ P04
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MC3(IM9Q1]9 SSEUN1P;+Y=/B\W)SGY'5^F=Q3T6Q8#[V(D](&!-)($IQ HG
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M9UX44=/(I.XAYF;FH1_3Z'^ 2DZ@! 5:4O,8FQ,P]A.-&W!&II0N7 8$(9T
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M%Y_9GO.KEY-MLC.M%X>_?<[U\L(,+,V2K<B*963Y856NBXH#JO,:E,J4A%3
M,*BJ$& *:9 R&# D).81XQ&Q*L+2/<[<S)R=F& OYZ!#L%.XFOF='* ULM$P
M!"C[<BG],+@JC')BE&E+H/2K>E3LY,SEP\C NC%SW8CYL.JE(CK=.UV2)$:^
MAV#$2 01D0ABI#9CL1=QZJ4I"X+0AD*<2C<WXGDGI6!5R8J'QI31E8.S\C=X
M3U:D*7.1[2:[U,4NUN!W4K:JF.@LA:XZPEG3M5U[X"U;:;E](\S([\7F>63*
M["D=?-(-_\Q(II6>X*A,L3Z7O.G9D5OS[B@SX(BMW<HV*<>/ NOARC#.(/;^
MOVJ\O$JTT:;NIXTV5C_++V1=957$*&8AIQ'D,=5U2H(($NI%:H4($ N#5$:)
M496K\T/-C>EK\32]/]0"FKL[SF!ZWMWE#JF1N5(+"EJ27H$&ML\2?'$,F[DK
MQQU\$_E;+H'1RA5BADR/O^+, R9S*I@ITM[Y&]XQ,$%Z0TOQCXUZTKM']9_&
M^2BE%_FAQ-!C0L>FT@!B7W?CX#+V?%U9);!J5-@YRMQX<R\DJ*2TS&ON!-+,
M(+T8GI')\A"9$4(S>B%PE8/<.<:T^<9]:A[E%O=>/.Q[UT12$+;^KVQ]]V93
MKI7A5D>\MP+BGPX+A@9AG(8RA"GW"4112&&*$@(E#ZB'PS"2V,I5-T"&V7%%
M*X.?W.M\[WJ?K&:" V7N M;H.+SOPY"9,J.;D?$?F8RVTH/?E?A@*_\5V/V^
M4J7U<ZN7A-[(JHV(R!ZK\YLQBW=> +(CNALBP:1D> %$AU1YR:.&%W'Z(HHL
MY^]6_*VRQ18B\5F:,@)C005$,>&0:L>D9%[LBR#!B*>VU9R>C3 W$MQ5-JJE
M!$I,H.6TK_#T',A^%G,"S\@<98W,H/)/G=I?5 ?J^1,G+PC5J5!79:CN"R\M
M$6701TOOQ0[67)_['M%=W".N#",4!1C2( XAX4&()488,:M:*Q?*,S>2:%M*
M^M0@7U6G"^HGQR<)E\ZCX59MNMD9>U/7FAC#!H3U.<%$-<\OPM=YU:IATKQ0
M+:N+H#M=X>JRQUZ0.ETNPH!&V*<IE$A$$/DQ@[HN"Z1ABJD7$8&2<+'.UV1I
M1K+U8ZVX<O?P\3[)&SU&4T)E0$JT51+TG)SQU_T:#TMR'B6M^242F?M3ER]U
M +\CQ2I;W9;*I*JZ<EW3LMI)+8+ 9R)A",9!3-1V)L208)G"..))JF8T0,2W
ML6M.#30W@V4K)WA0RV"I)?VSW;=X$E&SK],%3B-_KSN(E(QU5SWPZU9,A[;
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M&.D3T!I=U?ZYEE*M\R-+MKID&@VY;*+)&9OI+IR7$<Q)%\BZ8LM+1)F62QV
M=L2T+I[IOEOB)['>)VB9-\BC:J" QP0&02 @8I)!FH88<I*0@$44B\@J%,.]
MB'/C[/^&?1,'OAMFE/^R,S[R0F#005&?I.Z5G&\;Q<OF8H)>B@,%G$U#Q<L
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M*=^H?WXN;O+?5PL:^XP1W],E,B/=$8E [#$$@S"*HUA*/S#SL?6,,3=::$S
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M96<TQ$=>-ER";4WV@T!S1-9V8T]*MH-@.23+80\95LSL]=>%[R-/8"%A1&@
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MM)].,&T88JSC\ 6")(VY3T(<1R&SK8[K$.>I"]Z. ;&9)\P):*-OZKJB%:Y
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MGR O,2H_;S7JW+CAJ >I;J?9]II]'%JLTVP2S+C#.;0C<XD35 <$5UN@Y"S
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M9*)/7@1IZDGIJJ,TN0SVGJUW!<W6F^^-2R!(B)\F2$">4@%1("-(_41"3OV
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MQ2(5-)!QXD./( %1Z"-(/)E"*M3ME HF9#S \CH89J9FUK?]Z3#;"0P>M,2
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MJ0WXTLJH96;T>V6HX[I"!Z@.H_\FJ,88_FXH^0W_3A!"CO_S1L8G@$Y'+S)
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M$A2<2( %IB2%29ZBQ*.,H[]%5F-Z_(J/5>;72Q2P=<M/&1CXB9>S'2"%Y79
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MDSKHM0:G1DX]5<A>&6)RS'&XBK<=(85$<6 >ZH$N*O-$?C=61Z79 0G)%J%
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MI9C[]5J/I;+8S)?YP_?MYGXI/K%%70YW\UGJ0;K<SHH<4DH+"7)>Z*]-QC-
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M-GVK^KWWC[>V;^/&T0J_U0WN#'I6 MI(DVY>TXT4C?ISQEA!B@*HPJ@P8E4
MFO,"R P)3E&6ZAFK+8M>;6UJ3'I>+/VNE%S? &:,MN>&ZSA?Y]6@Z W,K5>
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M)SQ+DYB#O. *0(6H)L=< <1EG"(BH"RL*/'RXZ?&>*6%]K.:"WA=G][=AL+
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M*K=\YA#P]N4[W_3\\?*A0\!PE"\=Y(&^1_\?'U?+K]L5_T=9_G&&N-!A-,+
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MM3ZW:H(;OGI8FN7E]T(NMW,U-PO-9>V;6L7IN :._MON48KC0O<SC%%,<IX
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MX-_-)]$<QOMD])2_F_\W\R5-C>8K^D5NMNLYUZ1L_J"M._Y%Z\H9QARE#'-
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M$^RO=&OJ?#Y_4N]6:SE_6#:*OF_E>OZC3+#;)#,N:9R2&.F^X01 * I0Z%^
MHJ!)RA1)*+,Z6W63%5-CN]J):-UX$3W6;IB(1U6.1'O)<'%PQ;4TLD^7V='A
MX!TQ,"TV?;!W(/JUU0>U#P>9\;<6?>!1XO@&#(.5-/:Q8>02QC? =%ZR^):'
M>5+G8K'ZEQ'1TTV\7>W85NT6][Q4/-Q\D5SJ=MA"-C4U$X43 B$"16:$")DY
MCLJP !DKD(P9+E3L%!@ZM3XYJJP--5)7M:5ZEM]XY,J'3OU@R8-#H3LT_S7
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MY'&A4<H)H3H252*VK7G;T<;4N"[Y69OYOZ+2T$CL9&1,M2^=VH5D_[ -A,_
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M9*99CJVL:\4X&^$R7MJF##=L6L%N2RG,L=*+>V?8,<^P (^P8! =;+R+]MX
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MSXF2)@+BZI0O88E43W[$T B3Y4-8JG*8_V![BW=-C]\V;0)<%L=ISDU*+I8
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M6,008,0$4#%,8Z%BD;@%C)^,/S>::,6+FH1$Y]9X1^#9$<$5D(S\[._0>#^
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M*$N@2K,D!VE""[-QS0'A1:Y9C,6,XIC(PLKS/!UX;NQ4R^9Z;G\$U? QFB\
M(Q-)+9;' =J1^O:G9[XP3'1T9@N'T[E9E\X]AV9'ET]V8M8EY.%Q6>??/9-^
M%AOZ\%":O'^]F+?JLWR6JR=Y9US?7;/U>TX%$86*0<*A9A]((&!0(2"4*C*1
M8B655=55IUGG1DUM:WKCTX@C!<PG9:V"8_4"*_3M+*C@F([,=N_.(&PDCGZO
M9!['2')"*51FE-6<T^9 N<!PENWD=+-O7E,UIBG0U-7.81=!&[.<"H$S4.2F
M&155%) ,2].V!2*4IKS 3GMBEO/.C9O:1Z<J1=;=EL0[9MEV*>QH:@2 1_?O
M@F#KD4'EA%2PE"J[62?.L7*"XCSIRNUV=U_MKJ3_-A;QFP^-%2Z90CB1"B"8
MF5)OC .:I@AD,H&")QBSS"K0J&OPN9%/*Y^]PW(&U[#/=@T((Q-$*UKTZLV'
MGSS<MS,T[%VX:U"9R(US1,?)F[ND?H]'=W;+9%[=)6$//;N+U_AZ=\\+(5=B
M\XF^&.NL#=DKLHQ _3] XC@&4$D"*",QD$B*K$ABG!=.89 7YID;4>W$C!YK
M.5V]M6XT;?VSJS$:W2-KX6E$'"'P<0"%8!Y7]RP3^UB]JIY[5?V7>U:AI9NO
MYO\FH>R9+DU=BL]2FSL+4SK._.'U2AQ_<'!EO<_]8<5+23?RG:S_J_^]?!*+
MU</[[W4MZ<]T*]\K);4/0(N,4DXD8'G5\QTSXXD9LX<6(B-YQE%VOUUOZ=*.
M6*85WXFO=DJ,]T":<MV+1OSHE6@4^,G4[N9:U:KD3/6+W"OM6%IWVJ^''5/.
M=]%')F"CBN9<LZ('&MU$>V6C^A*S\"<?'M]1HQ!]V'UY6B!^NHEV6$0M&)%!
M(ZKA"%A_^(<L8ZC:QM,*/VW=Y!^R,&<UF7^,%.Z^_><U_]JFIN$<*QPK"C)%
M"8 42D"12 "1%'/(BU@@J^W&DW'G9BA7HMD[L(<(#7ORGGJ/O<MGI/)PW@]U
MM_?;/3&8R&6WQ,+)5>_0N,=+/[QZ,@>]0\1#W[SKSYY&^?K;-UGR!5U^HH^R
M;%M%,:A-O"0%G"AM.Y,, <QP"@CD")$L*PHAG;I#=,TR-Z;9"QE54KHVF^\"
MTM+*O!:>L8W!$V1&2 _HA2!8,_FN.29N(M^CYGGS^+Z+?3,.WTIS[+#\L!+R
M^_^2+_=QSE-.]1.>XM04:XM3P%A*32&63.9QD3)B533IX@QS>\Z;?+E&RJ@2
M,])RNF86G@+9_ZP'@6?DY]P9&8\,P@O:7Y$Y>#KBQ!F#%Q0ZSQ2\=*%O9?-G
M68=X:E=C_4VV!9CO>9K+C!00: =!/\\DQT"_S15 <:(2S+,D8:E;BY=+4UE]
M<R=MY[*K\+VH!'4M=WX!4;N7^%4H354 O14QJF4T.S"UE"%KH??C$*PH^H5I
M)JZ.WJ_L>9GT@>M]0Y0V4M]D]BG>R6>Y7#^:*9I:['6@_SV5@O,\)P J*$W'
M-V+VPPN ,BQ8@@I!8J>$88LYY_;F;T6N-BT/A&X; M25TU_S__NT**79L@15
M=[[-)KIXYZL/GS[_C7Y[_/N[GUQ#F8:7S(YX B_$V)L; VMP$S6)*:,FJ#A@
M%BR8:7C&B0.9K"$X#V*RO]5]D_/-TXMIR?M%+I>_;=ZMETO:>M.\@!BF% '*
MM54#B\R4E$8"4)J:,BD8YL1J6Z)WEKF1EA8T,I)N(B-K]-O/7WZ.:GDM#]CZ
M,1W>) V"U,BLTH+48+1I$/+81+V,E/V6:A#$IDMM.4Z)UA_\24MA,@>_+6IC
M<;N.#,!R#_"72%1JA=F0'<2K9WOV\KV3;=8.BG^X=3M\L>]&KAZ*K<LJM?EU
M69HSIRH!<-?F8Y_%(9,XIE#$(,8H!C!A2)N"A((T26&*,DXQ3]VV=ZWGGAN[
M'HB^7M7V7UUY[4 -UT &AY6PW1\>!=_1=XT/I#[$\Z@1T2CFG0=@P?:8[6>>
M>.?9&9+S_6CW(?S(S'2&->'Q"SW#BB_DYLW+1U/00=ZJ_<<O52,<"@F$5$!0
MI,8F-/U "60Y2'.J8FSZ^B5.1U7V4\^-RHSDT8&,42VW5]<AAP6PH[!Q8!V9
MP3P1=:8K=W "L97#Q).2E3L@IUSE,8+O@5K=Q?T^45DF-/4 "#'5SBE+ $EH
M!B1#7!M;5"E$W,[1CMO#SX5FFD.BWVOI+'GE#"W;PS)W#*8Y(QM4W^-H[%C7
M*T[$FH$F/@@[%O_\_.OD[^Z/VUO3AZ24].U:R'O*"!%Q@H!*D"F0RRA@7.D'
M+X6QC(M"VP56;05/!Y[;X_:VJMNCA8N,=/9/VQ%8PT^;+P1C^Q!VVCL];%VJ
M>CUL1P--]K!UB7_XL'7^W=<,7SW<R?+;.\FVGZ1>TM66/L@WDI;Z_?G?^J=)
M#FF/L$R ZSW7IKA(20)P$J< "H@ )@4&25H0J3#&"%IU]?&68&Z/;RMCI+TF
MQ_-H=_1M3?$1,1W=(E\] "-\9*2OD@L:^:-&@6B'>*O"T56?^Y;!PW#WA#*8
M_>XZ_\1FO"<\Y]:\[T!^Q/=ZLY';S:Z<1)K"C&0, HF*0ML:,@>:RI0V[55>
M%#DE,G7:+ST>?FZ454OGQE4G@-D1D3\,([-,+=@HE32Z=0Y$!R>#3_JL=RMV
M^B!?N,HW!.XTYZ;:NK]]E&:+<O7PECXNMG3Y46[O:8YBBC@$"<ZTARX3"2C&
M'.1Y@5E*L,!YT@;%W=D_R/826'V[CV/E[B9XUNNSCCI#:6.2.=>MZ!&M'P)S
M(K)<U 5$%Z8+S4IN384L:J)D-HO]L8DP)76UG_=4NM:S=EA'.V()O"Q3!>>=
M)4B:!:E7:"=Z]'J_+/\Z7!:M3,@8/E< @T7U64\\<9R?*R#GD7_.(WAG])@X
MG+H.K,E;;+N\[X]I=N]I"E.ED! @R[@ D"(,,,\12 O(&14RS6*K+D,><\_-
MZMG+JCV)E50+.P/@ZB6P8[21@!V9TCPQ]4D><D4G7$J1]<Q3)QJY0M*1?N0\
MA/\^T[9Q[^[T$,T9@4K3E"8) G%,-3OEII:'I#'(!(\Q99JHI-6)2O\T<R.B
M:HMCN]_B,)(ZGK8,X&J_370=6A/O!=D!Y;7'<QF'@!LY'9-,OEMS6=&N+9F>
MJZ]HEVI&_"*Y:=^A+=LF^)+0E,%8,)"G$ $()008QQ)PQ526"T@SPIR[I7;-
M-#<ZJ.W_S4Y*CUZIG8#:D4 0F$;F@1HA(V1TRY:+AR:4+WR.\B 8(1NE=LXS
M?9_4/G4[VZ3VWN">#/#E3_IH0MZ;B/>[M0F>;5NZ,R4ADAQ0(F, B38-6"HD
M4!F3)&<%%=CJ"'A@GKDQ@A'U* W Q&<;<>V#W/M0[2>&@%B-3 OG,-W5,'DD
M!?3A99\6$ BWB1(#KL#/*?C? I6>\/^^NR=+ +!0X3 %P.9R=Z9\#='']59N
MWCW)5$/4?#O3(BY$H@TEF9FH-)DPP/1Z@X+" N4X11I/6X[LG&%N[ A_1G^-
M*C$C+6=D!+5_SKLQ'&;$JY$9F0L[0/%@P6YT[/GO:I0F8CZ7KY 3U?4"T$-R
MW?=-1F^]8A\26_^%?B[A%[W:U:[3K?JR7?,_OJZ7^N:-*<"W?=GMHB*BBD*H
M',"XX !JXP]@FFM3$$H.82)25CB=T%O-.C?JVPEMSN<.Q?X?42VX]X:VW2+8
MN93!H1W;C@R!JK.OZ812(+_3;LY)?5 G&$[]4;>;_>CI%[HH_YLNG^2^LL>F
M"G?6SN_=5[I]2Y?<-.V6'^6V.KJM+OXDRR]?:2E_6ZFGE9"BSK6M[[Y'$(N4
MDQ3D*HE--@$!F.L?FL=(KK(\9YE3E]CP(LZ-^%H9([[+6:Z<XD6EL#E%?]8?
MF<P=7I^R1N9ZQZVT$5;:CC!_[/J-S*Y&N:@2V-0BVNEW$[4:1ENM8K33T<0Y
MU#$0]5TFMC.J%+V)=E^#?>IZP*[>XRU#(/H>0<!)N7X\@$]?#"/.Y/<6T?.8
MJM*?RK5IO"#>O/RVD>+#ZI?%BJ[X8O7PFF\7SY5X.V.K('E,()9 <(4!I(0
M*F,%*L^!(*(_P"YO"7<1YO86J$K/_[)<_[FI^Z/M1(_VLKM1OL>RV%'ZN&"/
M3-F&@2NL6_$C]A*],AKH-^U/G;"/8B+[@QB(<#T$F)10_0$Z)<PK1O(CQ'_0
MQ<JD\-ZN#BAZ7S:#4LQI*@J0)$@;QEDA 4;:\2<H451Q00HN7,BO?[JY$=UA
M]U]:(_\2E=*\L(0Q>_5$$7VFBZ7)B@!J78(-U5?[GB$/K(4=XX5#>&1V,X)&
MKXRH/T7K5;0_RARU%[ =/(%X:V"R23G*3O%3/K*\RX][?EV7VP>37D3Y'U*<
M!4ZDR)PY9PC03$  DS0#6$ &"#:9R F#+'>*F>V?;F[<TTIK3I&TN-ZD,@"R
M':F$@VYD4JDJY^CEH<O%_].@[4"L!3\BF>!1*W8@!:*6@<DFI18[Q4^IQ?(N
MS\,,XS^^H9O*>=P%U]X+F!.89AE :6H.:64*"$]BD**X2 GD>48*I].+SFGF
M1B75GJSFD4V]<;>3,Y)U(5''(XIN:"W/)*X&;.Q#"",@J"0T'3&KXXB#"EPW
MT4?]3%2MUP:P<S^(Z(4FU,E#]R33'C7T*GIVMM!_]17AKP=97691F\:NE.0L
M5E@ ) 725@=%@"5Y"K#*8OTY8RAWJMY]>:JYT40=WKG:R7>8C>@1#-L-KQU-
MA %M9*JH\3K.#=S)&3@8MA>+D-&PW1--'P[;JW!G/&S_';Z)S_M*!Z::F=EP
M:0QGQ9'""8\!I2:C+RUR@&4B ",%I#%+8<$R%YZX/-7<>&+7^Z/J(-K*ZIR*
M?!%9.XH(@]?(%-$-U0B^QS :P?*&+TXT<9[PD,+G><&#=_B1Q)U),WXJ7RHS
MNT[>T[;*1@^^_;H6K[^MG_1[3T"D2%$0 #'%VJRHTFI4!@C..*%9CA,,/>HB
MV,QM]3Q,7Q'A(&=UK:)MHTBT,?:>(YE8K8 =K00#=!J":<6MXZ5,U^A*XIO(
MR!S50M]$M=CAV,8%I$"\8S7EI SD L(I%SG=ZQZA_JN^_]]TESC!H81,F<Q>
M*C0!Y;FF'64:E0F!%6.)X(75KL?YT',S35KI_O:7!,&_VP=<GP#63Q77P3 R
M(;2">42=GX!@'V[N#\9$<>;VH#A%F7?KW1->?G+#9''EW8(>!I1?N,+/('JW
MV#RN-W3YCW+]]/AV23>;A5KP:HV;Q'A64$XDXT IQ$U,#=>,A"! 62$%RU4B
MA=,FR^",<R.J5N"HDC@Z%MFS",$P['8F4% P1Z:[*W%TMGRLL0ED]@S/-ZG-
M8ZW^J<%C?Z,WY="'AU+6.>FWZK-\EJLG^:_%2G[8RF^;>T19PG.1 25-%!]A
M,<!Y@C4!)7&:YSRGF=-A\M"$,R2< WF-Q]5('/UN9(XJH=T)IQ]T:[X)!N7X
M=',-BCYT8P5-.+;IGVYJLK%2OH-K[.Z[XNSHDW;6RMT&1E-SZY/^KFS>Z=]6
M4C0?-;9T7F1(,)P!G"3:#3-))B2),U!(F K..,>I4Z:)APQS(Z3:ZY71/R5=
M;K]&C:Q1);_':9/C@C@<0XT'\R3G4\?BMSAO*J#'*MWB!UG(8RQ'":8_W_*#
MJ//@RW,H3T-+EHOGJB]9]_DNB7-$.66 <HP % 0"$NL?>0$306.J,H$]]KD'
MIIWI%G>X$_4AV"TMK0 H3F1H[23=';"_C'.\;HE)* MK8+9I#2P[U<_L*\O;
M+A',X=IIH^R/__R/]A/]PT2I_>=__']02P,$%     @ &5^;5C5 Q'T"B@
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M$KTAXB2!C@(,'_!L6LN)YNO?PCE.=&3H"W((CA=0BDR>4\J"CRHX5:+(6C<
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M>AL=/P&<PP4^0M2\F<XN*,R<,&X8+\Y"5MR38!2O([\%))U1!N[(K+9.)CQ
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M.T3N(]AV-R=K>R13>2'&WI5/X8_WM3\7Z6V]7D[CQ;I.<_NT>+_1P\0I[Z5
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M8'24=W7[[YM,<7Z(GD9FL=Z]FUZV;R-]WWK?GOTU">5%)D Q[6J#-Y[!8[;
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MLX7S5$IK\'4B;-CN0</CL+WV1@#)-V3?OV[*);<,W+C-B<9(-+2X2@KD@H0
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M?]N2KXU1->, VEI1A_4JDHQAX(7Q7A='[EOKN2RW"!BF]4U_)N1XZ8Y@=WG
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MSY?";/V/+=DVZI0RT<EB;=^82B;(DSO!0K12Y\)][I+>NO'(X?SHTW2R.%U
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MJ39E4L$S&Z2VK<\W'R!EF)K705RX%LH8)Z:V2RP7+64F*\F0N%%<*_ V% H
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MC6*L$OHI#4HH5:-U"USZQ%&9XN\3WVX]S7;Y5E\ .<2?TP&-V\$.<^=PWI
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MA."+ IV51&%)R; 3U<F1V?7SDHZ[:?6;=S?V<0=(WJ+&>I7[.K/!:0X9:P<
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M&\5_^G9G0UKJLYS"$7PE9M *?/ &E(D!(@\2BLQ&B6B-%*T? 3TCTOD3GQ\
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MB-XJR%Y8H[/0:D#LG15;TEY>WXLM:0\7= "G)\@R@C2N6!V@2.M 687@7$C
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MD@^6A<&&1#TIV?F_5FS:I-'*ASTA\TZ_P?RA?NME'"GU45(ST-ZG.I:&\I:
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M6;0!Y$[; [J/__M:#:U;_!*%1J5$!9)[\I02$H*E[*Z8;%*V3$0S8"3Y0_6
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M%RV.0Y0Y3T2U\<#1[Z_O45@_>AVQ_@?UEQCF^+__U_\'4$L! A0#%     @
M&5^;5K2I3@H$"   7"D  !\              ( !     &QL>2TP,S,Q,C R
M,W@Q,'%X97AH:6)I=#,Q,2YH=&U02P$"% ,4    "  97YM6E$Y!30 (  !B
M*0  'P              @ %!"   ;&QY+3 S,S$R,#(S>#$P<7AE>&AI8FET
M,S$R+FAT;5!+ 0(4 Q0    ( !E?FU8?M\7UT 0  *$;   >
M  "  7X0  !L;'DM,#,S,3(P,C-X,3!Q>&5X:&EB:70S,BYH=&U02P$"% ,4
M    "  97YM6/)%;7 =J @ \D!X $               @ &*%0  ;&QY+3(P
M,C,P,S,Q+FAT;5!+ 0(4 Q0    ( !E?FU;'8="U !$  ">[   0
M      "  ;]_ @!L;'DM,C R,S S,S$N>'-D4$L! A0#%     @ &5^;5IE!
M..'$&P  1@L! !0              ( ![9 " &QL>2TR,#(S,#,S,5]C86PN
M>&UL4$L! A0#%     @ &5^;5FDZ:;&38P  LT4$ !0              ( !
MXZP" &QL>2TR,#(S,#,S,5]D968N>&UL4$L! A0#%     @ &5^;5KYOW&)'
MX0  [3@) !0              ( !J! # &QL>2TR,#(S,#,S,5]L86(N>&UL
M4$L! A0#%     @ &5^;5C5 Q'T"B@  &#D& !0              ( !(?(#
K &QL>2TR,#(S,#,S,5]P<F4N>&UL4$L%!@     )  D :@(  %5\!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
